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Abstract 
 
Background 
Psychosocial and socioeconomic factors have previously been associated 
with cardiovascular disease (CVD). I ask: 1) Are these associations 
causal? 2) Do their pathways overlap with one another? 3) Can they 
account for international differences in CVD? 4) Can they improve clinical 
risk prediction models? 
 
Methods 
Causality between education and coronary artery disease was 
investigated with Mendelian randomization analyses. For mediation and 
international differences, data on participants aged 45–69 years from the 
population-based HAPIEE cohort study were analysed using Cox 
regressions. A novel risk prediction model was derived from this data, and 
external validation was performed using data from the Estonian BioBank 
study. 
 
Results 
1) Genetic predisposition towards longer education was associated with a 
reduction in coronary artery disease (Odds Ratio=0.67 [95% CI= 0.59 to 
0.77], per extra 3.6 extra years of education), as well as large reductions 
in smoking. 2) In observational analyses, cardiovascular mortality was 
independently associated with unemployment, low material amenities, 
depression, being single, infrequent contacts with friends and relatives. 
These associations were of similar magnitude when comparing minimally-
adjusted and fully-adjusted models. 3) International differences in CVD 
mortality between Russian & Central European cohorts remained 
unexplained after adjustment for conventional, psychosocial and 
socioeconomic risk factors. 4) Adding predominantly socioeconomic and 
psychosocial factors to risk prediction models improved their 
discrimination, clinical effectiveness, binary NRI and Net Benefit, in 
derivation and validation data. 
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Conclusions 
Education is probably a causal risk factor in the development of coronary 
heart disease. At least 6 socioeconomic/psychosocial factors appear to 
associate with CVD along pathways that may be relatively independent of 
one another and the conventional CVD risk factors. Uncovering their 
mechanisms may suggest novel avenues for intervention. While the 
causes of international differences in cardiovascular mortality remain 
unclear, socioeconomic and psychosocial factors substantially improved 
the performance of cardiovascular risk prediction.   
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Impact Statement 
 
The first long-term implication is that it supports policymakers in enacting 
population-wide policies that seek to lower exposure to life stress (incl. 
education, poverty, social isolation and unemployment). We already know 
that this would create a range of social benefits. After my research, we 
can now we can say with more certainty than before, that some of these 
policies will also prevent a large amount of heart disease. Such policy 
debates are relatively common. As more health professionals join these 
debates, it will make it more likely for these policies to be adopted more 
quickly in more places. Furthermore, my mediation analysis suggests that 
it is insufficient for us to rely exclusively on one core socioeconomic risk 
factor. Instead, policymakers should seek to intervene across a range of 
socioeconomic and psychosocial risk factors, including tackling social 
isolation, unemployment, low education and depression. I hope that such 
policy translation can occur anytime from the next 10 years (optimistic 
estimate), up until the next 50-100 years (pessimistic estimate). 
 
The medium-term implication is that healthcare practitioners and public 
health practitioners become more active in advocating for these policies. I 
hope that this change occurs in the next 5-20 years. The short-term 
implication is that psychosocial socioeconomic factors could receive 
greater priority in reviews of the literature, professional guidelines (e.g. the 
European guidelines on cardiovascular disease prevention in clinical 
practice), medical textbooks, and health policies (e.g. UK Public Health 
Outcomes Framework and Marmot Indicators for Local Authorities). I hope 
that this occurs in the next 0-5 years.  
 
The second implication is that general practitioners and national public 
health actors in Eastern European countries “catch up”, and start using 
clinical risk prediction tools in their everyday practice. This could prevent a 
large amount of heart disease in these high-risk areas, over the next 1-10 
years. For example in Estonia, I have begun working with the Ministry for  
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Health, and partners in the local equivalent of the NHS, with whom I am 
seeking to implement such a programme from autumn 2018 onwards. 
 
The third implication is that existing risk prediction tools in Western 
countries (such as QRISK) could be enhanced to make use of simple 
psychosocial and socioeconomic variables (employment; social isolation), 
in the next 5-15 years.   
 
Finally, from a research perspective, my work has shown how a wide set 
of conventional, psychosocial and socioeconomic risk factors do not 
mediate most of the association from psychosocial and socioeconomic 
risk factors to CVD. This means that more research is needed to 
determine these mechanistic pathways. Modifying these could open new 
avenues with which to prevent CVD (incl. pharmaceutical and other 
approaches), as well as adding to the evidence base about causality. 
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i. Introduction 
a)  Rationale for the thesis 
Cardiovascular disease remains the biggest cause of death globally, as 
well as the biggest cause of loss to disability-adjusted life years. More 
specifically, coronary heart disease makes the biggest contribution of all 
the cardiovascular diseases, and it remains the number one cause of 
death globally, when compared to other more specific causes of death. 
Although rates of coronary heart disease have been falling for about half a 
century in high-income countries such as those belonging to the Group of 
Seven (G7), more research and implementation is needed for coronary 
heart disease rates to continue falling in the future. There remain vast 
international and socioeconomic inequalities in coronary heart disease. 
More research is required to understand the origins of these differences, 
in order to suggest solutions about closing these gaps. 
 
Progress on cardiovascular diseases prevention has largely come from 
two streams: first, the discovery and modification of behavioural risk 
factors (such as smoking and diet). Second, the discovery and 
modification of biomedical risk factors (such as hypertension and raised 
cholesterol), combined with improvements in treating symptomatic cases. 
One promising domain of research is psychosocial and socioeconomic 
risk factors. Epidemiological studies over the past five decades have 
shown remarkably large and consistent associations for many of these 
risk factors with cardiovascular disease. Despite this, they are not yet 
recognized as classical cardiovascular risk factors in the conventional 
sense, and most doctors do not enquire about nor seek to modify 
psychosocial and socioeconomic risk factors. As for why, a part of this 
may stem from misplaced discipline-specific preconceptions. For example, 
psychosocial and socioeconomic risk factors may be dismissed as being 
too ill-defined, subjective, psychosomatic, lacking biological basis, and/or 
lacking strong evidence of causation. Nonetheless, many of these reasons 
do relate to on-going areas of uncertainty, which this thesis aims to inform.  
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Overall, the thesis aims to advance our understanding of the links 
between psychosocial/ socioeconomic factors and cardiovascular disease, 
in order to develop practical tools and recommendations for clinicians and 
public health practitioners, who wish to prevent cardiovascular disease. It 
gives special focus to regions of the world where rates of cardiovascular 
disease are highest, as well as to more vulnerable people at higher risk of 
cardiovascular disease within such countries.  
 
b)  Structure of the thesis 
This thesis has six main chapters, which are ordered to approximately 
follow the structure of a medical peer-reviewed article. Most chapters are 
themselves subdivided into around four subsections, to reflect the four 
overarching aims of the thesis. Chapter 1 summarizes literature on each 
of these four themes, beginning with the observational associations 
between psychosocial/socioeconomic factors and cardiovascular 
outcomes. Evidence is then summarized from other study designs with 
enhanced causal inference. This is followed with a description of 
international differences in cardiovascular disease, their temporal 
trajectories, and dominant theories to account for these. Finally, it 
describes the theoretical approaches to developing risk prediction models 
for clinical settings, how to evaluate new models, and examples of 
cardiovascular prediction models in use by general practitioners [a.k.a. 
family doctors] across Europe. Chapter 1 concludes by identifying four 
gaps in the evidence, which this thesis seeks to address (causality, 
mediation, international differences and prediction). It lists four 
overarching aims, with each one matched to one of the four gaps in the 
literature. A theoretical causal diagram is presented as a hypothesis to 
unite many of these aims, followed by more specific objectives and 
research questions.  
 
Chapter 2 describes the methods used. The first subchapter (“Mendelian 
randomization”) addresses aim nr 1, and the last subchapter (“prediction”) 
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addresses aim nr 4. The middle subchapter (“mediation and international 
differences”) addresses aims nr 2 & 3, as the methods used to achieve 
these two aims overlap substantially. The sources of data used to answer 
these questions can be divided in similar ways – data from the HAPIEE 
study (Health, Alcohol and Psychosocial factors In Eastern Europe) is 
used to answer all four aims of the thesis. Additional data sources are 
used for aim nr 1 (other observational data, and public Genome-Wide 
Association Study [GWAS] data), as well as for aim nr 4 (observational 
data from the Estonian BioBank). 
 
Chapter 3 presents results, with its three subchapters matched to the 
three methods chapter. In this way, each subchapter of the Methods, 
Results and Discussion sections begins to reflect a conventional peer-
reviewed article.  
 
Chapter 4 discusses the interpretation of the results. Each of the three 
subchapters discuss my results in comparison to the existing literature, 
strengths and weaknesses of my work, as well as implications for 
clinicians, policymakers and for future research.  
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1. Literature review 
 
1.1. Psychosocial and socioeconomic factors (and CVD)  
1.1.1. Scope 
Given the breadth of topics covered in this thesis, section 1.1 will not 
account a systematic literature review of each psychosocial and 
socioeconomic factor. Instead, each risk factor will be introduced with its 
theoretical underpinning and origin, followed by one of the first reported 
associations with CVD. Next, in case that a recent meta-analysis is 
available, this will be presented to summarize the current state of 
evidence, thereby omitting a detailed history of the intermediating 
trajectory of research. The primary outcomes of interest are twofold: first, 
the incidence of fatal/nonfatal coronary heart disease (CHD), as this is the 
outcome of my analysis assessing causality. Second CVD mortality is also 
reported, as this is the outcome of my subsequent sets of analyses. In the 
absence of published data on CHD or CVD outcomes, evidence for and 
against all-cause mortality will be presented instead. Studies where CVD 
risk factors are the outcome are not mentioned here, and the issue of how 
any causal effects might be mediated is discussed only briefly for selected 
risk factors.  
 
I will mainly present epidemiological data from prospective population-
based cohort studies, in the absence of which case-control and cross-
sectional data will be presented where available. Priority will be given to 
studies that have made efforts to exclude participants with prevalent CVD 
at baseline, and I will not cover studies that examined prognosis among 
those with prevalent CVD. Since the primary interest is in individual-level 
exposure, area-level exposures and ecological analyses are beyond this 
scope of chapter 1.1. Data from peer-reviewed journals will be presented, 
no books or grey literature will be considered. Where possible, I will 
summarize evidence for and against the hypothesis that associations are 
larger in the following subgroups: men (vs. women); in younger age 
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groups (vs. older age groups); in countries with shorter life expectancy 
(vs. in countries with longer life expectancy).  
 
For each of the subsections in chapter 1.1 the overwhelming majority of 
research reports on data collected from Western and Northern Europe, 
and Northern America, which have probably given rise to thousands of 
articles. In case that some data are available from Russia or countries in 
Central and Eastern Europe (hereinafter “Eastern Europe”), special effort 
will be made to document this. The intention is not to suggest that a 
considerable proportion of research has already been conducted in 
Eastern European countries. Instead, the intention is to clearly 
acknowledge any previous efforts to investigate these phenomena in 
Eastern European countries, despite the fact that some of these previous 
Eastern European studies may have been small in size or with 
methodological limitations. The reader could bear in mind that if equal 
detail were given to studies from non Eastern European countries, then 
this chapter would become impractically too large. 
 
Finally, my approach to discussing and commenting on published data on 
the seven risk factors presented in chapter 1.1 is intentionally selective. I 
assume that a comprehensive assessment of all the nuances and issues 
particular to this body of literature is too voluminous to replicate in each of 
the seven risk factors. Instead, I will capitalize on the unique features 
presented in the particular studies on a given risk factor, and use the 
opportunity to expand (for that risk factor alone) into some of the 
implications and complexities that such caveats may bring with them to 
this literature. 
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1.1.2. Education 
1.1.2.1. Early studies 
Education is one of most commonly used measures of socioeconomic 
status (SES). As alternatives, occupation is one another commonly used 
SES indicator often seen in studies from the UK, and income is another 
commonly used indicator often seen in studies from the USA.(1) While 
there is evidence that all three factors retain independent associations 
with health following mutual adjustment,(2) education is sometimes seen 
as the default factor of choice, especially for global health studies focusing 
on lower- and middle-income countries.(3) Moreover, countries with a 
history of communism previously had a social structure where social 
differences in income or occupational prestige were probably small.(4) 
Educational status is more time-stable within each individual, when 
compared to other measures of socioeconomic status.  
 
While the association between poverty and/or social class and health has 
been described for centuries (predominantly from studies in the UK and 
Germany), one of the first epidemiological association between education 
and CHD incidence was reported in 1968 in the journal Science.(5) One 
year later, it was shown how this association was not attenuated following 
adjustment for blood pressure, smoking and body weight.(6) One of the 
first associations between education and mortality was published in 
1973.(7) 
 
1.1.2.2. Recent meta-analyses 
Given the large quantity of papers that describe educational gradients in 
cardiovascular disease, it is perhaps surprising to see a limited number of 
meta-analyses on this topic. I am aware of three such analyses. The first 
focused on outcomes in acute myocardial infarction, and might be 
characterized as having a low threshold for including relatively 
heterogeneous studies.(8) The analysis included studies from both cohort 
and case-control designs; there were no restrictions on excluding 
participants with prevalent CVD; and the definition of exposure to low 
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education was somewhat oversimplified – while primary studies have 
reported education at either two, three or four categories, this meta-
analysis “Compared the lowest to the highest educational groups”. This 
may be one reason behind high statistical heterogeneity (I2=78% across 
42 studies). After pooling approximately 70 000 events, the authors found 
how participants with lowest education have a 1.34 fold [95% Confidence 
Interval (CI) = 1.22 to 1.47] higher risk of CHD when compared to 
participants with highest education. The Population Attributable Risk 
Fraction was reported as 25%. There was no statistical evidence of effect 
modification by a range of parameters, but this may be due to insufficient 
studies in some of the comparison groups. Point estimates were 
somewhat smaller in studies that rigorously excluded those with comorbid 
heart disease at baseline (Relative Risk [RR] = 1.29 [95% CI = 1.16 to 
1.43]) as opposed to those who did not (RR = 1.75 [95% CI = 1.14 to 
2.67]), suggesting that education might be more important in prognosis, as 
opposed to aetiology.  
 
A second meta-analysis focused exclusively on studies in Asia, analysing 
30 reports of educational gradients in all-cause mortality (of which 10 also 
reported a total of 10 790 CVD deaths)(9). Again, only limited attempts 
were made to harmonize or transform the exposure definition between 
studies, potentially leading to high heterogeneity (I2=92% for CVD 
mortality). This also makes it hard to compare the pooled estimate from 
these Asian studies (RR = 1.66 [1.23 to 2.25]) against those from Western 
studies reported previously. The authors also looked for effect 
modification (reported only for all-cause mortality), and found strong 
statistical support for the hypothesis that the six countries with lower levels 
of income inequality (Gini index < 0.3) had smaller educational gradients 
in heart disease (RR = 1.23 [95% CI = 1.16 to 1.35]), when compared to 
data from nine countries with intermediate inequality (0.3 ≤ Gini < 0.4; RR 
= 1.62 [95% CI = 1.46 to 1.80]), as well as data from four countries with 
high income inequality (Gini ≥ 0.4; RR = 1.76 [95% CI = 1.24 to 2.52]). 
This is generally consistent with data from Western countries, where point 
estimates from America (a country with high income inequality) are often 
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slightly larger than point estimates from Europe (a region with lower 
income inequality). 
 
A third meta-analysis reported a range of cardiovascular outcomes.(10) It 
too had the same limitations of heterogeneous exposure definitions and 
high heterogeneity in associations with CVD (83% < I2 < 99% across 16 
outcomes). Since the underlying studies were similar to the first meta-
analysis, the results were virtually the same for CHD incidence (RR = 1.36 
[95% CI = 1.11 to 1.66]). The reported estimate for CVD mortality 
(reported in predominantly Western European countries) was also very 
similar (RR = 1.39 [95% CI = 1.26 to 1.54]. The analysis of effect 
modification also found larger point estimates in studies from the USA, 
when compared to studies from Europe or Asia. 
 
1.1.2.3. Individual level data, comparing Western & Eastern Europe 
Meta-analyses of summary level data may show substantial heterogeneity 
from country-specific differences in how the educational system is 
organized and taken up, as well as study-specific differences in how 
educational attainment is measured during the baseline wave, how this 
variable is statistically transformed in the analysis, as well as which 
covariates are adjusted for during the analysis. As an alternative, pooling 
individual-level data may offer additional insights, particularly when 
seeking to demonstrate and effect modification on account of country-level 
factors that could cluster in geographical regions. As one example, the 
MORGAM (MOnica Risk, Genetics, Archiving and Monograph) project has 
collated data from 49 cohorts in Europe, altogether with 6522 CHD events 
in otherwise healthy participants.(11) Although this event count is two to 
ten times smaller than that seen in the aforementioned meta-analyses, 
some of this reduction in power may be offset by smaller measurement 
error in the exposure. Here, education was assessed by asking 
participants to self-report the “number of years” they believe they spent in 
full-time education. The researchers transformed this into population-
specific, sex-specific and birth cohort-specific tertiles. This particular 
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transformation presents some specific caveats. For example, if one 
country decided to shift the entire population’s distribution of exposure (or 
to compress the distribution of exposure) from lower to higher education 
slowly over time, then an analysis such as this one will assume that the 
associations to health outcomes are identical in both pre- and post-
intervention time periods. In other words, the analysis has assumed that 
education is only important in a relative sense, when one participant’s 
education is compared to that of their peers, as opposed to it being 
important in an absolute sense. Nonetheless, such an analysis can still 
detect international differences in the size of educational gradients in 
health. In other words, assuming that a natural educational gradient 
invariably exists across time and place, these investigators could ask 
whether some countries created environments that nonetheless managed 
to dampen or mitigate the health effects of this gradient. They found some 
evidence that the age-adjusted Relative Risks among men were highest in 
Eastern European countries (2.05 [95% CI = 1.57 to 2.68]), intermediate in 
the UK (1.73 [1.23 to 2.43]), and lowest in Nordic and Western European 
countries (1.37 [1.08 to 1.66]).(12) Although the confidence intervals 
overlap somewhat to preclude the possibility that this could not have 
occurred by chance alone, these are nonetheless consistent with the 
wider literature that supports the following theory: that countries with 
higher levels of income inequality are less able to protect their most 
vulnerable people (as measured by relative educational status) from 
experiencing higher Relative Risks of CVD. 
 
Even if the Relative Risk between education and CVD were constant 
between different countries, then it’s important to observe what happens 
when some countries have higher baseline risks of CVD than others. For 
example, Chapter 1.3 will detail how rates of CVD are higher in Eastern 
European countries when compared to Western European countries. 
Seeking to reduce health inequalities in one Eastern European country 
would accordingly prevent more disease and create larger net benefits to 
population health, when compared to an equivalent intervention in a 
similarly sized country in Western Europe. If indeed the Relative Risks are 
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larger in Eastern European countries, then this creates an additional 
reason to focus efforts at such high-need areas. 
 
To demonstrate this, the MORGAM investigators have also presented the 
Slope Index of Inequality (SII). This measure presents the absolute 
difference in heart disease between least and most educated tertiles, and 
is sensitive to differences in baseline rates between country cohorts. Their 
analysis reports how in men, the SII of CHD mortality was much higher in 
Russia, Lithuania and Poland (321 [95% CI = 150 to 483]) when 
compared to Germany, France and Italy (44 [95% CI = -6 to 89]). A similar 
but weaker pattern was seen for women (72 [95% CI = 1 to 134]; and 31 
[95% CI = 5 to 56], respectively). The conventional cardiovascular risk 
factors accounted for just one third of the association between education 
and incidence of CHD.  
 
Another methodological approach is to examine mortality certificates and 
link these to educational attainment described in other registries, after 
which case-control analyses could be conducted. Mackenbach et al. did 
this systematically for 22 European countries for deaths occurring near the 
year 2000.(13) They looked at over 3 million deaths, of which 
approximately half occurred in Central European countries, and a further 
140 000 occurred in the Baltic States. This made the study sufficiently 
powered to examine, for the first time, whether the higher baseline rates of 
disease seen in the Baltics may be linked to larger and steeper 
socioeconomic gradients in health, as measured by absolute and relative 
metrics, respectively.  
 
The study findings were consistent with both of these hypotheses. In 
absolute terms, the age-standardized mortality rate was about 40% higher 
in the Baltic States, when compared to Central European countries 
(Slovenia, Hungary, Czech Republic, Poland). The absolute educational 
gradient (measured by SII) was larger in the Baltics, being about 20% 
larger for all-cause mortality and 20% larger for CVD mortality. This 
gradient was larger for deaths from injury, alcohol and causes strictly 
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amenable to healthcare. However, deaths from these three causes are 
altogether less common than deaths from CVD. Although these three 
other causes of death serve useful indicators of differential underlying 
processes, in themselves they are unlikely to explain international 
differences in life expectancy in this region. 
 
The Relative Index of Inequality (RII) is similar to conventional Relative 
Risk or Odds Ratio metrics, but is additionally able to account for 
international differences in the prevalence of a given category of 
education and differential category widths between countries. Results for 
male mortality are shown in figure 1. This shows strong statistical 
evidence in favour of the hypothesis that the association between 
education and mortality is much larger in Central/Eastern Europe, when 
compared to Western Europe, and that this is not only a reflection of 
higher baseline rates in this region, but is rather a reflection of higher 
relative rates in this region.  
 
 
Figure 1. Relative index of inequality (RII), showing the association 
between low education and all-cause mortality.  
High educational attainment is the reference category with RII of 1.0. 
Reproduced from (13). 
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Bobak et al. developed and applied a novel approach to collecting case-
control data, whereby data on participants who had died was recalled by 
their spouses in one study,(14) and siblings in another study.(15) In both 
cases, educational attainment was associated with all-cause mortality, 
even after adjustment for marital status, smoking and alcohol.  
 
The handful of Eastern European studies discussed above did not collect 
data about conventional cardiovascular risk factors, such as blood 
pressure and cholesterol. These could plausibly serve to mediate the risk 
from socioeconomic status to CVD (as has been investigated by many 
studies from non-Eastern European countries). The first study to measure 
these in an Eastern European country was an extension of the WHO 
MONICA cohort in Novosibirsk, Russia.(16) In this study, education was 
associated with all-cause mortality. These associations attenuated to a 
small degree following adjustment for the conventional cardiovascular risk 
factors, but no further following additional adjustment for marital status.  
 
Previous analyses of data from the Health, Alcohol and Psychosocial 
factors In Eastern Europe (HAPIEE) study have also shown that the 
magnitude of association between education and all-cause mortality did 
not differ substantially between the four countries of the study (Russia, 
Lithuania, Poland, Czech Republic).(2) These findings are consistent with 
earlier prospective studies conducted in Russia.(16-18) Altogether, the 
current body of evidence suggest that the relative association between 
education and mortality is likely to be larger in Eastern European 
countries, but it is probably unlikely to vary within Eastern European 
countries.  
 
1.1.2.4. Possible mechanisms  
The potential mechanisms that might mediate the association between 
education and CHD, if indeed some of this is causal, have received 
considerable study. Again, this is a huge body of literature and I will not 
attempt to cover this comprehensively. As a brief summary, traditional 
observational associations have estimated that the association between 
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education and CHD attenuates by around 30-45% after statistical 
adjustment for health behaviours and conventional cardiovascular risk 
factors (including smoking, blood pressure and cholesterol).(8) However, 
these inferences have a wide margin of error, which can come from 
primarily two sources. First, models may be mis-specified, for example if 
confounders of the mediator-outcome association are omitted. This can 
bias the quantity mediated in either direction.(19) Second, any 
measurement error in the mediator would bias the amount mediated down 
towards zero.(20) Indeed, it has been shown that by measuring the 
mediators at two time points and modelling these as time-dependent 
covariates, this can further increase the amount of attenuation to nearly 
100% for all-cause mortality. However, even after such a correction, the 
fraction mediated for CVD mortality increased only from 29% to 45%. 
Other studies have investigated the potential for psychosocial factors, 
inflammatory markers and/or healthcare behaviours as possible 
mediators. To date, the available evidence base suggests that these 
factors may account for a small part of the relationship between 
socioeconomic factors and CVD. It is possible that novel mediators remain 
to be discovered.  
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1.1.3. Material deprivation 
1.1.3.1. Scope 
Material deprivation has been defined generally as the inability for 
individuals or households to [potentially be able to] afford those goods and 
activities that are typical in a society at a given point in time, irrespective 
of people’s preferences to [and actual consumption of] these items.(21) By 
definition, this makes comparing findings across time and place difficult, 
since the questionnaire themselves must be tailored to each time/place 
context. Typical items in such questionnaires involve a mixture of 
consumables (e.g. heating, utilities), more durable household assets (e.g. 
ownership of house, car, TV, washing machine), and some dimension of 
cash flow stability and/or reserves with which to prevent interruptions to 
what we might consider to be fundamental expenditure (e.g. recently 
foregone food/clothing due to unexpected shortfall in income, or due to 
unexpected expenditure).  
 
Some investigators have used a single-item question as a proxy for 
material deprivation (e.g. car ownership, house ownership or gravestone 
height).(22) Others have used anthropometric short stature/height as a 
proxy for early childhood stunting from presumably nutritional deficiency 
stemming from material deprivation. However, as societies develop and 
stunting becomes less common, this renders the inter-individual variation 
of height under increasing genetic influence. Furthermore, height is 
socially patterned, and the genetic determinants of height appear to also 
associate with heart disease.(23) These nuances present a range of 
mechanisms by which height may be a problematic proxy of material 
deprivation. Perhaps for these reasons, it is less common in inventories 
used in recent decades of research. I will focus on studies where material 
deprivation is calculated as a composite, derived from more than one 
underlying item. 
 
Literature searches for “material deprivation” primarily result in studies 
where exposure is operationalized at the area level. Further to the 
features already identified above, some of these measures additionally 
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incorporate area-level items on employment and social isolation. This 
suggests that literature on area-level material deprivation is sometimes 
trying to describe a higher-order construct, which can be thought of as an 
average of multiple psychosocial and socioeconomic factors aggregated 
across multiple individuals. Perhaps, these analyses are sometimes 
presented since such area-level data is more readily accessible to 
researchers. Since the data used in this thesis uses only individual-level 
data, I will refrain from summarizing this voluminous area-level literature. 
Instead, I will summarize the comparatively smaller literature where 
material deprivation has been measured at the individual level, and 
additionally where employment and social status are not part of the 
exposure definition (since these two are addressed in separate sub-
chapters). Measures of income probably overlap substantially with 
measures of material deprivation, but are omitted from this thesis to 
facilitate a focused review.  
 
I found surprisingly few studies that associate individual-level material 
deprivation with a mortality or cardiovascular outcome. Few of these are 
from upper-middle or high-income countries, perhaps since the pace of 
material growth has overtaken the pace of inventing and calibrating new 
questionnaires. Theoretically, the advertisement industry should supply 
plenty of inspiration for the content for new potential questionnaire items 
(e.g. Does your car have air conditioning/cruise control; Do you pay extra 
every month for specific TV channels/ online TV content? Does your 
mobile phone have unlimited data? How often do you eat out? How much 
you normally spend on a pair of shoes? How often in the past 3 years 
have you left your continent? Have you ever used a payday loan 
service?).  
 
1.1.3.2. Relative versus absolute deprivation 
There is a debate about whether socioeconomic factors, such as material 
deprivation, exert their influence in an absolute or relative manner (as 
discussed in chapter 1.1.2.3). A policy which shifts or reduces the average 
level of material deprivation without altering its distribution would improve 
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health only in the presence of causal effects from absolute deprivation, but 
not in the presence of causal effects from relative deprivation. It has been 
suggested that the effects of absolute deprivation may be more 
pronounced in lower income countries, while the effects of relative 
deprivation may be more pronounced in higher income countries.(22, 24) 
Although the evidence base to support this remains limited at current, if 
expanded then this may have important policy implications. For example, 
perhaps lower income countries are right to focus on increasing average 
material growth, while higher income countries might improve health 
quicker by shifting focus away from average economic growth toward 
reducing socioeconomic inequalities. To date, such research has focused 
on area-level measures of inequality, such as the GINI index of income 
inequality.(25) Such research could be complemented, in the future, with 
novel individual-level studies using self-reported perceptions of relative 
inequality (particularly for high-income countries), which appear 
comparatively lacking to date. 
 
Some researchers have attempted to divide material deprivation into 
absolute and relative sub-domains. This is sometimes motivated by the 
view that absolute deprivation pertains more to objective measures of 
severe poverty, while relative deprivation pertains more to subjective 
reports of the absence of socially-desirable more luxury items. 
Vandenheede et al. used data from the HAPIEE study, and allocated 
“difficulty buying food” as a proxy for absolute deprivation, while amenities 
that lean towards the luxury scale (microwave, video recorder, colour 
television, washing machine, dishwasher, freezer, camcorder, satellite TV, 
telephone and mobile phone) represented relative deprivation.(2) Along 
similar lines Perlman at al. created a first index of luxury durable goods 
(colour TV, video cassette recorder, car, washing machine, country cabin), 
and a second index of basic utilities/amenities (central heating, central 
water supply, running hot water, centrally supplied gas, and central 
sewage).(17) Along similar lines, Pikhart et al. created three indices to 
reflect ownership of “basic needs” (a proxy for absolute deprivation), 
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“socially oriented” and “luxury” items (as proxies for relative 
deprivation).(26) 
 
1.1.3.3. Future prospects for extending and improving this construct 
It appears that decisions about which items to place into which sub-
domain, and how these should be named, have predominantly been done 
quite subjectively with limited inter-investigator agreement, theoretical 
basis, or empirical justification. An empirical way to improve this could be 
to borrow the main approach of psychometrics, and conduct a Factor 
Analysis (i.e. Principal Component Analysis). This could explore the 
covariance patterns of the underlying items, and derive higher-order 
facets that are less collinear with each other. This bottom-up approach 
could allow higher-order items to be empirically named and 
conceptualized. However, one challenge would be to derive 
questionnaires and higher-order facets that remain stable despite 
substantial cultural variation manifest across time and place in terms of 
desirable commodities. Perhaps with the spread of globalization, much of 
this variation could effectively be collapsed into a linear axis of economic 
development. 
 
1.1.3.4. Associations with all-cause mortality 
Bobak et al. used an indirect case-control technique, whereby data about 
participants who had died were retrospectively recalled by the participant’s 
partner. Ownership of three luxury items (colour TV, video 
recorder and car) predicted all-cause mortality.(14) This was not 
attenuated after adjustment for education, suggesting that material 
deprivation may be an important risk factor over-and-above education (at 
least in Eastern Europe). 
 
Perlman et al. found that luxury goods were not associated with mortality, 
while greater basic amenities were associated with a lower risk of all-
cause mortality in men (HR 0.95 [95% CI = 0.91 to 0.99] per each 
additional item, in the age adjusted model.)(17) This association became 
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insignificant once education was adjusted for, suggesting that education 
may be the strongest socioeconomic predictor of mortality in countries like 
Russia, and that it’s pathway of effect may potentially overlap in part with 
that from material deprivation.  
 
In the same study, an alternative dichotomous measure of more extreme 
poverty was asked with “Have you had to sell goods [to make ends 
meet]”. This was consistently associated with mortality (HR = 1.75 [95% 
CI = 1.17 to 2.63]), with no attenuation following adjustment for education. 
This suggests that some measures, such as extreme poverty, might have 
independent effects that are orthogonal to conventional measures of SES. 
However, as this particular exposure was very rare (3.5%), this is unlikely 
to have large effects on populations as a whole.  
 
Vandenheede et al.’s measured absolute material deprivation (foregone 
food because of financial trouble) was more prevalent in the HAPIEE 
study: 6%12%, 20% and 33% for men in Lithuania, Czech Republic, 
Poland and Russia, respectively.(2) Associations with all-cause mortality 
were consistently high, with hazard ratio point estimates ranging from 1.5 
to 2.3 across the four countries. There appeared to be no effect 
modification by varying the prevalence of exposure (e.g. by stratifying data 
from Russia Vs. elsewhere). This supports the theory that individuals 
make relative comparisons to their peers, and it is this subjective feeling of 
relative deprivation that may be harmful.  
 
Vandenheede et al.’s measure of relative material deprivation found 
weaker effects when comparing the middle group against the most 
privileged group (HR point estimates ranged from 1.1 to 1.4), and larger 
effects when comparing the middle group to the most deprived group (HR 
point estimates from 1.9 to 2.5). This is consistent with an explanation of 
non-linear effects, which has otherwise been seldom addressed in existing 
literature of material deprivation.  
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In cross-sectional studies, the association between material deprivation 
and self-reported health disappeared after adjustment for education in one 
study,(27) and perceived control in another study.(28) The authors 
speculated that material security may enhance general psychological well-
being and control, which may subsequently improve health. However, the 
alternate pathway is equally plausible: that individuals with a low sense of 
control struggle to obtain income and material resources, particularly in 
challenging times such as during a transition from communism towards a 
deregulated economy. A third study found little attenuation of the 
association between various measures of material deprivation and self-
reported health, after additional adjustment for perceived control.(26) 
 
To conclude, there are comparatively few studies that investigate whether 
material deprivation (measured at the level of the individual not area, and 
using multiple items) is associated with all-cause mortality. This is evident 
from an absence of quantitative reviews and meta-analyses on this topic. 
Furthermore, I am not aware any prospective reports associating 
individual-level material deprivation with cardiovascular outcomes from 
any country in the world. The few studies to date might suggest that 
absolute deprivation could be a stronger predictor of all-cause mortality in 
countries with a high prevalence of absolute deprivation, whereby high 
deprivation could, in turn, stem from either lower average economic 
development (e.g. Russia) or higher inequality in otherwise developed 
countries (e.g. USA). In Western European countries where absolute 
deprivation is less common and baseline rates of disease lower, relative 
deprivation might rise to become a more important risk factor. While these 
dimensions appear to be partly overlapping and partly orthogonal to other 
measures of socioeconomic position, their effect sizes have rarely 
equalled that of education. It is unclear whether this is due to greater 
measurement error when measuring material deprivation, or whether 
education is actually a more important predictor of health when compared 
to material deprivation. There is very little literature on how any putative 
causal effects from deprivation to disease might be mediated.  
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1.1.4. Unemployment 
Other measures of socioeconomic status, not covered in this literature 
review, might include occupation and the status and prestige associated 
with it. One of the extreme categorizations of this might be a binary 
classification of whether one is unemployed or not. This is not a 
socioeconomic variable in the conventional sense, particularly since 
episodes of unemployment tend to be transient. However, such episodes 
are nonetheless acutely stressful, potentially on a number of levels (e.g. 
the material loss of income and living conditions, the sudden change in 
social prestige and work-related social support, as well as psychological 
uncertainty, worry and anxiety about the future). 
 
Moser et al. were perhaps the first to demonstrate an association between 
individual level unemployment and all-cause mortality in 1984.(29) A 
recent meta-analysis of 42 studies reported unemployment to associate 
strongly with all-cause mortality at HR = 1.63 [95% CI = 1.49 to 1.79]. 
Hazard ratios were twice as large in men (1.78) when compared to 
women (1.37), and especially heightened for the youngest men (age < 40 
HR = 1.95;  age 40-49 HR = 1.86;  age > 50 HR = 1.17).(30)  
 
Some studies have suggested that the policy context may influence the 
effect size, with effects being bigger in countries with fewer social 
protections in case of unemployment (such as the USA).(31) This is 
consistent with observations of slightly higher point estimates from Russia. 
One prospective study reported a Hazard Ratio of all-cause mortality as 
1.88 [95% CI = 1.38 to 2.55](32), while another case control study found 
the Odds Ratio for CVD mortality to be 2.55 [95% CI = 1.44 to 5.00].(33) 
In the latter study, unemployment and education did not attenuate 
substantially after mutual adjustment for each other and marital status, 
while the hazard ratio for marital status attenuated to null. 
 
However, as the evidence of effect modification by country context 
remains rather circumstantial, alternative explanations could also be 
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considered for such heterogeneity. For example, the meta-analysis cited 
above found that the following methodological features of the study can 
account for heterogeneity in the final point estimate: age- and gender-mix 
of the sample; follow-up time (whereby hazard ratios were smaller after 
the 10th year of follow-up); and choice of comparison group (i.e. employed 
persons Vs. general population samples, including retired persons).(30) It 
is possible that the studies which reported higher point estimates (from 
Russia and the USA) were merely confounded by some of these above 
factors. In comparison to this literature for all-cause mortality, literature on 
cardiovascular outcomes is sparse and lacking a systematic review.  
 
One interesting question is whether it is the total time spent unemployed, 
or the number of transition spells, that associates most strongly with 
health. A large study published in 2012 compiled detailed retrospective 
employment histories of each participant, and regressed various 
unemployment constructs against subsequent self-reported MI incidence 
(1061 events).(34) They reported a clear dose-response effect with the 
number of unemployment spells. The Hazard Ratio was 1.22 for just one 
spell of unemployment, and this increased with each unemployment spell 
until a Hazard Ratio of 1.63 was observed for those with four or more 
spells of unemployment. In contrast to this, measures of the number of 
years spent being unemployed showed a non-significant trend in the 
opposite direction (HR 1.27 for up to one year of unemployment, 0.9 for 
more than five years of unemployment). If these associations denote 
causal effects, then this is consistent with the theory that the acute phase 
of transition is more harmful than sustained chronic unemployment, 
perhaps due to the psychological uncertainty and psycho-neuro-
immunological adaptive demands that such events bring.  
 
These data are also compatible with the theory that reverse causation is 
unlikely to drive the observed associations: it is more plausible for the 
latently ill to remain chronically unemployed without transient episodes of 
employment. However, in this study such presumably latently ill and 
chronically unemployed people did not have an increased incidence of MI. 
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In their discussion, the authors posit an effective comparison to other 
cardiovascular risk factors: although single time-period measures of 
current smoking and diabetes status predict MI adequately, evaluating 
their cumulative toll over time using time-dependent measures (such as 
“pack years of smoking” and “HbA1C”, both already used in routine clinical 
practice) allow for more precise quantification of the strain from these 
factors to the cardiovascular system. It is plausible that the same analogy 
could apply for transitions to unemployment, where measures of 
cumulative historic exposure (perhaps quantified by unemployment 
episodes, as opposed to the number of years unemployed) are stronger 
predictors than snapshots of current exposure.  
 
As an alternative putative confounder, frequent unemployment spells 
might instead be a marker of employment instability, which could be 
caused by poor team working ability and personality traits that might 
predispose towards that. For example, high neuroticism is associated with 
both the incidence of CVD and all-cause mortality, and could putatively 
cause more frequent unemployment episodes.(35) I am not aware of any 
study where personality and unemployment were both mutually adjusted 
for. 
 
Further to this study above, there have only been a handful of prospective 
unemployment studies were the outcome is the incidence of CVD. 
Nonetheless, these studies have been of good quality, size and 
consistency in their findings.(36, 37) Such associations were attenuated 
only partly following reemployment.(38) Although the association with 
disease incidence appears to be largest in the immediate year following 
unemployment and begins to decline thereafter, a statistically significant 
hazard can still be detected even decades after the primary event, 
supporting the notion that one unemployment event may lead to 
permanent “scars”.(39) It is also plausible that persons who never 
experience unemployment, but who frequently change the colleagues, 
location or type of their work they do, might have higher mortality when 
compared to those who remain employed in more stable circumstances. 
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Altogether, this small but consistent evidence base around health 
suggests a value system which is completely at odds with the value 
system of mainstream economic theory. There, high labour market 
turnover (and more unemployment events) are typically praised for 
delivering greater market efficiency, while most aversion is given to 
persistently high unemployment (for example, by monitoring national rates 
of unemployment). Better quantification of the health consequences of 
each unemployment event, as well as job-to-job transitions where formal 
unemployment is avoided, might inform and correct the perhaps excessive 
appreciation currently placed on high labour market turnover in economic 
discourse and subsequent public and political opinion. 
1.1.4.2. Mechanisms 
When the meta-analyses above compared age-adjusted models to fully 
adjusted models, then there was no attenuation in the magnitude of 
associations between unemployment and CVD. This suggests that, if 
some part of the association between unemployment and health is causal, 
then health behaviours are unlikely to account for much of this pathway. 
This observation is particularly pertinent to Eastern European countries 
like Russia, where those who are unemployment tend to drink more 
alcohol.(40, 41) One plausible mechanistic pathway would be for 
upstream macroeconomic stressors (e.g. privatization) to cause 
unemployment and psychological stress among those left in work, both of 
which themselves may cause an increase in alcohol consumption among 
both unemployed and employed persons. Each of these four factors 
(privatization, unemployment, fear of being made redundant, alcohol) may 
precipitate premature mortality. This is supported by indirect retrospective 
cohort data from the PrivMort study, where privatization, unemployment 
and alcohol consumption were all independently associated with all-cause 
mortality.(42) More specifically, it might be hypothesized that a part of the 
effect from unemployment to mortality could be mediated via alcohol, 
particularly in Eastern European countries. This hypothesis has yet to 
receive a standalone paper, since the published papers from Eastern 
Europe have focused on the primary effect from privatization or alcohol, 
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and so a more formal mediation analysis has not been explored. However, 
preliminary data from PrivMort appears not to support this hypothesis. The 
primary association between unemployment and mortality in simpler 
models adjusted only for education, occupation and town-level 
privatization (Incidence Ratio = 1.32 [0.94-1.70] in men and 1.56 [1.02-
2.37] in women) was not attenuated at all following additional adjustment 
for alcohol consumption and other variables (Incidence Ratio = 1.40 [1.08-
1.81] in men and 1.57 [1.04-2.39] in women). Accordingly, the preliminary 
data from Eastern Europe suggests that alcohol consumption is unlikely to 
be a mediator of the primary association between unemployment and 
mortality. However, this topic has received very little dedicated study.  
 
One analysis from the Great Recession suggest that in the USA (but not 
in Europe, perhaps on account of better unemployment protection 
policies), those on lower incomes were particularly vulnerable to increased 
depression following unemployment, while those on higher incomes did 
not show such an association.(43) However, in this study the absolute 
increase in depression symptoms over time was very small (3-5%) and 
hence unlikely to account for much of any putative pathway from 
unemployment to health. As thus, the mechanistic mediators of hazard 
from unemployment remain largely unknown. 
 
To conclude, unemployment has been consistently and strongly 
associated with the incidence of cardiovascular disease, as well as with 
all-cause mortality. This association appears strongest in younger men, 
and when additively counting the number of transition episodes into 
unemployment. Known cardiovascular risk factors (including health 
behaviours, alcohol consumption and depression) appear to account for a 
near-negligible part of this association.  
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1.1.5. Social support 
1.1.5.1. Theory  
Examples of how social connections influence health date back to at least 
one hundred years, when Durkheim described how suicide rates vary 
substantially by an individual’s social context.(44) During the 1970s, this 
concept was broadened into a generalized theory of social support.(45, 
46) Various conceptions of social support have been operationalized for 
the study of social epidemiology, such as the structural dimensions of a 
country (e.g. culture, inequality, public policy, social change), as well as 
the nature of social networks (e.g. their size, homogeneity, geographical 
spread, mode of communication, and reciprocity).(47) At least 
theoretically, the strict interpretation of such concepts is to study them at 
the aggregate level. For example formal network analysis requires 
bidirectional knowledge about whether person 1 and person 2 both agree 
that they believe to be friends.(48) Such aggregate measures are 
relatively difficult to construct and require distinct methodological 
approaches, so are considered beyond the scope of this review.  
 
Nonetheless, various individual-level constructs exist that also include the 
word “Social Network” in their name.(49) Detailed discussion of these 
nuances can be found in the textbook by Berkman and Kawachi.(47) From 
a theoretical perspective, individual-level constructs of “Social Network” or 
“Social Networked-ness” might be best categorized alongside other 
individual-level concepts, interchangeably named along the lines of social 
ties, social relationships, or structural social support. Most commonly, 
these are typically derived from self-reported levels of contact with 
approximately four groups of people: 1) a close partner such as a spouse 
(for which marital status is a non-intrusive proxy),   2) friends   3) family 
members outside the household, and   4) wider community groups (incl. 
trade unions, charities, church groups and professional bodies), also 
known as loose ties.  
 
The presence of structural social support may influence an individual’s 
health through various mechanisms, perhaps most importantly by how 
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related others provide functional social support to the index individual 
during their times of need. From the other side, of those providing social 
support, such participation has been called social engagement or social 
influence.(48) A range of constructs are available to measure these 
functional domains, but they are again beyond the scope of this review. 
Thus I will use the term social support to denote structural social support 
at the individual level, as measured by self-reported questionnaires. 
 
The word support in the phrase social support might denote that the index 
person experiences some stressor, is in acute or chronic need, and 
following this receives social support from others, which acts to 
compensate. This framing suggests that, social support would provide 
negligible benefit to those who experience few stressors. It also excludes 
the notion that the index person is engaged and supplies social support to 
others. To me, such a conceptualization resembles an inherently 
individualistic view of the human condition. Namely, strong individuals who 
are able to look after themselves have no intrinsic need for social relations 
and the benefit that this might otherwise provide. Social support becomes 
useful only for those who are unable to cope by themselves, denoting an 
interaction between perceived stress or perceived low self-efficacy. When 
we look at marital status for example, then this view might be partly 
supported by the observation that divorce rates and independent living 
may have increased over the past decades alongside increments to 
average material wealth. However, against this view argues the 
observation that even those individuals of high privilege, wealth and/or 
self-efficacy tend to still form pair-bonds, suggesting that the tendency to 
form social relationships may be more fundamental (perhaps partly innate) 
whose purpose may stretch beyond merely providing and receiving 
functional aid for those in need.  
 
When these concepts were first mentioned in the 1970s, it was frequently 
assumed that social support buffers and protects against the harm from 
life stressors.(50) However, there has been very little empirical support for 
this notion of interactive effects. Nonetheless these early thoughts around 
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interactions may have influenced the thinking of Karasek, who proposed 
that job stress emerges as an interactive function of high demands and 
low control at work.(51) Job stress itself is beyond the scope of this 
review. However, some studies have investigated whether job stress 
interacts with limited social support as provided by co-workers, and found 
some data to support this.(52) Although such observations have led to a 
range of proposed theories and models, it should be noted that these 
observations have not always replicated.(53, 54)  
 
If such proposed interactive effects do not exist, then it is plausible that 
social support may exert a homogenous effect, at all levels of life 
stress.(55) It could be posited that humans are intrinsically social 
creatures who require and benefit from social relationships, regardless of 
their level of self-efficacy or perceived stress. As thus, social relationships 
may exert their benefit not only via social support received from others, 
but also from the action of providing social support to others. Taking a 
more long-term view of human history and the human condition across a 
wide range of cultures, the transactional model described in the previous 
paragraphs (where social support interacts with stress) might merely be 
one of the manifestations of the pervasive influence of individualistic, 
transactional, non-committed and business-like manner in which 
economic concepts (such as utility self-maximization) have permeated our 
latent cultural norms and also social epidemiology. An alternative view of 
the underlying human condition, one often favoured by anthropologists, is 
that the mere act of interacting socially (regardless of any transactional 
need to do so, or functional utilities exchanged therein) reinforces the 
concept of belonging to some entity greater than the self, thereby 
enhancing subjective well-being.(56) If true, this might denote that the 
commonly used phrase “social support” might be best replaced with 
something broader, such as social ties, relations, connections or 
existence. This suggestion withstanding, as the term social support is 
relatively common in the existing epidemiological literature, I too will use 
the term “social support” in most instances hereafter. 
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The various mechanisms by which social support could influence health 
could perhaps be grouped into three broad headings, although again the 
evidence base behind this is extremely limited. Best understood are health 
behaviours, perhaps as these are most commonly measured. A second 
putative pathway is cognitive changes, particularly changes to subjective 
well-being and depression. Finally, adjustments for the above two have 
not always attenuated the relationships between social connections and 
health. While this might well be simply a reflection of measurement error 
in the mediators, a third set of unknown pathways have also been 
proposed that might be called physical-biochemical. This incorporates 
various psychoneuroendocrine alterations to the Hypothalamus-Pituitary 
Axis (possibly orchestrated by cortisol), subsequent inflammation, and 
cardiovascular reactivity. These novel biomarkers have been incorporated 
with existing cardiovascular biomarkers (e.g. blood pressure, BMI, 
glucose/HBA1C/diabetes) in a multifaceted measure called allostatic 
load.(57) Such psychoneuroendocrine pathways have been proposed to 
mediate the health hazard of not only social support, but also for many 
other psychosocial and socioeconomic risk factors. 
 
1.1.5.2. Links to CVD 
First, I summarize data from prospective cohort studies on cardiovascular 
mortality, non-fatal cardiovascular incidence, and all-cause mortality. 
Outcomes focusing exclusively on angina are not considered, as both 
exposure and outcome would be prone to self-report bias. The first study 
in 1979 found structural social support to predict mortality from all-causes 
(The reported Relative Risk, across various age and sex strata, ranged 
from 2 to 3 with no confidence interval presented).(49) Since then, 147 
prospective studies contributed data towards a broad meta-analysis.(58) 
This found social support to consistently predict all-cause mortality, 
regardless whether this was measured structurally (OR = 1.57 [95% CI = 
1.46 to 1.70]), functionally (OR = 1.46 [95% CI = 1.28 to 1.66]), or with a 
combination of the two (OR = 1.44 [1.32 to 1.58]). Strongest effect sizes 
were observed when structural social support was measured in a 
multifaceted manner, combining marital status, friends, family and 
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community dimensions (OR of the point estimate = 1.91). These 
associations were only partly attenuated following adjustment for health 
behaviours, implicating the possibility that cognitive or biological pathways 
may additionally be involved. There was no evidence of publication bias, 
but moderate to large heterogeneity among the studies. Just 12 studies 
reported outcomes for CVD mortality, with a suggestion that associations 
may be slightly larger for CVD mortality, in comparison to all-cause 
mortality. Virtually all of these studies were conducted in Western Europe, 
Scandinavia or Northern America. 
 
This broad review merged together studies that included, as well as 
studies that which excluded participants with disease at baseline. Some 
standalone studies have suggested that social support may be more 
important in prognostic studies of those with pre-existing disease.(59, 60) 
This concept has been echoed by some reviews on this topic.(61, 62). 
However, given the scarcity of studies that have excluded participants with 
disease from baseline, there is little statistical evidence to rule out the 
possibility that this difference may have occurred by chance alone. 
Virtually all studies report that men receive more protection from social 
support when compared to women,(63) possibly because social support 
correlates with socioeconomic status only in men.(64) Women tend to 
have larger associations with health outcomes for indices of marital quality 
as opposed to men for whom simple marital status has larger 
associations.(65) This is just one example of the large volume of research 
that has been conducted in Western countries around marital status and 
health. Further nuances like these are beyond the scope of this review. 
 
One of the largest studies, where prevalent cases were excluded from the 
baseline sample that were followed up for nonfatal CVD, was conducted in 
the USA. The study was plausibly designed to detect the largest 
associations, by sampling men not women, and by using a multifaceted 
instrument of structural support. At 4 years of follow-up, social support 
was associated with the incidence of non-fatal stroke (91 events) but not 
with non-fatal MI (275 events).(66) This did not change at 10 years of 
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follow-up (618 non-fatal MI events).(67) However, this study sampled only 
health professionals, which is not particularly representative of the general 
population. On the one hand, this group of participants might be relatively 
better protected from stressors that threaten income, job security or 
status, suggesting that they may have low need for social supports 
(according to a transactional, buffering model as discussed in section 
1.1.5.1). On the other hand, health professionals tend to work in a more 
reactive and acute setting, where witnessing the suffering of others might 
provoke more stressful workplace experiences than that seen in the 
general population. As a second weakness, it is possible that those with 
least social support would incur a longer delay before presenting for 
medical attention following a non-fatal MI, leading to differential 
misclassification of the outcome and bias towards the null. Another study 
tried to overcome this limitation by using carotid ultrasound data, to obtain 
objective measures of disease. They recruited women, and found marital 
quality to not associate with future subclinical atherosclerosis.(68) Finally, 
one Swedish study found the unadjusted Relative Risk of low social 
support to be 1.53 (95% CI = 1.02 to 2.28), in associating with a 
composite of fatal or nonfatal MI.(69) This effect size rose to 2.40 (95%CI 
= 1.36 to 4.25) when restricting the sample to men whose behavioural 
response was characterized as maladaptive to a stressful test. This 
suggests that true interactions, between social support and other 
personality or stress characteristics, might exist for cardiovascular 
outcomes. However, the latter example was based on an analysis of a 
subgroup with just 32 events, making chance and publication bias an 
equally plausible explanation. 
 
In Eastern Europe, analysis of routine WHO mortality data does not allow 
for the adjustment for confounders and the exclusion of prevalent cases 
from baseline. Nonetheless, using this data single marital status has been 
a strong predictor of CVD mortality. The magnitude of the point estimates 
appears to have increased following the breakup of the Soviet Union.(70) 
Bobak et al.’s case-control study, using data from siblings, found marital 
status to associate with all-cause mortality, even after adjustment for 
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education and smoking.(15) This study also found a trend whereby 
participants who saw their sibling on a daily/almost daily basis appeared 
to have a lower risk of mortality, whereby this association too did not 
attenuate after adjustment for education and smoking. The MONICA-
Novosibirsk study also found marital status to associate with all-cause 
mortality, even after adjustment for conventional CVD risk factors and 
education.(16)  
 
Qualitative research has suggested that the family institution (and 
particularly resourceful wives) became a central coping mechanism during 
the Soviet period, which helped to counterbalance the psychological 
frustration and stress of being in an inflexible and unsuccessful political-
economic system. In particular, the importance of family connections to 
gain access to goods and services that were in short supply, became 
increasingly acceptable in Soviet culture. This provided a material 
pathway via which family support could have boosted health.(71) After the 
transition of the 1990s, the newly embedded capitalist system has sought 
to replace a culture of nepotism with a culture where access to resource is 
determined by need, merit and/or purchasing ability. However, my own 
anecdotal experience in Estonia suggests that family connections are still 
used to allocate preferential access to taxpayer-funded healthcare 
resources as late as in 2017 – something which is rarely seen in Western 
countries like the UK. This observation might suggest that some of the 
associations between social support and health may not be entirely 
generalizable or replicated between countries from Easter and Western 
Europe.   
 
To conclude, there are many operationalizations of social support, each 
associated with health. In general population settings, social support has 
consistently been shown to predict all-cause mortality and CVD mortality. 
Social support appears to be particularly protective after the diagnosis of a 
cardiovascular condition, but its role in the preceding period (among 
otherwise healthy participants) has been less studied. Measuring social 
support as a time-varying confounder may increase its strength of 
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association with health outcomes. In Eastern Europe, marital status has 
consistently been associated with CVD mortality. However, the other 
dimensions of social support (such as contact with friends and relatives) 
have been less studied. To my knowledge, no study from any country has 
investigated whether the negative health association from single marital 
status can be offset by support from other domains (such as frequent 
contact with friends/relatives), or whether alternatively, these facets of 
social support are fully independent of one another. 
 
 
1.1.6. Personality traits 
Objective measures of personality might be defined as interrelated 
tendencies in thought, feeling and behaviour. They have traditionally been 
studied by psychologists interested in inter-individual variation 
(psychometricians). Personality may be further subdivided into heritable 
temperament, and acquired character, although most research 
operationalizations ultimately merge these two. Personality is thought to 
be relatively stable over time, in contrast to depression which has a more 
fluctuating course. It is plausible that various external stimuli combine and 
interact with personality, to create responses (such as depression or 
distress) that are more or less conductive for health.  
 
1.1.6.1. Personality types 
Personality can be conceptualized categorically as types, or continuously 
as traits. During the 1970s and 1980s, the Type A personality type was 
found to be associated with cardiovascular disease.(72) This was picked 
up by the general media and much of public discourse. However, these 
early associations, which were done often on smaller datasets, were not 
subsequently replicated. Despite this initial setback, one of the three 
components of Type A, namely anger and hostility, has been consistently 
associated with CVD in a meta-analysis of 25 studies, to a modest degree 
(HR = 1.19 [95% CI = 1.05 to 1.35]).(73) However, this association 
attenuated substantially following full adjustment for other conventional 
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and psychosocial risk factors. One RCT recruited type A patients with a 
recent diagnosis of AMI, and modified their hostility, anger, and 
depression, self-efficacy and well-being. This was reported to double their 
survival rate [CI].(74) This leaves possible the interpretation that this 
particular dimension of hostility is indeed a causal and modifiable risk 
factor for heart disease progression, and perhaps also aetiology. It might 
help to consider measuring this concept not as a discrete type as in the 
past, but also as a continuous scale, in future studies. 
 
 
1.1.6.2. Personality traits (and factors) 
Personality traits are measured by asking participants to self-report their 
tendencies (of thought, feeling and behaviour) along multiple items, which 
are weighted and combined to create normally distributed traits with a 
particular and intuitive meaning. Many personality traits are highly 
correlated, and the comprehensive interrogation of these (in Factor 
Analysis, similar to Principal Component Analysis),(75) has allowed most 
psychometricians to conclude that after considering around 30 traits, 
these load onto five mutually independent personality factors [which I 
have further annotated here in brackets]: Openness to [new] 
experience[s], Conscientiousness [and perfectionism], Extraversion [and 
sociability], Agreeableness [in wishing to please others], and Neuroticism 
[with a pessimistic outlook].(76-78) 
 
One individual-level meta-analysis of 3947 deaths found only 
conscientiousness to predict all-cause mortality (lowest tertile HR = 1.37, 
95% CI = 1.18 to 1.58; compared to top two tertiles).(79) In a second 
publication, the authors pooled data from approximately one third of the 
original dataset, to look at associations with 423 CHD deaths.(35) As 
expected, a 1-SD increase in conscientiousness was associated with 
lower CHD death (HR = 0.74, 95% CI = 0.67 to 0.81). Furthermore, a 
second independent association was seen for neuroticism (HR = 1.16, 
95% CI = 1.04 to 1.29), with very little attenuation after adjustment for 
CVD risk factors. A similar association has been reported in the UK Health 
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and Lifestyle Survey between neuroticism and CVD mortality (576 
events), as well as CHD mortality (314 events), but not in a Japanese 
cohort with just 90 CHD deaths (80), nor in a sub cohort from the original 
Whitehall study.(81) As one putative mechanism, a meta-analysis of 6 
studies found IL-6 to be associated with conscientiousness, but not with 
neuroticism.(82) However, it might be difficult to tease apart the sequence 
of cause and effect: an alternative explanation is that parental SES 
causes lower IL-6 (perhaps via parenting, diet, stress and/or direct genetic 
effects), which in turn increases (or is merely correlated non-causally) with 
conscientiousness. 
 
One area which these two meta-analyses may have overlooked is that a 
smaller trait might be more specific than a larger factor, in predicting CVD 
(much how we saw in the example of anger/hostility being more specific 
than Type A personality). For example, low perceived control and negative 
emotionality are both part of the Neuroticism factor; just how Sociability, 
Optimism and [physical- / hyper-]activity are all parts of Extraversion.(83) I 
am not aware of a sufficiently sized analysis which has screened all 20-40 
underlying factors for their association with CVD. This may be difficult to 
do with the existing datasets, as the largest datasets have used very brief 
questionnaire which are insufficient to derive accurate measures of the 
underlying personality traits. 
 
1.1.6.3. Perceived control 
Concepts around perceived control originate not from social epidemiology, 
but psychology (where recent interest has, to degree, been overtaken by 
renewed interest on the big five personality factors). Accordingly, 
epidemiological publications on the topic are relatively sparse. Related 
concept have intermittently been called either perceived control, internal 
locus of control, self-efficacy, sense of mastery, and sense of 
coherence.(84) Control can be measured at various settings, such as 
control over health, work, life or a combination of these. One study found 
that when compared to overall control as measured conventionally, 
stronger associations were reported for all-cause mortality if absence in 
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control was reported over a particular social role that appeared most 
important to that particular participant (e.g. control over being a functional 
spouse, parent, grandparent etc.).(85)  
 
One of the earliest studies from Norway in the 1980s found low control to 
predict all-cause mortality in men but not in women.(86) There was also a 
suggestion of an association with CVD mortality: if exposure was scored 
from 1 to 12, then a one-unit decrease in control was associated with a 
HR of 1.10 [95% CI = 0.94 to 1.28; P>0.05] for CVD mortality. This study 
also found additional associations between measures of social 
participation and CVD mortality. When controlling for these, the control 
dimension attenuated substantially, while associations for social 
participation did not attenuate. Assuming equivalent measurement error 
and causation, this might indicate that perceived control causes social 
participation, which causes a lower risk of CVD. However, as this study 
had only 43 events, this make chance an equivalent explanation for these 
findings. A larger German study in the 1990s found an association 
between a 1-SD lower control and an increased risk of fatal and non-fatal 
MI (HR = 1.33 [95% CI = 1.04 to 1.72]).(87) This did not attenuate at all 
following adjustment for conventional CVD risk factors, other dimensions 
of personality and depression. Neither of these two studies excluded 
prevalent cases from their baseline sample.  
 
A study from the Netherlands found control to associate with all-cause 
mortality, even after adjustment for education (HR = 2.19 [95% CI = 1.03 
to 4.70] for comparing extreme quintiles, with approximately 150 
events).(88) After 5 years of follow-up, the EPIC study found sense of 
mastery to predict CVD mortality (HR = 0.82 [95% CI = 0.72 to 0.93], 
adjusted for health behaviours and various personality traits including 
Neuroticism, in an analysis with 365 incident events), especially among 
those of manual social class in those with low CVD risk.(89) This was 
replicated after extending follow-up to 12 years, where again the 
association was twice as large in lower social classes.(90) Furthermore, 
they reported an interaction with conventional CVD risk factors, whereby 
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those with existing CVD risk factors showed greater associations between 
control and subsequent disease.  
 
In Eastern Europe, one analysis of data from the Polish arm of the 
HAPIEE study found low perceived control to associate exceptionally 
strongly with CVD mortality, even after adjustment for education, marital 
status, hypertension, hypercholesterolemia, smoking, body mass index, 
physical activity or diabetes (HR for quartile 1 Vs. 4 = 2.68 [95% CI = 1.36 
to 5.31] in men and HR = 5.18 [95% CI = 1.17 to 22.96] in women).(91) As 
studies from Western Europe have tended to use other transformation of 
their exposure variable, and furthermore given the large uncertainty of 
these point estimates, it is unclear whether the point estimate of the effect 
size may differ between Eastern and Western regions. 
 
Finally, one of the sub-question of controls, “I often have the feeling that I 
am being treated unfairly” has been associated with incident CHD 
independently of traditional risk factors, job features and employment 
grade (HR = 1.55 [95% CI = 1.11 to 2.17]).(92) However, I am not aware 
of studies that have compared whether unfairness is a stronger predictor 
of health than its larger construct (perceived control), nor its larger 
construct (Neuroticism). 
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1.1.7. Depression  
Clinical depression, also known as Major Depressive Disorder, is a 
common mental disorder, characterized by persistent sadness and a loss 
of interest in activities that you normally enjoy, accompanied by an 
inability to carry out daily activities, for at least two weeks. In addition, 
people with depression normally experience several of the following: a 
loss of energy; a change in appetite; sleeping more or less; anxiety; 
reduced concentration; indecisiveness; restlessness; feelings of 
worthlessness, guilt, or hopelessness; and thoughts of self-harm or 
suicide.  
 
Clinical depression can be thought of as an extreme state along a wider 
axis of mood, with various states of borderline or subclinical features 
before one approaches the average mood of a population. Affect denotes 
the external manifestation of mood, such as a visible smile, while mood 
itself remains a subjective psychological state.  
 
1.1.7.1 Observational epidemiology 
In comparison to the previously mentioned psychosocial and 
socioeconomic risk factors that have been epidemiologically studied for at 
least 30 years if not longer, then the epidemiological study of how 
depression predicts physical disease is more recent. This may be due to 
the clinical separation of “mind diseases” from “body diseases”, making 
links between them appear less plausible to researchers and perhaps also 
funders.  
 
One of the first prospective studies in 1994 identified how depressed 
affect was associated with both fatal and non-fatal CHD.(93) By 2007, a 
meta-analysis of 28 studies confirmed this.(94) They report exceptionally 
high hazard ratios (HR = 2.54 [95% CI = 2.07 to 3.10]) in those whose 
depression symptoms exceed clinical thresholds. The hazard ratio 
dropped to 1.39 (95% CI = 1.26 to 1.54) for those with subclinical 
depression. This observation of dose-response is consistent with the 
overall impression offered by other reviews. One earlier meta-analysis 
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suggested that clinically discrete major depressive disorder exerts an 
additional hazard, even when adjusted for depression symptoms.(95) This 
reflects the potential for a threshold effect: if symptoms cross a given 
threshold of severity (or they last a long time), then this may trigger 
biological system bifurcation, such as changes in various cognitive or 
neuroendocrine systems that alter their long-term set points and 
subsequent control via feedback loops. Such as newly programmed state 
may yield hazard either via cognitive-behavioural pathways (e.g. reduced 
help seeking) or neuroendocrine pathways (e.g. inflammation). Contrary to 
this biological explanation, the medical sociology explanation might posit 
that the act of diagnosing depression attaches iatrogenic stigma and 
otherwise disempowers the patient, which might manifest as greater 
cardiovascular risk. Other studies have found the somatic facets of 
depression (such as hunger, sleep and energy) to have a stronger 
association with cardiovascular disease than the cognitive 
components.(96) This offer more support for the biological interpretation, 
as opposed to the socio-cognitive interpretation. Finally, another study 
suggested that the dimension of hopelessness (which might correlate with 
depression) still exerts a hazard when depression is controlled for.(97) 
This is more consistent with a socio-cognitive aetiology (as opposed to 
biological), but might also denote the possibility of reverse causation. In 
Eastern Europe, the HAPIEE study found depressive symptoms to predict 
CVD mortality similar to reports from Western Europe. A 1 SD increase 
was associated with a HR of 1.20 (95% CI = 1.16 to 1.24) in men and 1.23 
(95% CI = 1.12 to 1.35) in women.(98) 
 
1.1.7.2 Experimental studies 
If depression causes heart disease, then using antidepressants (among 
those with or without depression) could prevent heart disease. The data to 
support this is limited. When studying healthy participants observationally, 
then confounding in such data presents perhaps insurmountable 
problems. Users of antidepressants might have more severe depression 
than non-users. However, they might also be more likely to seek help and 
comply with medical advice (both for depression as well as for 
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cardiovascular risk). As a result, the use of antidepressants has not been 
consistently associated with cardiovascular disease using observational 
data.(99) I am not aware of a randomized controlled study (RCT), where 
antidepressants are given to people free of cardiovascular disease, to see 
if this can prevent the development of cardiovascular disease. 
  
Among those participants with existing cardiovascular disease, trials of 
antidepressants have been noted to increase the risk of bleeding,(100) but 
despite this do appear to cause fewer cardiovascular events.(101) 
Another large trial, the ENRICHD study, did increase antidepressant use 
in the intervention arm from 9% to 21-28% (a mild change that was not-
randomized). Antidepressants were entered as time-varying confounders, 
thus amalgamating both baseline and intervention effects. Nonetheless, 
antidepressant use was strongly associated with better cardiac outcomes, 
and the effect size was substantial: 33-37% reductions in cardiac events 
and 29-37% reductions in all-cause mortality (in age- and fully-adjusted 
models, respectively).(102) Robust causal inference is further challenged 
by the observation that depression and cardiac disease do appear to 
share partially overlapping genetic aetiology.(103) Despite the null 
findings from the randomized ENRICHD intervention and a 
correspondingly cautious Cochrane review,(104) a more liberal meta-
analysis of 23 RCTs reported that psychological therapies do reduce 
mortality among those with pre-existing cardiovascular disease (OR = 
0.72 [95% CI = 0.56 to 0.94)].(105) The magnitude of effect was larger in 
men, and when the intervention was started on only those who survived at 
least 2 months post-MI (OR = 0.28 [95% CI = 0.12 to 0.70), which 
excludes the ENRICHD design. It is possible that further refining 
psychological interventions at this subgroup may substantially reduce 
cardiac mortality among those with cardiovascular disease. However, 
effects were also larger when limiting follow up to only 2 years, making it 
possible that any causal cardiovascular benefit might be quite short lived.  
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1.1.7.3 Distress and Vital Exhaustion 
Some scholars have defined constructs which might be thought to overlap 
with some personality traits, as well as with depression. One of these is 
psychological/psychiatric distress, as measured by the General Health 
Questionnaire. After an initial report in 1995 which predicted all-cause 
mortality,(106) a more recent report of 68 222 participants in England 
confirmed an association with cardiovascular disease (HR = 1.22 [95% CI 
= 1.14 to 1.31], per 1-SD increase in GHQ score).(107) 
 
Another construct related to depression is Vital Exhaustion, which was 
developed by Appels in 1987.(108) It is defined as excessive fatigue, 
feelings of demoralization, and increased irritability and is often 
considered a form of adaptation to prolonged distress or burnout. Studies 
examining the degree of overlap with depression have yielded conflicting 
results. It may be that while depression contains both cognitive and 
somatic components, vital exhaustion focuses on the somatic component. 
Furthermore, it seems to me that depression is marked more by low-effort, 
helplessness and reduced control, while vital exhaustion is characterized 
instead by higher effort among those who might otherwise be more pro-
active. One study associated vital exhaustion to CHD symptoms more 
strongly than with depression.(109) Another study from the Netherlands in 
2015 did not measure depression, but found vital exhaustion to be a more 
important predictor of CHD, as compared to dropping systolic blood 
pressure from the conventional risk prediction model (increased Harrell’s 
C-index = 0.01 [95% CI = 0.009 to 0.011], Net Reclassification 
Improvement = 32% [95% CI = 24 to 40%] Population Attributable Risk 
Fraction [PARF] = 21.1% [95% CI = 13 to 29%] in men and 27.7% [95% 
CI = 19 to 37%] in women).(110) 
 
Finally, another corollary of general stress constructs is general life 
satisfaction, which one study found to associated with incident angina 
(perhaps due to reporting bias) but not to objective measures of 
CHD.(111) 
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1.1.7.4 Anxiety 
Anxiety has partial overlap with depression. A meta-analysis of 20 studies 
of healthy subjects found more anxious participants (with an average 
prevalence of around 20%) to have a higher incidence of fatal and non-
fatal CHD incidence (HR = 1.26 [95% CI = 1.15 to 1.38]).(112) The 
magnitude of association was greater when omitting studies with 
composite outcomes, and instead focusing on 9 studies with exclusively 
fatal outcomes (RR = 1.48 [95% CI = 1.14 to 1.92]) or on 5 studies with 
exclusively nonfatal outcomes (RR = 1.43 [95% CI = 0.85 to 2.40]). 
Overall, these results are comparable those found for depression, but few 
of the studies on anxiety have controlled for depression. Perhaps just one 
study has shown how both anxiety and depression produce independent 
associations in univariate and multivariate models.(113) Adjustment for 
each other, as well as other socioeconomic variables, attenuated the 
univariate hazards by around one half.  
 
1.1.7.4 Conclusion on depression 
To conclude, observational studies have found a large and consistent 
association between depression and subsequent cardiovascular disease. 
One question that has not been investigated is whether it is the total time 
spent being with depression, or the fluctuation into and out of depression, 
which has the strongest association with cardiovascular disease. 
Causality in this whole field remains largely unexplored, due to limited 
experimental and mechanistic data. This might be improved by re-analysis 
of existing RCTs of antidepressants for long-term cardiovascular 
outcomes; or the application of instrumental variable analyses (where 
suicide rates might be the exogenous instrument, perhaps influenced by 
things like recession or the transition from communism to capitalism. 
Genetic variants for depression may also emerge in the future to 
sufficiently power Mendelian randomization analyses). 
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1.2. Is the socioeconomic-CVD association causal? 
My review so far has identified how the magnitude of association, 
prevalence and population-attributable fraction varies considerably across 
psychosocial and socioeconomic risk factors. At times, these measures 
can even exceed that seen for conventional cardiovascular risk factors. 
Despite this large evidence base, there is a huge translational gap: hardly 
any routinely recommended clinical interventions exist (either at the 
individual or population level), which aim to alter psychosocial and 
socioeconomic risk with view to preventing heart disease. One of the 
manifestations of this is illustrated in figure 2.  
 
 
 
 
Figure 2. Excerpt from a popular 2017 medical school textbook, 
written by Kumar & Clarke (114), on modifiable risk factors for 
coronary heart disease. 
 
 
Figure 2 lists 13 “potentially changeable” risk factors for CHD, denoting at 
least partial causality (and reversibility), which does not feature any 
psychosocial or socioeconomic risk factors. Furthermore, the evidence 
standard required to feature in this list appears comparatively low. For 
example, risk factors are included where there evidence over the last 10 
years has suggested that the observational associations are probably not 
causal in nature (e.g. fibrinogen,(115) CRP,(116) homocysteine,(117) 
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gout(118-120)). I concede that some of the psychosocial factors in my 
earlier review are not easy to modify (e.g. personality), but the vast 
majority of these are theoretically modifiable. It seems to me that one 
argument why clinical interventions are not recommended for 
psychosocial or socioeconomic risk factors may be that they are perceived 
as being non-causal.  
 
I will now summarize the causal evidence for and against one particular 
risk factor (education), since education is one factor whose causality I 
later study in more detail with original data. Although I will not have space 
to provide as much depth for each of the other factors, I will supplement 
my review of education with additional key references on the causality of 
other psychosocial/socioeconomic risk factors.  
 
 
1.2.1. Education 
There is a vast body of observational studies across a range of settings 
that report an association between education and CHD. In contrast, there 
have been comparatively few studies that have explicitly investigated the 
causality of this relationship. The existing studies on causal inference 
come primarily from three domains: natural experiments, sibling/twin 
studies, and molecular genetic data. 
 
1.2.1.1. Natural experiments 
Analyses of natural experiments have compared mortality before and after 
changes to compulsory schooling laws. For example, by looking at 
mortality rates in countries before and after the introduction of national 
legislation that increased minimum education, using the method of 
regression discontinuity analysis. In the Netherlands, such changes were 
associated with reductions in all-cause mortality.(121) In the UK, the 
largest study so far reported causal effects on improving physical activity, 
BMI, blood pressure, diabetes, stroke, CHD, and all-cause mortality.(122)  
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An extension of this design is to compare geographical areas, such as the 
various states within the USA. These studies initially suggested a large 
effect on all-cause mortality, but this effect disappeared when state-
specific baseline trends were taken into account.(123, 124) In Sweden, an 
intervention to extend compulsory schooling throughout a 13-year 
transition period in a stepped-wedge design across multiple municipalities 
reported lower all-cause mortality in those deaths occurring after age 40 
(equivalent to a hazard ratio of 0.86 (95% CI = [0.77 to 0.96]) per 3.6 
years of additional education).(125)  
 
1.2.1.2. Twins and siblings 
Another source of causal inference comes from studies on monozygotic 
twins. Within each pair, both twins are exposed to the same set of genetic 
exposures (both twins are also equally exposed to some risk factors in the 
environment, technically known as the “shared environment”). 
Consequently, any difference in disease outcome between twins cannot 
arise from genetic effects (or factors found in their shared environment). If 
differences in outcome associate with differential exposure to non-shared 
features of the environment (such as one twin pursuing education longer 
than the other twin), and if the magnitude of this association is comparable 
to that seen in the general population, this makes less likely the possibility 
that the observational association is confounded by genetic (or shared 
environmental) factors.  
 
Although the twin method does not eliminate the possibility of confounding 
from other factors in the non-shared environment, it is a design with which 
to eliminate the possibility of confounding from genetic factors. Twin 
studies initially found evidence both for and against causal effects from 
education to mortality and CHD incidence.(126-129)  
 
Much of this early discrepancy could be explained by insufficient statistical 
power, as well as what criteria are used to judge whether the data are 
consistent or inconsistent with an interpretation of underlying “causal 
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effects”. For example, analyses conducted within twin pairs often have 
substantially smaller sample sizes, rendering their confidence intervals 
wider. If this confidence interval crosses the null, then some authors and 
commentators might interpret this as “no statistical evidence of causal 
effects”. Although this is correct in the narrow sense of the term, such a 
conclusion can also be misleading, when a study is simply underpowered 
to definitively answer causal questions. Here, the safest interpretation is to 
not make an interpretation. However, if one is asked to hazard a guess, 
then it might be more helpful to examine whether the point estimate 
attenuates, when comparing results obtained from the between-twin 
analysis against the general population analysis. 
 
The largest study to date from Sweden (which has twice the statistical 
power of the previous largest study) found strong statistical evidence for 
causal effects, whereby the 99% confidence intervals did not cross the 
null in any of the analyses.(130) Furthermore, the association between 
years of education and lifespan did not attenuate at all when the 
conventional population based analysis was compared against the 
between twin analysis. Hence overall, the twin literature suggests that, 
although only a handful of sufficiently powered studies exist, shared 
environmental factors (such as parenting) might not cause substantial 
confounding. It also suggests that confounding from genetic factors (such 
as genetic differences in drive, motivation, personality, or innate intellect, 
all of which themselves may predispose towards longer education) are 
unlikely to account for the observational associations between education 
and disease. 
 
A parallel domain of research, using data from millions of non-identical 
siblings (that sometimes reached 100 times larger sample sizes than the 
twin studies), has also observed little attenuation of the association 
between education and subsequent mortality when comparing the general 
population analysis with the within-sibling analysis.(131, 132) As with twin 
studies, this also suggests that environmental and genetic factors shared 
by siblings are unlikely to confound the observational association seen 
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between education and disease. Nonetheless, the twin and sibling studies 
both leave open the possibility of confounding from environmental factors 
that are not shared between siblings. 
 
Other twin studies have reported a causal effect from longer education to 
lower depression symptoms.(133) Depression might plausibly be one of 
the mediators, on a putative pathway from education to depression to 
heart disease.  
 
1.2.1.3. Molecular genetic data 
Finally, some recent studies have also looked at specific genetic variants 
for education. An association was found between parental longevity and 
genetic markers for education in their offspring.(134) However, causal 
directions and pleiotropy were not tested in this study.  
 
I am aware of two reports which tried to apply the conventional Mendelian 
randomization (MR) approach to a socioeconomic exposure. Both tried to 
exploit the findings from a GWAS analysis of education published in 
Science in 2013, which found 3 single-nucleotide polymorphisms (SNPs) 
to associate with education.(135) In 2016, Nguyen et al. used these 3 
SNPs as instruments to see these also associate with subsequent 
dementia.(136)  Although the point estimate was suggestive of a causal 
effect, the 95% confidence interval crossed the null, suggesting that the 
study was underpowered and/or used a weak instrument. Furthermore, 
this study did not investigate the pleiotropy of its genetic instruments. 
 
The other study from 2016 was by Cuellar-Partida et al, who were 
interested in myopia as the outcome.(137) Faced with the same problem 
of a weak instrument and limited statistical power, they took an 
unconventional approach towards selecting their instruments. They opted 
for a polygenic score that used the 17,749 “top hit” SNPs that associated 
weakly with education. In statistical terms, it was possible that 17,746 of 
these associations arose by chance alone. However, when summed 
together the entire polygenic score was strongly associated with the 
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education phenotype in multiple cohorts. This was associated with 
myopia, which they interpret as evidence of causal effects. The core 
problem with this interpretation is that many if not most of the 17 749 
SNPs might plausibly have pleiotropic effects which associate with myopia 
via pathways that bypass education. This was not explored in their 
analysis. Another problem with this study is the temporal sequence of 
events: most people develop myopia before they complete their 
educational attainment. It may be that these 17 749 SNPs tag pathways 
that might predispose children towards spending more time towards 
reading and writing. It is plausible for the myopia-inducing effect of this 
activity to have its greatest causal effect between the ages of 0-16. This 
means that any extension of education, between the ages of 16-25, may 
or may not cause myopia. This example illustrates the problem of 
identifying “causal effects” in the abstract sense, since all causal effects 
are by nature tied down to a particular context of time, place and person. 
 
No Mendelian randomization studies of socioeconomic exposures have 
investigated any other disease outcome, such as cardiovascular diseases. 
Furthermore, most of the other designs listed above (including natural 
experiments, twin and sibling designs) have reported outcomes for all-
cause mortality. Few have reported cardiovascular mortality and virtually 
none have reported fatal/nonfatal CHD, as I plan to study. 
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1.2.1.4. Conclusion on the causality of education 
Data from twin/sibling studies, as well as natural experiments, are on 
balance more compatible with an interpretation of causal effects from 
education to all-cause mortality. Both study designs make entirely different 
assumptions, which further strengthens causal inference via effective 
triangulation. Furthermore, the sibling design investigates the 
consequence of raising or lowering the population mean (also known as 
the average treatment effect). In contrast, natural experiments with 
compulsory schooling laws only alter exposure in the high-risk subgroup 
and may not influence the mean. Convergent results across both domains 
suggest that a causal effect could operate monotonically (perhaps even 
linearly) across a range of different educational exposures. 
 
To counterbalance these direct investigations of causality, other 
inferences from more indirect sources are less compatible with a causal 
interpretation. For example, even after adjusting for parental and 
household factors, the presence of childhood health conditions (such 
diabetes, asthma, attention-deficit hyperactivity disorder, and obesity) 
have all predicted subsequent educational attainment, possibly via missed 
school.(138) This has been interpreted to denote reverse causation: that 
environmental or genetic predisposition towards poor health causes lower 
education.(47) However, this argument becomes more tenuous for 
cardiovascular disease, which does not manifest itself until much later in 
life. One could suppose a general “frailty phenotype” which may already 
be operating during childhood. It is possible that this frailty phenotype 
causes childhood illness, which causes low education. The frailty 
phenotype could, in parallel, also cause cardiovascular disease (figure 3, 
top). Although plausible, this interpretation is not compatible with the twin 
and natural experiment data discussed above. An alternative explanation 
is a simple serial one, where frailty causes childhood illness, which causes 
low education, which causes heart disease (figure 3, bottom). 
 
 
 
 
 
62 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Two alternative indirect inferences, made from the 
observation that childhood illness associates with lower subsequent 
educational attainment. 
 
A second indirect inference comes from the fact that educational gradients 
in smoking behaviour are typically established before educational 
attainment is completed. For example, such gradients are already seen at 
the age of 17, when grouping participants based on their future 
educational attainment.(139) One interpretation is that the pathology of 
smoking and subsequent illness happens independently of education. 
Instead, the common cause of both smoking and low education might be 
something such as “excess focus on the short term, at cost to long-term”, 
and so education is merely a non-causal marker of this (figure 4, top). 
However, this interpretation is also incompatible with the natural 
experiment data.  
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Figure 4. Two alternative indirect inferences, made from the 
observation that educational gradients in smoking are established 
before the completion of education. 
 
Another interpretation is that education is a consequence of “short-term 
focus”. Nonetheless, this does not stop education from also being a cause 
of subsequent cardiovascular disease.  
 
In conclusion, indirect evidence, such as the two examples discussed, 
offer some criticism of the model that lower education causes heart 
disease. The direct causal evidence, from twin/sibling studies and natural 
experiments are by no means definitive, but both sources suggest that a 
causal effect is more likely than not. 
  
 
 
64 
 
  
 
 
65 
 
1.2.2. Unemployment 
1.2.2.1. Twin studies 
The twin design has also been used to study unemployment as the 
exposure, and all-cause mortality as the outcome. One study reported 
results separately for men and women.(140) My meta-analysis of their 
data suggests that if one twin is discordant on unemployment, then this is 
associated with a Hazard Ratio of mortality of 1.62 (95% CI = 1.35 to 
1.89). This suggests that unmeasured genetic confounders and 
confounders in the shared environment are unlikely to drive the 
observational association between unemployment and mortality, which 
may indeed be causal at the individual level. 
 
1.2.2.2. Natural experiments 
Since unemployment can be a comparatively transient and dynamic state 
(as opposed to educational status is which is more permanent), the 
epidemiological study of exposure to unemployment has more explicitly 
discussed the possibility of reverse causation, also known as “health 
selection”. Here, healthier individuals could be selected into employment, 
while latently unhealthy individuals may find themselves more likely to be 
made redundant and/or having less success in their job applications. 
Martikainen et al. showed how the magnitude of association, between 
unemployment and subsequent mortality, varies by as much as twofold in 
Finland, when comparing a period high countrywide unemployment with a 
period of low countrywide unemployment.(141) In times of recession, 
when unemployment rates are higher, the strength of association with 
subsequent mortality was substantially lower. This is compatible with an 
explanation that the cohort of participants who are employed during 
economic grown, but face job loss during recession, are healthier than the 
cohort of participants who are chronically unemployed. This is compatible 
with a hypothesis of health selection/reverse causation. Another 
interpretation of this data is that length of time spent being unemployed 
has a monotonic dose- response causal effect on subsequent mortality: 
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the former cohort have simply been exposed less, while the latter cohort 
have been exposed more. In both cases, causal effects may operate. 
 
The health selection/reverse causation hypothesis has also been 
supported by observations during the Great Recession, during which 
individuals with a chronic illness were twice as likely to lose their job when 
compared to healthy individuals.(142) Most studies of the great recession 
looked at mortality outcomes at the aggregate level, without access to 
individual level data. Such studies found that greater national 
unemployment rates were associated with increased suicide rates.(143) 
Some investigators have also reported increased unemployment to 
associate with lower national levels of cardiovascular and all-cause 
mortality,(144) especially among the working age population.(145) These 
results have been contested on methodological grounds,(146, 147) but 
more importantly it is inconsistent with the opposite direction of 
association found from epidemiological studies that use individual-level 
data. Indeed, this example has been held as an example of 
ecological/individual fallacy: that associations at the individual level of 
analysis may not be found in higher levels of analysis. Nonetheless, a 
recent synthesis looked at individual level data over a period of 18 years 
with varying rates of unemployment.(148) The researchers essentially 
looked for a binary two-by-two interaction between individual-level 
unemployment and area-level unemployment. The results reconciled the 
previously opposing results, by confirming that recessionary periods 
amplify the individual-level mortality hazard for those people who are 
made unemployed (hazard ratio of recession = 2.54, 95% CI = 1.39 to 
4.65). However, for the vast majority of individuals who managed to 
escape being made redundant, periods of recession were associated with 
large reductions in mortality (hazard ratio of recession = 0.50, 95% CI = 
0.31 to 0.78). Altogether this more nuanced picture of the subgroup-
specific associations reconciles the findings of previously critical studies 
by Martikainen et al.  
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1.2.2.3. Conclusion 
One way to synthesize this body of evidence, in my personal opinion, 
would be to conceptualize individual-level unemployment (and 
interventions which might lower that), as conceptually different to area-
level unemployment (and interventions which might lower that). If one 
were to take a single unemployed person and put them into employment, 
then there is a reasonably strong evidence base that this is likely to 
improve their well-being, mental health, and all-cause mortality. Such 
causal effects, at the individual level, may be larger during times of 
recession. 
 
As for what happens when a country lowers its national unemployment 
rate, then this remains less clear. Mortality from suicide will probably fall 
while mortality from road traffic accidents and alcohol-related causes will 
probably increase. Mortality from cardiovascular disease and all-cause 
mortality may increase, but the evidence for this is extremely limited. 
Based on this historical picture, it is likely that future recessions may 
create similar effects, at the national level. However, it also remains 
possible to decouple these effects using other societal factors (such as 
government social spending, and/or active labour market programmes). It 
is also possible that these associations are confounded, or modified by 
other factors, such as changes to disposable income, as well as popular 
predictions about the duration of recession and the feeling of hopefulness 
or hopelessness that this may bring. For example, a recession that is 
expected to resolve quickly may promote a positive adaptive response 
among those still employed, similar to the “flight or fight” response (e.g. 
“drink less, drive less & savour your good fortune”). By contrast, a 
prolonged recession with little hope, such as that seen after the collapse 
of the Soviet Union, may promote a distress response (e.g. “drink more & 
despair at your poor fortune”). I posit that one mechanism through which 
increases to the national unemployment rate could cause reductions to all-
cause mortality (driven by the large fraction of people who remain in 
employment) might be via the mechanism of hopefulness or “I’ve had 
better luck than my neighbour”. This could create a psychological state 
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that could protect against depressive symptomology which may cause 
cardiovascular disease. Although such a theory could be tested using data 
similar to that used by Noelke et al, (148), I still struggle to see the real-life 
translation of such research: should governments seek to tolerate 
occasional acute recessions, in order to lower population mortality, or 
should they seek to reduce their occurrence, in order to protect those 
most vulnerable and lower health inequalities? 
 
 
1.2.3. Psychosocial risk factors 
A relatively small study of 2350 twins reported causal effects from 
divorced/never married marital status, and subsequently greater smoking 
behaviour and depression symptoms.(149) I am not aware of natural 
policy experiments that have altered marital status. 
 
Two randomized controlled trials (RCTs) have altered depression and 
social support with the intention of preventing recurrent cardiovascular 
events and delaying mortality. The ENRICHD trial did not find an effect, 
while the SUPRIM trial found a benefit from using Cognitive-Behavioural 
Therapy.(102, 150) Both trials recruited patients with pre-existing 
cardiovascular disease. It may be that interventions at this stage of 
disease aetiology find it challenging to alter sequelae. To my knowledge, 
there are no RCTs that altered psychosocial or socioeconomic exposure 
in otherwise healthy participants with the intention of preventing the 
development of CVD. It is plausible that as traditional risk factors recede 
with period effects and effective public health intervention, this opens up 
the possibility that the fraction preventable from psychosocial interventions 
may correspondingly increase. In other words, cardiovascular disease 
may be becoming less common, but more psychosocial in its nature. 
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1.3. International differences in CVD 
1.3.1. Trends in mortality across Eastern and Western Europe 
Temporal fluctuations in mortality and life expectancy have been more 
dramatic in Eastern Europe than anywhere else in the world, when 
excluding periods of war and famine. Figure 5 shows most of the countries 
from Western Europe as coloured green, and most of the countries from 
Central- and Eastern-Europe as coloured red. (Of note, membership of 
the OECD has slightly changed since the production of this figure.) As the 
definition of “Central and Eastern Europe” can vary, in this definition three 
countries (Poland, Slovakia, Hungary) that are conventionally be thought 
of as being in Central/Eastern Europe, are here marked green as 
OECD/Western Europe instead. Nonetheless, other than for these three 
countries, figure 5 provides a reasonable approximation of the trends in 
life expectancy across these two regions. 
 
Trends in Western Europe have been remarkably stable, showing a near 
linear increase in life expectancy over a 65 year period, with little change 
in the rank between each country. The absolute speed of progress for a 
country such as the UK has been around 2.2 months of additional life 
expectancy gained, pear each calendar year.  
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Figure 5. Trends in life expectancy (1950-2015) among selected 
Western and Eastern-European countries.   
Visualization website: Gapminder.org  
Data source: United Nations Department of Economic and Social Affairs. 
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Trends in Eastern Europe, however, might be characterized into four 
periods. Between 1950-1965, life expectancy improved dramatically. In 
Russia, life expectancy improved by 10 months per each calendar year. 
This period coincided with Nikita Khrushchev’s leadership of the Soviet 
Union. By 1965, life expectancy in each of the three Baltic States, for 
example, was higher than that seen in Finland or Austria.  
 
Between 1965-1990 improvements in life expectancy stagnated. This 
period coincided with the wider “Era of Stagnation” (predominantly with 
the USSR being under Leonid Brezhnev’s leadership) when little progress 
was also seen in other aspects of society (such as cultural freedoms and 
economic growth). During this era, there was one notable temporary 
deviation: life expectancy increased in Russia very quickly, by 14 months 
per year between 1984-1986. This is largely attributable to Gorbachev’s 
anti-alcohol legislation. However, life expectancy in the subsequent two 
decades fell and never regained the temporary peak it attained during 
1986.  
 
More specifically, between 1990-1994, the collapse of the Soviet Union 
was accompanied by the largest fall in life expectancy ever seen without 
war or famine. In Russia, life expectancy fell by 5.4 years (at a speed of -
16 months of life expectancy, per each calendar year). Graphically, this is 
equivalent to going back to 1957, i.e. the loss of 37 years of intermittent 
progress. This decline accounts for why international inequalities in life 
expectancy diverged spectacularly between 1990-1994. Furthermore, 
inequalities within Eastern European counties diverged. Countries that 
were members of the Soviet Union saw large decreases to life 
expectancy, while other communist countries elsewhere in Central Europe 
did not see such a decline. 
 
Between 1994-2015, the overall pattern is one of slow and almost parallel 
progress in East, Central and Western Europe, with little changes to the 
rank order of countries.  Some smaller fluctuations are still visible. Due to 
the Russian Rouble crisis, between 1998-2003, life expectancy in Russia 
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fell by 1.5 years. At the same time, life expectancy in Estonia increased by 
2.5 years (speeds of -4 months and +6 months / calendar year, 
respectively).  
 
Estonia is also the ex-USSR country that has made the biggest progress 
against closing the mortality gap seen against the other Central European 
countries. In 1994 this gap with Poland was 5.4 years of life expectancy. 
By 2015 Estonia had overtaken Poland (with average annual increases of 
life expectancy at +7 and +3 months, respectively). Nonetheless, ignoring 
these smaller fluctuations still shows an overall pattern between 1994-
2015 where improvements in countries like Russia (+4 months of life 
expectancy per calendar year) were slightly faster than corresponding 
improvements in the West (e.g. +2.5 and +2.7 months of life expectancy 
per year, in the UK and Spain, respectively). This slight increase in speed 
in Russia has not been at all sufficient to close the large international gaps 
in life expectancy that were created during the fall of communism. For 
example, were trends from these two decades extrapolated linearly, then 
life expectancy in Russia would overtake that in the UK only by 2095 (at a 
life expectancy of 98). As another perspective of the vastness of the 
current gap, life expectancy in Russia today (71.0 years) is only one year 
longer than it was in Russia 50 years ago (69.8 years). Furthermore, male 
life expectancy in Russia (62.0 years) is dramatically lower when looking 
at countries with comparable levels of GDP per capita (approximately 72 
years), and lower than in the countries named in figure 6, whose 
economic development is also substantially lower (e.g. India and North 
Korea). 
 
By further stratifying these trends by age and sex, it appears that the 
strongest fluctuations over time have occurred in men aged 25-64. In 
absolute terms, these changes were driven by changes to cardiovascular 
mortality, most specifically to changes in ischaemic heart disease (data 
not shown).  
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Figure 6. Scatter plot of all countries, comparing economic 
development against male life expectancy. Highlighted countries have 
lower levels of economic growth and higher life expectancy than Russia, 
and have populations >25 million. Visualization website: Gapminder.org  
Data sources: World Bank; United Nations Department of Economic and 
Social Affairs.  
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1.3.2. Proposed explanations 
1.3.2.1. Conventional cardiovascular risk factors 
The Multinational MONItoring of trends and determinants in 
CArdiovascular disease (MONICA) study was a detailed investigation of 
CHD cases from 38 countries, spanning West and East Europe between 
the mid-1980s to the mid-1990s. Although they did not collect detailed 
exposure data from the cases, they used an ecological design to look at 
national trends in conventional CVD risk factors from other data sources. 
The conventional factors were blood pressure, consumption of cigarettes, 
serum cholesterol, and BMI, which were assessed from 2-3 time points. 
This was used to construct a linear time trend in exposure, and calculate a 
mean annual change in exposure.(151) The authors regressed time-
trends in CHD rates against time-trends in risk factors. Better fit was seen 
with a 4-year lag between changes to exposure and changes to CHD 
rates (figure 7).  
 
 
Figure 7. Lagged regression between mean changes in CVD risk 
factors between 1984 to 1993 (x-axis) against mean changes in CHD 
events between 1988 to 1993 (y-axis).  
Yellow highlight denotes four studies from Russia. 
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In figure 7, the regression coefficient was r = 0.46 (0.01 to 0.91) This 
means that, assuming that temporal changes within Western and Eastern 
countries had similar origins, about 22% of the within-country change in 
CHD is attributable to within-country change in conventional risk factors. 
Of note, this may be an underestimate, since all measurement error in risk 
factors is likely to bias the correlation coefficient towards the null. There 
are also methodological considerations. For example, using multiple 
regressions for each of the four risk factors (instead of one single 
regression), the percentage finally explained increased to 46%, however, 
with substantially greater risk of overfitting and larger uncertainty (as few 
of the four risk factors showed conventional levels of significance). 
 
Of note in the plot above, all of the yellow Russian samples are 
consistently above the trend line. The absolute annual improvement in 
CHD in Russia was about 4 percentage points less than might be 
predicted from the otherwise decline in conventional CVD risk factors. 
One might be tempted to exclude the Western data, and when looking 
only at the four Russian data points themselves, then their correlation 
might be informative. However, this correlation is more likely to arise from 
random error. For example, both the extremes (RI and RT) are in fact 
intervention arms, which might plausibly be expected to appear in the 
bottom left corner.   
 
Altogether, although the MONICA study did tell us about the possible 
causes of temporal changes in CHD trends (controlling for international 
variation), it was not designed to account for international differences in 
baseline CHD, as it did not analyse individual-level data. Furthermore, it 
was not sufficiently powered to look at the causes of temporal variation 
within Eastern European countries alone. However, they were able to 
attribute up to half of the temporal variation in an average country (pooling 
data across West and East) to changes in conventional CVD risk factors. 
This leaves open the possibility that (assuming zero measurement error) 
around half of the causes of temporal variation remain to be found. This 
study could be improved methodologically. For example, more 
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sophisticated methods for capturing the total lagged effect over a wider 
longer tail period have been recently proposed,(152) which might increase 
the attributable amount. It is also possible that changes to conventional 
risk factors are themselves confounded by other causal confounders (for 
example, increased societal democracy and optimism). It is also possible 
that results are different in Eastern Europe, where temporal variation in 
outcomes was much larger. Nonetheless, the reasons as to why Eastern 
European countries experienced substantially worse temporal trajectories 
than Western countries appears to be unexplained, and probably 
unrelated to, changes to conventional CVD risk factors.  
 
A separate line of enquire has been developed by Capewell, who has 
examined the drivers of temporal changes within one country. He has 
applied the IMPACT model to multiple time points, each of which should 
specify mortality, the prevalence of conventional CVD risk factors, as well 
as any other proposed explanatory factors (such as the uptake of 
evidence-based medical treatments). These analyses attributed the 
gradual secular decline in mortality seen in Western European countries 
to improvements in risk factors and medical treatments. Most of these 
models have found both to play a role, with preventative factors playing a 
larger role. Similar results have been observed when analysing data form 
Poland and the Czech Republic.(153, 154) However, neither of these two 
countries experienced the large drop in mortality that was observed in the 
ex-USSR countries between 1989-1994. To date, the IMPACT model has 
not been applied to ex-USSR countries. 
 
1.3.2.2. Diet 
It has been speculated that diet may be one of the main reasons why 
Eastern Europe has seen higher total and cardiovascular disease (CVD) 
mortality when compared with Western Europe.(155-157) Empirical 
evidence to support this has been sparse, including relatively crude cross-
national comparisons,(158) time-series analyses within Poland,(159) and 
Global Burden of Disease models, where diet-disease associations from 
the West are extrapolated onto the higher disease burden seen in Eastern 
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Europe, to infer that diet should play a large role in Eastern Europe.(160) 
To the best of my knowledge, only the HAPIEE study has collected 
individual-level data about diet from multiple countries, to make inferences 
about the source of international variation.(161) In a pooled analysis 
across countries, a composite of healthy diet indicator had a PARFs of 
14% for CVD mortality, and 3% for all-cause mortality. This suggests that 
diet was able to predict who is at risk within each country. They also 
reported additional analyses, where the baseline rate of CVD mortality in 
Czech Republic was compared against that in Russia. Mortality was 2.86 
(2.23-3.67) times higher in Russia in a model adjusted for age and sex. 
Following additional adjustment for the Healthy Diet Indicator, this did not 
attenuate the inter-cohort difference at all (HR = 2.89 [2.25-3.71]). This 
suggests that diet was unable to explain international differences in 
outcome. This finding does come with some caveats. It may still be 
plausible for international differences in non-responders to be caused by 
variables such as diet. However, this still leaves unanswered the cause of 
variation among responders, and it is more plausible for the cause of 
international difference between responders and non-responders to be the 
same. Furthermore, the hypothesis of diet driving international differences 
is less compatible with the rapid changes seen in mortality just 1-2 years 
after the breakup of the Soviet Union. One would anticipate much longer 
lag periods between exposure to diet and changes to mortality. 
 
1.3.2.3. Alcohol 
Another early hypothesis for the cause of international divergence in 
mortality from 1991 onwards was alcohol.(162) Ecological data showed 
how short-term fluctuations in national rates of consumption correlated 
with similar fluctuations to mortality from cardiovascular diseases(163, 
164) and all-cause mortality.(165) Rehm et al. again modelled alongside 
the Global Burden of Disease framework, to take exposure-disease 
associations from the West, and coupled this with estimates of higher 
prevalence of exposure and outcome in Eastern Europe, to calculate that 
male alcohol-related mortality is higher in Eastern Europe when compared 
to Western Europe.(166) However, the absence of individual level data in 
 
 
78 
 
such ecological and modelling approaches leaves open the possibility that 
their findings are confounded by third factors, which cause both higher 
rates of disease and alcohol. For example, if psychological stress is the 
underlying cause, then removing alcohol may not prevent CVD. Using 
individual-level data, case-control and cohort studies from Russia have 
associated some subtypes of alcohol with CVD outcomes. However, each 
of these studies did employ somewhat unconventional analytical 
techniques, as discussed below.  
 
The first case-control study by Leon et al. initially recorded alcohol 
consumption from a range of sources (incl. beer, wine, spirit, and non-
beverage sources, such as specialty perfumes).(167) The existing 
literature might suggest that one solution is to consider the primary 
exposure as Total alcohol consumption, from all these sources combined. 
However, as associations for this outcome were not reported, it is possible 
that such associations were not distinguishable from occurring by chance 
alone. Instead, the paper reported large mortality associations (unlikely to 
happen by chance alone) exclusively for three exposures: non-beverage 
alcohols; one type of spirit (vodka); and social features of problematic 
alcohol dependence (defined as having one or more episodes of zapoi in 
the past year [a cultural phenomenon more common in Eastern Europe, 
where a person is continuously drunk for >2 days] and/or at least twice 
weekly occurrence of excessive drunkenness, hangover, or going to sleep 
at night clothed because of being drunk). Altogether, the prevalence of all 
of these risks might be approximately 15-20% in the Russian general 
population. Coupled with a large Odds Ratios for death in men aged 25-
54, this analysis suggested that as much as 43% of premature male 
mortality in this age group might be attributable to these subtypes of 
alcohol. However, the presumed absence of effect from total alcohol 
consumption makes possible that these results were confounded by 
residual socioeconomic status (which was statistically adjusted relatively 
simply, as just three categories of education), smoking (which was 
statistically adjusted as five categories), or other psychosocial variables 
(such as material deprivation, unemployment, depression and/or social 
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isolation, neither of which were measured). Data from other high- and low-
income countries suggests that higher SES individuals are more likely to 
consume more alcohol.(168) At first, this observation may seem to be 
against my critique of the Leon et al. study (since SES is not a plausible 
confounder of the association between total alcohol consumption and 
mortality). However, the SES gradient appears to reverse when one 
considers other measures of alcohol behaviour, such as binge drinking. 
This now makes it plausible for SES to be a confounder of the association 
between problematic alcohol behaviours and mortality. 
 
Secondly, these exposures were collected from proxies after death. It is 
possible that proxy informants up weighted recollections of alcohol and 
down weighed recollections of these measured confounders. For 
example, smoking behaviours may be less visible than alcohol 
behaviours, thereby inducing more measurement error, which leads to 
overinflating the attribution made to alcohol. 
  
A subsequent case-control study by Zaridze et al. dealt with the problem 
of differential reporting bias among proxy informants, by setting the control 
group to not be those who are still alive, but those who died from cause 
plausibly unrelated to alcohol.(169) The investigators reported 
associations with total alcohol consumption, for a range of mortality 
outcomes. Critically, however, their analysis made no adjustment for 
education, marital status, ethnicity, job loss, or income, despite reporting 
in the same paper that these variables were collected at baseline. 
Furthermore, while smoking history was originally measured in much 
detail, this variable was dichotomized (yes/no) during the analysis stage, 
thereby substantially increasing residual confounding from smoking. In a 
prospective follow-up of the same baseline study, Zaridze et al. omitted 
associations with total alcohol exposure and presented instead exposure 
for vodka consumption.(170) In this paper, the statistical analyses made 
finer adjustments for smoking and education, but did not adjust for marital 
status, ethnicity, job loss or income. 
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To summarize, three articles in a reputable journal (The Lancet) make a 
convincing case that subtypes of alcohol are strongly associated with 
alcohol in a relatively crude analyses. However, only one paper out of 
three presents results for total alcohol consumption. This leaves open the 
possibility that it may not be exposure to ethanol molecules per se, but 
rather the socioeconomic confounders of certain types of alcohol, that 
causes both mortality and alcohol behaviour. The argument of a large 
causal effect from alcohol to mortality could be strengthened if those 
analyses could be repeated, where total alcohol consumption is 
considered as the primary exposure, and where the various putative 
confounders that have been measured around smoking, socioeconomic 
and psychosocial factors are rigorously adjusted for. This withstanding, if 
alcohol is a causal mediator of the association from SES to mortality, then 
policies that lower alcohol consumption should reduce health inequalities, 
which would be praiseworthy outcome. This is consistent with a report by 
Mackenbach at al., where an increase in alcohol affordability over time 
was associate with an increase in  educational inequalities in alcohol-
related mortality, over time.(171) Nonetheless, the contribution made to 
inequalities in total mortality (at age 35-79) were a modest 2-9%, 
suggesting that the mediators of socioeconomic differences in mortality, 
as well as the cause of temporal and geographical variations, remain to be 
determined. 
 
Prospective analyses from the HAPIEE cohort reported associations 
between total alcohol intake >60g/day and mortality from CHD, CVD and 
all-causes.(172) This level of drinking is equivalent to 3.8 times more than 
the UK Chief Medical Officer guidelines, making it quite a rare exposure. 
When consumption was categorized into various groups below this 
threshold, then these were not consistently associated with any mortality 
outcome. These associations for >60g/day in men were attenuated by 
29%, 40% and 56% after adjustment for a range of behavioural, 
socioeconomic and psychosocial factors (incl. education, marital status, 
economic activity, material possessions, economic hardship, depressive 
symptoms, smoking, physical inactivity, BMI, and prevalent CVD and 
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cancer). There were no associations with other measures of alcohol, such 
as binge drinking, drinking frequency or drinking pattern. Since exposure 
to >60g/day of alcohol was so rare (2.8% prevalence), the population 
attributable risk fraction among men was also only 2.8%. Additional 
sensitivity analyses suggested that, even if the point estimate was biased 
by twofold, and even if non-responders had 13x greater prevalence of 
exposure, and even if non-responders had twice the hazard ratio of 
responders, then the population-attributable fraction for all-cause mortality 
would only come as high as 22% (what can only be considered an 
extremely upper margin of the likely underlying estimate). These 
calculations could be further enhanced, in future analyses, by also 
accounting for borderline significant associations among those who drink 
between 1 to 3.8 times above the recommended safe limit (for example, 
by using polynomial splines to model a nonlinear exposure-outcome 
associations). These refinements may indeed be warranted, in light of 
emerging evidence from Mendelian randomization studies, which suggest 
that alcohol may indeed be a causal risk factor in the development of 
CHD.(173) Nonetheless, it seems unlikely to me, that total alcohol 
consumption in the HAPIEE study would be associated with more than 
50% of all-cause mortality in the adjusted analyses, even after additionally 
accounting for the hazard from lower levels of consumption.  
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1.3.2.4. Psychosocial and socioeconomic factors – area level data 
It has been hypothesised that the transition from communism to capitalism 
in Eastern Europe could have exacerbated the influence of psychosocial 
hazards on CVD.(155) More specifically, a greater proportion of the total 
population may have become exposed (when compared to the proportion 
who are exposed in countries from Western- and Central-Europe). 
Alternatively, the magnitude of presumably causal effects could have 
increased in Eastern Europe. During the 1990s, countries of the former 
Soviet Union experienced a recession many times larger than the Great 
Recession of 2008. In Russia, the period 1990-1996 saw GDP per capita 
(constant, adjusted for purchasing power parity), fall by 40%. Even by 
2015, it was only 17% higher than in 1990, in contrast to a 65% increase 
between 1990-2015 for the World average.(174)  
 
When a recession of unprecedented magnitude is coupled with vanishing 
social welfare, rising crime, political uncertainty, and changing cultural 
expectations, it is only fair to call the speed and magnitude of net social 
change as literally otherwise unprecedented during modern times. One 
can speculate that this might have led to persistent and unresolved 
anxiety about the future, and possibly feelings of collective failure, shame 
and loss of purpose. This might result in greater exposure to low 
perceived control, greater depressive symptoms, greater material 
deprivation and perceptions of loss in social status. This hypothesis has 
received very little empirical study.  
 
Within this region, countries whose residents report greater perceived 
control also have lower levels of mortality, in a cross-sectional 
analysis.(175) However, as this analysis did not adjust for putative 
confounders, a range of alternative causal chains could be constructed to 
account for this (e.g. alcohol/diet → high mortality → low perception of 
control). This period of massive social change coincided with large 
increases in suicide and CVD mortality. Formal time-series analyses, 
where suicides are taken as a proxy marker of stress and CVD is the 
outcome, have not been conducted.  
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Figure 8. Temporal trends in suicide mortality, in selected countries 
from Central and Eastern Europe.  
Source: https://gateway.euro.who.int/en/hfa-explorer/#9aZl40c8fU  
Data: WHO Health For All Database 
 
 
Temporal changes to income inequality have been correlated with 
temporal changes to life expectancy at the population level, when 
comparing countries ecologically.(175) However, this analysis did not 
adjust for putative confounders such as GDP per capita, or country-level 
fixed effects. Despite these weaknesses, this observation is consistent 
with other ecological and econometric analyses that have found an 
association between countries who chose to privatize their state-controlled 
industries quicker, and corresponding higher mortality.(176) 
 
One age-period-cohort analysis suggested that it may not be purely period 
effects that are associated with mortality, as the literature has assumed so 
far, but in addition cohort effects may be seen for that cohort of men who 
lived through much of the hardship of the second World War and 
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subsequent Stalin’s regime.(177) In other words, it was not the social 
change of the 1990s per se which caused an increase in mortality, but 
instead this happened to coincide with the increase in mortality that would 
have happened, regardless of whether the Soviet Union collapsed or not.  
 
The “Global Burden of Disease Study 2015” study constructed a measure 
of Socio Demographic Index (SDI).(178) This ecological indicator is a 
composite of income per capita, educational attainment, and fertility, and 
is seen as proxy for general societal advancement. What I found striking 
in their analysis is how dramatically the life expectancy in Eastern Europe 
deviates away from an otherwise close correlation, when world regions 
are plotted so that each data point is a particular point in time. While this 
analysis captures temporal trajectories, it is most suited to thinking about 
over- and under-achievers in terms of mortality outcomes, given a fixed 
level of societal development.  
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Figure 9. Association between Socioeconomic development and 
male mortality, among the Global Burden of Disease super-regions 
between 1980 to 2015. Adapted from (178). 
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The most revealing observation from figure 9 is that if countries in Eastern 
Europe increase economic productivity, educational attainment and lower 
fertility, then this may not be sufficient to close the international gap with 
other high-income countries. Personally, I dislike the coupling of these 
disparate measures of “development”, as political discussions rarely give 
as much focus to educational attainment or fertility, as they give to 
economic productivity. Moreover, Eastern Europe may be a deviant also 
in these facets: while levels of educational attainment are nominally quite 
high, the quality of educational qualifications may deserve additional 
attention. Similarly for fertility: low rates of fertility may be interpreted as a 
state of high-development (as suggested by the GBD authors). An 
alternative interpretation would be one of uncertainty and shock, since 
fertility rates tend to fall at times of recession or other times of large social 
change.(179) In this context, future research efforts could concentrate on 
the association between economic growth (and perhaps inequality therein) 
and mortality, while attempting to adjust for confounders like fertility and 
perhaps also education. 
 
1.3.2.5. Psychosocial and socioeconomic factors – individual data 
The area-level studies above are better able to identify factors that have a 
homogenous association with health, for all residents of that population. In 
other words, if income inequality causes mortality, and if the magnitude of 
effect is homogenous regardless of the whether the individual has low or 
high health behaviours, then area-level analyses would be able to detect 
this. However, this method has two weaknesses. First, area-level studies 
are less able to capture various confounders (such as a different pattern 
of drinking or eating in one country, but not the next), particularly as an 
analysis of Eastern European countries will usually include fewer than 20 
countries, thereby limiting statistical power. In comparison, individual-level 
data may be better placed to control for measured confounders, thereby 
enabling analysts to produce a less biased estimate of whether their 
primary exposure may account for temporal or international variation. 
 
 
87 
 
Second, area-level studies cannot comment on how any temporal 
variation may be socially patterned.  
 
My review of studies, that have investigated whether psychosocial or 
socioeconomic factors may account for temporal or international mortality 
differences in Eastern Europe, resulted in three studies. Each of these 
analysed routine mortality data, and were therefore unable to adjust for 
potential confounders such as smoking and blood pressure. These have 
found that the rise in mortality in Eastern Europe during the 1990s was 
largest among single middle-aged men of low education.(4, 70, 180) Apart 
from these, I am not aware of other individual-level studies that have 
investigated whether international or temporal variation in mortality in 
Eastern Europe might be associated with psychosocial or socioeconomic 
factors.  
 
However, my own reinterpretation of the data presented by Vandenheede 
gave me some early clues to be more sceptical about this hypothesis.(2) I 
looked at mortality rates of the most privileged men across the various 
country cohorts (whereby privilege could be measured through education, 
relative deprivation or absolute deprivation). Privileged Russian men had 
about twice the baseline mortality than equally privileged men in the other 
three countries. This suggested to me, that a large part of the mortality 
gap between Russia and Central Europe is operating outside of 
socioeconomic differences, at all levels of society (at least among the 
responders of the HAPIEE study).  
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1.4. Predicting total cardiovascular risk in individuals 
Before evaluating the literature on the performance of existing CVD risk 
prediction models, it may be helpful to summarize the optimum practice 
for developing and validating a clinical prediction model, as well as how to 
best measure performance and other measures of their utility. This is 
particularly timely, since the best practice recommendations around model 
development have improved considerably in the last 10 years. This 
reflects the expansion in literature of both methodological simulation 
studies, as well as real life evaluations of risk prediction models. 
Accordingly, many of the popular models that are now recommended for 
clinical use (e.g. SCORE, QRISK2) were developed with methods that are 
now seen (with hindsight) to have some weaknesses that could be 
avoided when developing new models. Thus my review of existing models 
(and their performance) needs to be situated in a context of quickly 
changing norms and standards. Annex 2 provides a summary of current 
methodological thinking around the best practice for developing and 
evaluating risk prediction models. Key elements relevant to my review of 
the literature are mentioned below. Key elements relevant to why I chose 
a particular method are additionally mentioned in my Methods section 2.3. 
 
1.4.1. History of CVD prediction models 
I will focus on models that have predicted the development of CVD (i.e. 
fatal/nonfatal CHD, +/- stroke, +/- other atherosclerotic CVD, +/- other 
non-atherosclerotic CVD), among participants free from CVD at baseline.  
 
1.4.1.1. In Western Europe 
The first CVD model in my opinion, was probably derived by Kannel et al. 
in the mid-1970s from the Framingham study (hereinafter the “Fra-Kannel” 
model).(181) This paper is remarkable for fulfilling many of the modern 
criteria for model development (incl. arguing against dichotomizing 
continuous variables; Fitting nonlinear effects such as age-squared in an 
appropriately theory-driven manner; Suggesting a suitable ratio of 
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predictors to events; and the accurate identification of 6 core predictors 
that later replicated in practically all subsequent CVD models). 
 
In 1982 a refined version of the model was summarized onto a simple 
clinical reference card.(182) This innovation allowed continuous risk 
factors (such as age, blood pressure and cholesterol) to be categorized 
into around 10 categories each, so that clinicians could use them without 
a calculator. This card also was remarkable in operationalizing the age-
cholesterol interactive term (figure 10), a feature that then disappeared 
from subsequent CVD models until its reintroduction in 2014. Curiously, 
this innovative publication received little clinical or academic attention (for 
example, by attracting just 19 citations over 35 years). 
 
 
Figure 10. The first semi-A4 sized risk guide, to calculate CVD risk in 
clinical settings, from (182).  
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In 1991, Anderson et al. again slightly refined the Framingham models, 
and persuaded the American Heart Association to endorse them. This 
lead to their adoption by a wider pool of clinicians.(183, 184) 
 
In 2003 The European Society of Cardiology published and endorsed the 
SCORE model.(185) This was the first attempt to offer one model for use 
across multiple countries. The European cohorts that were used to derive 
SCORE were separated into “low risk” and “high risk” regions, with each 
deriving its own model. It is unclear by what criterion they decided on the 
allocation of countries into these two categories. For example, figure 11 
illustrates how there is a negligible difference in the incidence of the 
primary outcome between Sweden (a high-risk country) and Belgium (a 
low-risk country). Perhaps the authors were intending a 50:50 split in the 
sample size, as this turned out to be 56:44 for the low- and high-risk 
models, respectively. (This intention could be further criticized, since the 
high-risk model, having more events, was better powered for model 
derivation than the low risk model.) In essence, already from inception, the 
allocation of countries into “high” and “low” risk status appears relatively 
arbitrary, thereby limiting its real life calibration. This is further aggravated 
by the passing of time. Most of the CVD events occurred in the late 1980s, 
by which point international differences between Russia and capitalist 
European countries were not half as large as they were in the 2010s. 
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Figure 11. Derivation of the male SCORE model. Countries that 
contributed to the “high risk equation” are highlighted in red box, 
while countries that contributed to the “low risk equation” are not 
highlighted. Adapted from (185). 
 
 
2007 saw the publication of the ASSIGN model in Scotland, which 
additionally incorporated family history and area-level deprivation.(186) 
Shortly thereafter, QRISK was published for England being the first and 
only CVD model derived from electronic healthcare records, during the 
period 2007-2017.(187) One of the strengths of the QRISK project is how 
models are derived in settings virtually identical to where they will 
ultimately be used, which is likely to lead to much better calibration when 
compared to deriving models from cohorts studies with greater selection 
bias. However, the QRISK project is only able to explore predictors that 
GPs already consider important and record in their notes. As such, it is not 
able to test the potential benefits from asking GPs to consider new 
predictors. In contrast to models from USA where the hazard of age 
increases with age (using an age2 term) the English model included the 
opposite interaction (log-age). Perhaps this alteration could reflect how the 
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hazard of old age may additionally be captured by comorbidity markers, 
like Diabetes and Rheumatoid Arthritis, in QRISK. 
 
One year later, QRISK was updated into QRISK2.(188) As these 
researchers had access to a large database (with 96 709 events) they 
added details of further comorbidities, as well as negative interactions for 
most risk factors with age. The latter could be a marker of latent gene-
environment interactions, whereby smokers who survive until age 70 
without CVD are unlikely to contract CVD due to smoking alone, after the 
age of 70. However, as cholesterol was missing for most participants, this 
prompted considerable methodological critique. In particular, when 
imputing cholesterol and omitting the outcome from the predictor matrix 
(as was originally done), the imputed cholesterol values were substantially 
different as opposed to using a predictor matrix that included the outcome 
(as was later recommended). From this high-profile example, the former is 
now recommended as standard established practice for dealing with 
missing data in prediction settings. Omitting the outcome biases the 
imputed cholesterols towards the mean, thereby inducing a type of 
regression dilution bias that attenuates the beta coefficient of cholesterol 
artificially downwards towards the null.  
 
In 2014 the American Heart Association switched its endorsement away 
from the Framingham models, towards the Pooled Cohorts Equation 
(PCA).(189) This added to the Original Framingham and Framingham 
Offspring Studies three further cohorts: ARIC (Atherosclerosis Risk in 
Communities); Cardiovascular Health Study; and CARDIA (Coronary 
Artery Risk Development in Young Adults). Most of the participants were 
recruited in the 1980s, with events occurring during the 1990s.   
 
A summary of the predictors used by these better established models is 
shown in table 1. 
 
 
 
94 
 
 
Table 1. List of predictors used in popular CVD risk prediction 
models from Europe and the USA  
(Fra=Framingham; PCE=Pooled Cohorts Equation; 
ECG=Electrocardiography; AF=Atrial Fibrillation; BMI=Body Mass Index; 
HDL=High-Density Lipoprotein; CVD=Cardiovascular Disease) 
 
 
Importantly, in each of these popular risk prediction models above, the 
publication which detailed the model derivation did not include any data 
about external validation. Best practice in model development suggests 
that external validation is probably one of the most rigorous steps one can 
take, to demonstrate that the models are not overfitted and will perform 
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similarly well when adopted to real-life clinical situations (Annex 2). The 
importance of this cannot be overstated, since most of the caveats and 
considerations around deriving accurate risk prediction models are 
centred around trying to minimize overfit (e.g. how to select variables, any 
departures from linearity, interactions, and ensure sufficient power). 
However, external validation is difficult to conduct, which is why it is rarely 
reported papers that derive new models. One external validation study 
found that the Framingham performed well in the UK among those of mid-
to-high risk, but underestimated risk among those of lowest risk.(190) This 
is a relatively rare finding. In contrast, most external validation studies find 
how risk is overpredicted in the validation dataset, where events are less 
common than expected. This has happened in the USA after testing the 
PCA model.(191-193) Typically this is because the validation dataset is 
healthier, for example due to period effects (194), or alternatively due to 
overfitting. 
 
Of note, early models like Framingham omitted socioeconomic status. If 
this model was implemented, then this would have widened 
socioeconomic inequalities in CVD.(195, 196) By same token, it is 
plausible that widespread use of an international model such as SCORE, 
which does not sufficiently capture the underlying difference in baseline 
rates between Russia and Western Europe, may widen international 
health inequalities, by encouraging underuse of preventative interventions 
in those countries of greatest risk. 
 
1.4.2. Previous multi-country scores 
As described above SCORE was the first attempt to provide risk estimates 
for multiple countries. However, it is applicable only to Europe, period 
effects have substantially weakened the models’ utility, and they probably 
did not account sufficiently for heterogeneity in CVD rates across Europe. 
 
A second attempt was made by the WHO in its guidelines on the 
assessment and management of CVD risk.(197) This was the first time 
that a global approach was taken, to provide an approximate risk model 
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for countries with limited prospect of deriving their own models. The 
project can be further congratulated on a further conceptual innovation: 
instead of taking the risk factor Hazard Ratios from the same dataset 
where the estimate of baseline risk is taken from, it was perhaps the first 
CVD model to draw these inferences from separate sources.  
 
However, the application of this idea had substantial limitations. The 
baseline disease risk was taken from an early iteration of the Global 
Burden of Disease Study that had not been peer reviewed. The underlying 
data quality of this has been subject to much criticism. The WHO risk 
developers compounded this limitation by opting to predict not just fatal 
CVD, but also nonfatal CVD whose international data quality is extremely 
heterogeneous. Secondly, the risk factor Hazard Ratios (HR) were taken 
not from a single joint regression that involved all risk factors, but 
apparently some HRs were estimated from univariate models that had 
only been adjusted for age and sex.(198) This can lead to large errors in 
overestimating risk for persons with more than one risk factor, and 
subsequent problems with discrimination and calibration. As such, the 
WHO model has never been published in a peer-reviewed form and will 
be discarded in the rest of this thesis. 
 
A third attempt was made in 2015 with the derivation of GLOBORISK, 
initially for 11 countries (198) which was later extended to 182 
countries(199). Their second publication was published in March 2017, by 
which point I had completed most of the analyses later presented in this 
thesis. Therefore, this publication could be viewed as a parallel 
development to my own work.  
 
The GLOBORISK project should be congratulated for continuing the vision 
of the earlier WHO model, but managing to translate this into a reliable 
model that could contend as the default option for most countries of the 
world. However, the GLOBORISK model contains two considerable 
limitations, the first around calibration and the second around 
discrimination. 
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In contrast to SCORE, GLOBORISK added nonfatal events to its 
outcome. This can be seen as a strength in terms of trying to bring the 
rest of the world to a state comparable to Western Europe and the North 
America, in terms of studies of interventions, guidelines and national 
programmes. However, adding nonfatal events also weakens the model, 
by introducing substantial inter-country heterogeneity in data quality. This 
may be the reason why the GLOBORISK website 
(http://www.globorisk.org) predicts higher risk of fatal/nonfatal CVD for 
male participants in Finland, when compared to risk estimates for 
equivalent participants from Estonia, Poland and the Czech Republic. This 
is inconsistent with the epidemiology of this region, as demonstrated in 
figure 12. 
 
Figure 12. Comparison of the burden of ischaemic cardiovascular 
disease across four European countries.  
The data describe the Disability-adjusted Life Year (DALY) burden for 
men of all ages in 2016. Data are from (200). This geographical pattern is 
not capitulated in the GLOBORISK CVD risk prediction model.  
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A second explanation for these implausible predictions is how the 
GLOBORISK predicts risk for the year 2024, using linear extrapolation 
from trends between 2001-2015. Trends in Eastern Europe have been 
chaotic, and there is little evidence to suggest that these extrapolations 
will hold true. Finally, although the GLOBORISK project set out with a 
focus on improving calibration, no calibration data are presented in either 
paper nor its appendices, other than the largely discredited Hosmer-
Lemeshow χ² test. To summarize this first limitation, I would have found 
the GLOBORISK project much more useful, had it focused exclusively on 
predicting fatal CVD events, and had it demonstrated calibration.  
 
As a second limitation, the authors assumed that the HRs found in the 
USA are generalizable to the other 181 countries. There is very little 
prospective cohort data to empirically test this claim. The authors cited 
one analysis, where HRs from Australia/New Zealand were compared 
against “Asia”. Small differences were found for some HRs (such as blood 
pressure and cholesterol).(201) However, this study amalgamated data 
from primarily China and Japan into one large region, despite the fact that 
these two countries have very different profiles of economic development 
and CVD. The GLOBORISK team secondly cite the INTERHEART study 
as evidence for the homogeneity of Odds Ratios between regions. This 
study explored the range of Odds Ratios for 6 risk factors, across 11 
regions (i.e. 60 comparison groups). Across all 6 risk factors, there 
appeared to be considerable evidence that heterogeneous Odds Ratios 
were unlikely to arise from chance alone (figure 13).  
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Figure 13. Regional variation in Odds Ratios for six risk factors for 
acute myocardial infarction, from the INTERHEART study.  
Confidence intervals are 99%, while 95% confidence intervals will be 
narrower. Adapted from (202), where I have purposefully selected those 
regions with the greatest heterogeneity.  
 
 
However, the INTERHEART authors did not explore this observation 
statistically, for example no significance tests nor Bonferroni corrections 
are reported. It is also possible that the decision to present 99% 
Confidence Intervals, as opposed to the established practice of 95% 
Confidence Intervals, may have been with the intent of projecting an 
illusion of homogeneity to those who were unaware of this detail. 
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Therefore to summarize, at current there are no reliable analyses from 
which to infer whether it is appropriate or not to extend Hazard Ratios and 
other risk factor coefficients from Western European/North American 
studies onto other regions of the world. The answer to this question 
informs the design of risk prediction models elsewhere, but also estimates 
of global burden of disease, and priority setting for national public health 
authorities.  
 
1.4.3. CVD prediction in Eastern Europe 
Vikhireva et al. dichotomized the high-risk SCORE at threshold of >5% 
predicted risk of fatal CVD, and applied this to 8 MONICA and HAPIEE 
cohorts from Eastern European countries. Calibration was good for the 
earlier MONICA Central European samples, with Predicted/Observed 
(P/O) ratios ranging from 0.9 to 1.3. However, calibration became entirely 
useless in the more recent HAPIEE sample (with P/O ratios ranging from 
3.0 to 7.8).(18) In other words, Applying SCORE predictions to men from 
the Polish HAPIEE cohort would lead to 8 times as many predictions, 
while in reality there was only one event. This has the potential to lead to 
overtreatment, side effects, and resource waste. 
 
This mismatch between MONICA and HAPIEE is probably driven by three 
complimentary mechanisms. First, period effects in Central Europe led to 
lower baseline rates of disease by the time of the HAPIEE study, thereby 
lowering observed rates. However, this alone may not account for the 
eight-fold difference in calibration. Second, it is likely that the MONICA 
sampling frame was more similar to the sampling frame used in the other 
cohorts used to derive SCORE, while HAPIEE may have oversampled 
higher SES participants comparatively more, with lower baseline rates of 
disease. Third, there is a secular trend across the world, whereby 
response rates were highest during the 1970 (i.e. the derivation of 
SCORE), slightly lower in the 1980s (i.e. MONICA) and lower still in the 
2000s (i.e. HAPIEE). It is plausible that non-response bias, which tends to 
produce artificially low mortality rates, is greater in more recent time 
periods. 
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Vikhireva et al. also reported extremely low discriminatory power of the 
SCORE model across all cohorts, with C-statistics ranging from 0.54 (very 
close to a random coin flip) to 0.74. There was some indication of 
improvement in discrimination over time (the average C-statistic in 
MONICA was 0.63, Vs. 0.67 in HAPIEE). Even after restricting analyses to 
HAPIEE data only, the C-statistic was lower among men than women 
(0.63 Vs. 0.70), while men face much higher needs for accurate CVD 
prediction. 
 
Jdanov et al. published a SCORE model that was recalibrated to the 
Moscow and St. Petersburg populations. This is unlikely to generalize to 
the wider Russian population, on account of higher SES and better health 
outcomes in larger cities. Its use elsewhere would lead to undertreatment. 
Their model was based on 652 events detected between 1975-2009.(203) 
Unfortunately, the publication did not present measures of calibration, 
discrimination or reclassification. I am not aware of other English-
language publications that evaluate the performance of CVD risk 
prediction tools in Eastern Europe.  
 
1.4.4. Attempts to augment models with new predictors 
Attempts to date to improve CVD risk prediction with new risk factors have 
on the whole been disappointing. Usually, these efforts are focused 
around improving discrimination, with some papers additionally reporting 
reclassification.  
 
Biomarkers such as CRP, troponin, and fibrinogen have typically improved 
C-statistics by around 0.003 to 0.010.(204) Downstream markers that are 
more specific to latent cardiac pathology may to have greater potential to 
improve discrimination. For example, BNP improved C-statistic by an 
outstanding degree - 0.08 units in one study(204), but only 0.011 in 
another(205). Coronary Artery Calcium Score (CAC) improved C-statistic 
by a similarly outstanding 0.05 units.(206) This study also improved Net 
Reclassification Improvement (NRI, discussed methodologically in Annex 
2, section A2.2.10) reported across three categories by 0.25, which was 
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driven primarily by improvements among cases. However, this study had 
15 events per parameter, shrinkage was not performed, and data were not 
externally validated. This makes it possible for chance overfit to account 
partly for these findings. The same authors also studied improvements 
from CAC in the same cohort again, this time focusing on improvements 
exclusively among those of intermediate Framingham risk (5% < FRS < 
20%).(207) This improved C-statistic by 0.124, as well as a categorical 
formulation of Net Reclassification. However, the baseline risk model had 
an unusually poor fit (C-statistic = 0.642). Furthermore, with an event-to-
parameter ratio of 8, no shrinkage of coefficients, and no external 
validation, a part of this is may again reflect statistical overfit. 
 
1.4.4.1 How good is good enough? 
Many of the studies in this field are difficult to compare with one another. 
Much like elsewhere in epidemiology, there may be slight differences in 
the population, response rate, definitions to risk factors or outcomes, or 
follow-up. However, studies of improvements to risk prediction are made 
less comparable by the use of a range of various reclassification 
measures. For example, one study may report reclassification across the 
entire risk gradient, a second study may dichotomize risk at a particular 
threshold, a third study may dichotomize risk at another threshold, a fourth 
study may use multiple risk categories, while a fifth study may look at 
multiple risk categories after having restricted the sample to those of 
intermediate risk. Changes in C-statistic are less prone to such inter-
investigator variation, but are nonetheless sensitive to the ability of the 
baseline model to discriminate. 
 
In the absence of guidance, I will consider the following interpretations 
throughout this manuscript. I will assume that baseline conventional CVD 
models all discriminate to similar levels (i.e. C-statistic of between 0.70 to 
0.80). The following guidelines are informed by the observation that 
omitting blood pressure from a conventional risk prediction has resulted in 
a ΔC of only 0.004.(110) 
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ΔC < 0.004 = no improvement 
ΔC ≥ 0.004 = minor improvement 
ΔC ≥ 0.01   = substantial improvement 
ΔC ≥ 0.02   = impressive improvement 
ΔC ≥ 0.03   = outstanding improvement 
 
1.4.4.2. Genetic predictors 
Abraham et al. evaluated the utility of adding a genomic-risk-score, 
incorporating beta coefficients from 49 310 SNPs, to two conventional 
CVD models across three external cohorts. This improved C-statistics 
substantially - by 0.011 to 0.017 across the 6 comparisons. NRI, 
measured across 4 categories, was between 3 to 15% across the 6 
comparisons, with continuous NRI being between 25 to 37%.(208) In 
contrast to this, previous studies that have included less than 50 SNPs 
which all met conventional levels of GWAS-significance have been much 
more disappointing (ΔC = 0.003, continuous NRI = 17%).(209, 210) This 
is consistent with current advice about selecting predictors into risk 
prediction models, which advise against using conventional thresholds 
(like p<0.05) to evaluate if a predictor should be included, but advocate for 
more relaxed thresholds. 
 
To my mind, one large weakness in the current paradigm of genome-wide 
association studies is how they tend to adjust for just age and sex, and do 
not routinely adjust for conventional risk factors. This means that although 
readers and users of the top hits tend to think of these as “genetic signals” 
which can be compared and contrasted against “conventional risk factor 
signals”, they may in fact me measuring the same thing. That is, a 
seemingly cardiac SNP may actually be a mere marker of cholesterol, 
blood pressure, smoking and/or glycaemia. Accordingly, some high-profile 
applications of such “top cardiac SNP” have been interpreted to mean that 
genetics adds incremental value over and above conventional risk factors. 
However, some of these papers have not even defined what they mean by 
“conventional risk factors”, but merely claim to adjust for these in a 
multivariable manner.(211) The field could be improved by a rigorous 
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examination of cardiac GWAS signals, before and after adjustment for 
conventional CVD risk factors. If the cardiac GWAS do not attenuate, this 
would suggest that they are indeed independent. If they do attenuate, this 
would suggest that minor gains to prediction could be made either by 
measuring or modelling the conventional risk factors more precisely 
(which may turn out to be more cost-effective), or by using genetic 
proxies. 
 
1.4.4.3. Physical inactivity 
The benefit of adding physical inactivity to prediction models has been 
substantial in two studies (one among healthy participants, the other 
among participants with prevalent disease)(212, 213), and null once.(214) 
One study added physical activity, its interaction with gender, waist 
circumference, and peripheral artery disease, to find this package 
substantially improved the C-statistic.(215) However in another study, the 
addition of added physical activity, diet, alcohol, BMI and waist 
circumference made no improvement to C-statistic.(216) I am not aware of 
any study that has derived a model that includes physical inactivity, which 
has subsequently been externally validated. 
 
1.4.4.4. Psychosocial and socioeconomic predictors 
There are two motivations for including socioeconomic risk factors to risk 
prediction models. First, it may improve reclassification in the entire 
cohort, thereby fostering personalized preventative medicine for the 
population as a whole. In case of equitable access to, and uptake of 
healthcare, this has the potential to reduce healthcare inequalities. 
Second, even if socioeconomic risk factors do not improve reclassification 
in the entire cohort as a whole, they may still reduce health inequalities. 
Consider a new model that adds SES, whereby all those of low SES are 
given a very large risk coefficient. This could improve True Positive rates, 
sensitivity and reclassification among cases, but this could be offset by 
worse False Positive rates, specificity and reclassification among controls. 
There may be no change to unadjusted metrics, such as the C-statistic, or 
NRI. However, more statins may nonetheless be redirected towards those 
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with lower SES. In order to accurately predict whether the cost-to-benefit 
of such a divergence could be accompanied by a change in health 
inequalities (after considering the benefits and side effects of statins), 
these costs and benefits would need to be appropriately weighted (such 
as by using Net Benefit and Decision Curve Analyses). My thesis 
nonetheless, will ignore the aim of measuring health inequality, and will 
instead focus on the prospect of improving average health. 
 
Table 2 presents an overview of 10 studies that have added a 
socioeconomic/ psychosocial risk factor, and reported either ΔC or NRI. 
(12, 18, 110, 212, 214, 217-221) Other studies have also reported the 
effects of adding SES variables, but these studies did not report either C-
statistics, NRI, Net Benefit or Decision Curves.(222) All of the studies to 
date have looked at changes taking place within one cohort, and few have 
replicated their findings in external cohorts. Another common limitation is 
how most measures of performance have not considered clinically 
relevant improvements across clinically relevant risk thresholds (e.g. 
Binary NRI, detailed in Annex 2), but instead present measures that are 
sensitive to improvements at any risk threshold (e.g. Continuous NRI, C-
statistic). 
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Table 2. Summary of methods and findings from 10 studies, that 
evaluated the addition of psychosocial/socioeconomic risk factors to 
CVD risk prediction models. (Cont.=continuous; Cat.=Categorical; 
Intermed.=Intermediate; PCE=Pooled Cohorts Equation; NRI=Net 
Reclassification Improvement) 
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Broadly speaking, of these 10 papers, the methodologically more robust 
studies have found no or little improvement, while methodologically 
weaker studies have found good improvement. This might suggest the 
potential for publication bias. Furthermore, I am not aware of a single 
study that has found improvement, and thereafter tested this beta 
coefficient in an external dataset. Another weakness of these studies is 
that they have typically dichotomized their exposure thereby discarding 
available information, although more granular categories may be easy to 
model.  
 
Only one paper out of these 10 reported the benefit of adding up to three 
risk factors simultaneously.(221) (One Danish study did evaluate 15 novel 
predictors, but it only reported improvements in univariate models(214).) 
By analogy to the work with genetic and genomic markers, it may be more 
fruitful to add lots of markers simultaneously. Vikhireva et al. evaluated the 
benefit of adding education and marital status to the SCORE model.(18) 
They fitted 16 separate models stratified by each country, cohort and 
gender. This means that all the female models were substantially 
underpowered (with an event to parameter ratio ranging from 2 to 12, 
mode=4). In conjunction with no shrinkage and no external validation, this 
increases the risk of overfit substantially, so I will instead concentrate on 
their 8 male models (where the event to parameter ratio ranged from 4 to 
25, mode=9), and report the modal statistic for each analysis. They found 
impressive improvements to discrimination following the addition of 
education (modal ΔC = 0.02), marital status (modal ΔC = 0.02), and that 
these improvements seemed to not to overlap with one another after 
adding both factors simultaneously (modal ΔC = 0.04). With a similar 
methodological approach, Veronesi et al. evaluated the benefit of adding 
education and family history,(220) and also found these two components 
to contribute independently when added together. 
 
In contrast to measures of SES, which has been the main focus of these 
10 studies, there has been comparatively little focus on the contribution of 
psychosocial factors. Only one study has reported on the impressive 
 
 
108 
 
improvement after adding marital status. I am not aware of another study 
that has evaluated the addition of employment status or depression into 
an established CVD risk score. However, the addition of vital exhaustion 
has led to no improvement,(214) or minor improvement(110) in the C-
statistic. Another study found substantial improvements after adding 
psychological distress.(212)  
 
1.4.5. Summary of risk prediction  
A decade ago, there was little need for clinicians to predict total risk, as 
each risk factor was thought to have a complimentary, reductionist effect. 
Recent thinking has shifted towards taking a more holistic approach. For 
example, statins appear to create additional off-target benefits, which do 
not involve cholesterol. This has created a growing clinical appetite for 
better risk prediction models. The methodology of how to create these is 
developing quickly. Basic models to predict cardiovascular disease have 
been around for over 40 years. However, there are considerable 
questions about how valid these models are to real-life populations from 
where their cohorts are drawn (due to selection bias and period effects); 
and even bigger challenges with exporting such models to other countries 
that lack their own derivation data. Accordingly, one avenue for 
development is the refinement of CVD models for countries where they 
are currently lacking. Eastern Europe has the world’s highest burden of 
CVD, but both the SCORE and GLOBORISK models available there 
contain considerable weakness in calibration and discrimination.  
 
A second avenue of development is the addition of psychosocial and 
socioeconomic risk factors.(223) A handful of studies that have tried this, 
with some finding impressive improvements while other not. None of these 
studies have externally validated their findings in another cohort. No study 
has evaluated the benefit of depression or employment status. No study 
has evaluated the benefit of adding four psychosocial/socioeconomic 
factors at the same time. And finally, no study has summarized clinically 
relevant benefits and harms in a single metric, such as Net Benefit. 
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1.5. Summary of the literature review 
A large body of observational epidemiological studies, predominantly 
conducted in countries of Western Europe and Northern America over the 
past 50 years, have described a replicable and sizable associations 
between educational status, material deprivation, unemployment, social 
support, personality and depression in their ability to predict the incidence 
of cardiovascular disease among healthy middle-aged participants. At 
current, it remains relatively unknown to what extent they may mediate 
each others’ effects, as well as to what extent similar associations may be 
found in Eastern European countries. 
 
Data from twin/sibling studies, as well as natural experiments, are on 
balance more compatible with an interpretation of causal effects from 
education to all-cause mortality. Despite this, there remains considerable 
scepticism about whether changes to socioeconomic risk factors can 
cause changes to the incidence of cardiovascular disease. 
 
Eastern European regions, and particularly ex-USSR countries like 
Russia, have substantially higher rates of cardiovascular disease when 
compared to countries in Central and Western Europe. The causes of this 
remain relatively unknown. The IMPACT model and MONICA studies 
suggest that conventional risk factors and healthcare may have played a 
smaller role in accounting for temporal changes in CVD. However, these 
studies have not investigated the causes of divergence among the ex-
USSR countries after the breakup of the USSR. Dietary factors and 
alcohol have been proposed, but the data so far does not suggest that 
these can account for international differences observed in the 2000s. 
Area-level analyses have implicated rapid privatization, income inequality 
and low perceived control with higher mortality rates. However, these 
analyses cannot use individual level data to adjust for confounders. 
Existing individual-level analyses have implicated single marital status and 
low education as two factors that correlated with earlier death, however 
these analyses too did not adjust for confounders. 
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Models to predict cardiovascular disease have been around for over 40 
years. However, these may not be accurate in Eastern Europe. Secondly, 
few studies have investigated whether psychosocial and socioeconomic 
risk factors can improve risk prediction. Where this has been reported, 
there has been no quantification of whether these benefits are clinically 
relevant, and there have been no subsequent reports of external 
validation. 
 
In terms of translational impact, there is currently quite limited coverage of 
psychosocial and socioeconomic risk factors in medical textbooks and 
clinical guidelines. Their assessment is beginning to become a routine 
part of some aspects of public health practice, however this is not the 
case among primary care physicians and cardiologists. The causes 
behind this are numerous. There is potential for this to change over time, 
which in turn could be assisted by: 
 
1) Clarifying the causal and mechanistic nature of the associations 
between psychosocial/socioeconomic factors and cardiovascular 
disease. 
 
2) Using psychosocial/socioeconomic factors to explain why the burden 
of cardiovascular disease is inexplicably high in some countries of the 
world.  
 
3) Demonstrating the utility of psychosocial/socioeconomic factors in 
improving the prediction of cardiovascular risk in individuals.  
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1.6. Aims and objectives 
1.6.1. Overall aims  
1. To investigate whether education is a causal risk factor in the aetiological 
development of coronary heart disease. 
2. To investigate what could mediate the presumed causal association 
between psychosocial/socioeconomic factors and CVD. 
3. To investigate whether the higher burden of CVD mortality found in 
Russia, when compared to Central European countries, could be 
attributed to psychosocial and socioeconomic factors. 
4. To investigate whether the addition of psychosocial and socioeconomic 
factors to CVD risk prediction models can enhance their clinical 
performance. 
 
1.6.2. Theoretical orientation and hypotheses formulation 
After reading the literature and specifying my overall aims, I formed the 
following causal diagram of how socioeconomic/psychosocial factors 
could cause CVD, among those free from CVD at baseline (figure 14). 
 
 
Figure 14. Theoretical direction of causal effects from three groups 
of risk factors, in influencing mortality from cardiovascular disease 
(CVD). 
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1.6.3. Specific objectives 
 
1) Causality using Mendelian randomization 
a. To investigate the association between genetic predisposition towards 
education and subsequent risk of CHD, using two-sample Mendelian 
randomization (MR). This will inform the question of whether the 
association between education and CHD is causal or not.  
 
b. To further investigate the robustness and plausibility of my findings, 
additional analyses will be performed as: 
 
i. To evaluate whether the two-sample MR estimate obtained under 
1a) could have been confounded by pleiotropy, using MR-Egger, 
Median-MR, Modal-MR, reverse-MR, as well as by triangulation of 
published results from twin studies and natural policy experiments. 
 
ii. To triangulate the results from 1a-b) with estimates of the 
observational association between education and: 
1. CHD prevalence, by using public data from NHANES. 
2. CHD incidence, by transforming published estimates from 
MORGAM. 
3. CHD incidence, by using unpublished data from HAPIEE. 
 
iii. To investigate the association between genetic predisposition 
towards education and subsequent changes to conventional CVD 
risk factors, using two-sample Mendelian randomization (MR). 
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2) Mediation 
a. To investigate to what extent the observational association between 
socioeconomic factors and CVD might be mediated by conventional 
CVD risk factors and/or psychosocial factors. 
 
b. To investigate to what extent the observational association between 
psychosocial factors and CVD might be mediated by conventional 
CVD risk factors and/or other psychosocial factors. 
 
 
3) International differences 
a. To investigate whether the inclusion of psychosocial and 
socioeconomic risk factors attenuates the additional cardiovascular 
hazard seen among participants from Russia, that is not seen among 
participants from Poland or the Czech Republic. 
 
4) Prediction 
a. To construct two new models that predict the incidence of CVD 
among healthy participants: 
i. A recalibrated SCORE: To recalibrate the existing SCORE model, 
using contemporary data from Eastern Europe.  
ii. An augmented SCORE: To extend the New SCORE model, by the 
addition of four psychosocial/socioeconomic predictors (education, 
marital status, unemployment, depression) and three behavioural 
factors (BMI, physical inactivity, antihypertensive use). In 
evaluating performance (internally), to specifically attend to 
reclassification around clinical intervention thresholds. 
 
b. To externally validate both new models, using data from the Estonian 
Biobank.  
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2. Methods 
 
2.1. Mendelian randomization 
A range of study designs exist that offer additional insights into causal 
inference, beyond that of conventional epidemiological observational 
studies. These include natural policy experiments (and interrupted-time 
series designs) where exposure is suddenly modified at the population 
level. Regression discontinuity designs exploit the instances where social 
systems force a dichotomous threshold on a naturally continuous trait, 
such as forcing children with a biological age range of 12-months into 
annual educational cohorts. Studies of monozygotic twins can clarify 
whether observational associations might be attributable to unmeasured 
confounding from genetically inherited material, or parental influences 
shared by both twins. As an extension of this, siblings share only 50% of 
each other’s genetic material but such studies can be many times larger, 
thereby increasing net statistical power. Finally, instrumental variables 
induce changes to exposure, but cannot have independent effects on the 
outcome. The randomization and allocation of treatment which occurs 
during a randomized controlled trial can be thought of as an instrument 
and is often seen as the gold standard. Examples of other instruments 
include random allocation into military service (as was done in the USA 
during the war against Vietnam), as well as the genetic instruments used 
in Mendelian randomization studies.  
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2.1.1. Background to Mendelian randomization 
2.1.1.1. Principles of Mendelian randomization 
Mendelian randomisation analysis uses genetic variants associated with a 
risk factor (e.g. education), to make causal inferences about how 
environmental changes to the same risk factor would alter the risk of 
disease (e.g. CHD).(224) By comparing the risk of disease across 
participants who have been grouped by their genotype, this enables the 
causal effect of a risk factor to be approximated with substantially less 
bias than that in a traditional observational analysis. Genetic markers of a 
risk factor are largely independent of confounders that may otherwise 
cause bias, as genetic variants are randomly allocated before birth.(225) 
This, as well as the non-modifiable nature of genetic variants, provides an 
analogy to trials, where exposure is allocated by random and is non-
modifiable by subsequent disease.(225)  
 
Finally, observational epidemiological analyses may be biased in cases 
where some participants show systematic reporting bias (when reporting 
either the exposure or outcome), which is different in magnitude when 
compared to the response bias shown by other participants. In Mendelian 
randomization analyses, both exposure and outcomes are proxied using 
genetic markers, which themselves are derived from GWAS analyses that 
best fit the average of the population sampled. The genetic markers 
themselves are objective, and do not suffer from the same problem of 
differential response bias. This is another example of where Mendelian 
randomization analyses may produce estimates that are closer to the true 
cause an effect. 
 
2.1.1.2. Two-sample Mendelian randomization 
Up until relatively recently, Mendelian randomisation (MR) analyses have 
been conducted on single datasets where data on genotype, risk factor 
and outcome were measured for all participants (known as “one-sample 
Mendelian randomisation”). However, performing advanced analyses on 
pleiotropy requires larger sample sizes in order to maintain statistical 
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power. This would require data pooling across dozens of studies, which is 
administratively difficult to organize. As an alternative, summary-level data 
from large genome-wide associations study (GWAS) consortia have 
become increasingly available in the public domain. It is possible to use 
such data to conduct Mendelian randomisation analyses, whereby gene-
exposure measures are taken from one GWAS and gene-outcome 
measures are taken from another GWAS (altogether known as “two-
sample Mendelian randomisation”).(226)  
 
2.1.1.3. Sensitivity analyses for pleiotropy 
Further methodological developments, including Mendelian 
randomisation-Egger (MR-Egger), weighted median MR, and mode-based 
methods, can all be employed as sensitivity analyses to additionally 
investigate any pleiotropic effects of the genetic variants (i.e., when 
genetic variants for education exert their influence on heart disease 
through an “off-target” pathway that bypasses the education phenotype 
(See Figure 15 for details).(226-228) The Mendelian randomisation 
method has successfully been applied to a range of biological and 
behavioural exposures.(229, 230) I am aware of just two studies that have 
applied it to investigate a socioeconomic exposure: a polygenic score for 
education has previously been associated with the development of myopia 
and dementia.(136, 137) However, these studies did not investigate the 
possibility of unbalanced horizontal pleiotropy.  
 
Complex exposures, especially those instrumented by multiple SNPs of 
unclear biological role, may result in unbalanced horizontal pleiotropy. If 
this possibility is not examined, then such an omission might be 
considered to be the single most important weakness of such an MR 
study. Accordingly, I wanted to examine the potential for pleiotropy as 
rigorously as possible. 
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Figure 15. Theoretical illustration of pleiotropic phenomena on 
estimates derived from Mendelian randomization (MR) analyses. 
In the case of vertical pleiotropy, the conventional MR assumptions are 
satisfied as the intermediating phenotype lies on a single causal pathway. 
In the case of horizontal pleiotropy, one or more phenotypes lie on a 
different parallel causal pathway. When the effects of the SNPs on the 
outcome through various parallel intermediating phenotypes are balanced, 
then estimates derived with conventional MR estimates should be valid. 
However, when the effects of SNPs on the outcome are systematically 
distorted towards one of the parallel alternative pathways (unbalanced 
horizontal pleiotropy), conventional MR estimates are invalid and biased 
due to confounding from the parallel pathway. Advanced MR techniques 
(representing techniques such as MR-Egger and weighted median MR), 
accounting for presence of unbalanced pleiotropy of the genetic 
instrument, should nonetheless produce an estimate that is closer to the 
true underlying association between the risk factor and outcome.  
Figure adapted from White J. et al. JAMA Cardiol. 2016.(231) 
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2.1.2. Background to GWAS 
In order to conduct a valid Mendelian randomization study, researchers 
need to identify a valid genetic instrument which induces changes to the 
exposure of interest (e.g. education). This is typically done by searching 
the literature of published genetic association studies.  
 
Genome-wide association studies (GWAS) were originally often case-
control studies in their nature, where a group of patients with the disease 
were compared against those without disease. Logistic regression 
(adjusted for age and sex) was used to test approximately one million 
genetic exposure (typically single-nucleotide polymorphisms [SNPs]), and 
identify those SNPs surpassing a standard Bonferroni adjustment   
(5 x 10-8, also known as genome-wide significant).  
 
In case that genome-wide significant associations are found, then some of 
these significant SNP may be located physically close to one another on 
the same genomic region of a chromosome in a process known as genetic 
linkage. Genetic linkage is one the reasons behind linkage disequilibrium, 
which denotes how two SNPs may not be inherited in a completely 
random fashion. In case that a GWAS identifies a cluster of correlated and 
physically co-located SNPs, such studies typically present just one ‘lead 
SNP’ in their final results. A process of pruning is performed to identify 
such lead SNPs, which ultimately selects the SNP with the smallest P-
value as the lead SNP.  
The central dogma of molecular biology states that alterations to DNA 
cause alterations to RNA which causes alterations to proteins (and 
subsequently, function and phenotype). Notably, alterations to the lead 
SNP may or may not cause downstream phenotypic change in the trait of 
interest. For example, it may be that the SNP with the largest P-value, 
identified as a ‘lead SNP’ is not causal for the trait of interest but is merely 
co-inherited with a causal SNP. Despite this nuance, people that carry 
non-causal lead SNPs are, on average, likely to also carry the unknown 
causal SNPs linked to the lead SNP, and are thereby likely to be randomly 
allocated to the trait of interest. 
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The case-control approach to a GWAS can also be modified to investigate 
traits which are distributed normally (such as BMI or education). In this 
case, linear regressions are used to predict the trait (e.g. education) as 
the outcome with age, sex, and each SNP being entered, one-by-one, in 
millions of univariate models. Some analyses additionally control for 
population stratification and additional cohort/period dummy variables. 
 
During the start of my PhD (in May 2015), I performed a literature search 
for GWAS findings for any of the commonly measured socioeconomic and 
psychosocial traits. I was unable to find any study which had identified 
more than 5 SNPs which were subsequently replicated in an external 
cohort. Using less than 5 SNPs for an MR study is prone to weak-
instrument bias, as well as eliminating the possibility of performing 
advanced tests for pleiotropy. 
 
2.1.2.1. Details of GWAS on education 
In May 2016, the Social Science Genetic Associations Consortium 
(SSGAC) published a GWAS of education that identified 74 independent 
lead SNPs, replicated in an external cohort. This was an important and 
unexpected finding for me, as this was the first time that so many 
independent SNPs had been identified for a socioeconomic/psychosocial 
trait. This created the potential to investigate in more detail whether 
education causes a common health outcome, such as coronary heart 
disease.  
 
The GWAS of education was conducted by meta-analysing summary-level 
data from 64 cohorts (each with sample sizes ranging from n=318 to 
n=76,155), altogether on 293,723 participants. Participants were men and 
women of a wide age range, of European ancestry. All cohorts were 
recruited in either European countries, USA and Australia.  
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Missing data in SNP-education associations 
Most common genotyping chips measure between 0.2 to 2 million SNPs. 
Okbay et al wanted to evaluate associations across almost the entire 
genome, i.e. 9,256,490 SNPs. While it may be unreasonable to impute 90% 
for non-genetic studies, this is less problematic in genetic studies, as the 
degree of correlation between individual SNPs (i.e. linkage disequilibrium) is 
so high. 
 
Each of the 64 cohorts imputed their missing genotype data with reference 
to some version of the 1000 Genomes project. Association analyses were 
performed within each cohort on all genotyped and imputed SNPs. and 
summary statistics were meta-analysed by Aysu Okbay. Prior to meta-
analysis, a set of quality control (QC) filters were applied to cohort-level 
association results to make sure they were statistically reliable. SNPs with 
low imputation accuracy were filtered out as part of QC. The actual 
imputation accuracy thresholds used to filter out badly imputed SNPs 
differed by the type of imputation software used by the underlying cohort: 
0.6 for MaCH, 0.7 for IMPUTE2, and 0.8 for PLINK.   
      
As a result of differences in genotyping chips and imputation reference 
panels (different versions of the 1000 Genomes reference panel, or in a 
handful of cohorts, other sequence data comprising a similar set of SNPs) 
used by cohorts, and the quality control filters applied to cohort-level 
results, a slightly different set of SNPs from each cohort entered the meta-
analysis. Hence, some SNP-exposure estimates were derived from larger 
samples while other SNP-exposure estimates were derived from smaller 
samples (max 349,306 participants, in the sample which did not overlap 
with my outcome dataset. Median SNP=347,477 participants. Least 
available SNP= 220,565 participants). In case that GWAS results were 
available for the full sample (349,306 participants), I report this below as 
“100% available / complete”. For the vast majority of SNPs (141 out of 162 
SNPs, i.e. 87% of SNPs), data were non-missing for 90% of participants.  
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For an average SNP, GWAS results were missing for just 3.5% of 
participants. The distribution of missing data across SNPs ranked by their 
degree of missingness is shown in figure 16. 
 
 
 
 
Figure 16. Amount of missing data for each of the 162 instrumented 
educational SNPs. 
 
 
 
 
Overall, data completeness in SNP-exposure associations appears to be 
very good. Additional details about these SNPs, including details on 
missing data, are provided in “Data supplements.xls”, on the website of 
the journal where this research was published: 
www.bmj.com/content/358/bmj.j3542  
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Biological function 
At current, it is unknown how these 74 SNPs (if causal) might exert their 
influence on education. Most of these loci are not known genes, making it 
possible that they may regulate the function of other unknown genes. Still, 
Okbay et al. went into considerable detail to investigate biology using 
other approaches, some of which is relevant to the question of whether 
these 74 SNPs may have pleiotropic effects on cardiac function in a 
pathway that bypasses education. To paraphrase their key findings [my 
additions in square brackets]: 
 
“SNPs in regions that are DNase I hypersensitive in the foetal brain are 
more likely to be associated with education by a factor of ~5. Moreover, 
the 15% of SNPs residing in regions associated with histones marked in 
the central nervous system explain 44% of the heritable variation. This 
enrichment factor of ~3 for CNS is greater than that of any of the other 
nine [non-neurological] tissue categories in this analysis [such as cardiac 
tissue]. Given that our findings disproportionately implicate SNPs in 
regions regulating brain-specific gene expression, we examined whether 
genes located near education associated SNPs show elevated expression 
in neural tissue. Remarkably, the 13 GTEx tissues that are components of 
the CNS—and only those 13 tissues—show significantly elevated 
expression levels of genes. [i.e. no expression in non-Central Nervous 
System tissues].  
 
The resulting 34 [gene] clusters paint a coherent picture, with many 
corresponding to stages of neural development: the proliferation of neural 
progenitor cells and their specialization, the migration of new neurons to 
the different layers of the cortex (forebrain development, abnormal 
cerebral cortex morphology), the projection of axons from neurons to their 
signalling targets (axonogenesis), the sprouting of dendrites, and neuronal 
signalling and synaptic plasticity throughout the lifespan (voltage-gated 
calcium channel complex).”  
 
Altogether, this suggests that these 74 SNPs are primarily involved in 
neuronal development and are unlikely to directly (by alternative parallel 
pathways) cause changes to cardiac or vascular tissues. 
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2.1.2.2. Details of GWAS on CHD 
To conduct two-sample MR, I needed to access summary-level data on 
the handful of top SNPs associated with education, and see if they are 
also associated with heart disease. For this, I primarily used data from the 
2013 release of the Coronary ARtery DIsease Genome wide Replication 
and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease 
(C4D) Genetics) consortium. They meta-analysed data from 39 studies, to 
look at genetic differences between 63,746 CHD cases against 130,681 
controls. Most of these cases were relatively early onset (the typical age 
of presentation was between 50 to 60), with predominantly non-fatal as 
opposed to fatal cases. 
  
 
2.1.2.3. Details of GWAS on 10 CVD risk factors 
To look at causal effects from education where the outcome is not 
disease, but a CVD risk factor, I used data on 10 risk factors from 6 
GWAS studies, described in table 3. 
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Consor-
tium 
Outcome 
Parti-
cipants 
Website for data download 
 TAGC Smoking 74,053 
www.med.unc.edu/pgc/result
s-and-downloads 
ICBP 
Blood 
pressure 
74,064 
 
www.ncbi.nlm.nih.gov/ 
projects/gap/cgi-
bin/study.cgi? 
study_id=phs000585.v1.p1 \ 
GLGC 
 
LDL-, HDL-
cholesterol, 
and 
triglycerides 
 
188,577 
csg.sph.umich.edu/abecasis/
public/lipids2013/ 
DIAG-
RAM 
 
Type 2 
diabetes 
 
149,821 
 
diagram-consortium.org 
 
MAGIC 
Glucose 
 
133,010 
 
www.magicinvestigators.org 
 
GIANT BMI, height 339,224 
portals.broadinstitute.org/coll
aboration/giant/ 
    
    
 
Table 3 Identification of potential Mediators (education to 
conventional CVD risk factors) 
TAGC, Tobacco and Genetics Consortium. ICBP, International 
Consortium for Blood Pressure. GLGC, Global Lipids Genetic Consortium. 
DIAGRAM, DIAbetes Genetics Replication And Metaanalysis. MAGIC, 
Meta-Analyses of Glucose and Insulin-related traits Consortium. GIANT, 
Genetic Investigation of Anthropometric Traits. 
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2.1.3. Overview of the Mendelian randomization analyses 
performed 
 
Prior to conducting an MR analysis, it is sometimes useful to check 
whether the exposure and outcome traits of interest share some common 
underlying genetic architecture. To investigate the genetic correlation 
between education and CHD, I used the “Lookup Center” function of the 
LD Hub platform (http://ldsc.broadinstitute.org).(232) On 28th October 
2016, I downloaded an XLS file of genetic correlations, based on latest 
data that has been previously uploaded onto the LD Hub platform. 
Analyses were done by Linkage Disequilibrium Score Regression. After 
integrating two GWAS datasets and examining millions of SNPs across 
the entire genome, there was strong evidence for a negative genetic 
correlation between education and CHD (rg=-0.324; rg2=0.104; P-
value=2.1 x 10-12).(233) To interpret this, educational outcomes can vary 
due to genetic and non-genetic variance. Within the domain of genetic 
variance, approximately 10% of it appears to be shared with the genetic 
variance of CHD (and vice-versa), whereby this correlation is negative. 
This correlation can arise for various reasons, so I next conducted 
Mendelian randomisation analyses to investigate the presence and 
direction of any causal effects.  
 
My study of causality was composed of four research questions, indicated 
in blue in figure 17. 
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Figure 17. Overview of the main steps in this study.  
Existing datasets (grey), hypothesis formulation (blue), key findings 
(green), their interpretation (yellow), conclusion (orange) and final 
suggestions for discussion (red). 
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Throughout all analyses, education was initially coded as “highest 
educational qualification”. Using the International Standard Classification 
of Education 1997 classification system (see supplementary table 1.3 of 
the original GWAS study(234), this was transformed into the number of 
typical years spent in education, to obtain that qualification (using country-
specific conversion guidelines). Following harmonization, self-reported 
educational attainment was modelled linearly, expressed as one standard 
deviation (i.e. 3.6 years) of additional schooling. In this form, one year of 
vocational education was equivalent to one year of academic education, 
and I did not assume any qualitative differences in the type of education. 
CHD was defined as a composite of myocardial infarction, acute coronary 
syndrome, chronic stable angina or coronary stenosis of >50%, or 
coronary death. 
 
 
 
2.1.4. Mendelian randomization data sources (exposure to 
education) 
 
I will now describe in more detail the steps taken for question 1 (which 
additionally informs the steps taken for question 3, as illustrated in Figure 
18. 
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Figure 18. Flowchart of the derivation of two sets of education SNPs 
(162 and 72 SNPs), used in Mendelian randomization estimates from 
education.  
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The Main MR analysis was performed on a slightly larger set of SNPs 
than what was discovered and replicated in the original GWAS of 
education. Namely, I used 162 independent SNPs associated (P<5.10-8; 
linkage disequilibrium r2<0.1) with education in a meta-analysis of the 
discovery (Social Science Genetic Association Consortium) and 
replication (UK Biobank) datasets combined. This has the disadvantage 
that these 162 have not been validated in an external dataset, making it 
possible that they have more type1 errors and are hence not sufficiently 
predictive of education in external datasets (such as the outcome 
datasets); and they may be more pleiotropic for other traits. However, if 
there are few type-1 errors, then they can form a more powerful genetic 
instrument, which is particularly useful for sensitivity analyses of 
pleiotropy. Altogether, these 162 SNPs explained 1.8% of the variance in 
education in this discovery stage. This is sufficient to generate a strong 
genetic instrument with which to derive precise causal estimates (see 
Table 4 for power calculations).  
 
As a sensitivity analysis, I repeated all analyses in a second set of MR 
analyses, where I used another a smaller set of 72 independent SNPs (at 
r2<0.1) that were associated with education in the smaller discovery 
dataset (SSGAC) alone (293,723 participants; P<5.10-8) and which 
subsequently tested to be directionally consistent in an independent 
replication dataset (UK Biobank). Ultimately, I decided to use the larger 
set of instruments (with 162 SNPs) in the main analysis instead of the 
smaller set of instruments (with 72 SNPs) in order to maintain sufficient 
statistical power for my sensitivity analyses. 
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To avoid biases due to overlapping datasets (i.e. where data from the 
gene-education association and gene-CHD association are derived from 
the same samples, and which can lead to bias in the direction of the 
observational association in the presence of a weak instrument),(235) 
excluded data from the following studies from the SNP-education data 
source: deCODE, WTCCC, KORA, THISEAS, and 23andMe, by 
contacting the authors of the original GWAS study.(234) The SNP-
education estimates from this restricted dataset (n= 349,306) were highly 
correlated with the SNP-education estimates from the complete SSGAC 
dataset (Pearson’s r for 162 SNPs=0.96 [p-value<0.001] and Pearson’s r 
for 72 SNPs=0.92 [p-value<0.001]) (Figures 19 & 20 on subsequent 
pages), and were hence used in subsequent MR analyses.  
 
 
 
 
Genetic instrument of education 
1st set of SNPs 
(162 SNPs) 
2nd set of 
SNPs (72 
SNPs) 
R-squared (of variance in 
educational phenotype) 
0.018 0.008 
Actual N (CARDIoGRAM 
plusC4D) 
194,427 194,427 
Proportion of cases 
(CARDIoGRAM plusC4D) 
0.327 0.327 
Observational OR 0.8 0.8 
N required for 80% power 42,832 96,372 
Power at actual N >0.99 0.98 
 
Table 4. Power for conventional Mendelian randomization analysis 
(two-sided α=0·05). Based on the method developed by Brion et al.(236). 
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Figure 19. Scatter plot of SNP-education association estimates, 
comparing complete dataset vs. non-overlapping dataset (n=162 
SNPs). The complete SSGAC dataset (x-axis) was based on 405’072 
participants. The restricted dataset (y-axis) was based on 349,306 
participants without sample overlap. Median standard errors (SE) in the 
complete SSGAC and restricted dataset were both of 0.003. Red points 
indicate 51 SNPs that remained associated with the education phenotype 
above the GWA threshold (P>5 x 10-8) in the smaller dataset without 
sample overlap.  
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Figure 20. Scatter plot of SNP-education association estimates, 
comparing complete dataset vs. non-overlapping dataset (n=72 
SNPs). The complete SSGAC dataset (x-axis) was based on 293’723 
participants. The restricted dataset (y-axis) was based on 349,306 
participants without sample overlap (and where the replication data was 
additionally used, to allow for most precise estimates while concurrently 
minimizing bias). Median SE in the complete SSGAC and restricted data 
dataset were both of 0.003. Red points indicate 29 SNPs that remained 
associated with the education phenotype above the GWA threshold (P>5 
x 10-8) in the dataset without sample overlap.  
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2.1.5. Mendelian randomization data sources (CHD outcome) 
 
Once the instruments had been selected and the strength of association 
between SNP-exposure (i.e. beta coefficients) had been determined, I 
looked to see if the same SNPs are associated with the outcome of 
interest, namely CHD. The CARDIoGRAMplusC4D dataset I used (237) is 
actually a collection of 4 datasets (genotyped CARDIoGRAM, genotyped 
C4D, genotyped Metabochip, Imputed data). I retrieved summary-level 
data for either the same SNP (115 out of 162 SNPs) or for a proxy SNP in 
high linkage disequilibrium (47 out of 162 SNPs at r2>0.8) following a 
flowchart of preferential data quality as detailed in Figure 21. Along similar 
lines, outcome data for the secondary set of 72 instruments is presented 
in figure 22. 
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Figure 21. Flowchart illustrating how SNPs identified in the SSGAC 
education GWAS were mapped against SNPs reported in 
CARDIoGRAMplusC4D (n=162 SNPs). Where necessary, proxies were 
retrieved using the SNP Annotation and Proxy Search online tool (SNAP, 
http://archive.broadinstitute.org/mpg/snap/ldsearch.php ; reference panel 
= 1000 Genomes; LD threshold r2>0.80). 
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Figure 22 Flowchart illustrating how SNPs identified by SSGAC 
education GWAS were mapped against SNPs listed in 
CARDIoGRAMplusC4D (n=72 SNPs). Where necessary, proxies were 
retrieved using the SNP Annotation and Proxy Search online tool (SNAP, 
http://archive.broadinstitute.org/mpg/snap/ldsearch.php ; reference panel 
= 1000 Genomes; LD threshold r2>0.80). 
  
 
 
138 
 
2.1.6. Statistical analysis (main Mendelian randomization estimate) 
 
For all MR analyses, alleles from SSGAC and CARDIoGRAMplusC4D 
datasets were aligned to correspond to an increase in educational 
attainment. This step, if not performed (as is done in some of published 
papers) invalidates some advanced analyses such as MR-Egger, 
discussed later.  
 
Conventional Mendelian randomization 
I used conventional (also termed ‘inverse variance weighted’) Mendelian 
randomisation analyses, by regressing the SNP-education associations 
against the SNP-CHD associations (outcome), where each SNP was one 
data point. This regression was weighted by the standard error of each 
SNP (whereby standard errors are larger for rarer genetic variants, and 
also larger if measured on a smaller subset of participants). Contrary to 
MR-Egger, the conventional MR regression line was forced to pass 
through the origin.(227)  
 
 
2.1.7. Statistical analysis (sensitivity Mendelian randomization) 
 
A range of sensitivity analyses were used to investigate to what degree 
the presence of unbalanced horizontal pleiotropy might bias the result of 
conventional Mendelian randomisation. These methods allow some of the 
Mendelian randomisation assumptions to be relaxed, and replaced with 
different and somewhat orthogonal assumptions. Consistency of results 
across a range of methods that make different assumptions regarding 
pleiotropy strengthens causal inference, while divergent results may 
indicate that genetic pleiotropy is biasing some of these results.  
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2.1.7.1. Penalized weighted median Mendelian randomization 
A penalized weighted median MR analysis was conducted (implemented 
in Stata using the mrrobust package; available at: 
https://github.com/remlapmot/mrrobust).(226) This gives more weight to 
genetic variants close to the median causal estimate. Weighted Median 
methods yield robust and precise results even when up to 50% of the 
weight in the analysis stems from invalid genetic variants.(226) 
 
2.1.7.2. Standard MR-Egger regression 
MR-Egger regression was applied as described by Bowden et al.(227) 
Based on the same principles as the Egger test (which assesses small 
study bias in meta-analysis) the method is similar to conventional MR 
analyses. However, the regression is not constrained to pass through the 
origin. A significant departure of the y-intercept from the origin gives 
evidence for the presence of unbalanced pleiotropy. If the level of 
pleiotropy is independent of the strength of the association between SNPs 
and education, the MR-Egger estimate thus represents the true causal 
effect, even if all the genetic variants present pleiotropic effects (as per the 
InSIDE rule).(227) The standard error (SE) of the causal estimate was 
corrected by dividing the reported SE of the estimate by the residual SE.  
 
2.1.7.3. Adjusted MR-Egger (+SIMEX) 
All MR approaches rely on the fact that the SNP-exposure association is 
true (NO Measurement Error [NOME] assumption). Whenever the SNP-
exposure association estimates are spurious (violation of the NOME 
assumption), weak instrument bias can distort the causal effect estimate 
(specifically diluting it towards the null value).(238) Using the I2 statistic, I 
quantified the expected dilution in the MR-Egger causal effect estimates 
due to the variance of the estimates of the SNP-education association: I2 
was only moderate for the set of 162 SNPs (I2=66%; potential dilution of 
44%), whereas I2 for the set of 72 SNPs indicated a reduced risk of bias 
(I2=93%; potential dilution of 7%). As described by Bowden et al, I applied 
simulation extrapolation (SIMEX; implemented in R using the simex 
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package) to adjust the MR-Egger causal estimates to account for 
violations to the NOME assumption, using 10,000 simulations (238). 
Simulation extrapolation analyses were conducted using R v3.3.1, with the 
assistance of Julien Vaucher and Jack Bowden. 
 
2.1.7.4. Mode Based Methods (assuming Zero Modal Pleiotropy)  
Recently developed methods relax the conventional MR assumptions, and 
instead form a less stringent assumption of Zero Modal Pleiotropy.(239) 
This postulates that pleiotropic SNPs are unlikely to converge on the 
same modal (most common) estimate due to pleiotropic effects not being 
identical. In contrast, valid SNPs are more likely to converge on the same, 
common modal estimate. I performed three analyses to exploit this 
assumption (with the assistance of Julien Vaucher, Fernando Pires 
Hartwig and Jack Bowden). 
 
a) Mode-Based Estimate 
In my first analysis, I used the Mode-Based Estimate (MBE). With an 
infinite sample (i.e. no measurement error), the MBE would use the 
modal causal estimate (i.e. the most common instrumental variable 
estimate out of the 162 SNPs, where the instrumental variable 
estimate for each SNP is derived by dividing the SNP to CHD 
estimate by the SNP to education estimate). In finite samples, the 
MBE uses the mode of the smoothed empirical density function of 
causal estimates (where the instrumental variable estimate for each 
SNP is up weighted by its relative precision, in comparison to other 
SNPs). A tuning parameter 𝜑 regulates the bias-variance trade-off. I 
explored a range of these, following which 𝜑=0.5 was chosen to best 
fit the data. The analysis makes the assumption that the most 
commonly observed causal effect estimate comes from valid genetic 
instruments, and it can provide a consistent causal effect estimate 
even if the majority of (non-modal) genetic instruments are invalid.  
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One advantage of the Mode-Based Estimate is that it is less 
influenced by outlying (and possibly pleiotropic) genetic instruments 
without formally removing them from the analyses, thus making full 
use of the data. However, the uncertainty around the point estimate 
can sometimes be prohibitively wide. For this reason, I exploited the 
Zero Modal Pleiotropy assumption using another strategy, which 
involves actually removing some genetic instruments from the 
analysis.  
 
b) Largest Homogeneous Subset-MR 
In my second modal analysis, SNPs were removed, one-by-one, until 
the final set of SNPs contained only sufficiently similar (according to 
some criteria) effect estimates. As such this final set of SNPs can be 
thought of as a relatively “homogeneous subset”. The steps I took are: 
1. Begin with the set of 162 SNPs. Evaluate the heterogeneity 
among each of the 162 causal estimates, using Cochran’s Q 
statistic.(240) 
2. Remove the SNP which contributes most to heterogeneity. 
3. Repeat the proves, until a P-value threshold of heterogeneity is 
reached (e.g. P>0.05). Smaller P-values denote more 
heterogeneity (close to the original set of 162 SNPs) while larger 
P values include fewer SNPs and are hence more stringent. 
 
c) Largest Homogeneous Subset-MR: removing most causal variants 
My third analysis was similar to the second one described above. This 
time, instead of removing any SNP (either at the left- or right-hand tail 
of the causal effect distribution) I only removed those SNPs that 
provided the strongest causal estimates (on one side of the tail), until 
the heterogeneity P value was attained as above. This method is 
unlikely to provide a valid causal estimate, as its result will be biased 
towards the null. However, it is an extreme example of a very stringent 
sensitivity check which asks the question “What if the most outlying 
SNPs, all of which produce the strongest causal estimates, were 
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deemed as invalid (due to having suspected horizontal, unbalanced 
pleiotropic effects on CHD)?”  
 
2.1.7.5. Reverse direction MR 
To check for whether genetic risk for coronary events might be a causal 
factor for educational attainment (my fourth research question), I 
performed Mendelian randomisation in the opposite direction (so-called bi-
directional Mendelian randomisation) using 53 SNPs associated with 
CHD. Under conditions of massive pleiotropy, genetic risk of coronary 
events might also predict educational outcomes. 
 
I used data from the CARDIoGRAMplusC4D Consortium to extract SNP-
CHD estimates for 53 independent SNPs (at r2<0.02) that were GWAS 
significant (P<5x10-8).(237, 241-243). I directly matched these with the 
corresponding SNPs from the SSGAC GWAS, involving 328,917 
individuals (Supplementary Dataset 3).(234) This analysis was 
performed using data where the underlying participants overlapped 
slightly between the SNP-exposure and SNP-outcome estimates. 
However, as such overlap biases results away from the null,(244) and 
since my finding was quite definitively null, I did not purse seeking non-
overlapping data in this instance, for this post-hoc sensitivity analysis. The 
causal MR analyses were conducted similar to the analyses described 
above, including the main sensitivity analyses.   
 
2.1.7.6. From education to CVD risk factors 
For my third research question, I applied conventional Mendelian 
randomisation to investigate whether genetic predisposition towards 
longer education could lead to improvements in the established 
cardiovascular risk factors. In this analysis, I discarded 60 SNPs with 
missing data on one of the cardiovascular risk factors, and thus used a 
smaller set of 102 SNPs.  
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2.1.8. Comparison with observational data 
 
Once I had assembled a range of causal estimates, it is useful to compare 
this against a similar estimate derived from conventional observational 
epidemiological methods (e.g. estimate of incidence from cohort studies, 
and/or cross-sectional prevalence from case-control studies). Since the 
MR estimates are likely to be less precise than observational estimates, 
such direct comparisons can assist in making inferences about whether 
the observational estimates are likely to be biased upwards, downwards 
or neither. Importantly, the exposure and outcome should be defined in 
similar ways in observational data, as I did in my causal analysis.  
 
After reviewing the literature of observational epidemiological findings in 
this area, I concluded that the vast majority of studies used a substantially 
different definition of exposure. Virtually all the time, an ordinal categorical 
definition was used in observational studies, as opposed to the continuous 
trait used in my causal analysis. Moreover, the number of categories 
varies substantially from around two to five categories. One recent meta-
analysis summarized this evidence by comparing estimates of “least 
educated” against “most educated categories”, which might artificially 
increase between-study heterogeneity simply from the range of categories 
applied in various studies.(8)  
 
I decided to provide my own observational estimates, using a mixture of to 
provide estimates from a case-control design, plus two methods to provide 
estimates from a prospective cohort design.  
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2.1.8.1. Observational case-control data 
For prevalent CHD cases in cross-sectional data, I analysed 43,611 
participants (1,933 cases) from 8 baseline samples of the National Health 
and Nutrition Examination Surveys (NHANES), from an instantly 
downloadable website www.cdc.gov/nchs/nhanes/ .(160) Figure 23 
illustrates the sample selection process. 
 
Just as in the causal analysis, I transformed the self-reported highest 
qualification into number of years in education, using the ISCED 1997 
system. The association between education and self-reported CHD 
prevalence was calculated using multivariable logistic regression adjusting 
for age and sex, and with their recommended weighted to account for 
non-random sampling, response bias and geographical clustering.(160) 
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Figure 23. Flowchart of participants in observational NHANES 
analysis. 
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2.1.8.2. Observational prospective data 
The association between education and the incidence of clinically-verified 
CHD was derived from two data sources. First, I first analysed 23,511 
participants (632 cases) from the Health, Alcohol and Psychosocial factors 
In Eastern Europe (HAPIEE) study,(245) using a Cox proportional hazard 
regression adjusting for age, sex, and country.(245) Further details of the 
HAPIEE study are shortly provided in Chapter 2.2.  
 
Second, I reanalysed published summary-level data from 97,048 
participants (6,522 cases) of the MOnica Risk, Genetics, Archiving and 
Monograph (MORGAM) study in Europe. Here, the published hazard 
ratios (HR) were initially expressed in terms of country-specific top vs. 
bottom tertiles of education.(246) I took the log of the hazard ratios 
corresponding to the lowest and highest educational tertiles, and divided it 
by the number of years of education between the lowest and highest 
tertiles from another publication,(12) and inverted the sign (to express the 
estimate per 1-year of additional education). Results were multiplied by 1-
SD (3.6 years of education), and log HRs were back transformed into HR 
of CHD per 1-SD increase in education. Country and sex-specific 
MORGAM estimates were then pooled using fixed-effects inverse-
variance meta-analysis. HAPIEE and MORGAM estimates were meta-
analysed similarly, to derive a summary estimate of incidence. These 
observational analyses are summarized in Table 5.  
 
Since my MR analyses assumed a linear relationship between education 
and CHD, I additionally used the individual-level data from NHANES and 
HAPIEE to model the dose-response observational association between 
years of education (as an ordinal categorical variable) and risk of CHD. 
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Study NHANES (1) HAPIEE (2) MORGAM (3) 
Access policy Public domain, 
with all required 
data instantly 
downloadable 
Access upon application to 
principal investigators. 
Access upon 
application to 
principal 
investigators.   
My analysis has not been 
previously published. 
My analysis is 
based on 
previously 
published work. 
Design Cross-sectional Longitudinal Longitudinal 
Country United States of 
America 
Russia, Czech Republic, 
Poland, Lithuania 
9 European 
countries. 
Baseline 1999-2014 (8 
waves) 
2002-2008 1983-2004 
Age at 
baseline 
20-85 43-74 35-64 
Initial sample 43,611 34,876 unknown 
Exclusion 
criteria 
Not applicable Self-reported 
hospitalization/diagnosis 
with AMI, stroke, coronary 
heart disease or angina. Or 
positive score on the Rose 
Angina Questionnaire 
Documented or 
self-reported history 
of myocardial 
infarction or 
unstable angina 
pectoris 
Analytic 
sample 
43,611 23,511 97,048 
Incident/ 
Prevalent 
CHD cases 
Prevalent Incident Incident 
Case 
ascertainment 
Self-reported “Has 
a doctor ever said 
you had a heart 
attack or CHD?” 
National MI and mortality 
registries 
National MI and 
mortality registries 
 
Sensitivity 
analyses further 
restricted to “heart 
attack” only  
  
Cases (n) 1,933 309 (fatal) + 323 (non-fatal) 
= 632 total 
6 522 
Follow-up 
(median) 
- 6.9 years 10.0 years 
Statistical 
model 
Logistic 
Regression 
Cox Proportional Hazards 
Regression 
Cox PH regression 
within each country 
& gender, followed 
by meta-analysis. 
Weighting/ 
adjustment 
Adjusted for age, 
sex. 
Adjusted for age, sex, 
country 
Adjusted for age 
 
Weighted to 
account for non-
random sampling, 
response bias and 
clustering 
  
 
Table 5. Description of observational studies. 
SD, standard deviation. CHD, coronary heart disease. MI, myocardial 
infarction. 
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2.2. Mediation and international differences 
2.2.1. Rationale of the HAPIEE study, and this analysis 
The Health, Alcohol and Psychosocial factors In Eastern Europe 
(HAPIEE) study is a multi-centre prospective cohort study of urban 
populations living in Russia, Poland and the Czech Republic. The 
rationale for study was described in a cohort description published in 
2006,(245) as well as in the study’s funding proposal (Box 1).  
 
Briefly, the study was designed to investigate the role of nutritional, 
psychosocial and alcohol-related factors in the incidence of common 
disease (both at the within-country level, as well as to account for 
international differences in rates of disease). Previous publications from 
this study have reported mortality associations for nutrition,(161) alcohol 
consumption,(172) and socioeconomic status.(2) Nutrition and alcohol did 
not explain differences in rates of disease between cohorts. The current 
publication therefore assesses, in a systematic fashion, several original 
objectives of the study. I do not use data from Lithuanian arm of the 
HAPIEE study, as its baseline questionnaire did not include all the 
psychosocial variables of interest. 
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DETERMINANTS OF CARDIOVASCULAR DISEASES IN EASTERN 
EUROPE: A MULTICENTRE COHORT STUDY 
 
Summary  
The aim of the proposed research is to investigate the causes of the high 
rates of cardiovascular and other non-communicable diseases in the 
restructuring countries of central and eastern Europe. Specifically, we will test 
the hypotheses that cardiovascular mortality is related to (i) low dietary intake 
of fruits and vegetables and its biomarkers; (ii) high plasma levels of 
homocysteine and low levels of folate, possibly interacting with a 
polymorphism in MTHFR gene of folate metabolism; (iii) heavy alcohol 
consumption and/or binge drinking pattern; and (iv) unfavourable 
socioeconomic and psychosocial environment. This proposal builds on a 
successful validation study funded by the Trust, and on our previous work in 
the region. We propose to set up a multi-centre cohort study in Krakow 
(Poland), Novosibirsk (Russia), and 4 cities of the Czech Republic, with 
30,000 men and women aged 45-69 randomly selected from population 
registers. At the baseline, exposures to suspected risk factors will be 
measured by questionnaires, short examination and analysis of blood 
samples. Participants will be prospectively followed up for mortality, using the 
national death registers, and for non-fatal events by annual postal 
questionnaires. In addition to the primary scientific purpose, the study will 
have an important training function by contributing to establishing a local 
research expertise.  
 
Lay summary  
Life expectancy in the restructuring countries of central and eastern Europe 
and the former Soviet Union is substantially lower than in the west. Most of 
the gap is due to high mortality from cardiovascular diseases and injuries. 
The aim of the proposed research is to study the causes of cardiovascular 
and other non-communicable diseases in eastern Europe. In particular, our 
hypotheses are that low dietary intake of fresh fruits and vegetables (and 
related substances in blood), high alcohol intake and binge drinking, and 
unfavourable socio-economic and psychosocial conditions are related to the 
high levels of cardiovascular diseases. On the basis of a successful pilot 
study, funded by the Trust, and our previous collaborations in the region, we 
propose to establish a prospective study of 30,000 men and women aged 45-
69 years, recruited in Krakow (Poland), Novosibirsk (Russia), and 4 cities of 
the Czech Republic. At the baseline, we will measure their exposure to the 
suspected risk factors, and we will then follow these subjects for mortality. 
The study will be large enough to detect biologically meaningful effects of the 
risk factors. In addition to improving the understanding of the mortality crisis 
in eastern Europe and of the causes of cardiovascular diseases in general, 
the research will have an important training function, contributing to 
establishing a local research expertise.   
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i. AIMS OF THE PROJECT  
In 1998, we applied to the Wellcome Trust for funding to establish a multi-
centre cohort study in three countries of Central and Eastern Europe (CEE) 
and the former Soviet Union (FSU) to examine the causes of the high rates of 
cardiovascular disease (CVD) and other non-communicable diseases (NCD) 
in the region. The Trust recognised the scientific importance of the subject 
but suggested that we first conduct a pilot study to test the feasibility of the 
project and validate the measurements. The pilot study, summarised in the 
next section, was extremely useful; it established the feasibility of the study, 
answered the questions about the methodology, and provided solution for 
logistics problems.  
 
The specific objectives of the proposed cohort study are to test the following 
hypotheses:  
1) that psychosocial factors, both individual based and population based, are 
related to CVD and other non-communicable diseases;  
2) that low consumption of fresh fruits and vegetables, and their nutrient 
biomarkers, are associated with increased risk of CVD;  
3) that elevated concentration of homocysteine and low levels of folate and 
related B vitamins are related to CVD;  
4) that the binge drinking pattern of alcohol consumption is related to CVD 
(and injury);  
5) that CVD risk is affected by interaction between different groups of risk 
factors, in particular between heavy drinking and folate deficiency, and 
between the MTHFR genotype (of folate metabolism) and folate deficiency.  
 
The high rates of NCD, large variation in exposure, and low cost of data 
collection provide an ideal opportunity. In the five years covered by the 
proposed programme support, the cohorts would be established, and data 
from the cross-sectional phase and early longitudinal stage (the first 3 years 
of follow up) will be analysed. Further follow up, enabling the more definite 
test of aetiological hypotheses, will continue beyond the 5 years covered by 
the proposal, using administrative records and tracing death certificates. If the 
success of the pilot study is translated into a success of the main study, it 
would form a basis of a centre for training in non-communicable diseases in 
the restructuring countries. 
 
Box 1. Uninterrupted extract of the first two pages of the original 
funding proposal. This was submitted to the Wellcome Trust in 2001. 
Key sentences relevant to this thesis are highlighted in darker font. 
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2.2.2. Participants  
Random population samples of 28 945 men and women aged 43–
72 years at baseline in 2002–2008 were selected from population 
registers and electoral lists. The overall response rate was 59% (61% in 
Russia and Poland; and 55% in the Czech Republic). I excluded 7173 
participants (25%) with a history of Acute Myocardial Infarction, Stroke, 
Chronic Heart Disease or Angina, as well as those who scored positively 
on the Rose Angina Questionnaire. A further 905 participants (4.2%) were 
lost to follow-up, primarily since they did not give consent to link their 
records with the national mortality registries, or due to migration (losses of 
4%, 7% and 1% in Czech, Polish and Russian samples, respectively). 
This left an analytical sample of 20 867 participants. The study was 
approved by the University College London/University College London 
Hospital ethics committee and by the local ethics committee in each 
participating centre. All participants gave written informed consent. 
  
2.2.3. Cardiovascular outcomes 
In the Czech Republic, linkage was done with the national mortality 
register, in Poland with the regional (Voivodship) mortality register, and in 
Russia with Novosibirsk city mortality register. Participants were linked to 
deaths records using a national personal ID number in the Czech 
Republic and Poland. In Russia, linkage was done using surname, initials 
and date of birth, where any potential inconsistencies were corrected 
manually. 905 participants (4.2%) were lost to follow-up, primarily since 
they did not give consent to link their records with the national mortality 
registries, or due to migration. Political developments and subsequent 
changes to Russian law meant that the study team (both Russian and 
international colleagues) were unable to access mortality data after 2011. 
For this reason, Russian follow up is slightly shorter. Follow-up was 
available to 31st December 2010 in Russia and Poland, and 30th June 
2013 in the Czech Republic (maximum follow up of 8.0, 8.9, and 11.3 
years respectively). The primary end-point was CVD mortality (ICD-10 
codes I00-99).  
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2.2.4. Socioeconomic factors  
At baseline, participants completed an extensive structured questionnaire, 
and underwent a standardized nurse examination in a clinic. English 
versions of the exact questionnaire items used are shown in Annex 1, with 
a brief summary below. Highest educational qualification was categorized 
as primary or less; secondary and tertiary. Assuming that the average 
participants in these groups were separated by around three and six years 
of additional schooling respectively, I modelled a linear relationship 
between these three categories. For self-reported economic activity, 
participants were classified into three groups: economically active; retired 
and no longer working; and currently unemployed. Participants were also 
asked about long-term unemployment, with 4 options (never; up to 3 
months total, up to 3-12 months total, more than 12 months total); 
responses were dichotomized, comparing the extreme group to the rest. 
 
Possession of 10 material amenities (microwave, video recorder, colour 
television, washing machine, dishwasher, freezer, camcorder, satellite TV, 
telephone and mobile phone; each coded 0/1) was used to derive a 
standardized continuous scale. For current material deprivation, three 
questions asked about how often the subjects had difficulties with paying 
for food, clothes, or bills. Each item was scored 0-3 to yield a total score of 
0-12. This was modelled per one standard deviation greater material 
deprivation. All standardization procedures used the mean and SD 
obtained from all three cohorts in combination (as opposed to 
standardizing, so that the standardized mean in each country is zero). 
Similarly to current material deprivation, another scale of early-life material 
deprivation asked about the same items, this time with participants 
retrospectively recalling their childhood. 
 
In addition, participants were asked whether the “Changes since 1989 
have been good or bad for your general social position?” Original 
responses in 5 categories (Very good, good, no change, bad, very bad) 
were regrouped into three categories.  
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2.2.5. Psychosocial factors  
Social support is typically measured with a multifaceted instrument, 
covering aspects of friends, family, social clubs and marital status. Given 
the larger power of this study, I did not combine these separate domains. 
For marital status, I compared the “married/cohabiting” reference group 
against “divorced/widowed”, or “single”. “Are you a member of a 
club/organization” was kept binary. “How often do you see relatives 
outside of your household?” originally had 6 options (“several times a 
week”; “About once a week”; “Several times a month”; “About once a 
month”; “Less than once a month”; “I don’t have any relatives”). I 
dichotomized this at the “at least monthly” threshold. A separate question 
“How often do you see friends outside of your household?” was handled 
similarly. 
 
Depressive symptoms were assessed with the CESD-20 questionnaire 
(range 0-60). A binary trait for depressive symptoms was defined as 
CESD-20 score ≥ 16. Perceived control was assessed with a scale 
developed by the MacArthur programme on midlife development.(247) 
The subscale “control over life” (range 0-40) was used as a standardized 
continuous variable. 
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2.2.6. Conventional CVD risk factors  
Covariates measured at baseline included country, age, gender, and 
eleven conventional CVD risk factors: smoking status (5 categories of 
never smoker; ex-smoker; 1–10, 11–20, and 21+ cigarettes a day), 
diabetes, and physical activity (dichotomized at 2.5 hours a week) were 
determined by self-report. Clinical examination13 determined systolic blood 
pressure (modelled linearly from 115mmHg onwards)(248); as well as 
BMI, total and HDL serum cholesterol (whereby all three were modelled 
with linear and square terms after centring at 23 kg/m2, 6 mmol/L and 1.5 
mmol/L, respectively). Alcohol intake in the last 12 months was self-
reported using the graduated frequency questionnaire (GFQ).(249) The 
UK Chief Medical Officers’ alcohol guideline advises men and women to 
consume less than 14 units of alcohol (equivalent to 112 grams of 
ethanol) per week. Participants were categorized as either non-drinkers, 
drinking within these guidelines, drinking up to twice the guideline limit, or 
drinking more than twice the guideline limit. For completeness, I included 
three additional alcohol-related covariates. Frequency of alcohol 
consumption was dichotomized at the once a week threshold. A pattern of 
binge drinking was defined if men/women reported consuming more than 
100g/60g of ethanol in one episode at least monthly. The CAGE 
questionnaire was used to evaluate symptoms of problems with alcohol, 
and was dichotomized at 2 or above. 
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2.2.7. Statistical analyses 
2.2.6.1. Missing data 
Between 0-12% of the data was missing for each variable (Table 10). This 
was imputed from 10 multiple imputation models that included vital status, 
follow-up time, all covariates. The predictor matrix additionally included 
key variables that were associated with missing variables and their 
missingness (from either the baseline survey, or a follow-up survey done 3 
years later on the same participants). These predictors were further self-
reported details about the time that participants spent on sports, games 
and hiking; the tendency to rely only on self (as opposed to others); over-
commitment at work; amount of trust in the local area; perceptions that 
money influences health; perceptions that others treat the participant 
unfairly; unemployment of others in the participant’s household; 
hypercholesterolemia; antihypertensive drug and statin usage; and 
subsequent depression in wave 2.  
 
2.2.6.2. Main analysis 
Cox regression was used to estimate hazard ratios (HR) and 95% 
confidence intervals (CIs) for associations between psychosocial factors 
and mortality end-points, using follow-up time as the time scale. Data 
were pooled across three cohorts and both genders. Three models were 
created with increasing levels of adjustment. Model 1 was adjusted for 
age, sex and country. International differences in cardiovascular mortality 
in this region are known to be much larger in men than women. To 
examine potential causes of this, I looked whether gender and/or being 
placed in Russia modifies the association between psychosocial risk 
factors and CVD mortality. I included interactions that met a Bonferroni-
adjusted P-value threshold of 0.05/14 = 0.0036. In model 2, I additionally 
adjusted for eleven conventional CVD risk factors for two reasons. First, 
as an indication of how much of the hazard from psychosocial exposures 
might plausibly be mediated indirectly via conventional risk factors, and, 
second, as an indication of their direct effect size, through pathways not 
measured in this study. Model 3 was additionally adjusted for the six 
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psychosocial factors that associated with CVD mortality (at p<0.05) 
following backwards-stepwise elimination from a larger model that began 
with all 14 candidate psychosocial factors. The proportional hazards 
assumption was tested using Schoenfeld residuals and checked 
graphically with log-log plots, with no evidence of its violation. 
 
In all three models, I assumed no differences in the size of the risk factor-
mortality associations between participants located in Poland, the Czech 
Republic and Russia. There was insufficient power to explore 
heterogeneity between Poland and the Czech Republic, but I examined 
effect modification between participants from Russian vs. Czech/Polish 
cohorts. Additional sensitivity analyses looked for effect modification by 
gender; repeating the main analysis after excluding imputed data; 
excluding participants with less than 2 years of follow-up (to reduce 
reverse causation bias); and using a similar 8-year follow-up for all three 
countries. 
 
2.2.6.2. Attenuation analysis 
Simpler and complex models were compared with each other, to evaluate 
the degree of attenuation, and thereby infer approximate degree of 
mediation, using the formula: 
 
Attenuation/amount mediated = [log(Fully adjusted HR) - log(Crude HR)] / 
[log(Crude HR)]. 
 
For example, if the association between education and mortality is 
HR=1.45 in model 1, and this attenuates to HR=1.20 in model 2, then one 
can infer that the conventional cardiovascular risk factors (which are 
additionally included in model 2 but not in model 1) might account and 
potentially mediate around half of the pathway from education to mortality. 
Of note, this is a relatively crude method which is prone to differential 
measurement error as well as model misspecification. Accordingly, I used 
this method only to provide very approximate and qualitative inferences 
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about whether putative mediators are likely to play a small or large role, 
respectively.  
 
When investigating the causes of international variation, literature 
suggested that these may be larger in men than women. Accordingly, I set 
up models where the reference group were women situated in either 
Poland or the Czech Republic. Mortality rates here were compared 
against three other groups: men from Poland or the Czech Republic (i.e. 
the pure gender effect); women from Russia (i.e. the pure country effect), 
and men from Russia (i.e. the interaction of gender and country 
combined). 
 
2.2.6.2. Population Attributable Fraction 
The Population Attributable Fraction denotes the proportion of mortality 
which could be prevented, if the entire population were not exposed to a 
given risk factor (and assuming a causal relationship between exposure 
and outcome).(250) In my study, it was calculated by fitting model 2 to the 
first set of imputed data, and then using punafcc command in STATA 14. 
As this package is unable to handle continuous risk factors, the 
continuous variable material amenities was dichotomized into two halves 
using the median as a cut off. For education, I calculated attribution if 
everybody without tertiary education would attain tertiary education. BMI 
was dichotomized as obese (BMI>30kg/m2) or not. The STROBE checklist 
was followed for presentation. 
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2.3. Prediction 
2.3.1. Description of the derivation dataset (HAPIEE) 
2.3.1.1 Sample and baseline data 
The HAPIEE study data collection methods were described in section 
2.2.1. In this section of my thesis, I excluded participants from Lithuania 
due to later entry into the study, slight differences in data collection, and 
shorter duration of follow-up. I excluded participants who self-reported a 
diagnosis or previous hospitalization for angina, myocardial infarction or 
stroke, as well as those who scored positive on the Rose Angina 
questionnaire (altogether 25%). Participants were included if they had 
chronic kidney disease, peripheral artery disease or diabetes, since CVD 
prevention is may be suboptimal for such participants in this region. I 
further excluded 9% of participants taking cholesterol lowering medication 
(mainly statins) at baseline, as they were unlikely to benefit from risk 
prediction and stratification. 23% of participants had missing data on at 
least one of variable. Between 9% to 13% of the observations were 
missing for depression, blood pressure, cholesterol and BMI. For other 
variables, missing observations formed less than 1.1% of each variable. 
Altogether, 23% of persons with some missing data were removed, so the 
analytical sample was a complete case sample. 
 
2.3.1.2 Outcome data 
International variability in coding nonfatal outcomes is likely to reduce data 
quality. For this reason, I adopted the same method as the original 
SCORE model, and only considered fatal outcomes. There is also 
international variability in the coding of smaller causes of death. Hence I 
took the primary outcome as any CVD mortality (ICD-10 classification: I00 
to I99).  
Median follow-up was 6.6, 7.1 and 9.6 years for Russia, Poland and 
Czech Republic. Time after 10 years of follow-up was censored. There 
were 102 female CVD deaths, and 236 male CVD deaths in the final 
analytical derivation sample.  
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2.3.2. Description of the external validation dataset (Estonian 
Biobank) 
2.3.2.1 Sample 
External validation was performed using data from the Estonian Biobank, 
whose details have been published previously.(251) Briefly, baseline data 
were collected between 2002-2011 (median date of recruitment = 
04/11/2008), from 51 141 participants aged 18-103 (median age = 43), 
typically by nurse practitioners at the patients’ primary care centre. The 
sampling frame can be thought of as a hybrid between a conventional 
population-based approach and a volunteer-initiated approach. On the 
one hand, no invitation letters were sent to participants. Instead, 
participants heard about the study either at special promotion events, from 
the media, from friends, or at their healthcare provider. As the sample was 
not selected from the general population, this does not enable the 
calculation of a response rate. It is plausible that when compared to the 
general population, the Biobank sample was enriched for healthy 
participants with higher SES (just as is seen in most population-based 
cohort studies). However, it is also plausible that recruitment via 
healthcare providers would have additionally enriched the sample from the 
other extreme: those with symptoms and early disease. Hence it is 
possible for the net all-cause mortality rate of the sample to be closer to 
the population average, when compared to conventional population-based 
cohort studies.  
 
Another dimension which increases the generalizability of the study is the 
wide coverage of recruitment sites. 56% of all the registered primary care 
physicians were involved with recruitment, spanning each of the 15 
administrative countries within Estonia, (figure 24). Hence the sample 
involves a mixture of urban and rural participants. 
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Figure 24. Map of Estonia’s 15 administrative counties, illustrating 
the recruitment centres of the Estonian biobank study. From (251). 
 
In comparison to the derivation cohort, the validation cohort has a different 
sampling frame (urban vs. urban-rural, respectively); different invitation 
method (postal invite only vs. opportunistic recruitment and self-referrals); 
and slightly different data sources to ascertain past medical history and 
current medication usage (discussed below). 
 
2.3.2.2 Data collection 
The derivation and validation cohorts both collected the majority of data 
using similar methods: a trained nurse performed computer-assisted 
personal interviewing, physical examination and blood tests. Past medical 
history and medication use was assessed by self-reported questionnaire 
in the derivation cohort (in this context, to determine baseline diabetes, 
CVD, antihypertensive and statin use). In the validation cohort, most 
nurses additionally had access to the participant’s primary care records. 
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Furthermore, the study team also performed linkage to the national acute 
myocardial infarction registry, as well as to the national electronic 
healthcare and prescriptions database. As of Dec 2011, approximately 
80% of inpatient discharge letters and 80% of all dispensed prescriptions 
were recorded in this system.  
 
Plasma cholesterol was measured by Proton NMR spectroscopy 
(Brainshake Ltd.) in Finland, on a random subset of the full cohort.(252) 
Cholesterol measures were available for 22% of the participants, meaning 
that cholesterols were missing completely at random for 78% of 
participants. Other variables were missing (at random) for up to 24% of 
the participants. For physical inactivity, employment and marital status, 
data were missing for 19% 6% and 4% of participants, respectively. All 
other variables were at least 99% complete. I performed the validation on 
the complete case sample. This discarded the majority of participants who 
had missing cholesterol. However, since the cholesterol was a completely 
random subsample, it is almost impossible for this decision (to omit 
participants with missing cholesterol) to lead to sampling bias. 
After median 7.6 years of follow-up, 91 CVD deaths were detected by 
linkage to the national mortality registry among the 4632 participants in 
the validation sample. 
 
2.3.2.3 Age selection 
Since Estonia is considering the development of a national CVD screening 
programme, I validated the newly-derived models as close as possible to 
eventual real-life settings where these may be used. One key variable is 
the age range among whom to conduct screening. In countries like the 
UK, screening for CVD among asymptomatic individuals is typically done 
for men aged >40 and women aged >50. Similar recommendations have 
been made by the European Society of Cardiology.(253) Given higher 
baseline rates in countries like Estonia, then recalibrating these Western 
European thresholds into the Estonian context equates to an equivalent 
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absolute level of risk as seen in men aged >37 and women aged >47 in 
Estonia (Figure 26), which I took as the lower age limits in my validation 
study. For the upper age limit, it is unclear at what age any geriatric risks 
associated with statins overshadow the cardiac benefits. In the meantime, 
a common upper threshold in other models is 74 years, which I also 
applied to Estonia. 
 
 
 
 
 
 
Figure 25. Flowchart illustrating sample selection in the derivation 
and validation cohorts.  
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Figure 26. Rates of CVD mortality, per 100 000 inhabitants, in Estonia 
and the UK. Data are from the Global Burden of Disease study, which 
relies predominantly on WHO Mortality data.(178) Bold italic font denotes 
age bands where screening for CVD has been suggested/attempted 
among Western European countries. 
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2.3.3. Predictor harmonization and selection 
2.3.3.1. Data harmonization  
Data were coded similarly across the two datasets for the following 
variables: age, sex, diabetes, systolic blood pressure, total cholesterol, 
Body Mass Index, employment and marital status. Of note, age was 
truncated to the nearest whole year in Estonia for privacy reasons, 
potentially leading to greater measurement error in the assessment of 
chronological age. 
 
To categorize smoking status, I combined data from three self-reported 
questions: self-reported smoking status, current smoking intensity, and 
smoking history as follows: 
 
 
Category 
 
 
Definition 
1) Never-smoker Self-reported never smoker 
 
2) Ex/light 
smoker 
Ex-smoker  
 
OR 
 
Current smoker who smokes <1 cigarette per 
day 
 
OR 
 
Current smoker who has smoked < 365 
cigarettes to date 
 
3) Current 
smoker 
Smokes ≥ 1 cigarette per day  
 
AND 
 
Has a smoked ≥ 365 cigarettes to date  
 
 
 
Educational qualifications were categorized as either “primary” (typically 
leaving school at the age of 16), “secondary” (typically leaving school at 
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the age of 18), or “tertiary” (a university or higher vocational degree), after 
consideration of the ISCED97 criteria in each of the 5 countries. 
 
In the validation dataset, depression was assessed by a single-item 
screening question, completed by self-report in the baseline 
questionnaire, with three options: “I do not have anxiety/depression” 
(reference), Vs. “I have moderate anxiety/depression” or “I have severe 
anxiety/depression”. The final two options were merged in my analysis to 
derive a dichotomous “possible depression” variable. In the derivation 
dataset, an equivalent “possible depression” variable was created by 
dichotomizing scores from the more comprehensive CESD-20 inventory. 
 
I initially sought to also harmonize alcohol consumption, as this is a 
plausibly novel risk factor for the development of heart disease. However, 
as the validation sample was much smaller (after discarding participants 
with missing data on cholesterol), there were insufficient CVD events 
among those participants who reported consuming more alcohol than 
advised. Furthermore, previous publications from the derivation sample 
have highlighted how various indices of alcohol excess do not associate 
strongly with subsequent CVD.(172) For this reason, alcohol was not 
considered. 
 
2.3.2.2. A priori predictor selection 
After harmonizing all risk factors, the list of candidate predictors was 
selected as follows. I selected all risk factors used in other CVD risk 
prediction models. I added those risk factors that have meta-analytic 
evidence of independent associations with cardiovascular disease. I 
eliminated invasive markers (e.g. those requiring blood tests). This 
resulted in seven candidate predictors which are not present in the 
conventional SCORE model. Four of these new predictors were 
psychosocial/socioeconomic (education, marital status, employment 
status, depression) and three were biological or behavioural (BMI, 
physical inactivity and antihypertensive use). 
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2.3.4. Derivation of new models 
 
2.3.4.1 Data pooling 
The ratio of events-to-parameters was low enough in some countries, that 
this risked causing overfitted models, if I fitted separate models in each 
country. As a solution, I divided the region into two halves. Cardiovascular 
mortality rates are higher in those Eastern European countries that were 
previously members of the Soviet Union (Estonia, Latvia, Lithuania, 
Belarus, Ukraine, Georgia) as well as those that border the Black Sea 
(Romania, Bulgaria). I allocated participants from these countries, with a 
higher baseline risk, an additional dummy variable (“high risk region”), 
which was compared against the reference dummy (“low risk region”) for 
countries from predominantly Central Europe that border Germany and 
Austria. My models assumed that individuals from each of these two 
regions are otherwise indistinguishable (that is, I did not fit random effects 
or country-level dummy variables). In relation to the particular data at 
hand, this meant that I grouped participants from Poland and Czech 
Republic into a similar baseline risk category. This assumption appears 
reasonable, given the nearly parallel trends in WHO mortality for these 
two countries over the past 25 years (figure 27). 
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Figure 27. WHO mortality rates for cardiovascular disease in Poland 
and the Czech Republic.  
Source: https://gateway.euro.who.int/en/hfa-explorer/#9aZl40c8fU  
Data: WHO Health For All Database 
 
The original SCORE model created separate models for men and women. 
In statistical terms, this is equivalent to fitting gender-by-risk factor 
interactions for all risk factors. Similarly, fitting separate models for 
high/low risk countries is equivalent to fitting area level interactions for all 
risk factors. While such approaches can improve risk prediction, this 
requires sufficient events in each arm to avoid overfitting the model. In my 
smallest arm for model development, I had just 43 female events in the 
high-risk region (Russia), making such a standalone model inappropriately 
small for my aims. Instead, I reasoned that the added benefit from gender-
by-risk factor interactions, and area-by-risk factor interactions, would be 
relatively small. I.e. I assumed that smoking increases the Relative Risk of 
CVD for women just as much as it does for men, and that this magnitude 
also should be similar across low- and high-risk regions alike. However, 
since international differences CVD tend to be larger in men than women, 
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I hypothesized that international differences in the baseline rate (among 
those with no CVD risk factors) should be larger in men than women. 
Accordingly, I fitted a single gender-by-area interaction term (male*high-
risk-area). Overall, my model development strategy was one where I 
made certain assumptions and brought associated limitations (e.g. I 
assumed homogeneous effects between risk factors and outcome across 
genders and regions), but this allowed me to derive my models on larger 
samples where the risk of overfitting would be lower. 
 
2.3.4.2. Model 1 (“ORIGINAL-SCORE”) 
I used the high-risk SCORE model,(185) where two parametric Weibull 
models generated the baseline hazard function for men and women, 
respectively. Here, the risk of CVD increased with the presence of one of 
three risk factors. Risks from cholesterol increased linearly from 6 mmol/L 
upwards (with no difference in risk among those whose cholesterol was 
less than 6 mmol/L). Similarly, risks for systolic blood pressure increased 
linearly from 120 mmHg. Smoking status was dichotomized.  
 
2.3.4.2. Model 2 (“EastEur-SCORE”) 
Cox regression was used to estimate new baseline hazards (using the R 
command survest), and coefficients for each of the SCORE risk factors 
(using the R command coxph), in a pooled dataset with data from both 
genders and both areas. My literature review suggested that additional 
benefit may be gained from more sophisticated modelling of the 
conventional SCORE predictors. Accordingly, I categorized smoking 
status into three as opposed to two categories (detailed in section 
2.3.3.1).  
 
I also tested quadratic functions to represent non-linear associations 
between cholesterol and CVD risk, and age and CVD risk. An a priori 
criterion for keeping these were that the quadratic should improve the LR 
test P-value by <0.05 and Harrell’s C-statistic by >0.0001. Age-squared 
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had no benefit and was dropped, but cholesterol-squared was kept after 
centring at 6 mmol/L. An LR test comparing models with and without 
cholesterol-squared gave p<0.001, and ΔC=0.003). Since cholesterol-
squared has not been previously used in risk prediction settings, I further 
checked the plausibility of this non-linear association, by plotting a 
detailed spline plot in the derivation data (figure 28). A similar curved 
relationship was also visible in the validation data (data not shown). 
 
 
Figure 28. Association between total serum cholesterol (mmol/L, x-
axis) and Hazard Ratio (HR) of CVD mortality (y-axis) in the HAPIEE 
derivation sample. Data are from a cubic spline model, restricted to 4 
knots. 
 
The spline plot suggested that the lowest risk of CVD may be found in 
those whose cholesterol is between 5.0 to 6.5 mmol/L. Since the original 
SCORE specification (6.0 mmol/L) falls within this range, I am happy to 
continue using a squared term that is centred at 6.0 mmol/L.  
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I also considered using a risk function that is more complex than a simple 
quadratic. However, since splines are difficult to interpret and transfer via 
paper to external researchers, and also as the spine plot above almost 
approximated a quadratic shape, then I was happy to keep a relatively 
simple quadratic risk function. With 10 coefficients in the final EastEur-
SCORE model, I had 34 events per each coefficient. This is much larger 
than the recommended 10 events per coefficient, meaning that there was 
a lower risk of overfitting the model. 
 
2.3.4.2. Model 3 (“HAPIEE-SCORE”) 
Seven candidate predictors were added to the newly created EastEur-
SCORE model, to create the final HAPIEE-SCORE model. BMI was 
modelled with linear and square terms, as previously suggested(254). 
Physical inactivity was dichotomized at <150 minutes of activity, when 
combining recreational and occupational activity levels. Educational 
attainment was modelled linearly across three categories, where the 
hazard of going from tertiary to secondary education is equivalent to the 
hazard of going from secondary to primary-or-lower education. 
Employment and marital status were coded to three categories 
(employed, unemployed, retired) (single, widowed/divorced, 
married/cohabiting). Possible depression was dichotomized at those 
scoring 16 or above on the CESD-20 questionnaire. Finally, the use of 
antihypertensive medications was dichotomized, and following the QRISK 
model I added an interaction between antihypertensive use and systolic 
blood pressure. 
 
I also explored the potential for interaction terms across the risk factors 
against three core variables: age, sex and education. For some of these 
interactions, the P value was 0.02. However, as these interactions arose 
from 21 multiple tests, I was concerned that these could have arisen by 
chance alone, and so decided to not include these. The final model had 
 
 
172 
 
21 coefficients. With 16 events per each coefficient, the possibility for 
overfit remained moderate. 
 
2.3.5. Evaluating the performance of single models 
Calibration plots were used to determine the degree of over/under-
prediction among participants grouped into six risk strata. The size of each 
strata was determined by dual consideration of having at least 10 events 
per strata, as well as clinically meaningful thresholds.  
 
Discrimination was assessed by Harrell’s C-statistic, using the R package 
rms (specifically, the commands cph & survest). 95% confidence intervals 
were calculated manually, by extracting standard errors from the package 
Hmisc (specifically, the command rcorr.cens).  
 
Classification ability was assessed by dichotomizing participants’ risk at 
the 5% risk threshold for CVD mortality, a commonly suggested threshold 
above which to consider clinical interventions like statins.(253) This 
dichotomized approach allowed the calculation of sensitivity, specificity, 
PPV and NPV as per usual conventions. 
 
Given how I defined the clinical threshold of interest as 5%, this was used 
to infer an appropriate weighting for the Net Benefit calculation. This was 
made with the initial assumption that benefit gained from correctly 
identifying one additional True Positives is approximately 20x as 
important, when compared to the cost of incorrectly labelling one 
additional person as a False Positive. This is based on the rationale as 
proposed by Vickers.(255) This assumption was relaxed by the visual use 
of Decision Curve Analysis, where the clinical intervention threshold was 
varied from 0% to 20% (denoting a Net Benefit weighting that ranges from 
infinity to 5x, respectively). 
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2.3.6. Evaluating change across two models 
 
Change in calibration was assessed visually. Change in discrimination 
was assessed by ΔC. Change in classification was assessed by ΔNet 
Benefit and Decision Curve Analysis. 
 
As sensitivity analyses, Reclassification Plots were used to inspect 
reclassification performance across the entire risk spectrum, and to gain a 
better insight about changes near and far away from clinical thresholds. 
Despite my reservations around using the Net Reclassification 
Improvement (NRI, detailed in Annex 2), given the popularity of this metric 
in the literature I will nonetheless present continuous NRI and binary NRI 
(also known as categorical NRI) stratified for cases and controls, using the 
R package PredictABEL.  
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2.3.7. Modelled clinical effect from statins  
 
It was beyond the scope of this thesis to produce a formal cost-
effectiveness analysis of these models, when scaled to real-life settings. 
Nonetheless, I wanted to briefly explore the viability of CVD screening for 
a country such as Estonia. The purpose of this was not to provide reliable 
estimates of anticipated consequences. Rather, this was done as a 
sensitivity analyses, which sought to identify how the risks and benefits of 
an intervention such as statins, when used across a range different clinical 
risk prediction models. It was beyond the scope of the thesis to formally 
test a range of parameters and assumptions built into the model. Instead, I 
calculated changes to costs, clinical outcomes and cost-effectiveness for 
just one hypothetical scenario with the following assumptions: 
 
• It costs around €50 of clinical care time to initiate statin treatment 
among one person of high risk. This is followed with €2/month for the 
price of the statin itself. Altogether, this amounts to €170 per person 
over 5 years. I assume 100% adherence to treatment in my models.  
• Statins lower LDL cholesterol by 2 mmol/L, which would lower CVD 
mortality by 23% (95% CI = 17 to 29%) (256) among the true positives 
over five years. One year of CVD mortality averted is equivalent to 
living with 100% quality of life. 
• Statins additionally cause benefits by preventing the development of 
non-fatal disease. However, as some of these later transition into fatal 
events within a 5-year window, then this requires more sophisticated 
modelling. Consequently, I did not model nonfatal benefits. 
• Statins cause serious adverse events (predominantly diabetes) in 
90/10 000 people treated over 5-years. I assume that these 
consequences are immediate and lifelong (i.e. lasting throughout the 
5-year window of my model), whereby one year of such illness is 
equivalent to 75% of full health.  
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Another way of illustrating this calculation is to consider a hypothetical 
dataset where 10 000 people are screened, following which 3000 are 
treated with statins. Of these 3000, 300 people are correctly treated since 
they would otherwise have developed the event, while the remaining 2700 
are potentially over treated, since they do not develop the event in the 
follow-up period. Of the 300 who are correctly treated, this may lead to 69 
events averted (since 300 * an intervention effect of -23% = 69 events 
averted). From this: 
 
The ratio of (Correct treatment : total treatment) [CT:TT] = 300÷69 = 4.34 
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2.3.7.1. Number Needed to Treat 
Following the example above, the Number Needed to Treat (NNT) 
denotes the number of people required to treat, to prevent one CVD 
fatality. 
NNT  =  (N treated * CT:TT)   ÷   (N correctly treated) 
NNT  =  (3000        *  4.34)     ÷   300                             =   43 
 
 
Optionally, this equation can also be rearranged for simplicity as: 
NNT  =  N treated ÷ (N of cases among those of predicted high risk × 0.23) 
 
 
2.3.7.1. Number Needed to Screen 
Following the example above, the Number Needed to Screen (NNS) 
denotes the number of people required to screen, to prevent one CVD 
fatality. 
NNS  =  (N screened * NNT)   ÷   (N identified as high risk) 
NNS  =  (10000          *  43)     ÷   3000                          =   145 
 
Optionally, this equation can also be rearranged for simplicity as: 
NNS = N screened ÷ (N of cases among those of predicted high risk × 0.23) 
 
 
A summary of the relationships is illustrated in table 6. 
 
 
 
Table 6. Hypothetical illustration of the calculation of the ratio of 
Correct Treatment to Total Treatment (CT:TT), the Number Needed to 
Treat (NNT), and the Number needed to Screen (NNS). 
  
Hypothetical cohort
Nr of events averted 69 1
Nr treated, correctly 300 4.3  = CT:TT
Nr treated, correctly + incorrectly 3000 43  = NNT
Nr screened 10000 145  = NNS
Calculations
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3. Results 
 
3.1. Mendelian randomization 
3.1.1. Conventional Mendelian randomization 
Using conventional MR analysis, 1-SD longer education (due to genetic 
predisposition across 162 SNPs) was associated with a 33% lower risk of 
CHD (OR= 0.67 [0.59 to 0.77]). Figure 29 additionally shows individual 
causal estimates from each of the 162 SNPs.  
 
 
 
 
Figure 29. Scatter plot of 162 SNPs associated with education and 
their risk of CHD (with 95% confidence intervals).  
Each dot represents one single nucleotide polymorphism (SNP). 
The red line represents the regression slope of the causal effect estimate 
of education on risk of CHD (where each SNP is weighted by its inverse 
allele frequency). CHD, coronary heart disease. OR, odds ratio. CI, 
confidence interval.  
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A secondary set of analyses using a set of 72 SNPs instead of 162 SNPs 
yielded consistent results in terms of direction, magnitude and statistical 
significance (OR=0.60 [0.49 to 0.74]). Results from each SNP are shown 
in figure 30. 
 
 
 
 
Figure 30. Scatter plot of the 72 SNPs associated with education and 
their risk of CHD (with 95% confidence intervals). 
Each dot represents one single nucleotide polymorphism (SNP). 
The red line represents the regression slope of the causal effect estimate 
of education on risk of CHD (where each SNP is weighted by its inverse 
allele frequency). CHD, coronary heart disease. OR, odds ratio. CI, 
confidence interval.  
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3.1.2. Sensitivity analyses for pleiotropy 
 
As expected, sensitivity analyses using MR-Egger and weighted median 
MR provided less precise estimates than with conventional MR. 
Nonetheless, their causal estimates were similar in terms of direction and 
magnitude, and were unlikely to have happened by chance alone (Figure 
31). There was little evidence of a non-zero intercept from the MR-Egger 
test (intercept beta = 0.004 [-0.056 to 0.013]; P-value=0.417), consistent 
with the hypothesis that pleiotropy was not driving the result. The MR-
regression slopes are illustrated in Figures 32 & 33.  
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Figure 31. Comparison of observational and causal estimates for risk 
of coronary heart disease, per 3.6 years of educational attainment. 
The two observational estimates are provided according to prevalent and 
incident CHD cases, respectively. The risk coefficient (RC) for 
observational incident cases was derived by meta-analysis of hazard 
ratios from the HAPIEE and MORGAM studies. The RCs for the 
observational prevalent cases, and the six causal estimates from 
Mendelian randomisation (MR) are all odds ratios (see Supplementary 
Methods for a full description of each analysis). CHD, coronary heart 
disease. CI, Confidence Interval. NHANES, The National Health and 
Nutrition Examination Survey. HAPIEE, Health, Alcohol and Psychosocial 
factors In Eastern Europe. MORGAM, MOnica Risk, Genetics, Archiving 
and Monograph. IVW, Inverse-variance weighted approach.  
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Figure 32. Scatter plot of 162 SNPs associated with education and 
their risk of CHD (with MR-Egger).  
The red line shows causal regression estimates from conventional 
Mendelian randomization (MR), inverse variance weighted (IVW).  
The blue line shows causal regression estimates from MR-Egger. 
SNP, single nucleotide polymorphism. CHD, coronary heart disease. OR, 
odds ratio. 
  
 
 
183 
 
 
 
 
Figure 33. Scatter plot of the 72 SNPs associated with education and 
their risk of CHD (with MR-Egger). 
The red line shows causal regression estimates from conventional 
Mendelian randomization (MR), inverse variance weighted (IVW).  
The blue line shows causal regression estimates from MR-Egger. 
SNP, single nucleotide polymorphism. CHD, coronary heart disease. OR, 
odds ratio. 
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Further sensitivity analyse are reported in Table 7. Briefly, an analysis, which 
can account for some measurement error in my genetic instruments for 
exposure (so-called MR-Egger + SIMEX)(238), gave similar findings to 
Standard MR-Egger, suggesting that any residual measurement error in the 
SNP-education estimate is unlikely to distort the main analysis.  
 
Results from modal-based MR approaches were overall consistent with the 
hypothesis that unbalanced directional pleiotropy was not driving the 
conventional MR result. Specifically, the first Mode-Based Estimate yielded 
directionally concordant point estimates. However, this test was grossly 
underpowered to detect a causal effect. The second Largest Heterogeneous 
Subset analyses, by contrast, were better powered. The vast majority of 
SNPs (i.e. 90%) were highly homogeneous in their causal effect estimates. 
Removing these 0-10% heterogeneous SNPs made little difference to the 
point estimates. Furthermore, all these MR estimates were highly unlikely to 
have been observed by chance alone.  
 
I also performed robustness checks by omitting SNPs with higher levels of 
missing data, as well as SNPs with proxy outcome data. These gave similar 
results in terms of direction, magnitude and statistical significance (Table 7). 
Collectively, all these sensitivity analyses make it less likely for presence of 
missing data or pleiotropic effects to have grossly biased my main causal 
analysis. 
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Analysis 
Causal effect (OR) 
estimate for risk of 
CHD (95% CI) 
Causal effect      
P-value 
Set of 162 SNPs (I2 statistic=0.661)   
  Conventional MR (IVW) 0.67 (0.59 to 0.77)  2.9 x 10-8 
  Weighted-Median MR 0.70 (0.58 to 0.85) 1.8 x 10-4 
  Standard MR-Egger  0.54 (0.31 to 0.93)  0.029 
  Adjusted MR-Egger (+SIMEX) 0.41 (0.19 to 0.87)  0.022 
  Mode-Based Estimate 0.84 (0.44 to 1.60) 0.255 
  Largest Homogeneous Subset-MR (3 tests below):   
      Minus 2 most heterogeneous SNPs = 160 SNPs  
      (Heterogeneity P≥0.05) 
0.68 (0.59 to 0.77) 1.8 × 10-8 
      Minus 4 most heterogeneous SNPs = 158 SNPs  
      (Heterogeneity P≥0.20) 
0.66 (0.59 to 0.75) 8.8 × 10-10 
      Minus 12 most heterogeneous causal SNPs = 150 SNPs  
      (Heterogeneity P≥0.20) 
0.75 (0.67 to 0.86) 1.8 × 10-5 
  Minus (47 proxies) = 115 SNPs.  
      Conventional MR estimate (IVW) 
0.62 (0.52 to 0.73)  1.3 x 10-7 
  Minus (21 with >10% missing data) = 141 SNPs.  
      Conventional MR estimate (IVW): 
0.70 (0.60 to 0.80) 1.4 x 10-6 
   
Set of 72 SNPs (I2 statistic=0.934)   
  Conventional MR (IVW) 0.60 (0.49 to 0.74)  6.2 x 10-6 
  Weighted-Median MR 0.71 (0.54 to 0.93) 0.014 
  Standard MR-Egger  0.54 (0.26 to 1.11)  0.099 
  Adjusted MR-Egger (+SIMEX) 0.43 (0.17 to 1.12)  0.088 
  Mode-Based Estimate 0.78 (0.40 to 1.54) 0.490 
  Largest Homogeneous Subset-MR (3 tests below):   
       Minus 2 most heterogeneous SNPs = 70 SNPs   
       (Heterogeneity P≥0.05) 
0.65 (0.53 to 0.79) 5.8 x 10-5 
       Minus 4 most heterogeneous SNPs = 68 SNPs   
       (Heterogeneity P≥0.20) 
0.64 (0.53 to 0.78) 9.4 x 10-5 
       Minus 5 most heterogeneous causal SNPs = 67 SNPs   
       (Heterogeneity P≥0.20) 
0.67 (0.55 to 0.81) 7.6 x 10-5 
 
Table 7. Sensitivity analyses of Mendelian Randomization estimates. All 
causal effects are expressed as change in Odds Ratio of coronary heart 
disease (CHD), per 3.6 years (1-SD) of longer education. The adjusted MR-
Egger regression estimates are the results of 10,000 simulations. SNP, 
single nucleotide polymorphism. MR, Mendelian randomization. IVW, 
inverse-variance weighted (analysis). SIMEX, simulation extrapolation.  
 
 
 
 
 
186 
 
3.1.3. Reverse direction Mendelian randomization 
 
I found little evidence for the hypothesis that genetic liability for CHD risk 
is associated with educational outcomes. Namely, 1-log greater genetic 
risk of CHD was associated with 0.2 (-1.3 to 1.6) days of longer 
educational attainment. Results were unchanged after applying MR-Egger 
and weighted-median MR (Figure 34). The results from individual SNPs 
are shown in Figure 35. 
 
 
 
 
 
 
 
Figure 34. Association of genetic liability to CHD (exposure) on the 
numbers of days of schooling (outcome). Causal estimates are 
expressed as difference in days of education, per 1-log unit increase in 
risk of coronary heart disease (CHD) as instrumented by 53 SNPs.  
CI, confidence interval. IVW, inverse variance weighted approach. 
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Figure 35. Scatter plot of the 53 SNPs associated with CHD 
development and their educational outcomes (with 95% confidence 
intervals). The red line represents the regression slope of the causal 
effect estimate (derived by the inverse-variance weighted Mendelian 
randomization method). SNP, single nucleotide polymorphism. CHD, 
coronary heart disease. OR, odds ratio. CI, confidence interval. 
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3.1.4. Mendelian randomization from education to CVD risk factors 
 
To identify potential risk factors that could mediate the association 
between education and CHD, I investigated whether genetic 
predisposition towards higher education was associated with established 
cardiovascular risk factors. Table 8 shows that, in conventional MR 
analyses, a 1-SD longer education (due to genetic predisposition across 
162 SNPs) was associated with a 35% lower odds of smoking, lower BMI 
(0.17 kg/m2), lower triglycerides (0.14 mmol/l) and a greater HDL-
cholesterol (0.15 mmol/l), with a P-value smaller than 0.001 for each of 
these four outcomes. Associations with diabetes and systolic blood 
pressure were in the anticipated direction, but these effects may have 
been due to chance and/or insufficient statistical power (P-values = 0.05 
to 0.08). 
 
 
3.1.5. Observational associations 
Based on NHANES data, each additional 3.6 years of education (1-SD) 
was associated with 27% lower odds of prevalent CHD (odds ratio = 0.73 
[95% confidence interval 0.68 to 0.78], illustrated in Figure 31 above). In 
prospective analyses, 3.6 years of additional education was associated 
with a 20% lower risk of incident CHD in the HAPIEE and MORGAM 
studies, with a pooled hazard ratio of 0.80 (0.76 to 0.83). Cohort-specific 
results from MORGAM are additionally shown in Figure 36.(245, 246) 
These observational estimates were robust to sensitivity analyses 
accounting for different case definitions, age at first CHD event, and 
confounding by other measures of socioeconomic position (Table 9). I 
also saw evidence for a dose-response relationship between the amount 
of education and risk of CHD (Figures 37 & 38). 
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Table 8. Causal effects from 3.6 years of education, to ten 
cardiovascular risk factors. All analyses are based on a common set of 
102 single nucleotide polymorphisms associated with education, available 
in 8 genome-wide association study consortia. Bold font denotes causal 
effect estimates with strong statistical evidence (p<0.001). Estimates are 
expressed per 1-standard deviation increase in years of education 
(equivalent to 3.6 years) as absolute values for continuous risk factors, 
and as odds ratios for binary traits. CI, confidence interval. LDL, low 
density lipoprotein; HDL, high density lipoprotein; BP, Blood Pressure; 
BMI, Body Mass Index. 
  
Outcome Causal effect (95% CI) P-value 
Binary traits                                                            
 Smoking status Odds Ratio = 0.65 (0.54 to 0.79) 0.001 
 Diabetes (type 2) Odds Ratio = 0.75 (0.56 to 1.01) 0.057 
Continuous traits                                      
 Systolic BP -1.36 (-2.85 to 0.12) mmHg 0.075 
 Diastolic BP -0.23 (-1.22 to 0.76) mmHg 0.645 
 LDL-cholesterol  -0.03 (-0.10 to 0.05) mmol/L 0.513 
 HDL-cholesterol  0.15 (0.07 to 0.23) mmol/L 0.001 
 Triglycerides  -0.14 (-0.22 to -0.06) mmol/L 0.001 
 Glucose  -0.02 (-0.08 to 0.03) mmol/L 0.441 
 BMI -0.17 (-0.26 to -0.08) kg/m2 0.001 
 Height  0.06 (-0.03 to 0.16) cm 0.208 
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Table 9. Sensitivity analyses for observational estimates.SD, standard 
deviation. CHD, coronary heart disease. AMI, acute myocardial 
infarction. 
* Adjusted for age and sex (additionally weighted to account for oversampled 
design, response rate, and geographical clustering). 
† Adjusted for age, sex, ethnicity, citizenship, country of birth, military 
service, marital status, household size, family income: poverty threshold 
ratio. 
‡ Adjusted for age, sex, and country of survey. 
  
 Case definition/      
sub-analysis 
Cases 
(n) 
Controls 
(n) 
Mean 
age at 
first 
event 
Association with 
CHD,  
per 1-SD longer 
education 
Used 
in 
figure 
31? 
Prevalence  
NHANES*  
 Nonfatal CHD      
  All ages 2,846 40,823 55.1 OR = 0.73 (0.68; 0.78) Yes 
  
All ages (no missing 
data, to compare with 
SES-adjusted 
estimate below) 
1,234 16,790 55.1 OR = 0.75 (0.67; 0.83) 
 
  
All ages, fully SES-
adjusted† 
1,234 16,790 55.1 OR = 0.73 (0.62; 0.85) 
 
  
Age of first event 
<66y 
1,907 40,823 48.7 OR = 0.72 (0.66; 0.78) 
 
 Nonfatal AMI only  
  All ages 1,933 41,678 54.7 OR = 0.71 (0.65; 0.77)  
Incidence  
HAPIEE‡  
 Fatal / nonfatal CHD  632 22,879 65.0 HR = 0.75 (0.69; 0.81) Yes 
 Nonfatal CHD only 338 23,138 64.1 HR = 0.81 (0.72; 0.91)  
 Fatal CHD only 309 23,202 67.2 HR = 0.71 (0.64; 0.79)  
 Fatal CVD  621 22,890 67.4 HR = 0.75 (0.70; 0.82)  
MORGAM‡  
 Fatal / nonfatal CHD  6 522 90 526 63.2 HR = 0.83 (0.80; 0.86) Yes 
 
 
191 
 
 
 
Figure 36. Observational estimates from the MORGAM consortium, 
showing cohort-level estimates and the results from meta-analysis. 
Meta-analysis performed using inverse-variance weighted fixed-effect 
modelling. CHD, coronary heart disease. SD, standard deviation. HR, 
hazard ratio. CI, confidence interval. 
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Figure 37. Dose response relationship between education and CHD 
prevalence, using observational NHANES data. Lowest education 
group represents “some high school” in USA system, i.e. typically 16-year 
old pupil. Logistic regression model was adjusted for age and sex. CHD, 
coronary heart disease; NHANES, National Health and Nutrition 
Examination Survey; OR, odds ratio CI, confidence interval. 
P for trend < 0.0001. 
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Figure 38. Dose response relationship between education and CHD 
incidence, using observational HAPIEE data. Lowest education group 
represents “Primary education or lower”, i.e. max. 4 years of education. 
Cox proportional hazard regression model was adjusted for age, sex and 
country. CHD, coronary heart disease; HAPIEE, The Health, Alcohol and 
Psychosocial factors In Eastern Europe Study; HR, hazard ratio CI, 
confidence interval. P for trend<0.001. 
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3.2. Mediation and international differences 
Section 3.2 will discuss results from the mediation analysis, as well as 
investigation of the causes of international differences. As a reminder, 
literature to date has been limited around to what extent psychosocial 
factors could mediate the presumably causal effect from socioeconomic 
factors to CVD. Secondly, literature to date has not explored whether 
psychosocial and socioeconomic factors could explain why CVD mortality 
is higher in ex-USSR countries, when compared to countries from Central 
Europe. 
 
3.2.1. Baseline data 
Baseline characteristics of participants in the analytical sample are shown 
in table 10. Participants who subsequently died of CVD had higher levels 
of most risk factors, when compared to those who did not die of CVD. 
There was an interaction between sex and country: men in Russia had 
higher hazard ratios than expected based on the sum of the “male” and 
the “Russian” indicator variables alone (HR for the interaction term=1.77 
[1.23-2.55], p=0.002). This term was kept in all subsequent models. 
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         Total sample  
% missing 
& imputed   
n / 
mean 
% / SD   
Participants 20 867 100%    
Follow-up years  
     (median, max) 
7.2,  11.3    
  Age (per year) 57.2 7.03   0% 
  Male  9 700 46%   0% 
Conventional CVD risk factors     
  Diabetes 1 554 7.4%   0.1% 
  Smoking Status:     
0.6% 
    Never-smoker 9 941 48%   
    Occasional/Past smoker 5 065 24%   
    Daily smoker,    
        1-10 cigarettes/day 
    Daily smoker,  
        11-20 cigarettes/day 
    Daily smoker,      
       >20 cigarettes/day 
2 074 
3 039 
747 
9.9% 
15% 
3.6% 
  
  Blood pressure, systolic  
     (mmHg) 
138.9 22.5   9.2% 
  Total cholesterol (mmol/L) 5.95 1.25   10.5% 
  HDL cholesterol (mmol/L) 1.48 0.46   10.6% 
  Body Mass Index (kg/m2) 28.0 4.85   9.2% 
  Physically inactive 1 666 8.0%   1.1% 
Alcohol intake:       
1.2% 
   Nil 4 033 19%   
   Up to UK guidelines 12 389 59%   
   Exceeding UK guidelines  
      (1-2x over) 
2 314 11%    
   Exceeding UK guidelines  
      (>2x over) 
2 131 10%   
Alcohol drinking frequency:     
1.4% 
   Non-drinker 3 942 19%   
   < once/week 10 534 50%   
   ≥ once/week 6 391 31%   
Binge drinking  
   (≥ once/month) 
2 705 13%   1.4% 
Possible problem drinking    
   (CAGE ≥ 2) 
1 408 6.7%   8.1% 
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Psychological factors         
  Marital Status:     
0.2% 
    Married/cohabiting 15 713 75%   
    Divorced/widowed 4 257 20%   
    Single 897 4.3%   
  Social Support       
    Contact with relatives  
        <once/month 
4 966 24%   0.4% 
    Contact with friends  
        <once/month 
7 554 36%   0.6% 
    Not a member of a club 17 487 84%   0.6% 
  Depression symptoms  
       (possible case) 
4 612 22%   11.9% 
  Low perceived control  
       (SD scale) 
0.00 1.01   1.5% 
Socioeconomic factors         
  Education     
0.2% 
    Tertiary 5 263 25%   
    Secondary 13 459 65%   
    Primary 2 143 10%   
  Material possessions      
    Low amenities, current  
         (SD scale) 
0.00 1.00   2.6% 
    Low amenities, early life  
        (SD scale) 
0.00 1.01   2.9% 
    Deprivation, current  
         (SD scale) 
0.00 1.02   0.9% 
    Deprivation, early life  
         (SD scale) 
0.00 0.99   1.0% 
  Unemployment, current 897 4.3%   0.4% 
  Unemployment, long term 1 690 8.1%   1.8% 
  Change in status  
        since 1989: 
     
 
0.9% 
  
            Improved 5 071 24%   
            Stayed the same 10 079 48%   
            Declined 5 718 27%   
 
 
Table 10a. Baseline characteristics of the analytical sample. 
The sample shown is multiply imputed, combined across three countries 
and two genders. The final column shows amount of missing/imputed 
data among the total sample. SD=Standard Deviation. 
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Czech 
Republic 
Poland Russia 
  
n / 
mean 
% / 
SD 
n / 
mean 
% / 
SD 
n / 
mean 
% / 
SD 
Participants 6 905 33% 7 039 34% 6 923 33% 
Follow-up years (median, 
max) 
9.6, 11.3 7.1, 8.9 6.6, 8.0 
Events (CVD mortality) 173 31% 134 24% 249 45% 
Conventional risk factors  
  Age, mean (SD) 57.6 7.1 56.8 7.0 57.3 7.0 
  Male  3 130 45% 3 460 50% 3 110 45% 
  Diabetes  677 10% 629    9% 248   4% 
Smoking Status:  
  Non-smoker 3 119 45% 2 805 40% 4 019 58% 
  Occasional/Past smoker 2 088 30% 2 051 29% 926 13% 
  Daily smoker,   1-10/day 746 11% 649   9% 679 10% 
  Daily smoker, 11-20/day 824 12% 1 167 17% 1 049 15% 
  Daily smoker, >20 /day 129   2% 368   5% 250 3.6% 
Blood pressure, systolic 
  (mmHg) 
138.4 20.3 137.0 21.8 141.3 24.3 
Cholesterol,total (mmol/L) 5.7 1.1 5.8 1.3 6.3 1.3 
  HDL (mmol/L) 1.4 0.4 1.5 0.4 1.6 0.5 
Body Mass Index (kg/m2) 28.0 4.6 27.8 4.6 28.2 5.3 
  Physically inactive 827 12% 572   8% 269   4% 
Alcohol intake:   
  Nil 789 11% 2 273 32% 971 14% 
  Up to UK guidelines 3 937 57% 3 335 47% 5 117 74% 
  Exceeding UK guidelines  
     (1-2x over) 
1 137 16% 670 10% 507   7% 
  Exceeding UK guidelines  
     (>2x over) 
1 042 15% 760 11% 328   4% 
Alcohol drinking  
  frequency: 
      
   Non-drinker 802 12% 2 206 31% 934 13% 
   < once/week 3 243 47% 3 106 44% 4 184 60% 
   ≥ once/week 2 859 41% 1 727 25% 1 805 26% 
Binge drinking (≥1/month) 968 14% 458   7% 1 279 19% 
Possible problem drinking 
(CAGE ≥2) 
366   5% 348   5% 694 10% 
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Psychosocial factors 
  Marital Status: 
    Married/cohabiting 5 244 76% 5 429 77% 5 042 73% 
    Divorced/widowed 1 469 21% 1 206 17% 1 586 23% 
    Single 191   3% 403   6% 295   4% 
  Social Support     
    Contact with relatives  
        <once/month 
757 11% 2 192 31% 2 008 29% 
    Contact with friends  
        <once/month 
1 730 25% 2646 38% 3 186 46% 
    Not a member of a club 4 992 72% 6 167 88% 6322 91% 
  Depression symptoms  
       (possible case) 
1 253 18% 1 642 23% 1 715 25% 
  Low perceived control  
       (SD scale) 
0.17 1.00 -0.17 0.99 0.02 0.98 
Socioeconomic factors             
  Education     
    Tertiary 1 016 15% 2 206 31% 2 042 29% 
    Secondary 5 089 74% 4 157 59% 4 214 61% 
    Primary 800 12% 677 10% 667 9.6% 
  Material possessions      
    Low amenities, current  
         (SD scale) 
-0.23 1.00 -0.07 0.98 0.30 0.95 
    Low amenities, early  
         life (SD scale) 
-0.48 0.75 -0.09 1.03 0.54 0.93 
    Deprivation, current  
         (SD scale) 
-0.31 0.75 0.10 0.97 0.41 1.15 
    Deprivation, early life  
         (SD scale) 
0.04 0.93 -0.14 0.92 0.10 1.09 
  Unemployment, current 194   3% 389   6% 313 4.5% 
  Unemployment,  
          long term 
398   6% 562   8% 735 11% 
  Change in status  
        since 1989: 
    
            Improved 2 244 33% 1 765 25% 1051 15% 
            Stayed the same 3 695 54% 3 274 47% 3113 45% 
            Declined 965 14% 1 997 28%  2758 40% 
       
 
Table 10b. Baseline characteristics of the analytical sample, stratified 
by country. 
The sample shown is multiply imputed, combined across two genders. 
HDL=High Density Lipoproteins.  
SD=Standard Deviation. 
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3.2.2. Independent associations with CVD mortality  
 
As expected, conventional CVD risk factors were associated with CVD 
mortality (Figure 38).  
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Figure 38. Associations of conventional cardiovascular risk factors 
with cardiovascular mortality. 
 
†Conventional factors = diabetes, smoking, blood pressure, cholesterol, 
HDL, BMI, physical activity. 
 
‡Full adjustment = conventional factors + material possessions, 
depression, seeing relatives, seeing friends, friends*gender interaction, 
marital status, unemployment.  
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Associations between 14 psychosocial and socioeconomic exposures and 
CVD mortality are subsequently tested. In model 1, 13 out of 14 factors 
tested were associated with CVD mortality, with HRs ranging from 2.96 
(1.97-4.46, p<0.0001) for current unemployment to HR= 1.14 (1.05-1.23, 
p=0.012) per one standard deviation increase in early life deprivation. 
Twelve associations remained significant after adjustment for eleven 
conventional CVD risk factors in model 2; this attenuated the remaining 
hazard ratios by around a quarter. 
 
Infrequent contact with friends was associated with outcomes more 
strongly in women than in men (Model 1 interaction with sex HR=1.83 
[1.26-2.66], p=0.002, thus satisfying Bonferroni criteria). Model 3 therefore 
included both the conventional binary variable “low friends” (which was 
handled similarly to the other five psychosocial and socioeconomic 
factors), as well as the interaction term “gender*low friends” (interactions 
were not used for the remaining five factors). There was no evidence of 
effect modification by country (data not shown).  
 
Following full adjustment for other psychosocial and socioeconomic 
factors in model 3, 6 factors remained associated with the outcome 
(0.00001 < p < 0.007): depression, low material amenities, current 
unemployment, infrequent contact with relatives, infrequent contact with 
friends (for female participants only), and single marital status (Figure 39). 
Following this full adjustment, the hazard ratio for education (HR = 1.11 
[0.96-1.29] per 3 years of additional education) was largely attenuated in 
comparison with age-sex adjusted models. Consequently, I did not 
consider education to be one of the core variables in subsequent 
multivariate analyses. The population attributable fractions (PAF), in 
models adjusted for conventional risk factors ranged from around 9% (for 
current unemployment, infrequent contact with relatives) to 22% (for low 
material amenities). Test of effect modification gave similar results in 
analyses stratified by gender or cohort (data not shown). Sensitivity 
analyses gave similar results when limiting follow-up time to 8 years in all 
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three countries; excluding those participants with less than 2 years of 
follow-up; or when excluding imputed data (data not shown).  
 
 
 
Figure 39. Associations of psychosocial and socioeconomic factors 
with cardiovascular mortality. 
 
†Conventional factors = diabetes, smoking, blood pressure, cholesterol, 
HDL, BMI, physical activity. 
 
‡Full adjustment = conventional factors + material possessions, 
depression, seeing relatives, seeing friends, friends*gender interaction, 
marital status, unemployment.  
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3.2.3. Attenuation and mediation 
I examined to what degree the hazard ratios associated with the 
psychosocial factors attenuated following various adjustments (Figure 40). 
Adjustment for eleven conventional risk factors attenuated these by about 
one quarter. Additional adjustment for other psychosocial factors 
attenuated these by an additional quarter. As two exceptions, the hazard 
ratios for limited contact with friends and relatives did not attenuate to this 
level. This suggests very little overlap between the potential effects of 
these facets of social support, and that conventional risk factors may play 
a negligible role in mediating any of these effects. Overall, this data 
suggests that depression and social support constructs, if causal, may 
operate independently to socioeconomic constructs, potentially along 
separate mechanistic pathways.  
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Figure 40. Attenuation among three socioeconomic (left side) and 
four psychosocial (right side) predictors of cardiovascular mortality. 
Created from four sequentially-adjusted models. The total height of each 
predictor (i.e. 100%) is equivalent to its association with cardiovascular 
mortality in the simple age- and sex-adjusted model 1. The yellow area 
represents the subsequent attenuation in association, following additional 
adjustment for eleven conventional CVD risk factors in model 2 
(equivalent to the yellow arrow in my causal diagram in figure 14). The 
green area represents the subsequent attenuation, following additional 
adjustment for four psychosocial variables (equivalent to the green arrow 
in figure 14). The blue area represents subsequent attenuation, following 
additional adjustment for two socioeconomic variables in model 3. The 
black area accounts for the unexplained part still present in model 3 (i.e. 
direct or non-mediated effects, equivalent to the black arrow in figure 14).   
Additionally explained 
by education, 
unemployment and 
material amenities 
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As few studies have reported to what degree the associations between 
alcohol and mortality attenuate after adjustment for psychosocial factors, I 
additionally report these here. There was little evidence that total alcohol 
consumption or binge drinking was associated with CVD mortality in 
models adjusted for conventional risk factors. However, people scoring 
positive on the CAGE screening questionnaire for possible problems with 
alcohol had 41% greater risk of CVD in crude models. This attenuated by 
around one half following adjustment for six psychosocial factors. This 
observation can be interpreted in two ways. First, some of the previously 
reported associations between alcohol and mortality in the literature may 
have been biased away from the null, since they did not control 
comprehensively enough for psychosocial factors which act as 
confounders. Second, it may instead be the case that alcohol excess 
causes psychosocial stress which causes mortality, and therefore 
psychosocial factors may be causal mediators. The existing literature 
does not appear to be developed enough to firmly inform which of these 
two explanations are more likely to be true. 
 
 
3.2.4. International differences 
CVD mortality risk was substantially higher in the Russian cohort. In 
analyses done among men only, the age-adjusted hazard ratio for being in 
Russia vs. Central Europe was 2.86 [2.31-3.54]; this excess risk was not 
reduced following adjustment for conventional CVD risk factors (HR=2.78 
[2.15-3.59]), or following adjustment for conventional and psychosocial 
factors (HR=2.77 [2.13-3.61]). In analyses done among women only, the 
hazard ratio of being in Russia vs. Central Europe was 1.59 [1.15-2.19]; 
this difference was exacerbated following adjustment for conventional 
factors (HR=2.15 [1.45-3.18]) but returned to a level comparable to crude 
models following additional adjustment for psychosocial factors (HR=1.64 
[1.09-2.46]). Similar results emerged in analyses where data from men 
and women were pooled together, and an explicit interaction was 
modelled between gender and country (Figure 41). 
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Figure 41. Associations of male sex and being in Russia (vs. being 
female in Central Europe) with cardiovascular mortality. There were 
109, 67, 198 and 175 events respectively in the four subgroups shown 
(from top to bottom).   
 
†Conventional factors = diabetes, smoking, blood pressure, cholesterol, 
HDL, BMI, physical activity, alcohol. 
 
‡Full adjustment = conventional factors + material possessions, 
depression, seeing relatives, seeing friends, friends*gender interaction, 
marital status, unemployment. 
 
Central Europe = Poland or Czech Republic.  
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3.3. Prediction 
Section 3.3 will describe the results from my work on risk prediction. As a 
reminder, current cardiovascular risk prediction models available in 
Eastern Europe have substantial limitations. The first aim was to fit a new 
risk prediction model, using conventional CVD risk factors, and 
contemporary cohort data using the HAPIEE study (known as Model 2 or 
EastEur-SCORE). A related aim was to externally evaluate how well this 
worked in the Estonian BioBank study.  
 
The second weakness in the current evidence is how it is unclear whether 
the addition of psychosocial and socioeconomic risk factors can improve 
the performance of clinical risk prediction models worldwide. To 
investigate this, I added new predictors to my newly created Model 2 
(EastEur-SCORE), to derive model 3 (known as HAPIEE-SCORE). I then 
evaluated the performance of HAPIEE-SCORE in external data from the 
Estonian BioBank study. 
 
3.3.1. Data and model description 
The derivation and validation samples are described in table 11 and figure 
42. The validation dataset was about 3 times smaller than the derivation 
dataset, which methodologically may be considered an appropriate 
balance. While the male-female split was almost equal in the derivation 
data, there were only 34% males in the validation data. In terms of age 
profiles, the validation cohort spanned the whole distribution of the 
derivation cohort, but additionally included younger participants (aged 37 
to 44) for whom predicted risk will be extrapolated. The validation cohort 
appeared to be slightly healthier in some respects (e.g. smoking, blood 
pressure, employment), but slightly less healthy in other respects (e.g. 
depression, single marital status, physical inactivity). Table 12 shows 
details of the two newly derived models (baseline risk, and beta 
coefficients from Hazard Ratios for each risk factor). Both new models 
were fully fitted, i.e. fully adjusted for all the risk factors, for which 
coefficients are shown.  
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Table 11. Baseline characteristics of the analytical sample. 
The sample shown are complete cases, combined across two genders.  
  
Dataset Derivation Validation 
Country  Poland, Czech   
Republic, or 
Russia 
Estonia 
Participants, N 14,598  4,632  
Follow-up, median years 7.2 8.3 
CVD mortality events (%) 338  (2.3%)  91  (2.0%) 
 
SCORE risk factors 
  
  Male, N (%) 6,910  (47%) 1,563  (34%) 
  Age, mean 57 (range 44 to 
74) 
51 (range 37 to 
74) 
  Diabetes (%) 953  (6.5%) 294  (6.3%) 
  Smoking Status 
    
     never (%) 6,853  (47%) 2,652  (57%) 
     ex/light (%) 3,615  (25%) 699  (15%) 
     current (%) 4,130  (28%) 1,281  (28%) 
  Blood pressure (mmHg) 139 129 
  Total cholesterol (mmol/L) 6.0 6.0 
 
Novel risk factors 
 
  Body Mass Index 27.9 27.2 
  Physically inactive (%) 1,057  (7.2%) 2,480  (54%) 
  Antihypertensive use 3,805 (26%) 1,163 (25%) 
  Education 
    
     tertiary (%) 3,874  (27%) 1,147  (25%) 
     secondary (%) 9,509  (65%) 3,423  (74%) 
     primary or less (%) 1,215  (8%) 62  (1.3%) 
  Employment Status: 
    
     Employed (%) 8,425  (58%) 3,714  (80%) 
     Unemployed (%) 679  (4.7%) 102  (2.2%) 
     Retired (%)  5,494  (38%) 816  (18%) 
  Marital Status: 
    
     Married/cohabiting (%) 11,129  (76%) 2,544  (55%) 
     Divorced/widowed (%)   2,843  (20%) 1,586  (34%) 
     Single (%) 626  (4.3%) 502  (10.8%) 
  Depression, suspected (%) 2,979  (20%) 1,530  (33%) 
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Figure 42. Age distributions of the derivation and validation samples. 
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  Name of new model 
  EastEur-SCORE HAPIEE-SCORE 
Baseline risk 0.002455 0.0009315 
SCORE risk factors     
  Male  1.457 (1.327 to 3.114) 1.940 (1.381 to 2.725) 
  Age (per 1 year) 1.100 (1.080 to 1.119) 1.092 (1.068 to 1.116) 
  Cholesterol, total  
    (per 1 mmol/L) 1.028 (0.932 to 1.135) 1.063 (0.962 to 1.176) 
  Cholesterol2  
    (centred at 6 mmol/L) 1.041 (1.019 to 1.062) 1.037 (1.016 to 1.059) 
  Smoking status   
    Non smoker ref. ref. 
    Ex/light smoker 1.590 (1.145 to 2.207) 1.544 (1.112 to 2.143) 
    Current smoker 3.483 (2.604 to 4.660) 3.081 (2.283 to 4.158) 
  Blood pressure, systolic  
    (per 1 mmHg) 1.017 (1.013 to 1.022) 1.020 (1.014 to 1.025) 
  Diabetes 2.302 (1.678 to 3.158) 2.226 (1.610 to 3.076) 
  High-risk area 2.033 (1.327 to 3.114) 1.803 (1.163 to 2.795) 
  High-risk are*Male  
    interaction 1.581 (0.968 to 2.584) 1.964 (1.189 to 3.244) 
Novel risk factors   
  BMI (per 1-unit kg/m2) - 0.956 (0.919 to 0.996) 
  BMI2  
    (centred at 23 kg/m2) - 1.005 (1.003 to 1.007) 
  Physical Inactivity  
    (<150 min./week) - 1.572 (1.135 to 2.178) 
  Antihypertensive use  1.243 (0.772 to 2.004) 
  Antihypertensives    
    *blood pressure      
     interaction  0.992 (0.983 to 1.002) 
  Educational attainment† - 1.213 (0.998 to 1.474) 
  Employment status -  
     Employed - ref. 
     Unemployed - 2.17 (1.321 to 3.564) 
     Retired - 1.386 (1.044 to 1.84) 
  Marital Status -  
     Married/cohabiting - ref. 
     Divorced/widowed - 1.482 (1.131 to 1.942) 
     Single - 2.662 (1.701 to 4.165) 
  Depression (possible) - 1.676 (1.299 to 2.161) 
 
Table 12. Parameters of the two newly created models.  
† = Education was treated as a categorical variable with three categories, 
and assuming a linear relationship across the three categories. The 
reference category was "tertiary education or above", which was compared 
against "secondary education" and "primary or less education" categories. 
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3.3.2. Calibration  
 
Calibration plots are shown in figures 43 and 44. In most of the six panels, 
most of the blue dots follow and approximately straight line of best fit (line 
not shown). This lack of curvature suggests that model calibration at the 
low end of the risk spectrum is comparable to model calibration at the high 
end of the risk spectrum. Each of the plots are now discussed in turn, 
beginning with figure 43 (for derivation data), going from top to bottom. 
 
Good calibration would be seen if some blue dots that appear above the 
grey diagonal line are compensated by some blue dots below the grey 
diagonal line. However, there appear to be some deviations from this in 
some of the panels, suggesting minor imperfections with calibration. The 
top panel suggests that the original SCORE model consistently 
overpredicted risk (across the entire risk distribution), in the derivation 
HAPIEE dataset. As expected, the newly derived models 2 and 3 appear 
better calibrated to the derivation data. This is typical and may reflect 
either a good model, or simply overfitting the derivation data. Hence 
calibration plots are most informative when looking at the externally 
validated data. These are shown in figure 44, and I will discuss these 
going from top to bottom. 
 
In the validation data, the original SCORE model was better calibrated 
(with some over prediction seen among the highest-risk groups, seen in 
the top right corner). When looking at the middle right panel, it appears 
that newly derived EastEur-SCORE model 2 partly overpredicted risk in 
the validation dataset, and after adding psychosocial factors to model 3 
then this over prediction became much larger (bottom panel). The pattern 
seen in these two panels is often seen in external validation studies, 
where newly derived models tend to over predict risk among those of 
highest risk. Such problems can sometimes be compensated by 
performing coefficient shrinkage, which was not done in my analyses. 
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Figure 43. Calibration plots in the derivation data. 
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Figure 44. Calibration plots in the validation data. 
 
 
218 
 
 
3.3.3. Discrimination  
 
The original SCORE model already had good discrimination performance 
in both derivation and validation datasets (C statistics of 0.78 and 0.83, 
respectively, table 13). This withstanding, the process of updating SCORE 
to create EastEur-SCORE resulted in impressive improvements to 
discrimination (ΔC = 0.04 and 0.02).  
 
Furthermore, the process of adding new predictors to create HAPIEE-
SCORE additionally led to substantial improvements (ΔC = 0.02 and 
0.014).  
 
Taken together, these two steps improved the original SCORE 
discrimination by an outstanding degree (ΔC = 0.06 and 0.03). 
 
 
 
Table 13. Discrimination performance of three cardiovascular 
prediction models, as measured by Harrell’s C-statistic (and 95% CI). 
Numbers without 95% CI denote changes in C-statistic, when comparing 
two models.  
Original SCORE EastEur-SCORE HAPIEE-SCORE
Derivation data
C-statistic 0.783 (0.735 - 0.831) 0.818 (0.774 - 0.862) 0.840 (0.800 - 0.880)
change in C-statistic 0.035 0.022
0.057
Validation data
C-statistic 0.832 (0.769 - 0.896) 0.851 (0.791 - 0.910) 0.865 (0.806 - 0.923)
change in C-statistic 0.019 0.014
0.033
Name of model
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3.3.4. Classification 
 
Table 14 shows classification performance across the three models. As 
previously described, the original SCORE overpredicted risk in the 
derivation set. This phenomenon can also be seen in higher sensitivity 
(77%) and lower specificity (64%) in the top row, when compared to the 
newly derived models. 
 
In the validation sample, the newly created models also tended towards 
over prediction. This too is visible in the pattern of increasing sensitivity 
and decreasing specificity, when looking down the three validation rows.  
 
 
 
 
Table 14. Classification performance of three cardiovascular 
prediction models.        
PPV = Positive Predictive Value; NPV = Negative Predictive Value 
  
Cohort Model
predicted 
low risk
predicted 
high risk TOTAL
Sensi- 
tivity
Speci- 
ficity PPV NPV
Derivation SCORE Whole sample 9,250        5,348        14,598 77% 64% 4.9% 99%
   Cases only 77              261           338       
   Controls only 9,173        5,087        14,260 
Derivation EastEur-SCORE Whole sample 11,376      3,222        14,598 66% 79% 7.0% 99%
   Cases only 114 224 338
   Controls only 11262 2998 14,260 
Derivation HAPIEE-SCORE Whole sample 11,431      3,167        14,598 69% 79% 7.3% 99%
   Cases only 106 232 338
   Controls only 11325 2935 14,260 
Validation SCORE Whole sample 3,814        818           4,632    58% 83% 6.5% 99%
   Cases only 38 53 91         
   Controls only 3776 765 4,541    
Validation EastEur-SCORE Whole sample 3,698        934           4,632    69% 81% 6.7% 99%
   Cases only 28 63 91         
   Controls only 3670 871 4,541    
Validation Whole sample 3,396        1,236        4,632    81% 74% 6.0% 99%
   Cases only 17 74 91         
   Controls only 3379 1162 4,541    
HAPIEE-SCORE
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3.3.4.1 Modelled clinical effect from statins 
To better understand the trade-offs between these two competing 
tensions, a brief cost-effectiveness simulation is presented in Table 15. 
Looking at the very top row (performance of the original SCORE in the 
derivation set), we have previously seen how this instance showed greater 
over prediction than in any of the other models. In this table, the same 
pattern of over prediction means that the model incorrectly labels people 
of intermediate risk as being of high risk, thereby recommending for them 
to consider statins, which in turn increases the programme costs. Since 
many of these statins will be recommended unnecessarily, then this 
reduces the programme cost-effectiveness. Indeed, for the top row the ““€ 
/ QALY” metric has the least favourable cost-effectiveness estimate of all 
the rows shown (€3,788, whereby large numbers are unfavourable. Of 
note, Western European countries generally tend to consider healthcare 
services that cost less than 20 000 or 30 000 per QALY to be sufficiently 
efficient to fund at scale).  
 
Recalibrating SCORE in the derivation data led to much fewer people 
being treated with statins and hence a smaller net QALY gain than in the 
first row. However, given the substantially lower programme cost 
(€384,109 Vs. €637,560 to screen 10 000 people and treat those who are 
identified as being at high risk), the overall cost-effectiveness estimate 
improved by 35% to €2,475. Augmenting SCORE with the novel risk 
factors led to slightly fewer people being treated, as well as slight 
increases to net QALY gains made to overall health, thereby slightly 
improving cost-effectiveness by a further 6% to €2,329. However, it is 
unclear to what degree these estimates may be biased by overfitting the 
models used to construct these estimates.  
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In the validation dataset (which should be less prone to overfitting), the 
original SCORE seemed to slightly under predict risk, as programme costs 
(€306,232) and clinical benefits here were smaller than with the other five 
scenarios. The recalibrated SCORE increased costs slightly, but this was 
offset by much better net QALY gains as more people were prevented 
from developing CVD. This clinical benefit outweighed the detriment to 
programme costs, and so overall cost-effectiveness (€2563) increased by 
5% when compared to the Original SCORE in the validation data. Finally, 
after adding the novel risk factors, the augmented SCORE tended towards 
slightly over predicting risk. This was not large enough to tip the balance 
of clinical effects towards a dominant increase in harm from side effects, 
but rather a dominant increase in benefit from preventing CVD, thereby 
leading to small improvements to net QALY gains. However, since the 
costs required to achieve this were considerable, augmentation with novel 
risk factors led to a 15% decrease in cost-effectiveness, when compared 
to the recalibrated model without novel risk factors. 
 
These brief examples of modelling approximate cost-effectiveness 
scenarios illustrate the importance of selecting the optimal intervention 
threshold. Importantly, programme costs can vary by as much as twofold 
simply by using slightly different models (with different degrees of 
calibration or interventional thresholds) For example, the final HAPIEE-
SCORE may well outperform the other models in the validation dataset, if 
the 5% threshold of clinical intervention was adjusted downwards to 
correct for this model’s tendency to over predict risk. This can be thought 
of as “altering the threshold to fit the model”. However, since I had 
specified a priori that I will only be interested in clinical changes at the 5% 
threshold, I am not going to optimize the threshold for the final model any 
further, and I will not perform any final recalibration of this model either.  
 
This withstanding, reclassification plots, shown in the next section, enable 
a preliminary inspection of potential reclassification across a range of 
interventional thresholds.  
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3.3.4.2 Reclassification plots 
Figure 45 illustrates reclassification in the derivation cohort, when 
comparing the original SCORE against the recalibrated model. If all dots 
lie along the diagonal, this denotes no change in risk prediction between 
the two models. Dots which lie upwards and left of the diagonal line have 
been reclassified upwards in risk, while dots which lie downwards and 
right of the diagonal have been reclassified downwards in risk with the 
new model. Of less importance are dots appearing in the bottom-left 
quadrant and dots appearing in the top-right quadrant, since all these dots 
denote various degrees of reclassification that is clinically of little 
consequence. In contrast, red dots appearing in the top left corner would 
suggest that the new model is clinically favourable (since it is better able 
to classify cases as being at high risk, who were previously classified as 
low risk). Along similar lines, blue dots appearing in the bottom right 
corner would suggest that the new model is clinically favourable (since it is 
better able to classify controls. 
 
Looking at figure 45, both blue and red dots are slightly more common 
down-and-right of the diagonal. This is consistent with the interpretation 
that the original SCORE overpredicted risk, which has now been corrected 
in EastEur-SCORE (model 2) following recalibration. The pattern is 
particularly prominent among the blue dots (denoting controls). In addition, 
a small cluster of red dots is seen above the diagonal, in the top right 
corner. This suggests that true positives have correctly been classified 
upwards, consistent with the anticipated benefits from adding a new 
smoking parameter (ex/light smoker), as well as more sophisticated 
nonlinear modelling of the risk functions for cholesterol and blood 
pressure. However, from this plot it is unclear whether these changes are 
clinically meaningful, as both blue and red dots are found in the clinically 
meaningful quadrants (top-left; bottom-right).  
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Figure 45. Reclassification in the derivation cohorts, comparing the 
original SCORE model (x-axis) against the recalibrated model  
(y-axis).  
Red dots denote participants who died of CVD during the follow-up.  
Blue dots denote participants who did not die of CVD during the follow-up.  
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Figure 46 illustrates the same reclassification, this time in the validation 
cohort. There are more data points with very low risk, possibly reflecting 
the slightly younger age profile and/or potential selection bias from a 
stronger “healthy volunteer” effect. In both the derivation and validation 
datasets, the curvature of the blue dots across the risk spectrum appears 
as a result of transitioning from a Weibull model to a Proportional Hazards 
model, as the hazard associated with age is modelled slightly differently 
across these two. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Reclassification in the validation cohort, comparing the 
original SCORE model (x-axis) against the recalibrated model  
(y-axis).  
Red dots denote participants who died of CVD during the follow-up.  
Blue dots denote participants who did not die of CVD during the follow-up. 
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In contrast to the derivation data (figure 45), the validation cohort in figure 
46 suggest a slightly opposite effect: that there is a slight upclassificaion 
of risk, among both cases and controls. One outcome of this is a relatively 
large number of red dots in the top left quadrant. These are participants 
who previously were classified as “low risk” (and not eligible for 
interventions like statins), but who have now been correctly classified as 
“high risk”. This is consistent with the increase in sensitivity across the two 
models (from 58% to 69%). Fortunately, the corresponding decrease in 
specificity, on account of blue dots also moving into the top left quadrant, 
is not as pronounced (from 83% to 81%), suggesting that the reclassified 
model might be generally superior. 
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Figure 47 illustrates reclassification after the second step, where the 
recalibrated EastEur-SCORE was augmented with seven new risk factors. 
The top left corner contains more red dots than the bottom right corner, 
consistent with an interpretation of superior discriminatory power in the 
newly augmented model. In addition, I also modified the location of the 
horizontal and vertical lines, thereby changing the size of these two 
quadrants, to denote alternative clinical interventions thresholds that are 
near to 5%. These plots are not shown in the thesis, but my inspection 
suggested that superior discriminatory power may be present across a 
range of intervention thresholds, such as from 2% to 8%. If the threshold 
is raised above 8%, then those few individuals who do develop CVD tend 
to do so for unknown risk factors that are not captured by my final 
augmented model. If the threshold is raised below 2%, then those few 
individuals who do develop CVD tend to do so for unknown risk factors 
that are not captured by my final augmented model. 
Figure 47. Reclassification in the derivation cohort, comparing the 
recalibrated model (x-axis) against the augmented model (y-axis).  
Red dots denote participants who died of CVD during the follow-up.  
Blue dots denote participants who did not die of CVD during the follow-up. 
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Figure 48 illustrates the same reclassification in the validation data. Again, 
the top left corner contains more red dots than the bottom right corner, 
consistent with an interpretation of superior discriminatory power in the 
new model. Again, modification of the 5% clinical interventions thresholds 
here suggested that superior discriminatory power may be present across 
virtually the entire range of intervention thresholds (from 2% to 50%). 
 
 
 
 
 
Figure 48. Reclassification in the validation cohort, comparing the 
recalibrated model (x-axis) against the augmented model (y-axis).  
Red dots denote participants who died of CVD during the follow-up.  
Blue dots denote participants who did not die of CVD during the follow-up. 
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3.3.4.3 Reclassification tables 
The next section will describe 6 tables, where each table makes a detailed 
comparison of the performance of two risk prediction models. In this case, 
data are presented with exclusive interest in differences across the 
clinically meaningful risk thresholds (5% risk of CVD mortality in 10 years’ 
time).  
 
(The sole exception to this focus is how Continuous NRI is still reported at 
the bottom for comparison, since this measure has been commonly 
reported in the existing literature. Theoretically, Continuous NRI assumes 
that there is not only one risk threshold [as is assumed by Binary NRI] or a 
handful of risk thresholds [as is assumed by Continuous NRI] but that 
there are even more – a total of infinite risk thresholds. As the number of 
thresholds increases, then NRI itself tends to increase in number. 
However, it can be argued that Binary forms of NRI are clinically more 
informative and useful, than Continuous forms of NRI. This is detailed in 
Appendix 2. For this reason, my use of the term “NRI” or “reclassification” 
will always refer to “Binary NRI” unless otherwise specified.) 
 
Data are further stratified to examine upwards and downwards movement 
across this 5% risk threshold for cases and controls. 
 
Table 16 shows the outcomes for reclassification, when the derivation 
data are used to compare the original SCORE (model 1) against the 
recalibrated SCORE (model 2, a.k.a. EastEur-SCORE). When looking 
only among the cases (top table), then 3% of participants changed 
correctly from a previously incorrect “low risk” classification to now being 
correctly classified as “high risk”. However, 14% of participants changed 
incorrectly from a high to a low risk classification. This resulted in a 
negative Binary NRI among cases (-11%). Among controls, the Binary 
NRI was positive (+15%). This pattern of change is consistent with the 
interpretation that the new model corrected for previous miscalibration. 
These two reclassification quantities can be added to yield a summative 
Binary NRI of +0.04. However, if 20x more weight is given to the changes 
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in classification among cases, when compared to changes in classification 
among controls (as is done by the Net Benefit metric), then Net Benefit is 
negative (-0.10). This is to be expected if the entire risk model 2 has been 
calibrated downwards in risk, as it has been in this case. 
 
If considering risk reclassification at infinite risk thresholds, then the 
continuous NRI was positive (+0.19). However, I will place less value on 
this metric as I find it clinically less informative. 
 
 
 
 
 
 
 
Table 16. Reclassification in the derivation cohorts, comparing the 
original SCORE against the recalibrated SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable.  
 
From model 1 (SCORE) to model 2 (EastEur-SCORE), derivation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 67 10 77 3%
predicted high risk 47 214 261 14%
TOTAL 114 224 338
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 8885 288 9173 2%
predicted high risk 2377 2710 5087 17%
TOTAL 11262 2998 14260
Summary
Net Reclassificaiton Improvement, continuous 0.19   (0.08 to 0.29) P < 0.0001
Net Reclassification Improvement, binary/categorical 0.04   (-0.01 to 0.08) P = 0.09
Net Benefit (with a casese:control weighting of 20:1) 0.10-   
New model (EastEur-SCORE)
New model (EastEur-SCORE)
Old 
model 
(SCORE) 15%
Correctly 
upclassified
Incorrectly 
downclassified
NRI in cases
Old 
model 
(SCORE) -11%
Incorrectly 
upclassified
Correctly 
downclassified
NRI in controls
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Table 17 shows subsequent reclassification performance, after adding 
seven new predictors (model 3) to the recalibrated model (model 2). There 
was a slight increase in reclassification performance among cases (+2%), 
alongside no change in reclassification among controls (+0.4%), 
altogether yielding a Binary NRI of 0.03. After up weighting the changes in 
performance among cases, there was a positive gain in Net Benefit 
(+0.02).  
 
 
 
 
 
 
 
Table 17. Reclassification in the derivation cohorts, comparing the 
recalibrated SCORE against the augmented SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable.  
From model 2 (EastEur-SCORE) to model 3 (HAPIEE-SCORE), derivation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 90 24 114 7%
predicted high risk 16 208 224 5%
TOTAL 106 232 338
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 10671 591 11262 4%
predicted high risk 654 2344 2998 5%
TOTAL 11325 2935 14260
Summary
Net Reclassificaiton Improvement, continuous 0.44 (0.33 to 0.55) P < 0.0001
Net Reclassification Improvement, binary/categorical 0.03 (-0.01 to 0.07) P = 0.14
Net Benefit (with a casese:control weighting of 20:1) 0.02
New model (HAPIEE-SCORE)
New model (HAPIEE-SCORE)
Old model 
(EastEur-
SCORE) 2%
Correctly 
upclassified
Incorrectly 
downclassified
NRI in cases
Old model 
(EastEur-
SCORE) 0.4%
Incorrectly 
upclassified
Correctly 
downclassified
NRI in controls
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Table 18 shows the total reclassification performance, after comparing 
model 1 against model 3. An overall downwards recalibration (possibly 
arising from the creation of model 2) can be seen in a negative NRI 
among cases (-9%). On the other hand, reclassification among controls 
was generally much improved (+15%), perhaps on account of the better 
discrimination created by model 3. Summing these two components in an 
unweighted manner yielded a Binary NRI of +0.07, but allocating 
appropriate clinical weighting led to a negative Net Benefit of -0.08. This 
may be expected in cases where the original SCORE overpredicted risk 
substantially, as the clinical Net Benefit measure is prone to rewarding 
over prediction since even slight increases in sensitivity are 
overshadowed (by 20 times) by any loss in specificity. 
 
 
 
 
Table 18. Reclassification in the derivation cohorts, comparing the 
original SCORE against the augmented SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable. 
From model 1 (SCORE) to model 3 (HAPIEE-SCORE), derivation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 60 17 77 5%
predicted high risk 46 215 261 14%
TOTAL 106 232 338
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 8774 399 9173 3%
predicted high risk 2551 2536 5087 18%
TOTAL 11325 2935 14260
Summary
Net Reclassificaiton Improvement, continuous 0.45 (0.34 to 0.56) P < 0.0001
Net Reclassification Improvement, binary/categorical 0.07 (0.02 to 0.11) P = 0.005
Net Benefit (with a casese:control weighting of 20:1) -0.08
Old model 
(SCORE) 15%
New model (HAPIEE-SCORE)
New model (HAPIEE-SCORE)
Old model 
(SCORE) -9%
Incorrectly 
upclassified
Correctly 
downclassified
NRI in controls
Correctly 
upclassified
Incorrectly 
downclassified
NRI in cases
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Table 19 shows reclassification in the validation cohort, comparing models 
1 and 2. Here, because the original SCORE was reasonably well 
calibrated (perhaps just slightly under predicting risk but not much), the 
NRI was positive in cases (+11%) with minor loss of performance among 
controls (-2%). The unweighted Binary NRI was 0.09, and weighting 
resulted in a positive gain in Net Benefit (0.11).  
 
 
 
 
 
 
 
 
 
 
Table 19. Reclassification in the validation cohorts, comparing the 
original SCORE against the recalibrated SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable. 
  
From model 1 (SCORE) to model 2 (EastEur-SCORE), validation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 27 11 38 12%
predicted high risk 1 52 53 1%
TOTAL 28 63 91
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 3572 204 3776 4%
predicted high risk 98 667 765 2%
TOTAL 3670 871 4541
Summary
Net Reclassificaiton Improvement, continuous 0.09-   (-0.28 to 0.10) P = 0.34
Net Reclassification Improvement, binary/categorical 0.09    (0.02 to 0.16) P = 0.02
Net Benefit (with a casese:control weighting of 20:1) 0.11   
Correctly 
downclassifie
d
NRI in controls
11%
-2%
Correctly 
upclassified
Incorrectly 
downclassifie
d
NRI in cases
New model (EastEur-SCORE)
Old model 
(SCORE)
Old model 
(SCORE)
Incorrectly 
upclassified
New model (EastEur-SCORE)
 
 
236 
 
Table 20 shows the change in validation cohorts, across model 2 and 3. 
The changes are very similar to the previous changes from models 1 and 
2: large NRI improvements seen among cases (+12%), coupled with 
minor deterioration among controls (-6%) led to an overall unweighted 
binary NRI of 0.06, and a large increase in weighted Net Benefit (0.12).  
 
 
 
 
 
 
 
 
 
Table 20. Reclassification in the validation cohorts, comparing the 
recalibrated SCORE against the augmented SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable. 
  
From model 2 (EastEur-SCORE) to model 3 (HAPIEE-SCORE), validation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 15 13 28 14%
predicted high risk 2 61 63 2%
TOTAL 17 74 91
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 3309 361 3670 8%
predicted high risk 70 801 871 2%
TOTAL 3379 1162 4541
Summary
Net Reclassificaiton Improvement, continuous 0.53   (0.37 to 0.68) P < 0.0001
Net Reclassification Improvement, binary/categorical 0.06   (-0.02 to 0.14) P = 0.16
Net Benefit (with a casese:control weighting of 20:1) 0.12   
New model (HAPIEE-SCORE)
New model (HAPIEE-SCORE)
Old model 
(EastEur-
SCORE)
Incorrectly 
upclassified
Correctly 
downclassifie
d
Old model 
(EastEur-
SCORE)
Correctly 
upclassified
Incorrectly 
downclassifie
d
12%
-6%
NRI in cases
NRI in controls
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Altogether, table 21 illustrates the change from model 1 to 3 in the 
validation data. As expected, this reports larger magnitudes of the 
previously described pattern: large improvements to reclassification 
among cases (+23%), coupled with small deterioration among 
reclassification among control (-9%). These two combined to yield an 
unweighted Binary NRI of 0.14. If weighted, there was a very large 
increase in Net Benefit (0.23).x 
 
 
 
 
 
 
 
 
Table 21. Reclassification in the derivation cohorts, comparing the 
original SCORE against the augmented SCORE.  
NRI=Net Reclassification Improvement.  
Green highlight = large percentages here are desirable.  
Red highlight = large percentages here are undesirable.  
From model 1 (SCORE) to model 3 (HAPIEE-SCORE), validation data
Among cases (observed events)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 14 24 38 26%
predicted high risk 3 50 53 3%
TOTAL 17 74 91
Among controls (observed no event)
predicted 
low risk
predicted 
high risk
TOTAL
predicted low risk 3310 504 3814 11%
predicted high risk 86 732 818 2%
TOTAL 3396 1236 4632
Summary
Net Reclassificaiton Improvement, continuous 0.13   (-0.03 to 0.28) P = 0.12
Net Reclassification Improvement, binary/categorical 0.14   (0.04 to 0.25) P = 0.006
Net Benefit (with a casese:control weighting of 20:1) 0.23   
Old 
model 
(SCORE) -9%
New model (HAPIEE-SCORE)
New model (HAPIEE-SCORE)
Old 
model 
(SCORE) 23%
Incorrectly 
upclassified
Correctly 
downclassifie
d
NRI in controls
Correctly 
upclassified
Incorrectly 
downclassifie
d
NRI in cases
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3.3.5. Decision Curve Analysis 
A decision curve analysis was used as a sensitivity check, to explore 
whether the benefits reported above are likely to hold in cases where the 
intervention threshold (where interventions are recommended to those 
whose predicted risk is above 5%) is relaxed so that this could be 
anything between 0-20%.  
 
Figure 49 reports results from the derivation dataset. Since the red line is 
consistently above the dotted line, this suggests that the recalibrated 
SCORE provides a large clinical net benefit across a range of 
interventional thresholds. Next, comparing the red and green lines 
suggest that the incorporation of seven new predictors in the HAPIEE 
model provides a small degree of additional net benefit for most scenarios 
(except for cases where the intervention threshold is between 0.09 and 
0.12 where the EastEur and HAPIEE models are indistinguishable).  
 
 
Figure 49. Decision Curve Analysis, in the derivation dataset. X-axis 
denotes the threshold at which clinical interventions are recommended (a 
scenario that is more concerned with side effects and costs is left of 0.05, while a 
scenario that is more concerned with preventing CVD at any cost is right of 0.05). 
SCORE = The original SCORE model. EastEur = the recalibrated model 2. 
HAPIEE = the augmented model 3 that incorporates 7 additional predictors.  
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Figure 50 reports the results from decision curve analysis performed on 
the validation dataset. All three models performed reasonably similarly 
across a range of interventional thresholds. This is consistent with the 
observation that the SCORE model performed relatively well in the 
validation data (when compared to the derivation data), and thus the 
baseline standard was already quite high. Inspection of the small changes 
in net benefit suggests that the final HAPIEE model appears to be 
superior in cases where the interventional threshold ranges from 2% to 
6%. 
 
 
 
 
 
  
 
 
Figure 50. Decision Curve Analysis, in the validation dataset. X-axis 
denotes the threshold at which clinical interventions are recommended (a 
scenario that is more concerned with side effects and costs is left of 0.05, while a 
scenario that is more concerned with preventing CVD at any cost is right of 0.05). 
SCORE = The original SCORE model. EastEur = the recalibrated model 2. 
HAPIEE = the augmented model 3 that incorporates 7 additional predictors.   
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4. Discussion 
 
4.1. Mendelian randomization 
In this Mendelian randomisation study, I found strong genetic support for 
the hypothesis that longer education has a causal effect on lowering the 
risk of coronary heart disease. My findings using genetic data, which can 
be considered as ‘nature’s randomized trials’,(257) were consistent with 
data from observational studies, and I found little evidence that these 
results may be driven by genetic pleiotropy. More specifically, 3.6 years of 
additional education (similar to an undergraduate university) degree is 
predicted to translate into about a one-third reduction in the risk of CHD.  
 
4.1.1. Comparison with previous studies 
There is a vast body of observational studies across a range of settings 
that show an association between education and CHD. In contrast, there 
have been comparatively few studies that have explicitly investigated the 
causality of this relationship. The existing studies come from three 
domains. First, analyses of natural experiments have compared mortality 
before and after changes to compulsory schooling laws. For example, by 
looking at mortality rates in countries before and after the introduction of 
national legislation that increased minimum education. In the Netherlands, 
such changes were associated with reductions in all-cause mortality.(121) 
In the UK, the largest study so far reported causal effects on improving 
physical activity, BMI, blood pressure, diabetes, CHD, and all-cause 
mortality.(122) An extension of this design is to compare geographical 
areas, such as the various states within the USA. These studies initially 
suggested a large effect on all-cause mortality, but this effect disappeared 
when state-specific baseline trends were taken into account.(123, 124) In 
Sweden, an intervention to extend compulsory schooling throughout a 13-
year transition period in a stepped-wedge design across multiple 
municipalities reported lower all-cause mortality in those deaths occurring 
after age 40 (equivalent to HR of death=0.86 (0.77-0.96) per 3.6 years of 
additional education).(125)  
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Another source of causal inference comes from studies on monozygotic 
twins. Within each pair, both twins are exposed to the same set of genetic 
exposures (and also some environmental exposures, called the “shared 
environment”). Consequently, any difference in disease outcome between 
twins cannot arise from genetic effects. If differences in outcome 
associate with differential exposure to nonshared features of the 
environment (such as one twin pursuing education longer than the other 
twin), and if the magnitude of this association is comparable to that seen 
in the general population, then this makes less likely the possibility that 
the observational association is confounded by genetic (or shared 
environmental) factors. While the twin method does not eliminate the 
possibility of confounding from other factors in the nonshared 
environment, it is a design with which to eliminate the possibility of 
confounding from genetic factors. Twin studies conducted in Denmark 
initially found evidence both for and against causal effects from education 
to mortality and CHD incidence.(126, 258) The largest study to date from 
Sweden (which has twice the statistical power of the previous largest 
study) found strong evidence for causal effects.(130) There, the 
association between years of education and lifespan did not attenuate at 
all, when comparing the conventional population-based analysis against 
the between-twin analysis. Hence the twin literature suggests that, while 
there are only a handful of sufficiently powered studies, shared 
environmental factors (such as parenting) are less likely to cause 
substantial confounding. It also suggests that confounding from genetic 
factors (such as genetic differences in drive, motivation, personality or 
innate intellect; all of which may predispose towards longer education) 
might not account for the observational associations between education 
and disease. A parallel domain of research, using data from millions of 
non-identical siblings (that sometimes reached 100-times larger sample 
sizes than the twin studies), has also observed little attenuation of the 
association between education and subsequent mortality, when 
comparing the general population analysis with the within-sibling 
analysis.(131, 132) As with twin studies, this also suggests that 
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environmental and genetic factors shared by the siblings, are unlikely to 
confound the observational association seen between education and 
disease. While twin and sibling studies both leave open the possibility of 
confounding from nonshared environmental factors, taken together with 
these results (using an entirely different method), the wider body of 
evidence is more compatible with a causal interpretation, suggesting that 
changes in education may lead to a reduction in CHD. 
 
Finally, some recent studies have also looked at specific genetic variants 
for education. An association was found between parental longevity and 
genetic markers for education in their offspring.(134) However, causal 
directions and pleiotropy were not tested in this study. Others have used 
conventional Mendelian randomisation and found genetic variants for 
education to predict myopia and dementia.(136) However, these studies 
did not investigate pleiotropy of their genetic instruments. No Mendelian 
randomisation studies of socioeconomic exposures have investigated any 
other disease outcome, such as cardiovascular diseases. Furthermore, 
most of the other designs listed above (including natural experiments, twin 
and sibling designs) have reported outcomes for all-cause mortality. Few 
have reported cardiovascular mortality and virtually none have reported 
fatal/nonfatal CHD, as I did. 
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4.1.2. Strengths and limitations 
 
My study has important strengths. I investigated the causality of the 
association between an easily measured socioeconomic factor (i.e. 
education) and a common disease (i.e. coronary heart disease). I applied 
the Mendelian randomisation design, which in conjunction with findings 
from other study designs, should improve our understanding of causality 
by reducing bias from confounding. By integrating summary-level data 
from over half a million individuals, my study was well-powered to derive 
robust causal effect estimates, and also powered for multiple sensitivity 
analyses (which typically require larger sample sizes). I used recent state-
of-the-art methodological developments to thoroughly explore the 
possibility of pleiotropy in the genetic variants analysed, for which I found 
little evidence. 
 
My study also has some limitations. First, it is possible that the genetic 
variants associated with education may instead mark more generic 
biological pathways (such as vascular supply or mitochondrial function), 
which could enhance systemic fitness, thereby leading to parallel 
increases in cognitive and cardiac function.(23, 129) In this scenario, 
which could violate the InSIDE assumption, policy interventions to raise 
education may not translate into lower heart disease incidence.  
 
However, such a scenario is less likely to lead to the consistent set of 
results I found across my sensitivity analyses, as this would require that 
pleiotropy occurs in a rather contrived scenario where: i) the InSIDE 
assumption is violated (so that MR-Egger is biased); ii) least 50% of the 
information comes from SNPs with highly pleiotropic effects on heart 
disease; iii) and these pleiotropic effects occurred in such a way as to 
make the causal estimates on heart disease appear very similar to one 
another.  
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At present, there are no definitive tests with which to verify such 
assumptions, meaning that triangulating data from other sources and 
subjective judgement are needed to evaluate the plausibility of gross 
pleiotropic bias.(259) I believe such pleiotropy to be less likely for four 
reasons. First, the effects from genetic pleiotropy would have to coincide 
with the non-genetic associations observed in studies of monozygotic 
twins, and second they would also have to coincide with the non-genetic 
associations observed in natural experiments. Third, if education and CHD 
share some of their underlying genome-wide genetic architecture (as seen 
in the LD score regression), and if most of the top hits for education are 
strongly pleiotropic for CHD, then one might imagine the top hits for CHD 
to also pick up some of these pleiotropic traits. However, my reverse-
direction Mendelian randomisation found a null estimate. Fourth, despite 
gaps in our understanding of the biological mechanisms through which 
these 162 SNPs influence education, they are disproportionately found in 
genomic regions that regulate brain development, they are enriched for 
biological pathways involved in neural development, and they are 
preferentially expressed in neural tissue.(234) Since these 162 SNPs do 
not appear to have any expression or enrichment in cardiovascular 
tissues, this further narrows the scope of pleiotropy: any potential 
pleiotropy might have to exert a large effect on CHD via predominantly 
neurological pathways (for example behaviours associated with obesity), 
as opposed to via global or systemic measures of fitness (such as 
mitochondrial function). Therefore on balance, I feel that the scenario 
where gross pleiotropy invalidates my sensitivity analysis is less 
consistent with the broader body of evidence, in comparison to the 
scenario where my sensitivity analyses are valid. If my sensitivity analyses 
are indeed valid, then policy interventions that mirror prolonged exposure 
to educational (as indexed by the genetic instruments) would, on balance, 
probably prevent heart disease.  
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As a second limitation, it is possible that these 162 SNPs are merely 
markers of cognitive ability and intelligence, which is the underlying factor 
that causes both higher education and lower heart disease. The body of 
evidence appears to suggest that intelligence can be a causal mediator 
along the pathway from education to heart disease.(260) This is most 
compatible with a simple “linear chain” model whereby the 162 SNPs I 
studied cause intelligence, which in turn predisposes towards longer 
education, which in turn increases intelligence further still, as a final result 
of which heart disease is ultimately prevented. This I believe to be the 
most likely causal pathway.  
 
Alternatively, critics could posit that genetic predisposition to greater 
intelligence may theoretically be a pleiotropic confounder, which 
invalidates my MR and observational analyses. However, this model is 
difficult to reconcile with the causal effects measured by natural 
experiments and twin studies. In both of those cases, causal effects are 
elicited by varying the environmental (i.e. non-genetic) component of 
education. Although it is possible for other biases in these study designs 
to coincidentally align with this bias in my MR and observational results, 
the probability of this appears to be low. 
 
As a third limitation, in order to arrive at policy recommendations, one 
would have to assume that genetic predisposition towards higher 
educational attainment causes the same behavioural and physiological 
consequences as environmentally-acquired changes to educational 
attainment, such as from a policy intervention. It may be however, that a 
year of additional education from genetic causes could trigger a different 
set of biological and behavioural mechanisms when compared to a year of 
additional education from policy change. Presently, we know very little 
about the mechanisms of these genetic effects. In the analyses I 
conducted in this study, I found some initial evidence that some of these 
genetic effects may be mediated via common cardiovascular factors like 
smoking, BMI and lipids. In keeping with this, policy changes to education 
in the USA and UK have also estimated some causal effects on smoking, 
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BMI, blood pressure and diabetes (122, 261), which are broadly 
consistent with my findings. Few studies have measured the causal 
effects of policy interventions on lipids. While a randomized controlled trial 
of education is difficult for CHD outcomes, due to approximately 50 years 
of lag, it may be conceivable for future research to measure effects on 
potential mediators, as these occur much sooner. A second response to 
this overall limitation is the analogy to other exposures (such as LDL-
cholesterol and systolic blood pressure), where genetic effects have 
mirrored findings from environmentally-acquired changes (such as from 
randomized controlled trials of pharmacological therapies.(262, 263)). 
Taken together, while my study makes no direct inference on what health 
effects may stem from a policy intervention that successfully raises 
education, I am cautiously optimistic that a policy which successfully 
increases education should lead to reductions in heart disease. 
 
As a fourth limitation, I assumed the absence of dynastic effects, an 
assumption that is broken when parental genes associate with parental 
behaviours that directly cause a health outcome in the child.(264) For 
example, parents with a genetic predisposition towards higher education 
may choose to feed their children a better diet. However, parental 
educational attainment has been shown to be a poor predictor of 
conventional cardiovascular risk factors in children.(265)  
 
Fifth, the observational and genetic data originate predominantly from 
European origin samples in high-income countries. I am thus unable to 
generalize these estimates to other populations, particularly to low-income 
countries where cardiovascular diseases are less common. However, it 
may well be expected that socioeconomic factors mirror the pattern seen 
in other cardiovascular risk factors, where similar effects are typically seen 
across the world.(202) Along similar lines, my findings are predominantly 
valid to describe phenomena which may occur among the types of people 
who are likely to participate in scientific studies. It is unclear to what extent 
they will generalize to people who are typical non-responders. 
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Sixth, I do not know whether increasing education for those of least 
education will be as cardioprotective as increasing education for those 
with above-average education. Nonetheless, the linear relationship seen 
in the observational data is more compatible with an explanation of dose-
response across the broad educational gradient.  
 
Seventh, education is to some extent a social construct, whose attainment 
in one place and time may be influenced by different factors, when 
compared to attainment in another place and time. Indeed, the original 
GWAS study where these 162 SNPs were discovered analysed 
participants whose year of birth ranged from 1893 to 1989 – nearly a 
whole century. This challenges the generalizability and validity of my 
findings. However, the GWAS study also examined whether the polygenic 
score was more or less strongly associated with educational outcomes 
across the period 1930 to 1955 in Sweden, a time of considerable 
educational reform. There was no evidence of genetic effects operating 
differently across this period, suggesting that international differences in 
culture may be a greater source of heterogeneity. However, this GWAS 
study was conducted exclusively on European and North American 
settings, with broadly similar cultures. Hence although theoretically 
possible, I find it less of a concern for period or cultural effects to 
invalidate my analyses. 
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4.1.3. Potential mechanisms 
 
4.1.3.1. Mediation via conventional cardiovascular risk factors 
Previous work on the mechanism that might mediate the association 
between education and CHD have accounted for some (but not all) of this 
association. Traditional observational associations have typically 
estimated that the association between education and CHD attenuates by 
around 30-45% after statistical adjustment for health behaviours and 
conventional cardiovascular risk factors (including smoking, blood 
pressure and cholesterol). It has been reported that by measuring these 
mediators at two time points and modelling these as time-dependent 
covariates, the explained fraction attributable can increase to nearly 100% 
for outcomes such as all-cause mortality. However, one study which 
applied such a correction found that the fraction mediated for CVD 
mortality increased only from 29% to 45%.(266) Hence it is plausible for 
some of the mechanism from education to CVD to be mediated along 
additional pathways that are independent of the conventional CVD risk 
factors. This is consistent with the data from my observational analyses 
(figure 40 in section 3.2.3.), where I also found conventional risk factors to 
account for 42% of the association between education and CHD. 
Altogether, this suggests that conventional factors could account for 
around half of the association between education and CHD.(8, 266)  
 
My Mendelian randomization study found genetic predisposition towards 
longer education to associate with improved smoking, BMI and blood lipid 
profiles (with some borderline results for blood pressure and risk of 
diabetes). In my analyses, I was unable to quantify to what degree these 
conventional risk factors (if indeed causal) could account for the pathway 
from education to CHD. This could be done in the future, for example by 
applying two-step Mendelian randomisation.(267, 268) I have interpreted 
my findings to mean that policy changes which increase educational 
attainment would probably reduce smoking and BMI among those who 
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have been pushed towards attaining higher education, when compared to 
a scenario without such policy change. 
 
On the one hand, this interpretation may be incorrect if indeed dynastic 
effects (discussed above in section 4.1.2, under the fourth limitation) have 
confounded my causal analyses. For example, parents with genes 
predisposing towards greater education may create early-life conditions 
for their child that are more conductive towards heart health in ways that 
are completely independent of cognitive development and subsequent 
educational attainment (e.g. healthier diets or fewer adverse childhood 
experiences). Under this scenario, the fact that these children later 
undertake longer education may be irrelevant, in terms of influencing 
smoking and BMI outcomes. Indeed, socioeconomic gradients in BMI and 
smoking rates are already visible before age 16, which is consistent with a 
non-causal interpretation from own education to smoking. One analysis of 
causal effects as a result of raising the school leaving age in the UK 
showed mixed findings, with no causal effect found from education to 
smoking, but causal effects found from education to BMI.(122)  
 
Given this mixed state of evidence, more work on the causal pathways 
operating in the first 25 years of life is warranted, perhaps even with 
randomized trial designs where possible. Until then, it appears sensible to 
suggest that interventions which seek to improve the early-life 
experiences of young children (both by increasing cognitive abilities as 
well as health behaviours) are likely to be of benefit, one way or another. 
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4.1.3.2. Mediation via other pathways 
It is plausible that conventional cardiovascular risk factors may not 
completely account for the mechanism between education and CHD. 
Additional mechanistic hypotheses for investigations are required. First, 
spending more time in education could lead directly to greater health 
knowledge (from being in contact with staff or students with better health 
knowledge). Education could also increase health knowledge indirectly, by 
equipping people with generic cognitive and reading skills with which to 
make sense of health-related information (particularly online content, 
which is can be written by more educated authors). Better health 
knowledge could then lead to greater uptake of healthcare services. 
Alternatively, better health knowledge could then lead to better dietary 
behaviours. These putative pathways are beyond the scope of this thesis, 
but are promising avenues for further enquiry.  
 
Second, education could improve people’s job prospects, income, material 
conditions, social ranking, frequency of social contacts, marital status, and 
well-being. Socioeconomic and psychosocial –factors like these have 
previously been associated with education as well as CHD. Indeed my 
own observational mediation analyses suggested that altogether, they 
may account for an additional 35% of the pathway from education to CHD. 
This quantity should be interpreted very approximately, on account of 
large collinearity between these variables, residual measurement error, as 
well as any omitted confounders between mediator and outcome, all of 
which could bias quantity mediated up or down.(1)  
 
Many of the putative mediators discussed above (including conventional 
cardiovascular risk factors, diet, uptake of healthcare, income, frequency 
of social contact, and overall well-being) are potentially amenable to 
clinical and/or public health interventions. These all present future 
opportunities to potentially lower health inequalities. Such attempts would 
benefit from rigorous evaluation where possible, in order to expand the 
comparatively light existing literature, on effective ways of reducing health 
inequalities. 
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4.1.4. What this study adds 
 
Following exposure to a socioeconomic factor, there is often a long 
incubation period before the occurrence of common diseases (in this 
example, around 50 years). Consequently, this line of research is not 
particularly amenable to randomized controlled trials, which would 
otherwise settle questions of causality. This does not mean these 
associations are less worthy of investigation, particularly as large point 
estimates open up the possibility of potentially large public health gains. 
The solution is to triangulate evidence from multiple study designs, each 
with their own strengths and weaknesses. The limited studies to date have 
suggested that a causal effect is more likely than not to exist, between 
socioeconomic exposures and all-cause mortality. My study adds to this 
evidence by using an entirely new technique, which also suggests that a 
causal effect is more likely than not to exist between education and CHD. 
 
4.1.5. Implications for researchers, clinicians and policymakers 
 
The main question for future research is “What mechanisms account for 
the strong association seen between genetic predisposition towards 
longer education, and substantially lower risk of CHD?” Were it found that 
a health behaviour (such as diet) is an important mediator, then 
interventions on diet could become the cornerstone of policies designed to 
reduce health inequalities.  
 
More molecular research is needed to delineate the mechanism, 
pleiotropic or not, through which these 162 education SNPs associate with 
cardiac outcomes. This could elucidate new aetiological mechanisms for 
CHD which, in turn, could lead to insights for potential drug discovery. 
 
Although there remains uncertainty around the precise function of each of 
the 162 SNPs, their degree of pleiotropy with cardiac traits, and the 
mechanisms by which these genetic variants exert their cardioprotective 
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influence, policy conclusions can still be drawn from the current body of 
evidence. First, policies that raise education probably lead to non-health 
benefits, such as increased economic productivity, voter turnout, better 
governance, and improved life satisfaction.(269, 270) Second, there is 
very little evidence that raising education might subsequently harm health 
or wellbeing. Third, although rigorous scientific debate needs to continue 
on the health consequences of raising education, the current balance of 
opinion appears to weigh towards the side where raising education will 
probably improve a range of health outcomes (either to a smaller or larger 
degree). There has been little discussion about how to raise education in 
a manner that is practical, acceptable, affordable and sustainable. While 
my data makes no claims on this, I note that interventions should be 
accompanied by careful monitoring for unforeseen side effects, especially 
of those individuals who may not thrive when forced into extended 
educational settings, which may otherwise aggravate health inequalities. 
To briefly begin this discussion, one can imagine a range of policies by 
analogy to how clinicians, public health practitioners and policymakers 
encourage patients to stop smoking: by raising awareness (e.g. mass-
marketing campaigns; personalized letters; individual counselling); 
convenience of access (e.g. changing the geographical dispersion of 
educational establishments; opportunities for flexible education); and/or 
finance (e.g. tuition fees; accommodation costs; stipends). One can also 
consider complementing some of these population-level policies with 
individual-level interventions (e.g. advising adolescents on whether to 
pursue higher education). 
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4.1.6. Conclusion 
 
This Mendelian randomisation analyses found genetic support for the 
hypothesis that longer education plays a causal role in lowering the risk of 
coronary heart disease. Although it is difficult to completely rule out 
possible pleiotropic effects, the sensitivity tests available to us gave little 
evidence that these could have driven my findings. In conjunction with the 
results from other study designs, increasing education is likely to lead to 
large health benefits. 
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4.2. Mediation & international differences 
 
I intended to investigate to what degree the pathways of various 
psychosocial and socioeconomic predictors of CVD may overlap with one 
another. In this large prospective cohort study, I found independent 
associations between six psychosocial factors and subsequent 
cardiovascular mortality following full mutual adjustment. Depression and 
social support factors did not substantially attenuate socioeconomic 
gradients in CVD mortality, suggesting that these mechanisms are more 
likely to be complementary, as opposed to being mediatory.  
 
As a second objective, I investigated whether the previously unexplained 
difference in CVD rates between Russia and Central European countries 
could be attributable to differences in psychosocial and socioeconomic 
risk factors. Contrary to my hypothesis, the substantial international 
difference in baseline mortality was not reduced following adjustment for 
conventional, psychosocial or socioeconomic factors.  
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4.2.1. Strengths and limitations 
 
Several limitations of this study should be considered when interpreting 
the results. First, these urban population samples are not necessarily 
representative of whole countries, as both exposures and mortality might 
be different in rural settings. Indeed, it is often the case for baseline 
mortality rates to be higher in rural settings, in which case the baseline 
rates I report may have been under-estimated. However, it is plausible for 
the international gradient that I describe to operate similarly across urban 
and rural settings. It is also plausible for biological and possibly 
psychosocial risk factors to operate similarly across urban and rural 
settings. Particularly in the absence of compelling evidence to support 
these putative interactive effects, it seems plausible to assume that the 
patterns I describe may generalize for most people, in each country under 
study. 
 
Second, study participants may have been healthier than non-responders, 
making us blind to what happens among those facing the greatest health 
and social problems. This would have led to underestimated hazard ratios 
and population-attributable risk fractions. That said, our sample still 
detected considerable variation in cardiovascular mortality by country and 
socioeconomic status, as well as a considerable burden of psychological 
distress (e.g. 22% of participants screening positive for possible 
depression). Therefore it is possible that my analyses are biased towards 
the null, and the true prevalence and burden of CVD from psychosocial 
and socioeconomic risk factors may be even larger. 
 
Third, although I used predominantly well-established instruments to 
assess psychosocial exposures, their self-reported nature may be affected 
by response bias. For example, those who report adverse profiles might 
be more neurotic or less conscientious in their personality, which might 
instead be the underlying cause of the observed associations. Indeed, 
both of these traits have been associated with CVD,(35) while their 
possibility of associating with the six psychosocial traits I describe has 
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been less studied. Reassuringly, in models where I additionally adjusted 
for the psychological trait “perceived control”, this did not substantially 
alter the other associations nor the summative conclusions (data not 
shown), suggesting that perhaps personality is not a particularly strong 
putative confounder. 
 
Fourth, measurement error in mediators leads to underestimation in the 
degree of attenuation,(20) and more importantly, any unmeasured 
confounders between mediators and outcome could have biased the 
results of my mediation analyses in either direction.(19) As such, the 
mediation analyses I present should only be considered as very 
approximate and indicative only. Two-step Mendelian randomization is 
one potential future avenue, with which to investigate the direct causality 
towards mediators, and the amount that they causally mediate.  
 
Fifth, this particular study makes no claims about causality due to its 
observational design. Some of the observational associations between 
CVD and social/psychosocial factors may be due to reverse causation or 
unmeasured confounding.(141) Further causal evaluation would benefit 
from analysis of policy interventions or Mendelian randomization methods 
applied to the other five risk factors that I describe.(224) Sixth, it is 
uncertain how generalizable these results might be to other countries, 
given the social history and high mortality rates in this region. Although 
such complex simultaneous analyses have not been previously performed 
in Western settings, it is nonetheless reassuring how most of the effect 
sizes I estimated in simple univariate models (adjusted for age and sex 
only) reflected broadly the effect sizes previously reported in Western 
literature. This suggests that perhaps these phenomena are similar across 
Western and Eastern Europe. This does not, however, allow any further 
extrapolation into potential effects in more diverse cultures, such as parts 
of Asia or Africa, that have received much less study. 
 
Sixth, although the data I analysed offered no support for the hypothesis 
that the gap in mortality between Russia and Central Europe is 
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attributable to psychosocial or socioeconomic factors, I am unable to 
firmly reject this hypothesis. For example, if data collection was conducted 
with large measurement error, then these variables may simply have been 
too insensitive to detect the latent true causes of international variation. 
However even in this scenario, one would expect to have still seen at least 
a small narrowing of the international gap. In my analysis, the international 
gap did not narrow at all but widened after adjustment for psychosocial 
and socioeconomic factors.  
 
Along similar lines, it is equally plausible that other psychosocial traits 
exist out there, which are the true causes of this international gap. 
However, these traits should not covary with any of the traits that were 
already measured by the HAPIEE study. As the HAPIEE study cast a 
relatively broad net over most of the known psychosocial and 
socioeconomic factors, this limits the state space where such 
undiscovered psychosocial or socioeconomic factors may potentially exist. 
 
Seventh, it is quite possible that powerful psychosocial and/or 
socioeconomic effects may be operating at the level of the culture of the 
entire country, which could influence the way in which participants from 
one country interpreted the questions asked of them, as well as their 
perception of the culturally most appropriate response. For example, if all 
Russian residents had experienced a collective feeling of shame, guilt or 
embarrassment over the fate of their country (either for 1991-2008; or for 
throughout 1964-2008), and if this could trigger an over-compensatory 
mechanism, whereby all Russians would report their 
psychosocial/socioeconomic state with an optimistic bias (to project that 
the glass remains half-full). This could have resulted in in differential 
measurement error and systematic bias, by underreporting the true 
burden of psychosocial and/or socioeconomic risk factors seen in Russia. 
However, if this were the case, then one would imagine that the 
magnitude of association, between a given psychosocial risk factor and 
CHD, to be greater in Russia than Central Europe (since those people 
who subjectively reported mild psychosocial distress would probably have 
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experienced more severe psychosocial distress, from an objective 
perspective). However, such a pattern was not found in my empirical 
screen of interactive effects (available on 
https://doi.org/10.1371/journal.pmed.1002459.s008). This means that if 
indeed important and collective psychosocial factors remain to be 
discovered, then these should not covary with the variables that have 
already been collected by the HAPIEE study. Such a psychosocial 
variable should not vary much within one country, and should not predict 
CVD within a country. This again limits the state space where these 
undiscovered traits may potentially exist, making their presence 
increasingly unlikely.  
 
A further extension of this idea is to posit that all Russians would be 
subject to an additional “Russian psychosocial stress” variable, which 
exerts a uniform CVD hazard, regardless of low or high SES status. While 
theoretically plausible and indeed quite possible, this is empirically very 
hard to test, as it is difficult to identify a suitable control or counterfactual 
group for comparison. 
 
As well as limitations, this study also has important strengths. First, this is 
possibly the first prospective cohort study of psychosocial factors with a 
standardized methodology across multiple countries, where one country 
has twice the mortality rate of the others. Second, it is one of the largest 
prospective cohort studies that has assessed multiple psychosocial 
factors whilst concurrently controlling for all the conventional 
cardiovascular risk factors (including cholesterol and blood pressure). 
Third, most of the risk factors and covariates were measured using well-
established and widely used psychosocial questionnaires and laboratory 
techniques.  
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4.2.2. Comparison with previous studies 
 
4.2.2.1. Individual risk factors 
Most of the associations I report are broadly consistent with prior studies, 
primarily from more affluent countries where all-cause mortality is often 
reported more commonly than my outcome of cardiovascular mortality.2 4 5 
However, I found current unemployment to be associated with an 
unusually high level of risk in my study (HR=2.96 [1.97-4.46] for all-cause 
mortality, age-sex adjusted), which is more than twice the estimate from a 
recent meta-analysis (HR=1.59 [1.42-1.77]).3 This strong effect may be 
plausible, however, if unemployment protections are weaker in Eastern 
Europe than elsewhere, which might highlight policy weaknesses for 
intervention.  
 
Literature on material conditions has mostly focused on area-level 
measures of exposure, while available studies at the individual level have 
often measured just 1-2 possessions,(22, 271) not aggregated such 
possessions into a summary score, or not controlled for blood 
pressure/cholesterol.(88) One comprehensive study in Russia did not find 
an association between material goods/amenities and all-cause mortality, 
once education was controlled for.(17) Our larger study found the opposite 
pattern: that material amenities was the principal socioeconomic factor, 
which displaced education in multivariate analysis. Our analysis is 
consistent with prior reports of how education and material conditions may 
be measuring the same underlying socioeconomic construct, and it 
emphasizes how material amenities might be a more sensitive 
socioeconomic predictor of cardiovascular mortality than education. Such 
phenomena, when two correlated measures “compete” for primacy in fully-
adjusted models, may be prone to slight differences in the measurement 
error in one variable, as well as its statistical form (i.e. continuous or 
categorical). Furthermore, it is plausible for one risk factor to dominate in 
one cultural context, while another risk factor dominates in another cultural 
context. 
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4.2.2.2. Mediators of socioeconomic risk 
Previous studies have suggested that conventional risk factors might 
account for around 30-50% of the primary association between 
socioeconomic factors and mortality,(11, 272, 273) consistent with my 
analysis of education. However, the proportion explained by conventional 
factors was much smaller for social support factors, such as only 3% for 
lack of contact with friends, and 8% for single marital status. Therefore, 
the role of conventional risk factors might be even smaller among the 
psychological factors such as social support and depression, factors that 
have been less studied to date.  
 
This might be the largest study to look at whether primary socioeconomic 
gradients in CVD can be attenuated following adjustment with 
psychological factors such as depression and social support. In Whitehall 
II, the occupational gradient in non-fatal CHD did not attenuate 
substantially following inclusion of social support measures,(274) 
consistent with my findings. Instead, work-related stressors accounted for 
half of the occupational gradient in Whitehall II. I did not evaluate 
psychosocial work factors, as a recent meta-analysis has shown their 
association with CHD to be comparatively small.(275) Other studies have 
typically used single-item instruments,(276) or not assessed social 
support and conventional risk factors.(272, 273)  My study has confirmed 
relatively robustly that depression and social support do not account for 
much of socioeconomic gradients, even in a large cohort with high 
prevalence of exposure and outcome.  
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4.2.2.3. Mediators of psychosocial risk 
Our results suggest that the primary association between 
depression/social support and cardiovascular disease is unlikely to be 
mediated or confounded by conventional and other psychosocial risk 
factors, an area of relatively limited prior study.(277) For example, 
exposure to one of the three dimensions of low social support was not 
offset by excess in another dimension, suggesting that cardiovascular 
health may be protected by some contact with friends, family and a 
partner. It appears that, in contrast to socioeconomic factors, each 
psychological factor is distinctly separate, and does not relate to a 
common underlying construct. While attempts have been made to identify 
biomarkers of socioeconomic gradients (e.g. inflammation), comparatively 
few have attempted to discover the mediators of psychological 
factors.(167) My analysis suggests that depression is unlikely to be a 
major mediator of social support and socioeconomic pathways. 
 
There is a paucity of studies investigating the potential mechanisms and 
mediators of psychosocial risk factors. I estimate, relatively crudely, that 
about one quarter of such hazards may be mediated by conventional CVD 
risk factors, and up to another quarter may come from other psychological 
factors such as depression. Measurement error in mediators biases 
estimates of mediation towards toward the null, so future studies with 
time-varying mediators may be able to demonstrate larger proportions 
mediated.(272) In case that such analyses fail to account entirely for the 
mechanistic pathways from psychosocial factors to CVD, then additional 
hypotheses for investigation are warranted. It may be particularly useful if 
future work could stratify analyses by gender. I will now present my initial 
suggestions, by explicitly using gender to denote putative pathways of 
greatest hypothesized magnitude.  
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First, it is plausible for socially isolated men (across all SES categories) to 
wait a longer time from symptom onset, before seeking formal or informal 
healthcare. For example, they could actively repress thoughts about 
symptoms, using various psychological avoidance-based coping 
mechanisms. It is plausible for some of these mechanisms to be cultivated 
more strongly in cultures that emphasize a greater gender differences 
between the sexes, as has been noted for Russia.(70, 71) To 
counterbalance this, the spouses of married men may pick up on changes 
to behaviour, to infer changed latent symptomology and biology, 
prompting inquisitive questions and ultimately urging their partners to seek 
healthcare. Men who live alone, but who have frequent contact with 
friends or relatives, may face a similar reaction, particularly to open-ended 
questions like “How are you?”. These could all serve as prompts which 
effectively disrupt the avoidance-style coping mechanism.  
 
Secondly spouses, friends and relatives may all impart practical health-
related knowledge (i.e. “I know a man who had the same symptoms and 
this is what he did…”) or knowledge about accessing healthcare (“If you 
say the following to your GP, they will refer you more quickly to a 
specialist”).  
 
Third, in countries where healthcare requires out-of-pocket expenditure 
(e.g. as is the case for some countries in Eastern Europe), then friends 
and family may be able to provide the necessary funds to receive care. 
This may be particularly important for people on a lower income, so an 
income*social support interaction effect may be anticipated.  
 
Fourth, it is plausible that men who eat dinner alone are more likely to 
cook quickly, relying on more processed and less healthy foods. In 
contrast, those who cooking communally with friends and family may be 
more likely to prepare a more time-consuming meal, which may be 
healthier. Bearing in mind that most events in my study occurred among 
participants in their 70s, it is also possible for men to have focused on 
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working roles throughout their life, and they may simply lack the basic 
cooking skills, to cook healthy food by themselves.  
 
However, none of these four mechanisms above could account for why 
even among women, living alone, having limited contact with friends, 
having limited contact with relatives, as well as depression all seemed to 
exert independent effects. As I discussed in the introduction (section 
1.1.5.1), it is plausible for the tendency and desire to form social 
relationships to be a more fundamental and innate property of the human 
condition, whose purpose may stretch beyond merely providing and 
receiving functional aid for those in need. If indeed such needs are so-
called “hard wired” into the human brain, then people who are socially 
isolated may experience a range of emotional, cognitive and behavioural 
effects that are currently little understood. These in turn may have 
downstream consequences on a range of bodily systems (for example on 
altered inflammation, metabolic rate and/or the balance between 
anabolism-catabolism) which have not yet been uncovered.  
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4.2.2.4. International differences 
The association between education and CHD varies somewhat between 
countries, in a pattern that typically follows the country’s stage of 
socioeconomic development. It is plausible that, in European countries 
from 1700 to 1900, people with higher education (or other measure of 
higher SES) had a higher risk of developing CHD when compared to 
people with less education. Some of this may reflect survivor bias in 
settings where average life expectancy was between 30 to 40 years. 
People with less education were more likely to die from infectious disease, 
accident or injury before atherosclerotic processes had time to manifest.     
Accordingly, more educated people who had survived these earlier risks 
were more likely to live long enough to develop CHD.  
 
Nonetheless, even after adjustment for age those with longer education 
may still have had a higher risk of developing CHD. This may have been 
since those with greater education were more likely to have been able to 
afford lifestyles that we now know are adverse cardiovascular risk factors: 
sedentary behaviour, a diet high in saturated fat and low in plant intake, 
smoking and alcohol excess. Some lower income countries today still 
show the same pattern. High SES people in non-Western settings today 
may still aspire to adopt Western lifestyles and unhealthy behaviours, 
particularly by shifting away from traditional food patterns towards more 
modern but less healthy diets, marked by greater BMI.  
 
As countries further continue their socioeconomic development, it is 
typical for high SES people to see such unhealthy behaviours as 
maladaptive. Accordingly, middle-income countries tend to show flat 
educational gradients in CVD.  
 
Following further socioeconomic development, the previously seen 
gradient tends to reverse in the opposite direction, whereby those with 
lowest education are now those with highest risk of CVD. These gradients 
may initially become particularly steep (as is seen in Eastern Europe, and 
especially Russia). Following this and with sustained socioeconomic 
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development towards high-income countries, socioeconomic gradients 
tend to persist but flatten somewhat (e.g. Russia → Baltic States → 
Central Europe → Scandinavia and Southern Europe (12, 13)). 
 
Similar to the description in the paragraph above, the association between 
education and CHD in Western Europe may have changed somewhat 
over time. A range of forces may be in operation, causing sometimes 
opposite effects. For example, Western economies have become 
increasingly oriented around the service sector, where educational 
attainment may plausibly be a more important factor in determining 
economic outcomes and social position. This may widen educational 
gradients in health. Of particular interest is to think about what happens 
when the proportion of people who are employed in manual occupations 
falls over time. Under the hypothesis that it is the manual work itself that 
causes CHD, and also assuming that the hazard of this should gradually 
fall over time on account of advances to occupational health & safety, then 
one could expect the magnitude of association between occupation and 
health to fall, over time. However, under the hypothesis that manual work 
does not cause CHD, but is merely a marker of poor systemic fitness, then 
one could expect the magnitude of association between occupation and 
health to increase over time, as the pool of people in manual occupations 
become increasingly concentrated among those of lowest fitness. While 
there are few studies that have directly investigated this, there is a little 
support for the former hypothesis.(141) This is consistent with the theory 
that occupation may be over time partially displaced by other SES 
measures, such as education.  
 
Assuming that education is causal for CHD (as discussed in earlier 
chapters), then the fact that educational opportunities and attainments 
have increased over time, may in itself have been a force which could 
have reduced health inequalities. However, evaluating this empirically 
would be difficult because of long lag effects of unclear duration, as well 
as how this shift over time is overlaid with other important period effects. 
Western Europe has seen notable political shits in the last century. The 
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period 1930-1980 was associated with greater public and political concern 
over socioeconomic inequalities being too steep, resulting in more 
redistributive policies (for example, inheritance taxes were raised to 80% 
in the UK and US, and stayed there throughout 1950-1980). It is plausible 
that this political shift could have also narrowed health inequalities. Such a 
health effect could have occurred immediately, or alternatively if 
considering 50 year lag times, by as late as 2030. After this initial shift 
towards the political left, the following period (1980-2018) has been 
marked by increasing socioeconomic inequality. It is plausible that this 
may increase health inequality, and under lagged phenomena these may 
continue to exert their effects until 2070. To summarize, Western 
European countries have seen considerable period effects over the last 
century. These include a shifting away from manual occupations, greater 
educational attainment, an initial period of reducing socioeconomic 
inequality, followed by a period of increasing socioeconomic inequality. 
While it is plausible for these changes to have altered the magnitude of 
health inequalities, it is difficult to make empirical attributions as such, on 
account of many of these changes occurring simultaneously and with 
different lagged effects. 
 
Returning to the topic of explaining current international differences, then I 
am not aware of other cohort studies that have used a standardized 
protocol to investigate why cardiovascular mortality is so dramatically high 
in Russia when directly compared to elsewhere. Ecological data from the 
MONICA study suggested that 0-50% of the variations across time and 
place over Europe and Russia might be attributable to differences in 
conventional risk factors, supported by studies of smoking and alcohol in 
Russia.(167, 170) Using different methods 30 years later, I find that 
conventional as well as psychosocial factors do not account for much of 
the difference between Central European and Russian cohorts. 
Colleagues from the HAPIEE study have previously shown that two other 
hypothesised factors, alcohol(172) and dietary factors,(161) made only 
minor contribution to explaining the inter-cohort differences in mortality.  
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After considering the results of the current study and the wider literature, I 
am unable to clarify the reasons for the very high cardiovascular mortality 
in Russian men. On the one hand, Russia appears to have always had 
historically higher mortality rates, lending thought to the hypothesis of 
there being either latent genetic vulnerability, or cultural indifference for 
socio-political organizations that drive comparatively low performance for 
health outcomes. It is also possible that international differences in access 
to healthcare, in healthcare seeking behaviour, or in the quality of care 
received, may help to clarify this question. Somewhat problematically, any 
such factors would need to have a large differential impact on male 
mortality, but only a small differential impact on female mortality. Another 
area of enquiry might be gender norms and expectations. For example, 
women in Russia retire 5 years earlier than men. It is plausible that gender 
roles are more extremely polarized in such countries, which ultimately 
harms the health of men more than women.(71)  
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4.2.3. Implications for clinicians and policymakers 
 
Similarly to elsewhere, psychosocial and socioeconomic factors are 
powerful predictors of cardiovascular mortality in Eastern Europe, and 
many of these mechanisms are probably causal. If conventional 
cardiovascular risk factors were to dramatically improve, then this would 
no doubt have large benefits on preventing cardiovascular disease. This 
may also attenuate socioeconomic gradients in cardiovascular disease to 
some degree. However, it is plausible that the vast majority of this may 
persist. The available body of evidence suggests that cardiovascular 
health could further improved, following the implementation of programs 
and policies that seek to: 
• increase educational attainment (e.g. by raising the school leaving 
age to 18, or by fostering uptake of tertiary education);  
• improve material conditions and lower unemployment (e.g. greater 
economic productivity and/or income redistribution);  
• lower depression (e.g. introducing well-being literacy programmes 
to children and/or adults);  
• provide more time for social relationships (e.g. awareness raising 
about the health benefits for example by integrating these into 
routine medical assessments; reducing total time spent at work; 
improving relationship literacy and skills)  
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4.2.4. Implications for future research 
 
First, I have examined in earlier chapters the causality of the association 
from education to CHD. Similar causal investigations are now warranted 
for the other three independent sets of risk factors identified above. 
Material conditions are difficult to instrument genetically, but may be 
possible to study using the twin study or econometric designs. GWAS 
studies are emerging for depression, allowing future researchers to use 
Mendelian randomization to evaluate if depression causes CHD. Along 
similar lines, emerging GWAS studies on social isolation will allow 
Mendelian randomization analyses to be conducted on CHD and other 
health behaviour outcomes. It would be particularly useful to perform 
gender-specific analyses (requiring the exposure GWAS to be gender 
specific, and the outcome GWAS to be gender specific), in order to better 
understand any gender-specific effects. 
 
Second, assuming that these pathways are causal, then the question 
remains as to “What mechanisms account for the residual association 
from education, material conditions, depression and social isolation to 
CVD?”  Identifying these may yield novel interventional approaches, which 
can be used in addition to the upstream interventions that I suggested in 
section 4.2.3. To better examine behaviours around seeking for 
healthcare, analyses could be constructed on electronic healthcare record 
data linked to marriage records. These linked data could be evaluated, to 
see if those men who are married present for healthcare with milder 
disease, when compared to those men who are not married. If found, 
tailored programmes could be constructed to try to mitigate this effect, for 
example by prioritizing unmarried people in cardiovascular screening 
programmes such as the NHS Health Check. Where dietary behaviours 
are the putative mediator, epidemiologists experienced with psychosocial 
analyses could collaborate closely with nutritional epidemiologists in 
explaining CVD outcomes. Although much existing observational cohort 
data can support such analysis, limited research to date has directly 
addressed this level of complexity. For metabolomic mediators, one could 
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screen between 100 to 225 plasma metabolomic outcomes (as have been 
measured by nuclear magnetic resonance techniques for a number of 
cohorts) against a shortlist of socioeconomic or psychosocial exposures. 
In the case of 225 markers, the conventional P<0.05 threshold could be 
Bonferroni-corrected to P<0.0002. Such an analysis may require 
collaboration with multiple cohorts, to be both sufficiently powered and 
investigate external replication. 
 
 
Third, better understanding of international differences may be furthered 
by a formal age-period-cohort analysis. These could be performed on 
each of the countries of Europe, and then cross-examined to search for 
any commonalities (or divergences) across the East-West axis. Another 
approach would be an econometric analysis. Approximately 20 Western 
and Easter European countries could be selected, to show up to 40 years 
of data each (whereby one data point is one country’s average, for that 
year). The outcome variable could be CVD mortality, and researchers 
could compare simple and multivariable models to identify those risk 
factors that are strongest in attenuating the coefficients for country-
dummies (and time-dummies). The top risk factors identified may or may 
not be causal, and would then need careful interpretation. A large obstacle 
to this agenda is the current absence of data availability to the granularity 
of annual population-level data, for many countries. As such, it may take 
many years if not decades until this analysis is feasible. Researchers 
interested in this may wish to collaborate with the Global Burden of 
Disease project(178, 200), as this project is also attempting to collate 
similar data.  
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4.2.5. Conclusion 
 
To conclude, psychosocial and socioeconomic factors are powerful 
predictors of cardiovascular mortality in Eastern Europe, similarly to 
elsewhere. For some risk factors, such as unemployment, these 
associations appear stronger than elsewhere, indicating potential areas 
for policy intervention. Surprisingly, most of the associations between 
psychosocial risk factors and CVD were attenuated by only a small 
amount when adjusted for each other. This suggests that there may be a 
lot of nuanced pathways which could be relatively independent of one 
another, although I am aware that the causality of these associations 
requires further confirmation. The massive burden of cardiovascular 
mortality seen in Russia remains largely inexplicable.  
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4.3. Prediction 
4.3.1. Summary of key findings 
My study of risk prediction aimed to first evaluate performance of the 
original SCORE risk prediction model. Second, to derive a conventional 
CVD risk prediction model for use in Eastern European countries, using 
contemporary data. Third, to see if the addition of predominantly 
psychosocial and socioeconomic variables can improve model 
performance.  
 
I found the existing SCORE model to be suboptimal in four contemporary 
Eastern European cohorts. In the derivation data it overpredicted risk, 
resulting in poor cost-effectiveness, while in the validation data it under 
predicted risk, resulting in poor clinical effectiveness. Recalibrating the 
original SCORE model and improving its mathematical format led to 
substantial improvements to calibration, discrimination, binary NRI and 
clinical cost-effectiveness in the derivation and validation datasets. The 
subsequent addition of seven novel cardiovascular risk factors led to 
further improvements to discrimination, clinical effectiveness, binary NRI 
and Net Benefit, in derivation and validation datasets. These findings were 
robust to sensitivity analyses that varied the clinical interventional 
threshold from 2% to 6%.  
 
Taken together, the final model outperformed the original SCORE model 
in terms of discrimination (change in C-statistic of 0.06 and 0.03 in both 
the derivation and validation datasets, respectively), as well as binary NRI 
(0.07 and 0.14, respectively). Cost-effectiveness, the main problem in the 
derivation dataset, improved there by 39%. Clinical effectiveness, the 
main problem in the validation dataset, improved there by 38%. 
Altogether, this suggests that the final models appear to be superior to the 
original SCORE model, for each of the four countries studied. 
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4.3.2. Strengths and limitations 
 
The main strength of this study was the use of an independent cohort from 
a different country for externally validating the two newly derived models. 
To the best of my knowledge, no previous study has added more than one 
socioeconomic or psychosocial factor to create a new prediction model, 
and validated its performance using extern data. Furthermore, as the 
derivation and validation datasets differed substantially in terms of their 
recruitment methods, urban/rural coverage, and data collection methods, 
this increases the likelihood that these findings may also replicate 
elsewhere.  
 
Second, the derivation dataset had an appropriate number of events per 
variable, thereby reducing the risk of overfitting in the newly derived 
models. Third, all seven newly added risk factors are non-invasive and 
cheap to collect via self-report, thereby increasing their potential for 
widespread use across the world. Fourth, continuous variables were 
modelled appropriately, including the inclusion of quadratic functions for 
BMI and cholesterol. I am not aware of previous studies that have used a 
quadratic risk function for cholesterol.  
 
Fifth, I used a comprehensive array of state of the art methods to 
thoroughly evaluate model performance. In particular, few cardiovascular 
risk prediction papers have attempted to combine the relative harms and 
benefits of intervention into an appropriately weighted metric, such as Net 
Benefit or cost-effectiveness. These have the potential to make risk 
prediction research more accessible, understandable and useful to a 
range of wider readers across clinical and public health specialties.  
 
This study had some limitations. First, although the external validation 
dataset was sufficiently large to demonstrate that change in some 
outcomes (like the Binary NRI) was unlikely to happen by chance alone 
when comparing the original SCORE against the final HAPIEE model, 
power nonetheless appears to have been too small to assess the role of 
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chance in the intermediate stage (the recalibrated model 2, which was not 
augmented with new risk factors). To counteract this, it would have been 
helpful to additionally assess validation in the validation dataset that 
included imputed validation data. However, statistical packages for these 
analyses were readily available in neither STATA nor R, precluding me 
from performing these additional analyses. 
 
Second, most cohort studies are subject to response rate bias, which also 
extends to my derivation and validation cohorts. This can be quite 
substantial, for example participants from the UK BioBank study have 
about half as many events when compared to those from the general UK 
population,(278) and it is likely that a similar healthy volunteer effect also 
appeared in my derivation data. This means that when I derived new 
models from the study participants, then I will make unrealistic 
expectations that the underlying population will be quite healthy (while in 
reality they are much more likely to develop CVD). 
 
Nonetheless, this problem appears to be curiously offset by a similar 
reduction in the true event rate owing to the secular period effect. For 
example, the national mortality data on CVD mortality in Poland and the 
Czech Republic was around 350 per 100’000 in 2007, the year when most 
events occurred in my derivation data (See in the Methods section “Figure 
27. WHO mortality rates for cardiovascular disease in Poland and the 
Czech Republic.”). It may take around 10 years for national mortality 
offices and the cohort study’s research team to collect and process such 
event data, derive a new clinical prediction model, publish this through 
peer-review and disseminate the model to policymakers and practitioners. 
It would then take another 10 years from implementation until the 
population being intervened upon start to develop event rates themselves 
(as most CVD models are operationalized with a 10-year follow-up time). 
If the current secular trends in WHO data are extrapolated until 2027, then 
this suggest that event rates may be around half of those seen in 2007. 
So if I apply my “unrealistically healthy model” derived in 2007 to the 
underlying population in 2007, then it will underestimate by around 50%. 
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However, if I apply my model to the underlying population in 2027, then it 
may estimate accurately. Hence by a coincidence, the healthy volunteer 
effect appears to be largely offset by unavoidable delays and 
corresponding period effects.  
 
It may however be unrealistic to imagine that both of these two biases 
operate at similar magnitudes in each of the four countries that I studied. 
Hence my third limitation begins with the observation that the Central and 
Eastern European region has within it a very diverse and complex pattern 
of cardiovascular disease mortality. Much like the original SCORE paper, 
this current study has overly simplified this complexity by dichotomizing 
the region into two halves (low- and high-risk). This is a relatively crude 
approximation, which is likely to lead to suboptimal performance for 
countries in the middle, such as the Baltic States. It is possible that my 
(high-risk) model would over predict risk in the general population of 
Estonia for the year 2028, and this miscalibration has been temporarily 
masked by the fact that the healthy volunteer effect is unusually small in 
Estonian BioBank study (on account of this cohort having a more complex 
sampling method that more proactively recruited participants from 
healthcare services were would not be as healthy).  
 
Ideally, such country-specific issues of miscalibration could be partly 
addressed by adapting the baseline hazard from each “off the shelf” 
model to the time and country context where it is being applied (such as 
“2027 Estonia”), by quantitatively triangulating and calibrating the baseline 
hazard from WHO mortality data. Such an approach was first tried by the 
GLOBORISK project, which was published in parallel to the writing of this 
thesis. However, as noted in my introduction chapter 1.4.3.2, the 
GLOBORISK model too may suffer from limitations of its own. Moreover, 
even if my models do have limitations with calibration, these do not 
distract from the overall finding from my analyses: that augmenting an 
existing model with 7 new CVD risk predictors led important improvements 
in model performance as measured by discrimination, clinical 
effectiveness, binary NRI and Net Benefit. 
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Fourth, the various performance metrics presented are difficult to reduce 
to a few key measures (despite the way that they occasionally appear to 
covary with one another), and furthermore these metrics present some 
internal inconsistencies. For example, the Net Benefit metric improved in 
the validation data, when comparing the original SCORE against the final 
HAPIEE-SCORE, but such improvement was not seen in the derivation 
data. This appears to have happened since the Net Benefit measure 
heavily rewards over prediction, which was rife when the original SCORE 
was used on the derivation data. Similarly, the results provided by the Net 
Benefit calculations (where I manually divided the NRI seen in controls by 
20, tables 16-21) do not always match the formal Net Benefit calculated 
by the automated Decision Curve Analysis package. Furthermore, these 
two do not always match the calculation I performed to obtain Net Clinical 
Effectiveness, where I instigated my own QALY-weights from the wider 
literature. Although the latter of these three makes a couple of different 
assumptions, the theoretical similarity of all three methods made me 
expect a greater degree of convergence between their findings. As this 
theoretical approach to measuring performance is very new, I was unable 
to clarify to what degree these discrepancies may have arisen due to 
chance (on account of small marginal differences) or other reasons. 
 
Fifth, it is possible that the process of augmenting EastEur-SCORE into 
the final HAPIEE-SCORE may have created a degree of overfitting. This 
can be seen in the drop in ΔC between the derivation (0.06) and validation 
(0.03) cohorts, as well as in the tendency for the final score to over predict 
risk in the validation set may have caused a drop in clinical cost-
effectiveness in the validation data.  Future work could seek to minimize 
this by performing shrinkage of the beta-coefficients, before the model is 
finalized. Additional benefits may be obtained by deriving the models on a 
dataset where missing data have been multiply imputed. However, such 
software is not readily available and missingness in the derivation data 
was low.  
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4.3.3. Comparison with previous studies  
 
4.3.2.1. Recalibration 
The newly recalibrated model I present (EastEur SCORE) appears to be 
superior to the original SCORE model. This is consistent with previous 
reports that found the SCORE model to perform poorly when validated 
with data from the HAPIEE study.(279) In some instances, calibration 
errors were so large as to show only one event, instead of the six that 
were predicted by SCORE. 
 
The European Society of Cardiology, who endorsed the original SCORE 
prediction model, have recommended that SCORE be recalibrated for 
each particular country in question, in collaboration with national societies 
of cardiology. Of the 25 countries allocated to the “low risk” region 
(predominantly from Western Europe) the heartscore.org website lists 7 
countries (i.e. 28%) who have recalibrated SCORE for their country 
context. This does not include countries such as the UK, who have 
derived their own cardiovascular risk prediction model without reference to 
SCORE. Of the 25 countries allocated to the “high risk” region 
(predominantly from Eastern Europe), the heartscore.org website lists 9 
countries (i.e. 36%) who have recalibrated SCORE for their country 
context. For example, the Polish Cardiac Society has recalibrated SCORE 
twice (first in 2007, and later updated in 2015) [Personal communication 
with Andrzej Pajak]. However, none of these recalibrated models have 
been published in English. This absence is present both on peer-reviewed 
journals, as well as elsewhere (such as the websites of heartscore.org or 
the European Society of Cardiology). The recalibrated models are freely 
available online to make individual risk predictions for one participant. 
However, it is impractical to use these if a researcher like myself wishes to 
evaluate prediction performance for a large cohort of participants. For 
such a purpose, the original SCORE models remain the default option. 
Another promising default model is the GLOBORISK model.(199) 
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However, this model combined fatal and non-fatal CVD end points, 
thereby increasing international heterogeneity in performance.  
 
I am aware of only one prior example, in the English-speaking peer-
reviewed literature, where the original SCORE has been compared 
against a new model. Jdanov et al. used cohort data from Moscow and St. 
Petersburg, collected from 1975-2001, to derive a new score for Russia 
(SCORE-MoSP).(203) However, this study did not adjust for the chaotic 
fluctuations in baseline rate during this period. Importantly, the model they 
created has not been externally validated, leaving open the possibility that 
they may not work for other cohort studies or real-life clinical encounters, 
with a different case mix. Future studies could compare the performance 
of the original SCORE against the SCORE-MoSP using validation data 
from Novosibirsk, such as the MONICA or the HAPIEE study.  
 
To summarize, the newly derived “EastEur SCORE” appears to be the 
first example in the English-speaking peer-reviewed literature, where a 
new cardiovascular risk prediction model has been derived for an Eastern 
European country, this has been validated with external data, and shown 
to be superior against the Original SCORE model. 
 
4.3.2.2. Augmentation 
Previous studies that tried to improve cardiovascular risk prediction by 
adding any kind of new predictors have typically found this to be a difficult 
endeavour. Derivation studies have sometimes reported improvements to 
discrimination as high as ΔC=0.08. However, these have rarely been 
matched in external validation studies, where ΔC greater than 0.01 to 0.02 
has rarely been achieved. In my study, ΔC of 0.022 in derivation and 
0.014 in validation is broadly consistent with this range. As one typical 
comparison, Abraham et al. added 49 310 genome-wide SNPs (strongly 
and weakly associated with CHD), and reported ΔCs of 0.011 to 0.017 
(depending on the particular cohort and analyses performed). Few of 
these studies have reported benefits in terms of clinically meaningful 
reclassification, while the clinically less relevant Continuous NRI is often 
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quoted. In the aforementioned genomic augmentation, clinical NRI was 
smaller (0.25 to 0.37) than what I report in my study (0.44 to 0.53). This 
suggests that the addition of simple behavioural and psychosocial 
questions may be at least as useful as the best data across the entire 
genome, if not better.  
 
Indeed, the literature on augmenting CVD risk prediction models is 
predominantly focused on technology-intensive measures, such as blood-
based ‘omics predictors as well as various imaging modalities. In 
comparison, the literature on augmentation following the addition of 
behavioural and/or psychosocial questions is very sparse. About 10 years 
ago, when well-known scores like ASSIGN and QRISK were developed 
(for Scotland and England, respectively) then these made a number of 
changes in comparison to their SCORE or Framingham benchmarks that 
they tried to improve. These included area-level psychosocial status and 
BMI. This means it is hard to disentangle what part of their improvement 
came from recalibration, and what part from the addition of novel risk 
factors. This is something that my study was able to separate into two 
distinct parts.  
 
There are at least 10 other studies that have investigated the benefit of 
adding psychosocial/socioeconomic risk factors (detailed in Table 2 in the 
introduction chapter). Some of the early studies were underpowered, 
where a low event-to-parameter ratios probably led to considerable overfit, 
the possibility of chance findings, and lower probability of succeeding 
theoretically, were these ever taken to external validation.(18, 212, 217). 
As such, although these studies reported very large improvements to 
discrimination (ΔCs of 0.02 to 0.04), it is difficult to tell if this reflects a true 
improvement or a chance finding from overfit. 
 
More recent studies with better statistical power have reported smaller 
benefits to discrimination (ΔCs of 0.004 to 0.01), after including one to 
three new predictors.(12, 110, 214, 218-221). My results are consistent 
with these, since I demonstrate a much larger improvement as a result of 
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adding seven new predictors. As some of these predictors are partly 
collinear with each other, this explains why the ΔC in my study was not as 
large as 7 * (0.004 to 0.01). Instead, the magnitude is in the middle of the 
range expected, based on the previous studies on some of these 
predictors in isolation. This is also broadly consistent with the magnitude 
of improvements seen in Continuous NRI (0.03 to 0.18 in previous 
studies; 0.44 to 0.53 in my study) and Categorical NRI (0.03 to 0.18 in 
previous studies, 0.03 to 0.06 in my study). To the best of my knowledge, 
no previous study has added psychosocial or socioeconomic risk factors, 
and evaluated changes using a Net Benefit, Number Needed to Screen, 
or clinical cost-effectiveness.  
 
Perhaps most importantly, no previous study has to the best of my 
knowledge demonstrated an added benefit of adding a range of 
psychosocial, socioeconomic and behavioural factors, which has then 
been externally validated. Perhaps my study could also inspire others to 
consider the potential benefit of adding such risk factors. If similar 
improvements could be generated in other settings, then this might create 
potential for such factors to become a part of CVD risk prediction models 
across the world. This may be particularly useful for low-resource contexts 
(e.g. India and possibly also China and Russia) which together have the 
largest burden of cardiovascular disease (figure 51). 
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Figure 51. Total burden of cardiovascular disease in selected world 
regions and countries. DALY = Disability Adjusted Life Year; MENA = 
Middle East and North Africa; HI = High Income countries; C & E = Central 
and Eastern. Data are from (200), which originally listed 7 regional areas. 
For the graph above, two countries from the two largest areas (India and 
China) were presented, thereby excluding data from the other Asian 
countries. Data from other world regions are all included in this illustration. 
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4.3.4. Implications for clinicians, policymakers and for future 
research 
 
Altogether, these findings of the utility of non-invasive predictors, supports 
a wider reconsideration of how and where personalized prediction 
services are delivered. To date, this has required all participants to attend 
a face-to-face appointment at a medical facility. Instead, a multi-stage 
approach could be considered in the future, whereby initial pre-screening 
is done with existing records, early screening is done virtually with online 
self-report data, and final-stage screening that involves face-to-face and 
more invasive data collection (e.g. cholesterol and blood pressure) is 
recommended only for those of intermediate or high risk.(280, 281). This 
could lower programme cost and create opportunities to target 
interventions and reduce health inequalities in an increasingly 
personalized way. In particular, as existing cardiovascular screening 
programmes have not yet demonstrated their effectiveness, such 
reconfigurations to service delivery may open up new ways of thinking 
about what an effective and cost-effective CVD screening programme 
could look like. 
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5. Conclusions 
 
People whose genetic predisposition causes them to attain more 
education also have a large reduction in their subsequent risk of CHD. In 
conjunction with the wider evidence, this suggests that policy changes 
which increase education are more likely than not to prevent a large 
fraction of CHD. This may be partly explained by changed smoking and to 
a lesser degree some of the other conventional CVD risk factors. As such, 
interventions that reduce smoking are likely to be among the most 
effective in terms of lowering health inequalities. However, conventional 
CVD risk factors are unlikely to account entirely for the putative causal 
mechanism from education to CHD, which is one potential area of future 
research. 
 
The large international difference seen between Eastern and Western 
European countries remains largely inexplicable. Fresh hypotheses are 
needed to investigate the causes of these. My own personal observations 
have made me wonder whether differences in the quality of healthcare 
may play a role in this. 
 
Most of the associations between a single socioeconomic or psychosocial 
risk factor and CVD mortality attenuate by only a small amount, after 
adjustment for other socioeconomic and psychosocial factors, or when 
adjustment for conventional CVD risk factors. This suggests that a range 
of nuanced pathways may associate various socioeconomic and 
psychosocial factors to CVD, and that these could be relatively 
independent of one another. If causal, this suggests that a range of 
changes to depression, social support, material conditions and 
unemployment are all likely to cause considerable CVD benefit. 
Furthermore, then conventional CVD risk factors are unlikely to account 
for the majority of these mechanisms. If future research could identify their 
underlying mechanisms, then this may suggest novel avenues for 
intervention that could assist in lowering health inequalities. 
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Adding predominantly socioeconomic/psychosocial risk factors to risk 
prediction models led to substantial and clinically meaningful increases in 
prediction performance. The new model (called HAPIEE-SCORE) could 
now be evaluated in clinical primary care settings (if necessary, with 
further recalibration beforehand). For example, some Eastern European 
countries might be well suited to conduct a cluster randomized trial of a 
CVD screening programme, since the control arm here would receive 
comparatively little baseline intervention. As the region has high event 
rates, such a study would be well-powered and cost-effective. 
 
Overall this thesis underscores the notion that although socioeconomic 
and psychosocial risk factors may not be that useful for understanding 
international differences, they do appear to be highly relevant to clinicians, 
public health professionals, and to those interested in the co-benefits from 
education to health. I hope that these findings will assist in translating 
such knowledge, which to date has been developed primarily between 
epidemiologists, more widely into the everyday practice of a wider body of 
health professionals. I hope that this offers some assistance towards the 
goal of eradicating heart disease, as well as the large social inequalities 
with which it currently manifests.   
 
 
  
 
 
287 
 
References 
 
1. Davey Smith G, Hart C, Hole D, MacKinnon P, Gillis C, Watt G, et al. 
Education and occupational social class: which is the more important 
indicator of mortality risk? J Epidemiol Community Health. 1998;52(3):153-
60. 
2. Vandenheede H, Vikhireva O, Pikhart H, Kubinova R, Malyutina S, 
Pajak A, et al. Socioeconomic inequalities in all-cause mortality in the Czech 
Republic, Russia, Poland and Lithuania in the 2000s: findings from the 
HAPIEE Study. J Epidemiol Community Health. 2014;68(4):297-303. 
3. Allen L, Williams J, Townsend N, Mikkelsen B, Roberts N, Foster C, et 
al. Socioeconomic status and non-communicable disease behavioural risk 
factors in low-income and lower-middle-income countries: a systematic 
review. The Lancet Global Health. 2017;5(3):e277-e89. 
4. Leinsalu M, Vågerö D, Kunst AE. Estonia 1989–2000: enormous 
increase in mortality differences by education. International journal of 
epidemiology. 2003;32(6):1081-7. 
5. Hinkle LE, Jr., Whitney LH, Lehman EW, Dunn J, Benjamin B, King R, 
et al. Occupation, education, and coronary heart disease. Risk is influenced 
more by education and background than by occupational experiences, in the 
Bell System. Science. 1968;161(3838):238-46. 
6. Shekelle RB, Ostfeld AM, Paul O. Social status and incidence of 
coronary heart disease. Journal of chronic diseases. 1969;22(6):381-94. 
7. Kitagawa EM, Hauser PM. Differential mortality in the United States: A 
study in socioeconomic epidemiology. 1st ed. Cambridge, Massachusetts: 
Harvard University Press; 1973. 
8. Manrique-Garcia E, Sidorchuk A, Hallqvist J, Moradi T. 
Socioeconomic position and incidence of acute myocardial infarction: a 
meta-analysis. J Epidemiol Community Health. 2011;65(4):301-9. 
9. Vathesatogkit P, Batty GD, Woodward M. Socioeconomic 
disadvantage and disease-specific mortality in Asia: systematic review with 
meta-analysis of population-based cohort studies. J Epidemiol Community 
Health. 2014;68(4):375-83. 
10. Khaing W, Vallibhakara SA, Attia J, McEvoy M, Thakkinstian A. 
Effects of education and income on cardiovascular outcomes: A systematic 
review and meta-analysis. European Journal of Preventive Cardiology. 
2017:2047487317705916. 
11. Veronesi G, Ferrario MM, Kuulasmaa K, Bobak M, Chambless LE, 
Salomaa V, et al. Educational class inequalities in the incidence of coronary 
heart disease in Europe. Heart. 2016;102(12):958-65. 
12. Ferrario MM, Veronesi G, Chambless LE, Tunstall-Pedoe H, 
Kuulasmaa K, Salomaa V, et al. The contribution of educational class in 
improving accuracy of cardiovascular risk prediction across European 
regions: The MORGAM Project Cohort Component. Heart. 
2014;100(15):1179-87. 
13. Mackenbach JP, Stirbu I, Roskam A-JR, Schaap MM, Menvielle G, 
Leinsalu M, et al. Socioeconomic inequalities in health in 22 European 
countries. New England Journal of Medicine. 2008;358(23):2468-81. 
14. Bobak M, Murphy M, Pikhart H, Martikainen P, Rose R, Marmot M. 
Mortality patterns in the Russian Federation: indirect technique using 
 
 
288 
 
widowhood data. Bulletin of the World Health Organization. 2002;80(11):876-
81. 
15. Bobak M, Murphy M, Rose R, Marmot M. Determinants of adult 
mortality in Russia: estimates from sibling data. Epidemiology. 
2003;14(5):603-11. 
16. Malyutina S, Bobak M, Simonova G, Gafarov V, Nikitin Y, Marmot M. 
Education, marital status, and total and cardiovascular mortality in 
Novosibirsk, Russia: a prospective cohort study. Annals of epidemiology. 
2004;14(4):244-9. 
17. Perlman F, Bobak M. Socioeconomic and behavioral determinants of 
mortality in posttransition Russia: a prospective population study. Annals of 
epidemiology. 2008;18(2):92-100. 
18. Vikhireva O, Broda G, Kubinova R, Malyutina S, Pająk A, Tamosiunas 
A, et al. Does inclusion of education and marital status improve SCORE 
performance in Central and Eastern Europe and former Soviet Union? 
Findings from MONICA and HAPIEE Cohorts. PloS one. 2014;9(4):e94344. 
19. Hafeman DM. Confounding of indirect effects: a sensitivity analysis 
exploring the range of bias due to a cause common to both the mediator and 
the outcome. American journal of epidemiology. 2011;174(6):710-7. 
20. Blakely T, McKenzie S, Carter K. Misclassification of the mediator 
matters when estimating indirect effects. J Epidemiol Community Health. 
2013;67(5):458-66. 
21. OECD. Society at a Glance: OECD Social Indicators 2006 Edition. 
Paris: Organisation for Economic Co-operation and Development (OECD); 
2007.  https://stats.oecd.org/glossary/detail.asp?ID=7326. 
22. Macleod J, Smith GD, Metcalfe C, Hart C. Is subjective social status a 
more important determinant of health than objective social status? Evidence 
from a prospective observational study of Scottish men. Social Science & 
Medicine. 2005;61(9):1916-29. 
23. Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes 
TL, et al. Genetically determined height and coronary artery disease. N Engl 
J Med. 2015;372(17):1608-18. 
24. Yngwe MÅ, Kondo N, Hägg S, Kawachi I. Relative deprivation and 
mortality–a longitudinal study in a Swedish population of 4, 7 million, 1990–
2006. BMC public health. 2012;12(1):664. 
25. Kondo N, Sembajwe G, Kawachi I, van Dam RM, Subramanian S, 
Yamagata Z. Income inequality, mortality, and self rated health: meta-
analysis of multilevel studies. BMJ. 2009;339:b4471. 
26. Pikhart H, Bobak M, Rose R, Marmot M. Household item ownership 
and self-rated health: material and psychosocial explanations. BMC public 
health. 2003;3(1):38. 
27. Stelmach W, Kaczmarczyk-Chałas K, Bielecki W, Stelmach I, Drygas 
W. How income and education contribute to risk factors for cardiovascular 
disease in the elderly in a former Communist country. Public health. 
2004;118(6):439-49. 
28. Bobak M, Pikhart H, Rose R, Hertzman C, Marmot M. Socioeconomic 
factors, material inequalities, and perceived control in self-rated health: 
cross-sectional data from seven post-communist countries. Social science & 
medicine. 2000;51(9):1343-50. 
29. Moser KA, Fox AJ, Jones D. Unemployment and mortality in the 
OPCS longitudinal study. The Lancet. 1984;324(8415):1324-9. 
 
 
289 
 
30. Roelfs DJ, Shor E, Davidson KW, Schwartz JE. Losing life and 
livelihood: a systematic review and meta-analysis of unemployment and all-
cause mortality. Social Science & Medicine. 2011;72(6):840-54. 
31. McLeod CB, Lavis JN, MacNab YC, Hertzman C. Unemployment and 
mortality: a comparative study of Germany and the United States. American 
journal of public health. 2012;102(8):1542-50. 
32. Perlman F, Bobak M. Assessing the contribution of unstable 
employment to mortality in posttransition Russia: prospective individual-level 
analyses from the Russian longitudinal monitoring survey. American Journal 
of Public Health. 2009;99(10):1818-25. 
33. Shkolnikov VM, Meslé F, Leon DA. Premature circulatory disease 
mortality in Russia: population-and individual-level evidence. Heart disease: 
environment, stress and gender. 2002:39-68. 
34. Dupre ME, George LK, Liu G, Peterson ED. The cumulative effect of 
unemployment on risks for acute myocardial infarction. Archives of internal 
medicine. 2012;172(22):1731-7. 
35. Jokela M, Pulkki-Råback L, Elovainio M, Kivimäki M. Personality traits 
as risk factors for stroke and coronary heart disease mortality: pooled 
analysis of three cohort studies. Journal of Behavioral Medicine. 
2014;37(5):881-9. 
36. Gallo WT, Teng H-M, Falba TA, Kasl SV, Krumholz HM, Bradley EH. 
The impact of late career job loss on myocardial infarction and stroke: a 10 
year follow up using the health and retirement survey. Occupational and 
environmental medicine. 2006;63(10):683-7. 
37. Meneton P, Kesse-Guyot E, Méjean C, Fezeu L, Galan P, Hercberg 
S, et al. Unemployment is associated with high cardiovascular event rate and 
increased all-cause mortality in middle-aged socially privileged individuals. 
International archives of occupational and environmental health. 
2015;88(6):707-16. 
38. Strully KW. Job loss and health in the US labor market. Demography. 
2009;46(2):221-46. 
39. Sullivan D, Von Wachter T. Job displacement and mortality: An 
analysis using administrative data. The Quarterly Journal of Economics. 
2009;124(3):1265-306. 
40. Bobak M, McKee M, Rose R, Marmot M. Alcohol consumption in a 
national sample of the Russian population. Addiction. 1999;94(6):857-66. 
41. Pomerleau J, McKee M, Rose R, Haerpfer CW, Rotman D, Tumanov 
S. Hazardous alcohol drinking in the former Soviet Union: a cross-sectional 
study of eight countries. Alcohol & alcoholism. 2008;43(3):351-9. 
42. Azarova A, Irdam D, Gugushvili A, Fazekas M, Scheiring G, Horvat P, 
et al. The effect of rapid privatisation on mortality in mono-industrial towns in 
post-Soviet Russia: a retrospective cohort study. The Lancet Public Health. 
2017;2(5):e231-e8. 
43. Riumallo-Herl C, Basu S, Stuckler D, Courtin E, Avendano M. Job 
loss, wealth and depression during the Great Recession in the USA and 
Europe. International journal of epidemiology. 2014;43(5):1508-17. 
44. Durkheim E. Suicide: A study in sociology (JA Spaulding & G. 
Simpson, trans.). Glencoe, IL: Free Press(Original work published 1897). 
1951. 
45. Cobb S. Social support as a moderator of life stress. Psychosomatic 
medicine. 1976;38(5):300-14. 
 
 
290 
 
46. Cassel J. The contribution of the Social Environment to Host 
Resistance. American journal of epidemiology. 1976;104(2):107-23. 
47. Berkman L, Krishna A. Social Network Epidemiolgy. In Social 
Epidemiology, 2nd Ed: Oxford University Press; 2014. 
48. Christakis NA, Fowler JH. The spread of obesity in a large social 
network over 32 years. n engl j med. 2007;2007(357):370-9. 
49. Berkman LF, Syme SL. Social networks, host resistance, and 
mortality: a nine-year follow-up study of Alameda County residents. 
American journal of epidemiology. 1979;109(2):186-204. 
50. Cohen S, Wills TA. Stress, social support, and the buffering 
hypothesis. Psychological bulletin. 1985;98(2):310. 
51. Karasek Jr RA. Job demands, job decision latitude, and mental strain: 
Implications for job redesign. Administrative science quarterly. 1979:285-308. 
52. Johnson JV, Hall EM. Job strain, work place social support, and 
cardiovascular disease: a cross-sectional study of a random sample of the 
Swedish working population. American journal of public health. 
1988;78(10):1336-42. 
53. Bosma H, Marmot MG, Hemingway H, Nicholson AC, Brunner E, 
Stansfeld SA. Low job control and risk of coronary heart disease in Whitehall 
II (prospective cohort) study. Bmj. 1997;314(7080):558. 
54. Kaufmann GM, Beehr TA. Interactions between job stressors and 
social support: Some counterintuitive results. Journal of Applied Psychology. 
1986;71(3):522. 
55. Vilhjalmsson R. Life stress, social support and clinical depression: a 
reanalysis of the literature. Social science & medicine. 1993;37(3):331-42. 
56. Graeber D. Debt-updated and expanded: the first 5,000 years: Melville 
House; 2014. 
57. McEwen BS. Stress, adaptation, and disease: Allostasis and allostatic 
load. Annals of the New York Academy of Sciences. 1998;840(1):33-44. 
58. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and 
mortality risk: a meta-analytic review. PLoS medicine. 2010;7(7):e1000316. 
59. Ramsay S, Ebrahim S, Whincup P, Papacosta O, Morris R, Lennon L, 
et al. Social engagement and the risk of cardiovascular disease mortality: 
results of a prospective population-based study of older men. Annals of 
epidemiology. 2008;18(6):476-83. 
60. Ikeda A, Iso H, Kawachi I, Yamagishi K, Inoue M, Tsugane S. Social 
support and stroke and coronary heart disease. Stroke. 2008;39(3):768-75. 
61. Barth J, Schneider S, von Känel R. Lack of social support in the 
etiology and the prognosis of coronary heart disease: a systematic review 
and meta-analysis. Psychosomatic Medicine. 2010;72(3):229-38. 
62. Kuper H, Marmot M, Hemingway H, editors. Systematic review of 
prospective cohort studies of psychosocial factors in the etiology and 
prognosis of coronary heart disease. Seminars in vascular medicine; 2002: 
Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, 
New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662. 
63. Schmaltz HN, Southern D, Ghali WA, Jelinski SE, Parsons GA, King 
KM, et al. Living alone, patient sex and mortality after acute myocardial 
infarction. Journal of general internal medicine. 2007;22(5):572. 
64. Stringhini S, Berkman L, Dugravot A, Ferrie JE, Marmot M, Kivimaki 
M, et al. Socioeconomic status, structural and functional measures of social 
 
 
291 
 
support, and mortality: The British Whitehall II Cohort Study, 1985–2009. 
American journal of epidemiology. 2012;175(12):1275-83. 
65. Robles TF, Slatcher RB, Trombello JM, McGinn MM. Marital quality 
and health: A meta-analytic review. Psychological bulletin. 2014;140(1):140. 
66. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, 
Stampfer MJ, et al. A prospective study of social networks in relation to total 
mortality and cardiovascular disease in men in the USA. Journal of 
Epidemiology & Community Health. 1996;50(3):245-51. 
67. Eng PM, Rimm EB, Fitzmaurice G, Kawachi I. Social ties and change 
in social ties in relation to subsequent total and cause-specific mortality and 
coronary heart disease incidence in men. American journal of epidemiology. 
2002;155(8):700-9. 
68. Gallo LC, Troxel WM, Kuller LH, Sutton-Tyrrell K, Edmundowicz D, 
Matthews KA. Marital status, marital quality, and atherosclerotic burden in 
postmenopausal women. Psychosomatic medicine. 2003;65(6):952-62. 
69. André-Petersson L, Hedblad B, Janzon L. Social support and behavior 
in a stressful situation in relation to myocardial infarction and mortality: who 
is at risk? Results from prospective cohort study “Men born in 1914,” Malmö, 
Sweden. International journal of behavioral medicine. 2006;13(4):340. 
70. Hajdu P, Mckee M, Bojan F. Changes in premature mortality 
differentials by marital status in Hungary and in England and Wales. The 
European Journal of Public Health. 1995;5(4):259-64. 
71. Watson P. Explaining rising mortality among men in Eastern Europe. 
Social Science & Medicine. 1995;41(7):923-34. 
72. Rosenman RH, Brand RJ, Jenkins CD, Friedman M, Straus R, Wurm 
M. Coronary heart disease in the Western Collaborative Group Study: Final 
follow-up experience of 8 1/2 years. Jama. 1975;233(8):872-7. 
73. Chida Y, Steptoe A. The association of anger and hostility with future 
coronary heart disease: a meta-analytic review of prospective evidence. 
Journal of the American college of cardiology. 2009;53(11):936-46. 
74. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, et 
al. Alteration of type A behavior and its effect on cardiac recurrences in post 
myocardial infarction patients: summary results of the recurrent coronary 
prevention project. American heart journal. 1986;112(4):653-65. 
75. Eysenck HJ, Eysenck S. The Eysenck personality inventory. 1965. 
76. McCrae RR, Costa PT. Validation of the five-factor model of 
personality across instruments and observers. Journal of personality and 
social psychology. 1987;52(1):81. 
77. Digman JM. Five robust trait dimensions: Development, stability, and 
utility. Journal of personality. 1989;57(2):195-214. 
78. Goldberg LR. An alternative" description of personality": the big-five 
factor structure. Journal of personality and social psychology. 
1990;59(6):1216. 
79. Jokela M, Batty GD, Nyberg ST, Virtanen M, Nabi H, Singh-Manoux 
A, et al. Personality and all-cause mortality: individual-participant meta-
analysis of 3,947 deaths in 76,150 adults. American journal of epidemiology. 
2013;178(5):667-75. 
80. Nakaya N, Tsubono Y, Hosokawa T, Hozawa A, Kuriyama S, Fukudo 
S, et al. Personality and mortality from ischemic heart disease and stroke. 
Clinical and experimental hypertension. 2005;27(2-3):297-305. 
 
 
292 
 
81. Batty GD, Jokela M, Kivimaki M, Shipley M. Examining the Long-Term 
Association of Personality With Cause-Specific Mortality in London: Four 
Decades of Mortality Surveillance in the Original Whitehall Smoking 
Cessation Trial. American journal of epidemiology. 2016;184(6):436-41. 
82. Luchetti M, Barkley JM, Stephan Y, Terracciano A, Sutin AR. Five-
factor model personality traits and inflammatory markers: New data and a 
meta-analysis. Psychoneuroendocrinology. 2014;50:181-93. 
83. Keltikangas-Järvinen L, Pulkki-Råback L, Puttonen S, Viikari J, 
Raitakari OT. Childhood hyperactivity as a predictor of carotid artery intima 
media thickness over a period of 21 years: the cardiovascular risk in young 
Finns study. Psychosomatic medicine. 2006;68(4):509-16. 
84. Bandura A. The explanatory and predictive scope of self-efficacy 
theory. Journal of social and clinical psychology. 1986;4(3):359-73. 
85. Krause N, Shaw BA. Role-specific feelings of control and mortality. 
Psychology and aging. 2000;15(4):617. 
86. Dalgard OS, Håheim LL. Psychosocial risk factors and mortality: a 
prospective study with special focus on social support, social participation, 
and locus of control in Norway. Journal of Epidemiology & Community 
Health. 1998;52(8):476-81. 
87. Stürmer T, Hasselbach P, Amelang M. Personality, lifestyle, and risk 
of cardiovascular disease and cancer: follow-up of population based cohort. 
BMJ. 2006;332(7554):1359. 
88. van Oort FV, van Lenthe FJ, Mackenbach JP. Material, psychosocial, 
and behavioural factors in the explanation of educational inequalities in 
mortality in The Netherlands. Journal of Epidemiology & Community Health. 
2005;59(3):214-20. 
89. Surtees PG, Wainwright NW, Luben R, Khaw K-T, Day NE. Mastery, 
sense of coherence, and mortality: evidence of independent associations 
from the EPIC-Norfolk Prospective Cohort Study. Health Psychology. 
2006;25(1):102. 
90. Surtees PG, Wainwright NW, Luben R, Wareham NJ, Bingham SA, 
Khaw K-T. Mastery is associated with cardiovascular disease mortality in 
men and women at apparently low risk. Health Psychology. 2010;29(4):412. 
91. Kozela M, Doryńska A, Stepaniak U, Szafraniec K, Topór-Mądry R, 
Misiowiec W, et al. Perceived control as a predictor of cardiovascular 
disease mortality in Poland. The HAPIEE study. Cardiology journal. 
2015;22(4):404-12. 
92. De Vogli R, Ferrie JE, Chandola T, Kivimäki M, Marmot MG. 
Unfairness and health: evidence from the Whitehall II Study. Journal of 
Epidemiology & Community Health. 2007;61(6):513-8. 
93. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, et 
al. Depressed affect, hopelessness, and the risk of ischemic heart disease in 
a cohort of US adults. Epidemiology. 1993:285-94. 
94. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, 
Beekman A. Depression and the risk for cardiovascular diseases: systematic 
review and meta analysis. International journal of geriatric psychiatry. 
2007;22(7):613-26. 
95. Rugulies R. Depression as a predictor for coronary heart disease: a 
review and meta-analysis. American journal of preventive medicine. 
2002;23(1):51-61. 
 
 
293 
 
96. Bekke-Hansen S, Trockel M, Burg MM, Taylor CB. Depressive 
symptom dimensions and cardiac prognosis following myocardial infarction: 
results from the ENRICHD clinical trial. Psychological medicine. 
2012;42(1):51-60. 
97. Barefoot JC, Brummett BH, Helms MJ, Mark DB, Siegler IC, Williams 
RB. Depressive symptoms and survival of patients with coronary artery 
disease. Psychosomatic Medicine. 2000;62(6):790-5. 
98. Kozela M, Bobak M, Besala A, Micek A, Kubinova R, Malyutina S, et 
al. The association of depressive symptoms with cardiovascular and all-
cause mortality in Central and Eastern Europe: prospective results of the 
HAPIEE study. European journal of preventive cardiology. 2016;23(17):1839-
47. 
99. Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant 
medication use and future risk of cardiovascular disease: the Scottish Health 
Survey. European heart journal. 2010;32(4):437-42. 
100. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of 
bleeding associated with combined use of selective serotonin reuptake 
inhibitors and antiplatelet therapy following acute myocardial infarction. 
Canadian Medical Association Journal. 2011;183(16):1835-43. 
101. Glassman AH, O'connor CM, Califf RM, Swedberg K, Schwartz P, 
Bigger Jr JT, et al. Sertraline treatment of major depression in patients with 
acute MI or unstable angina. Jama. 2002;288(6):701-9. 
102. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan 
MJ, et al. Effects of treating depression and low perceived social support on 
clinical events after myocardial infarction: the Enhancing Recovery in 
Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA: 
Journal of the American Medical Association. 2003. 
103. Scherrer JF, Xian H, Bucholz KK, Eisen SA, Lyons MJ, Goldberg J, et 
al. A twin study of depression symptoms, hypertension, and heart disease in 
middle‐aged men. Psychosomatic Medicine. 2003;65(4):548-57. 
104. Rees K, Bennett P, West R, Davey Smith G, Ebrahim S. 
Psychological interventions for coronary heart disease. Cochrane Database 
Syst Rev. 2004(2):CD002902. 
105. Linden W, Phillips MJ, Leclerc J. Psychological treatment of cardiac 
patients: a meta-analysis. European heart journal. 2007;28(24):2972-84. 
106. Huppert FA, Whittington JE. Symptoms of psychological distress 
predict 7-year mortality. Psychological medicine. 1995;25(5):1073-86. 
107. Russ TC, Stamatakis E, Hamer M, Starr JM, Kivimäki M, Batty GD. 
Association between psychological distress and mortality: individual 
participant pooled analysis of 10 prospective cohort studies. bmj. 
2012;345:e4933. 
108. Appels A, Höppener P, Mulder P. A questionnaire to assess 
premonitory symptoms of myocardial infarction. International journal of 
cardiology. 1987;17(1):15-24. 
109. Kopp MS, Falger PR, Appels A, Szedmak S. Depressive 
symptomatology and vital exhaustion are differentially related to behavioral 
risk factors for coronary artery disease. Psychosomatic medicine. 
1998;60(6):752-8. 
110. Schnohr P, Marott JL, Kristensen TS, Gyntelberg F, Gronbaek M, 
Lange P, et al. Ranking of psychosocial and traditional risk factors by 
 
 
294 
 
importance for coronary heart disease: the Copenhagen City Heart Study. 
Eur Heart J. 2015;36(22):1385-93. 
111. Boehm JK, Peterson C, Kivimaki M, Kubzansky LD. Heart health 
when life is satisfying: evidence from the Whitehall II cohort study. European 
Heart Journal. 2011;32(21):2672-7. 
112. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of 
incident coronary heart disease: a meta-analysis. Journal of the American 
College of Cardiology. 2010;56(1):38-46. 
113. Phillips AC, Batty GD, Gale CR, Deary IJ, Osborn D, MacIntyre K, et 
al. Generalized anxiety disorder, major depressive disorder, and their 
comorbidity as predictors of all-cause and cardiovascular mortality: the 
Vietnam experience study. Psychosomatic Medicine. 2009;71(4):395-403. 
114. Kumar P, Clark M. Clinical Medicine. 9th Ed. ed: Elsevier; 2017. 
115. Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, et 
al. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian 
randomization’. International journal of epidemiology. 2006;35(4):935-43. 
116. Wensley Fea. Association between C reactive protein and coronary 
heart disease: mendelian randomisation analysis based on individual 
participant data. Bmj. 2011;342:d548. 
117. Van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen 
SH, et al. Common genetic loci influencing plasma homocysteine 
concentrations and their effect on risk of coronary artery disease. The 
American journal of clinical nutrition. 2013;98(3):668-76. 
118. Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen M-H, et 
al. Multiple genetic loci influence serum urate and their relationship with gout 
and cardiovascular disease risk factors. Circulation: Cardiovascular 
Genetics. 2010:CIRCGENETICS. 109.934455. 
119. Palmer TM, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Smith 
GD, Lawlor DA, et al. Association of plasma uric acid with ischaemic heart 
disease and blood pressure: mendelian randomisation analysis of two large 
cohorts. Bmj. 2013;347:f4262. 
120. White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, et al. 
Plasma urate concentration and risk of coronary heart disease: a Mendelian 
randomisation analysis. The lancet Diabetes & endocrinology. 
2016;4(4):327-36. 
121. van Kippersluis H, O'Donnell O, van Doorslaer E. Long run returns to 
education: does schooling lead to an extended old age? Eur J Hum Resour. 
2009;4:1-33. 
122. Davies NM, Dickson M, Davey Smith G, van den Berg G, Windmeijer 
F. The Causal Effects of Education on Health, Mortality, Cognition, Well-
being, and Income in the UK Biobank. bioRxiv. 2016. 
123. Lleras-Muney A. The relationship between education and adult 
mortality in the United States. Review of Economic Studies. 2005;72:189-
221. 
124. Mazumder B. Does education improve health? A reexamniation of the 
evidence from compulsory schooling laws. Economic Perspectives. 
2008;33:2-16. 
125. Lager AC, Torssander J. Causal effect of education on mortality in a 
quasi-experiment on 1.2 million Swedes. Proceedings of the National 
Academy of Sciences of the United States of America. 2012;109(22):8461-6. 
 
 
295 
 
126. Madsen M, Andersen AM, Christensen K, Andersen PK, Osler M. 
Does educational status impact adult mortality in Denmark? A twin approach. 
Am J Epidemiol. 2010;172(2):225-34. 
127. Madsen M, Andersen PK, Gerster M, Andersen AM, Christensen K, 
Osler M. Are the educational differences in incidence of cardiovascular 
disease explained by underlying familial factors? A twin study. Social science 
& medicine (1982). 2014;118:182-90. 
128. Lundborg P. The health returns to schooling - what can we learn from 
twins? J Pop Economics. 2013;26:673-701. 
129. Arden R, Luciano M, Deary IJ, Reynolds CA, Pedersen NL, Plassman 
BL, et al. The association between intelligence and lifespan is mostly 
genetic. Int J Epidemiol. 2016;45(1):178-85. 
130. Lundborg P, Lyttkens CH, Nystedt P. The Effect of Schooling on 
Mortality: New Evidence From 50,000 Swedish Twins. Demography. 
2016;53(4):1135-68. 
131. Naess O, Hoff DA, Lawlor D, Mortensen LH. Education and adult 
cause-specific mortality--examining the impact of family factors shared by 
871 367 Norwegian siblings. Int J Epidemiol. 2012;41(6):1683-91. 
132. Sondergaard G, Mortensen LH, Nybo Andersen AM, Andersen PK, 
Dalton SO, Madsen M, et al. Does shared family background influence the 
impact of educational differences on early mortality? Am J Epidemiol. 
2012;176(8):675-83. 
133. McFarland MJ, Wagner BG. Does a college education reduce 
depressive symptoms in American young adults? Social Science & Medicine. 
2015;146:75-84. 
134. R E Marioni, S J Ritchie, P K Joshi, S P Hagenaars, A Okbay, K 
Fischer, et al. Genetic variants linked to education predict longevity. PNAS. 
2016; in press. 
135. Rietveld CA, Medland SE, Derringer J, Yang J, Esko T, Martin NW, et 
al. GWAS of 126,559 individuals identifies genetic variants associated with 
educational attainment. Science. 2013;340(6139):1467-71. 
136. Nguyen TT, Tchetgen Tchetgen EJ, Kawachi I, Gilman SE, Walter S, 
Liu SY, et al. Instrumental variable approaches to identifying the causal 
effect of educational attainment on dementia risk. Annals of epidemiology. 
2016;26(1):71-6.e1-3. 
137. Cuellar-Partida G, Lu Y, Kho PF, Hewitt AW, Wichmann HE, Yazar S, 
et al. Assessing the Genetic Predisposition of Education on Myopia: A 
Mendelian Randomization Study. Genetic epidemiology. 2016;40(1):66-72. 
138. Case A, Fertig A, Paxson C. The lasting impact of childhood health 
and circumstance. Journal of health economics. 2005;24(2):365-89. 
139. Smith JP. The impact of socioeconomic status on health over the life-
course. Journal of Human Resources. 2007;42(4):739-64. 
140. Voss M, Nylén L, Floderus B, Diderichsen F, Terry PD. 
Unemployment and early cause-specific mortality: a study based on the 
Swedish twin registry. American journal of public health. 2004;94(12):2155-
61. 
141. Martikainen PT, Valkonen T. Excess mortality of unemployed men 
and women during a period of rapidly increasing unemployment. The Lancet. 
1996;348(9032):909-12. 
142. Reeves A, Karanikolos M, Mackenbach J, McKee M, Stuckler D. Do 
employment protection policies reduce the relative disadvantage in the 
 
 
296 
 
labour market experienced by unhealthy people? A natural experiment 
created by the Great Recession in Europe. Social Science & Medicine. 
2014;121:98-108. 
143. Chang S-S, Stuckler D, Yip P, Gunnell D. Impact of 2008 global 
economic crisis on suicide: time trend study in 54 countries. Bmj. 
2013;347:f5239. 
144. Toffolutti V, Suhrcke M. Assessing the short term health impact of the 
Great Recession in the European Union: a cross-country panel analysis. 
Preventive medicine. 2014;64:54-62. 
145. Margerison-Zilko C, Goldman-Mellor S, Falconi A, Downing J. Health 
Impacts of the Great Recession: a Critical Review. Current epidemiology 
reports. 2016;3(1):81-91. 
146. Ruhm CJ. Recessions, healthy no more? Journal of health 
economics. 2015;42:17-28. 
147. Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M. The public health 
effect of economic crises and alternative policy responses in Europe: an 
empirical analysis. The Lancet. 2009;374(9686):315-23. 
148. Noelke C, Avendano M. Who suffers during recessions? Economic 
downturns, job loss, and cardiovascular disease in older Americans. 
American journal of epidemiology. 2015;182(10):873-82. 
149. Osler M, McGue M, Lund R, Christensen K. Marital status and twins’ 
health and behavior: an analysis of middle-aged Danish twins. 
Psychosomatic medicine. 2008;70(4):482. 
150. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svärdsudd K. 
Randomized controlled trial of cognitive behavioral therapy vs standard 
treatment to prevent recurrent cardiovascular events in patients with 
coronary heart disease: Secondary Prevention in Uppsala Primary Health 
Care project (SUPRIM). Archives of Internal Medicine. 2011;171(2):134-40. 
151. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, 
Tolonen H, et al. Estimation of contribution of changes in classic risk factors 
to trends in coronary-event rates across the WHO MONICA Project 
populations. The Lancet. 2000;355(9205):675-87. 
152. Gasparrini A, Armstrong B, Kenward M. Multivariate meta‐analysis for 
non‐linear and other multi‐parameter associations. Statistics in medicine. 
2012;31(29):3821-39. 
153. Bandosz P, O’Flaherty M, Drygas W, Rutkowski M, Koziarek J, 
Wyrzykowski B, et al. Decline in mortality from coronary heart disease in 
Poland after socioeconomic transformation: modelling study. bmj. 
2012;344:d8136. 
154. Bruthans J, Cífková R, Lánská V, O'flaherty M, Critchley JA, Holub J, 
et al. Explaining the decline in coronary heart disease mortality in the Czech 
Republic between 1985 and 2007. European journal of preventive 
cardiology. 2014;21(7):829-39. 
155. Bobak M, Marmot M. East-West mortality divide and its potential 
explanations: proposed research agenda. The European Journal of General 
Practice. 1996;2(1):8-. 
156. Ginter E. Cardiovascular risk factors in the former communist 
countries. European journal of epidemiology. 1995;11(2):199-205. 
157. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and 
all-cause mortality in Western and Eastern Europe between 1970 and 2000. 
European heart journal. 2005;27(1):107-13. 
 
 
297 
 
158. Pomerleau J, McKee M, Lobstein T, Knai C. The burden of disease 
attributable to nutrition in Europe. Public health nutrition. 2003;6(5):453-61. 
159. Zatonski WA, McMichael AJ, Powles JW. Ecological study of reasons 
for sharp decline in mortality from ischaemic heart disease in Poland since 
1991. Bmj. 1998;316(7137):1047. 
160. Powles JW, Zatonski W, Vander Hoorn S, Ezzati M. The contribution 
of leading diseases and risk factors to excess losses of healthy life in 
Eastern Europe: burden of disease study. BMC public health. 2005;5(1):116. 
161. Stefler D, Pikhart H, Jankovic N, Kubinova R, Pajak A, Malyutina S, et 
al. Healthy diet indicator and mortality in Eastern European populations: 
prospective evidence from the HAPIEE cohort. European Journal of Clinical 
Nutrition. 2014;68(12):1346. 
162. Leon DA, Chenet L, Shkolnikov VM, Zakharov S, Shapiro J, 
Rakhmanova G, et al. Huge variation in Russian mortality rates 1984–94: 
artefact, alcohol, or what? The lancet. 1997;350(9075):383-8. 
163. Britton A, McKee M. The relation between alcohol and cardiovascular 
disease in Eastern Europe: explaining the paradox. Journal of Epidemiology 
& Community Health. 2000;54(5):328-32. 
164. McKee M, Britton A. The positive relationship between alcohol and 
heart disease in eastern Europe: potential physiological mechanisms. 
Journal of the Royal Society of Medicine. 1998;91(8):402-7. 
165. Shkolnikov VM, Meslé F. The Russian epidemiological crisis as 
mirrored by mortality trends.  Russia’s Demographic Crisis, Conference 
Proceedings 1996. 
166. Rehm J, Sulkowska U, Mańczuk M, Boffetta P, Powles J, Popova S, 
et al. Alcohol accounts for a high proportion of premature mortality in central 
and eastern Europe. International journal of epidemiology. 2007;36(2):458-
67. 
167. Leon DA, Saburova L, Tomkins S, Andreev E, Kiryanov N, McKee M, 
et al. Hazardous alcohol drinking and premature mortality in Russia: a 
population based case-control study. The Lancet. 2007;369(9578):2001-9. 
168. Grittner U, Kuntsche S, Gmel G, Bloomfield K. Alcohol consumption 
and social inequality at the individual and country levels—results from an 
international study. The European Journal of Public Health. 2012;23(2):332-
9. 
169. Zaridze D, Brennan P, Boreham J, Boroda A, Karpov R, Lazarev A, et 
al. Alcohol and cause-specific mortality in Russia: a retrospective case–
control study of 48 557 adult deaths. The Lancet. 2009;373(9682):2201-14. 
170. Zaridze D, Lewington S, Boroda A, Scélo G, Karpov R, Lazarev A, et 
al. Alcohol and mortality in Russia: prospective observational study of 151 
000 adults. The Lancet. 2014;383(9927):1465-73. 
171. Mackenbach JP, Kulhánová I, Bopp M, Borrell C, Deboosere P, 
Kovács K, et al. Inequalities in alcohol-related mortality in 17 European 
countries: a retrospective analysis of mortality registers. PLoS medicine. 
2015;12(12):e1001909. 
172. Bobak M, Malyutina S, Horvat P, Pajak A, Tamosiunas A, Kubinova R, 
et al. Alcohol, drinking pattern and all-cause, cardiovascular and alcohol-
related mortality in Eastern Europe. European Journal of Epidemiology. 
2016;31(1):21-30. 
173. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. 
Association between alcohol and cardiovascular disease: Mendelian 
 
 
298 
 
randomisation analysis based on individual participant data. Bmj. 
2014;349:g4164. 
174. The_World_Bank. International Comparison Program database. 
Accessed on 17 Nov 2017. 2017 [Available from: 
https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.KD?locations=GR-
RU-1W. 
175. Marmot M, Bobak M. International comparators and poverty and 
health in Europe. BMJ. 2000;321(7269):1124. 
176. Stuckler D, King L, McKee M. Mass privatisation and the post-
communist mortality crisis: a cross-national analysis. The Lancet. 
2009;373(9661):399-407. 
177. Jukkala T, Stickley A, Mäkinen IH, Baburin A, Sparén P. Age, period 
and cohort effects on suicide mortality in Russia, 1956− 2005. BMC public 
health. 2017;17(1):235. 
178. Feigin V. Global, regional, and national life expectancy, all-cause 
mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a 
systematic analysis for the Global Burden of Disease Study 2015. The 
Lancet. 2016;388(10053):1459-544. 
179. Sobotka T, Skirbekk V, Philipov D. Economic recession and fertility in 
the developed world. Population and development review. 2011;37(2):267-
306. 
180. Shkolnikov VM, Leon DA, Adamets S, Andreev E, Deev A. 
Educational level and adult mortality in Russia: an analysis of routine data 
1979 to 1994. Social Science & Medicine. 1998;47(3):357-69. 
181. Kannel WB, McGee D, Gordon T. A general cardiovascular risk 
profile: the Framingham Study. The American journal of cardiology. 
1976;38(1):46-51. 
182. Brittain E. Probability of coronary heart disease developing. Western 
Journal of Medicine. 1982;136(1):86. 
183. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular 
disease risk profiles. American heart journal. 1991;121(1):293-8. 
184. Anderson KM, Wilson P, Odell PM, Kannel WB. An updated coronary 
risk profile. A statement for health professionals. Circulation. 1991;83(1):356-
62. 
185. Conroy R, Pyörälä K, Fitzgerald Ae, Sans S, Menotti A, De Backer G, 
et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: 
the SCORE project. European heart journal. 2003;24(11):987-1003. 
186. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation 
and family history to cardiovascular risk assessment: the ASSIGN score from 
the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172-
6. 
187. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, 
Brindle P. Derivation and validation of QRISK, a new cardiovascular disease 
risk score for the United Kingdom: prospective open cohort study. Bmj. 
2007;335(7611):136. 
188. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, 
Sheikh A, et al. Predicting cardiovascular risk in England and Wales: 
prospective derivation and validation of QRISK2. Bmj. 2008;336(7659):1475-
82. 
 
 
299 
 
189. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, 
Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of 
cardiovascular risk. Circulation. 2014;129(25 suppl 2):S49-S73. 
190. Ramachandran S, French J, Vanderpump M, Croft P, Neary R. Using 
the Framingham model to predict heart disease in the United Kingdom: 
retrospective study. Bmj. 2000;320(7236):676-7. 
191. Ridker PM, Cook NR. Statins: new American guidelines for prevention 
of cardiovascular disease. The Lancet. 2013;382(9907):1762-5. 
192. Cook NR, Ridker PM. Further insight into the cardiovascular risk 
calculator: the roles of statins, revascularizations, and underascertainment in 
the Women’s Health Study. JAMA internal medicine. 2014;174(12):1964-71. 
193. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, 
Blumenthal RS, et al. An analysis of calibration and discrimination among 
multiple cardiovascular risk scores in a modern multiethnic cohortcalibration 
and discrimination among CVD risk scores. Annals of internal medicine. 
2015;162(4):266-75. 
194. Woodward M. On validation of cardiovascular risk scores. BMJ. 2016. 
195. Brindle PM, McConnachie A, Upton MN, Hart CL, Smith GD, Watt GC. 
The accuracy of the Framingham risk-score in different socioeconomic 
groups: a prospective study. Br J Gen Pract. 2005;55(520):838-45. 
196. Tunstall-Pedoe H, Woodward M. By neglecting deprivation, 
cardiovascular risk scoring will exacerbate social gradients in disease. Heart. 
2006;92(3):307-10. 
197. Organization WH. Prevention of cardiovascular disease: guidelines for 
assessment and management of cardiovascular risk: World Health 
Organization; 2007. 
198. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-
Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in 
national populations (Globorisk): a pooled analysis of prospective cohorts 
and health examination surveys. The Lancet Diabetes & Endocrinology. 
2015;3(5):339-55. 
199. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-
Salinas CA, et al. Laboratory-based and office-based risk scores and charts 
to predict 10-year risk of cardiovascular disease in 182 countries: a pooled 
analysis of prospective cohorts and health surveys. The Lancet Diabetes & 
Endocrinology. 2017;5(3):196-213. 
200. Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM, 
et al. Global, regional, and national comparative risk assessment of 84 
behavioural, environmental and occupational, and metabolic risks or clusters 
of risks, 1990-2016: a systematic analysis for the Global Burden of Disease 
Study 2016. The Lancet. 2017;390(10100):1345-422. 
201. Collaboration APCS. A comparison of the associations between risk 
factors and cardiovascular disease in Asia and Australasia. European 
Journal of Cardiovascular Prevention & Rehabilitation. 2005;12(5):484-91. 
202. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. 
Effect of potentially modifiable risk factors associated with myocardial 
infarction in 52 countries (the INTERHEART study): case-control study. 
Lancet (London, England). 2004;364(9438):937-52. 
203. Jdanov DA, Deev AD, Jasilionis D, Shalnova SA, Shkolnikova MA, 
Shkolnikov VM. Recalibration of the SCORE risk chart for the Russian 
population. European journal of epidemiology. 2014;29(9):621-8. 
 
 
300 
 
204. Ruwanpathirana T, Owen A, Reid CM. Review on cardiovascular risk 
prediction. Cardiovascular therapeutics. 2015;33(2):62-70. 
205. Sattar N, Welsh P, Sarwar N, Danesh J, Di Angelantonio E, 
Gudnason V, et al. NT-proBNP is associated with coronary heart disease risk 
in healthy older women but fails to enhance prediction beyond established 
risk factors: results from the British Women's Heart and Health Study. 
Atherosclerosis. 2010;209(1):295-9. 
206. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, 
Guerci AD, et al. Coronary artery calcium score and risk classification for 
coronary heart disease prediction. Jama. 2010;303(16):1610-6. 
207. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, 
O’Leary D, et al. Comparison of novel risk markers for improvement in 
cardiovascular risk assessment in intermediate-risk individuals. Jama. 
2012;308(8):788-95. 
208. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, 
Yetukuri L, et al. Genomic prediction of coronary heart disease. European 
heart journal. 2016;37(43):3267-78. 
209. Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, 
et al. Risk prediction by genetic risk scores for coronary heart disease is 
independent of self-reported family history. European heart journal. 
2015;37(6):561-7. 
210. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. <span 
hwp:id="article-title-1" class="article-title">Genetic Risk Prediction and a 2-
Stage Risk Screening Strategy for Coronary Heart Disease</span><span 
hwp:id="article-title-19" class="sub-article-title">Significance</span>. 
Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(9):2261-6. 
211. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, 
et al. Genetic risk, coronary heart disease events, and the clinical benefit of 
statin therapy: an analysis of primary and secondary prevention trials. The 
Lancet. 2015;385(9984):2264-71. 
212. Ingle L, Carroll S, Stamatakis E, Hamer M. Benefit of adding lifestyle-
related risk factors for prediction of cardiovascular death among cardiac 
patients. International journal of cardiology. 2013;163(2):196-200. 
213. Georgousopoulou EN, Panagiotakos DB, Bougatsas D, 
Chatzigeorgiou M, Kavouras SA, Chrysohoou C, et al. Physical Activity Level 
Improves the Predictive Accuracy of Cardiovascular Disease Risk Score: 
The ATTICA Study (2002–2012). International journal of preventive 
medicine. 2016;7. 
214. Graversen P, Abildstrøm SZ, Jespersen L, Borglykke A, Prescott E. 
Cardiovascular risk prediction: Can Systematic Coronary Risk Evaluation 
(SCORE) be improved by adding simple risk markers? Results from the 
Copenhagen City Heart Study. European journal of preventive cardiology. 
2016;23(14):1546-56. 
215. Sacco RL, Khatri M, Rundek T, Xu Q, Gardener H, Boden-Albala B, et 
al. Improving global vascular risk prediction with behavioral and 
anthropometric factors: the multiethnic NOMAS (Northern Manhattan Cohort 
Study). Journal of the American College of Cardiology. 2009;54(24):2303-11. 
216. Paynter NP, LaMonte MJ, Manson JE, Martin LW, Phillips L, Ridker 
PM, et al. Comparison of Lifestyle Based to Traditional CVD Prediction in a 
Multiethnic Cohort of Non-Smoking Women. Circulation. 
2014:CIRCULATIONAHA. 114.012069. 
 
 
301 
 
217. Fiscella K, Tancredi D, Franks P. Adding socioeconomic status to 
Framingham scoring to reduce disparities in coronary risk assessment. 
American heart journal. 2009;157(6):988-94. 
218. Ramsay SE, Morris RW, Whincup PH, Papacosta AO, Thomas MC, 
Wannamethee SG. Prediction of coronary heart disease risk by Framingham 
and SCORE risk assessments varies by socioeconomic position: results from 
a study in British men. European Journal of Cardiovascular Prevention & 
Rehabilitation. 2011;18(2):186-93. 
219. Pujades-Rodriguez M, Timmis A, Stogiannis D, Rapsomaniki E, 
Denaxas S, Shah A, et al. Socioeconomic deprivation and the incidence of 
12 cardiovascular diseases in 1.9 million women and men: implications for 
risk prediction and prevention. PloS one. 2014;9(8):e104671. 
220. Veronesi G, Gianfagna F, Giampaoli S, Chambless L, Mancia G, 
Cesana G, et al. Improving long-term prediction of first cardiovascular event: 
the contribution of family history of coronary heart disease and social status. 
Preventive medicine. 2014;64:75-80. 
221. Colantonio LD, Richman JS, Carson AP, Lloyd‐Jones DM, Howard G, 
Deng L, et al. Performance of the Atherosclerotic Cardiovascular Disease 
Pooled Cohort Risk Equations by Social Deprivation Status. Journal of the 
American Heart Association. 2017;6(3):e005676. 
222. Backholer K, Hirakawa Y, Tonkin A, Giles G, Magliano DJ, Colagiuri 
S, et al. Development of an Australian cardiovascular disease mortality risk 
score using multiple imputation and recalibration from national statistics. 
BMC cardiovascular disorders. 2017;17(1):17. 
223. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores 
S, et al. Social determinants of risk and outcomes for cardiovascular disease. 
Circulation. 2015;132(9):873-98. 
224. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic 
epidemiology contribute to understanding environmental determinants of 
disease? Int J Epidemiol. 2003;32(1):1-22. 
225. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us 
about modifiable behavioural and environmental exposures? BMJ. 
2005;330(7499):1076-9. 
226. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent 
Estimation in Mendelian Randomization with Some Invalid Instruments Using 
a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14. 
227. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with 
invalid instruments: effect estimation and bias detection through Egger 
regression. International journal of epidemiology. 2015;44:512-25. 
228. Burgess S, Dudbridge F, Thompson SG. Re: "Multivariable Mendelian 
randomization: the use of pleiotropic genetic variants to estimate causal 
effects". Am J Epidemiol. 2015;181:290-1. 
229. The interleukin-6 receptor as a target for prevention of coronary heart 
disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-
24. 
230. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. 
Association between alcohol and cardiovascular disease: Mendelian 
randomisation analysis based on individual participant data. BMJ : British 
Medical Journal. 2014;349. 
 
 
302 
 
231. White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions 
with risks for coronary artery disease and diabetes. JAMA Cardiology. 
2016;1(6):692-9. 
232. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, 
Haycock PC, et al. LD Hub: a centralized database and web interface to 
perform LD score regression that maximizes the potential of summary level 
GWAS data for SNP heritability and genetic correlation analysis. 
Bioinformatics. 2016. 
233. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, 
et al. An atlas of genetic correlations across human diseases and traits. 
Nature genetics. 2015;47(11):1236-41. 
234. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, 
et al. Genome-wide association study identifies 74 loci associated with 
educational attainment. Nature. 2016;533(7604):539-42. 
235. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap 
in two-sample Mendelian randomization. Genet Epidemiol. 2016. doi: 
10.1002/gepi.21998. [Epub ahead of print]. 
236. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in 
Mendelian randomization studies. International journal of epidemiology. 
2013;42(5):1497-501. 
237. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, 
Thompson JR, et al. Large-scale association analysis identifies new risk loci 
for coronary artery disease. Nature genetics. 2013;45(1):25-33. 
238. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, 
Thompson JR. Assessing the suitability of summary data for two-sample 
Mendelian randomization analyses using MR-Egger regression: the role of 
the I2 statistic. International journal of epidemiology. 2016. 
239. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary 
data Mendelian randomisation via the zero modal pleiotropy assumption. 
International Journal of Epidemiology. 2017;[forthcoming]. 
240. Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting 
pleiotropy in Mendelian randomisation studies with summary data and a 
continuous outcome. Statistics in Medicine. 2015;34(21):2926-40. 
241. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, 
et al. Large-scale association analysis identifies 13 new susceptibility loci for 
coronary artery disease. Nature genetics. 2011;43(4):333-8. 
242. A genome-wide association study in Europeans and South Asians 
identifies five new loci for coronary artery disease. Nature genetics. 
2011;43(4):339-44. 
243. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A 
comprehensive 1,000 Genomes-based genome-wide association meta-
analysis of coronary artery disease. Nature genetics. 2015;47(10):1121-30. 
244. Burgess S, Thompson SG. Multivariable Mendelian randomization: 
the use of pleiotropic genetic variants to estimate causal effects. American 
journal of epidemiology. 2015;181(4):251-60. 
245. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas 
A, et al. Determinants of cardiovascular disease and other non-
communicable diseases in Central and Eastern Europe: rationale and design 
of the HAPIEE study. BMC public health. 2006;6:255. 
 
 
303 
 
246. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, 
et al. MORGAM (an international pooling of cardiovascular cohorts). Int J 
Epidemiol. 2005;34(1):21-7. 
247. Bobak M, Pikhart H, Hertzman C, Rose R, Marmot M. Socioeconomic 
factors, perceived control and self-reported health in Russia. A cross-
sectional survey. Social Science & Medicine. 1998;47(2):269-79. 
248. Collaboration PS. Age-specific relevance of usual blood pressure to 
vascular mortality: a meta-analysis of individual data for one million adults in 
61 prospective studies. The Lancet. 2002;360(9349):1903-13. 
249. Rehm J. Measuring quantity, frequency, and volume of drinking. 
Alcoholism: clinical and experimental research. 1998;22(S2). 
250. Lane PW, Nelder JA. Analysis of covariance and standardization as 
instances of prediction. Biometrics. 1982:613-21. 
251. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, et 
al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, 
University of Tartu. Int J Epidemiol. 2015;44(4):1137-47. 
252. Fischer K, Kettunen J, Wurtz P, Haller T, Havulinna AS, Kangas AJ, et 
al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the 
prediction of all-cause mortality: an observational study of 17,345 persons. 
PLoS medicine. 2014;11(2):e1001606. 
253. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, 
et al. 2016 European Guidelines on cardiovascular disease prevention in 
clinical practice: The Sixth Joint Task Force of the European Society of 
Cardiology and Other Societies on Cardiovascular Disease Prevention in 
Clinical Practice (constituted by representatives of 10 societies and by invited 
experts) Developed with the special contribution of the European Association 
for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart 
Journal. 2016;37(29):2315-81. 
254. Kivimaki M, Ferrie JE, Batty GD, Davey Smith G, Elovainio M, Marmot 
MG, et al. Optimal form of operationalizing BMI in relation to all-cause and 
cause-specific mortality: the original Whitehall study. Obesity (Silver Spring). 
2008;16(8):1926-32. 
255. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for 
evaluating prediction models. Medical Decision Making. 2006;26(6):565-74. 
256. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et 
al. Interpretation of the evidence for the efficacy and safety of statin therapy. 
The Lancet. 2016;388(10059):2532-61. 
257. Hingorani A, Humphries S. Nature's randomised trials. The 
Lancet.366(9501):1906-8. 
258. Madsen M, Andersen PK, Gerster M, Andersen A-MN, Christensen K, 
Osler M. Are the educational differences in incidence of cardiovascular 
disease explained by underlying familial factors? A twin study. Social 
Science & Medicine. 2014;118:182-90. 
259. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological 
epidemiology. International Journal of Epidemiology. 2016;45(6):1866-86. 
260. Hansen KT, Heckman JJ, Mullen KJ. The effect of schooling and 
ability on achievement test scores. Journal of econometrics. 2004;121(1-
2):39-98. 
261. de Walque D. Does education affect smoking behaviors? Evidence 
using the Vietnam draft as an instrument for college education. Journal of 
health economics. 2007;26(5):877-95. 
 
 
304 
 
262. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann 
JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, 
and bodyweight: evidence from genetic analysis and randomised trials. 
Lancet. 2015;385(9965):351-61. 
263. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et 
al. Effect of long-term exposure to lower low-density lipoprotein cholesterol 
beginning early in life on the risk of coronary heart disease: a Mendelian 
randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-9. 
264. Fletcher JM. The promise and pitfalls of combining genetic and 
economic research. Health economics. 2011;20(8):889-92. 
265. Kvaavik E, Glymour M, Klepp KI, Tell GS, Batty GD. Parental 
education as a predictor of offspring behavioural and physiological 
cardiovascular disease risk factors. European journal of public health. 
2012;22(4):544-50. 
266. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, et al. 
Association of socioeconomic position with health behaviors and mortality. 
Jama. 2010;303(12):1159-66. 
267. Richmond RC, Hemani G, Tilling K, Davey Smith G, Relton CL. 
Challenges and novel approaches for investigating molecular mediation. 
Hum Mol Genet. 2016;25(R2):R149-r56. 
268. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, 
Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, 
and blood pressure as mediators from obesity to ischemic heart disease. 
Circulation research. 2015;116(4):665-73. 
269. Botero J, Ponce A, Shleifer A. Education, Complaints, and 
Accountability. J Law Econ. 2013;56(4):959-96. 
270. Oreopoulos P, Salvanes KG. Priceless: The Nonpecuniary Benefits of 
Schooling. J Econ Perspect. 2011;25(1):159-84. 
271. Filakti H, Fox J. Differences in mortality by housing tenure and by car 
access from the OPCS Longitudinal Study. Population Trends. 1995(81):27-
30. 
272. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, et al. 
Association of socioeconomic position with health behaviors and mortality. 
Jama. 2010;303(12):1159-66. 
273. Kershaw KN, Droomers M, Robinson WR, Carnethon MR, Daviglus 
ML, Verschuren WM. Quantifying the contributions of behavioral and 
biological risk factors to socioeconomic disparities in coronary heart disease 
incidence: the MORGEN study. European Journal of Epidemiology. 
2013;28(10):807-14. 
274. Marmot MG, Bosma H, Hemingway H, Brunner E, Stansfeld S. 
Contribution of job control and other risk factors to social variations in 
coronary heart disease incidence. The Lancet. 1997;350(9073):235-9. 
275. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson 
L, et al. Job strain as a risk factor for coronary heart disease: a collaborative 
meta-analysis of individual participant data. The Lancet. 
2012;380(9852):1491-7. 
276. Fiscella K, Franks P. Does psychological distress contribute to racial 
and socioeconomic disparities in mortality? Social Science & Medicine. 
1997;45(12):1805-9. 
277. Hintsa T, Shipley MJ, Gimeno D, Elovainio M, Chandola T, Jokela M, 
et al. Do pre-employment influences explain the association between 
 
 
305 
 
psychosocial factors at work and coronary heart disease? The Whitehall II 
study. Occupational and Environmental Medicine. 2010;67(5):330-4. 
278. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et 
al. Comparison of Sociodemographic and Health-Related Characteristics of 
UK Biobank Participants With Those of the General Population. American 
journal of epidemiology. 2017;186(9):1026-34. 
279. Vikhireva O, Pająk A, Broda G, Malyutina S, Tamosiunas A, Kubinova 
R, et al. SCORE performance in Central and Eastern Europe and former 
Soviet Union: MONICA and HAPIEE results. European heart journal. 
2013;35(9):571-7. 
280. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. 
Laboratory-based versus non-laboratory-based method for assessment of 
cardiovascular disease risk: the NHANES I Follow-up Study cohort. The 
Lancet. 2008;371(9616):923-31. 
281. Gaziano TA, Abrahams-Gessel S, Denman CA, Montano CM, 
Khanam M, Puoane T, et al. An assessment of community health workers' 
ability to screen for cardiovascular disease risk with a simple, non-invasive 
risk assessment instrument in Bangladesh, Guatemala, Mexico, and South 
Africa: an observational study. The Lancet Global Health. 2015;3(9):e556-
e63. 
282. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, 
Steyerberg EW, et al. Transparent Reporting of a multivariable prediction 
model for individual Prognosis or diagnosis (TRIPOD): Explanation and 
Elaboration. Annals of internal medicine. 2015;162(1):W1-W73. 
283. Harrell F. Regression modeling strategies: with applications to linear 
models, logistic and ordinal regression, and survival analysis. 2nd ed: 
Springer; 2015. 
284. Steyerberg E. Clinical prediction models: a practical approach to 
development, validation, and updating: Springer Science & Business Media; 
2008. 
285. Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, et 
al. How to develop a more accurate risk prediction model when there are few 
events. Bmj. 2015;351:h3868. 
286. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues 
in developing models, evaluating assumptions and adequacy, and measuring 
and reducing errors. Statistics in medicine. 1996;15(4):361-87. 
287. Peirce CS. The numerical measure of the success of predictions. 
Science. 1884;4(93):453-4. 
288. Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. 
Net Reclassification Improvement: Computation, Interpretation, and 
ControversiesA Literature Review and Clinician's Guide. Annals of internal 
medicine. 2014;160(2):122-31. 
289. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net 
reclassification indices for evaluating risk-prediction instruments: a critical 
review. Epidemiology (Cambridge, Mass). 2014;25(1):114. 
 
  
 
 
306 
 
  
 
 
307 
 
Annex 1 – Questionnaire items (HAPIEE study) 
 
A1.1. Socioeconomic factors 
 
 
Education 
 
 
 
 
 
Unemployment (current and previous) 
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Material depravation (current, and early life) 
 
 
 
 
Material amenities (current and early life) 
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A1.2. Psychosocial factors 
 
Depression  
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Perceived control 
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Social change 
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Social Support 
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Annex 2 – Best practice in model development and 
evaluation 
 
In writing Annex 2, I have mainly been influenced by the 2015 Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD) Statement,(282) which was the first attempt to agree 
and disseminate common standards of best practice to a wide platform of 
the epidemiological and medical research community. In some instances 
where the TRIPOD statement does not go into sufficient detail, I have 
added additional guidance from two textbooks, written by two of the 
leading experts in this area of methodology, one written by Harrell,(283) 
and the other by Steyerberg.(284) Since this body of recommendations is 
remarkably consistent with each other (for example, I have never found an 
instance of disagreement between these three sources), I will forego 
detailed annotation as to which of the three sources supports each of the 
summary statements I make. I focus on those suggestions around model 
development which directly inform on the strengths and weaknesses of 
the existing models I reviewed in section 1.4.3, as well as methodological 
decisions I have to make around my own model development in section 
2.3. 
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A2.1. Best practice in model development  
A2.1.1. Cleaning and preparing the derivation dataset. 
If >10% of data is missing for a key predictor of the outcome, then 
multiple imputation of these values will lead to models that are more valid 
(whereby validity was evaluated in studies where the true events were 
masked during model development, or in studies were validity was 
examined by testing performance in an external and independent 
dataset). 
 
Continuous variables should not be categorized or dichotomized. If their 
distributions are not normal, then reasonable attempts should be made to 
normalize these (e.g. log transformation or similar). This is particularly 
important in the case of continuous variables that are collinear with each 
other, where one variable is left-skewed while the other is right-skewed 
(e.g. metabolites determined via proton nuclear magnetic resonance 
spectroscopy). After normalizing, the number of independent predictors 
can be lowered, while failure to do so may result in more seemingly 
independent predictors, whereby the extra predictors are merely an 
artefact from incomplete normalization. Too many predictors increase the 
risk of overfitting, that is models may be excessively tailored to the data 
used to derive the model, leading to artificially inflated measures of 
performance during model derivation. However, this will not replicate in 
external settings, where performance will drop proportionately to the 
degree of overfitting. 
 
If continuous variables have nonlinear properties, then restricted cubic 
splines are the most effective way to fit these shapes (as opposed to 
choosing a-priori thresholds or fitting simple quadratic functions with a 
user-defined nadir of risk). Each knot in the spline will add another 
parameter, so an a priori number of knots should be specified. However, if 
the model is made with splines and the parameters need to be 
communicated to other researchers (for example, for external validation), 
then it can be difficult to extract and write out the spline function in written 
text format in the manuscript text. One solution is to supply the model in 
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electronic format (e.g. by creating a purpose-build website using the R 
package “shiny”). A reasonable compromise towards simplification is to 
revert to quadratics functions, since this can often fit biological data 
almost as well as splines, but are simpler to communicate, understand, 
and use in external settings. 
 
A2.1.2. Variable selection 
When deciding which candidate predictors to keep or drop for the final 
model, then the worst approach is to use univariate tests of association 
with the outcome. Consider if strong predictor A is associated strongly 
with bad predictor B, and where strong predictor A is associated weakly 
with good predictor C. Univariate testing will incorrectly identify A and 
subsequently B as the top predictors, while in a mutually adjusted model, 
A and C would be better predictors. Instead, predictor selection should be 
done a priori where possible and failing that, by an automated 
multivariable method. I will use the term “predictor selection”, which is 
thought to be synonymous with “variable selection” and “parameter 
selection” in statistical terminology, which is synonymous with “feature 
selection” in machine-learning terminology. 
 
A priori approaches can combine considerations around: 
 
1) Review of published literature for predictors that have demonstrated 
external validity before.  
 
2) Clinical reasoning and expert opinion.  
a. Note that causality is an advantage, as causal predictors are 
more likely to replicate externally. However, causality is not a 
requirement, since noncausal predictors can sometimes perform 
better. For example, a causal predictor A can be displaced by a 
noncausal predictor B, in case that noncausal predictor B has a 
lower measurement error and thereby larger magnitude of 
association with the outcome of interest. 
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b. Another consideration is the cultural preferences of clinicians 
and patients who may be end users of the model. For example, 
some users may consider psychosocial factors are perceived as 
less legitimate (for example, staff trained in surgery or A+E) when 
compared to settings where psychosocial factors are more 
established (for example, paediatrics, primary care, geriatric 
medicine and palliative medicine). In part, this need not reflect the 
empirical evidence of utility, but also the personality types who are 
attracted to these respective specialties. 
  
3) Perceived collinearity and overlap with more established predictors. 
 
 
* = I have not previously seen the following suggestions in the 
literature, but from my own reasoning, these seem natural extensions 
to this set of considerations. 
 
 
4) *Data availability in validation dataset(s). This is a pragmatic step 
for researchers, but (similar to the derivation of QRISK) will bias the 
final models towards including predictors that are already commonly 
established and accepted, as opposed to inducing potentially true 
predictors that have been less studied. 
 
5) *Externalities created during data collection: 
a. Negative externalities – e.g. cost, discomfort, pain and/or 
convenience of variable collection (especially to increase 
response rate, and to maintain a positive long-term clinical 
relationship in otherwise asymptomatic and happy participants). 
b. Positive externalities – e.g. after collecting ‘omics data from the 
patient, to complete a particular clinical model, then the same 
‘omics data may subsequently be reused for other utilities, 
outside this particular model and outcome.  
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i. For example, predictors that are relatively distal and upstream 
to the disease process (e.g. genomics, and socioeconomic 
and psychosocial variables) may have lower predictive power 
for a given outcome (such as CVD) when compared to a more 
proximal predictor (such as Troponin), however investments in 
the data infrastructure for upstream predictors are more likely 
to be repurposed to predict other outcomes (such as 
predicting cancer). 
ii. Another secondary utility is not risk prediction but established 
clinical care. For example, genomic data is stable throughout 
the lifetime of the patient, and can be repurposed in case that 
the participant is later diagnosed with a malignancy with 
known gene-specific therapy (e.g. HER2-positive breast 
cancer). 
 
 
Once the five a priori considerations have been exhausted, then automatic 
predictor-selection could be considered next, particularly if there are fewer 
than 10 to 20 events per each candidate parameter in the derivation 
dataset, to reduce the risk of overfitting. There remains disagreement 
around when to use each of the following, so much of the below reflects 
my personal understanding. 
 
1) Backwards-selection: this remains the default approach, when it is 
desirable to eliminate a small proportion of variables, and where the 
candidate predictors have lower levels of collinearity. There are three 
ways of choosing between two competing models: 
a. Take the larger model, and inspect the weakest predictor in that 
model for its P-value. Predictors included in the final chosen 
model do not have to demonstrate independent associations with 
the outcome at conventional levels of significance (e.g. P < 0.05, 
whether adjusted for Bonferroni or not). Hence the optimum P-
value threshold is typically relaxed to 0.1 < P < 0.2.  
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b. Run a Likelihood-Ratio test comparing model A with model B. This 
is likely to result in a number comparable to the P-value of the 
weakest predictor. This approach is agnostic to the question of 
how overfitted the data are likely to be. 
c. Compare the AIC of model A against model B as the criterion. 
This approach makes considerations for how overfitted the data 
are likely to be. 
 
2) Forwards-selection: this is similar to backwards selection, and is 
preferred in cases of increasing collinearity between the candidate 
predictors (e.g. ‘omics data) 
 
 
In cases when there are more predictors than events:(285) 
 
3) and where there is a small group of strong predictors (i.e. most 
candidate predictors need to be dropped), then the LASSO (also 
known as L1 penalization technique) is increasingly recommended, 
since it shrinks many predictor coefficients to zero, thereby dropping 
these predictors.  
 
4) alternatively, in case where a large group of weak predictors are 
thought to be superior, then ridge regression is recommended. This 
does not necessarily drop predictors, as beta coefficients are 
shrunken down towards zero but not necessarily to zero. 
 
 
Of note, all these four methods of automatic predictor-selection will 
increase the possibility of overfitting the model (especially the 
forwards and backwards methods that give less consideration to the 
event-to-parameter ratio). Accordingly, when evaluating model 
performance: 
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a. if performing internal validation, then allowance for overfitting 
during predictor selection needs to be made, by incorporating 
predictor-selection into each bootstrapped sample. 
b. If performing external validation, then allowance for overfitting 
during predictor-selection does not need to be specially accounted 
for, as this will already be detected in the external valuation 
sample. 
 
Finally, the more sophisticated types of automatic predictor selection 
(such as LASSO and ridge) are beginning to resemble the methods of 
machine learning such as support vector machines (where this process is 
called “feature selection”). The main disadvantage of these methods is 
that, being nonparametric, they do not produce any measures of 
uncertainty, confidence intervals or p-values. They also require much 
more data to result in stable models. However, if uncertainty is less 
important and much data is available, then they can be exploited to fit 
more complex models. For example, many fit non-linear dose-response 
curves, as well as lots of interaction variables. However, nonparametric 
machine learning is beyond the scope of this review, so I will now return to 
parametric statistical methods. 
 
A2.1.4. Interactions 
Interactive effects can be specified a priori (if there are strong reasons to 
expect their occurrence from the previous literature or expert opinion). If 
these are absent, then Harrell advises against the process of screening 
individual interactions. Instead, he recommends testing a model with no 
interactions against a full model that incorporates a wide set of putative 
interactions. A single Log-Rank (LR) test can assess whether this bundle 
improves performance. However, it remains unclear to me what should be 
done if there is strong statistical support for the model with many 
interactions.  
 
The practical application of interaction bundles is clearer in case that the 
interacting variable is binary. For example, a common historical practice 
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has been to split the model into multiple underlying models (for example, 
separate models based on gender or country, as was frequently done in 
the early CVD prediction models like SCORE). However, when should two 
separate models be fitted for men and women, and when should a single 
pooled model be created for them both, instead? My understanding is that 
a pooled model is always preferred, unless there is convincing reason to 
suggest otherwise. For example, model A could be a simple pooled 
model, and model B could be the same pooled model, which additionally 
includes all the possible gender-by-risk factor combinations. If an LR test 
finds strong statistical evidence that B is superior, then this would argue in 
favour of smaller, gender-specific models. 
 
A2.1.5. Reducing overfit 
The problem of deriving overfitted models remains a large one which is 
difficult to comprehensively mitigate. Many of the steps outlined in section 
A2.1. help towards this, however there are some specific steps that can 
be further done to reduce the problem of overfitted models, in some 
special cases.  
 
Namely, if: 
1) the final set of predictors has been chosen in a method that does not 
include shrinkage (i.e. the predictors were chosen by a priori 
reasoning, forwards- regression and/or stepwise-regression) AND  
2) if the derivation dataset has <10 events per parameter, then  
 
there remains a substantial risk that the model has been overfitted. This 
should be corrected with shrinkage or other coefficient penalization 
procedures. These are similar to the method of ridge regression: 
predictors are not dropped from the model, but their coefficients are 
merely shrunken. 
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A2.2. Best practice in evaluating model performance 
Once the model has been developed, it is important to measure its 
performance as robustly as possibly, to give an indication of how the 
model might perform if used by other researchers or clinicians working on 
similar questions elsewhere. A key objective is to reliably capture, 
measure and account for any optimistic bias which may have resulted in 
an overfitted model.    
 
A2.2.1. Selecting the dataset where performance is measured  
Simpler approaches are listed at the top of this list, which moves on to 
increasingly superior approaches at the bottom of the list: 
 
a. Performance can be evaluated in the derivation sample. This is never 
recommended due to the near certain probability of overfitting to a 
smaller or greater degree. 
 
b. Performance can also be evaluated by dividing the initial dataset into 
two random parts, one for derivation and one for validation (perhaps 
with a 66:33 ratio of these two). Although used in the derivation of 
models like QRISK, this is now less advised, since omitting 33% of the 
data results in a less precise and a more overfitted model. This is a 
type of internal validation. 
 
c. Divide the initial dataset into two non-random parts, either by using a 
geographical or temporal split. This is superior to method (b), since 
the validation data is less similar to derivation data, thereby reducing 
the possibility that spurious overfit will falsely be detected as “good 
performance” during validation. However, the problem of wasting data 
to derive more precise beta coefficients remains for both (b) and (c). 
This too is a type of internal validation. 
 
d. Keep all the data together for model derivation. Generate 
bootstrapped datasets, in order to estimate internal validity (indeed, 
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this is what is most commonly meant by internal validity at time of 
writing). This approach carries forward the weakness of (b), since 
derivation and validation data are geographically more similar (in each 
bootstrap), thereby being less sensitive to detect any potential overfit. 
However, it is superior to both (b) and (c), since a larger derivation 
sample results in smaller measurement error in the beta coefficients 
used in the final model.  
 
e. Perform model derivation in one independent dataset, and model 
validation in another independent, external dataset. The more 
different the two datasets are the better. This can mean differences in 
the country, sampling frame, inclusion criteria, response rate, data 
collection purpose (e.g. RCT, cohort, registry, electronic healthcare 
records), and outcome definition. This approach avoids the 
weaknesses of the internal validation approaches outlined in (b), (c), 
and (d), as the accidental overfit patterns in derivation are unlikely to 
also recapitulate in the external dataset. 
 
A2.2.2. Introduction to prediction metrics 
Unlike in other domains of epidemiology, where key results can often be 
interpreted in the light of a single statistical metric, risk prediction science 
is informed by holistic evaluation of multiple, mutually independent 
metrics. When evaluating the performance of a single model, and where 
this model returns predicted risks as a continuous outcome, then 
Calibration and Discrimination are the two more pertinent areas to assess. 
In case that predicted risks are subsequently dichotomised into 
categorical outcomes (which can assist in the implementation and 
interpretation of prediction models in clinical and public health settings, 
where interventional decisions are dichotomous in their nature), then 
classification statistics can additionally be used to complement calibration 
and discrimination. 
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When additionally looking at performance differences between two 
models, then measures of Reclassification can additionally help. These 
can handle both continuous and dichotomous risk prediction models.  
 
I consider other measures that are sometimes used in risk prediction 
science (such as R2 and the Brier Score) to add little additional 
information, as this is already reasonably reflected in the more clinically-
established metrics of calibration, discrimination, classification, and 
reclassification. 
 
A2.2.3. Single model - Calibration 
Consider a hypothetical example, where a model predicts that 10% of the 
entire sample will develop an event. If the observed data also reports that 
10% of the sample developed events, then this is known as perfect 
calibration. Some papers will rightly report how the Predicted/Observed 
ratio (P/O ratio) is 1.0. However, those precise individuals who were 
designated in the “at risk” group need not be those individuals who later 
developed the real life outcome. As thus, a perfectly calibrated model may 
theoretically be able to label as many as 100% of their predictions as false 
positives, if this is offset by an equal number of false negatives. Such a 
hypothetical example may be clinically useless, to advise doctors about 
whether they ought to prescribe the particular patient in front of them a 
statin. However, they are nonetheless very useful to those who are trying 
to plan and budget future healthcare resource needs (e.g. pharmaceutical 
companies, regional or national healthcare insurance system managers, 
such as NHS England) as they will be correctly provided with an 
aggregate measure of demand, calculated from a correct estimate of 
population health need. This example underscores the notion that 
calibration and discrimination are conceptually distinct measures. Good 
calibration is necessary and sufficient for population-level interventions. 
Good calibration is necessary but not sufficient for individual-level 
interventions.  
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In many tests of calibration, the population is broken down into smaller 
subgroups, so that calibration can be assessed within each subgroup. 
One approach is to break the sample into deciles or quintiles of risk. This 
allocates the same number of participants into each group. However, this 
means that there will often be many times fewer events in the subgroup 
with lowest risk, when compared to the subgroup with highest risk. It 
makes more sense to me, that subgroups could also be defined such that 
these contain equal or similar number of events at the end of the study, to 
further improve statistical robustness. I am not aware of discussion of this 
in the statistical literature. A third approach would be to define subgroups 
based on clinically meaningful thresholds of intervention. For example, 
when predicting CVD mortality, it might be useful to use the absolute risk 
thresholds 1%, 5% and 10% to create four categories, based on the 2016 
European Society of Cardiology guidelines.(253) Despite seeming 
pragmatic, this third approach has been little discussed in the literature, 
and is rarely used in research papers reporting the results of calibration.  
 
Once thresholds have been defined with which to divide the entire cohort 
into subgroups, then calibration needs to be evaluated. Visual calibration 
plots are the most common form. These are sometimes accompanied by 
formal statistical tests such as the Hosmer–Lemeshow test. However, this 
is typically too insensitive to detect poor calibration, and its result is 
heavily influenced by the sample size of the study. For this reason, most 
guidelines suggest that calibration be evaluated visually, where one dot 
represents one subgroup, x-axis denotes predicted risk in that subgroup 
(from 0-100%) and y-axis the observed risk in that subgroup (from 0-
100%). These dots could either be left as they are for the eye to judge 
alone (whereby a 45-degree diagonal line denotes perfect calibration in all 
subgroups). Alternatively the dots could be connected with a straight line 
of best fit (permitting the calculation of the calibration slope); or 
alternatively connected with a smoothed (lowess) curve. 
 
It helps to note that, at the level of the entire sample (where subgroups 
are not defined), calibration in the derivation sample may well be perfect 
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or near-perfect. This can be thought of as the result of a type of overfit that 
occurs in both small and large studies alike. For this reason, it is less 
useful to report overall calibration in the derivation sample, while 
calibration in the validation sample is more informative. In cases where 
validation data are not available, bootstrapping methods can be used to 
evaluate the degree of overfit in the derivation sample and correct for it. 
 
A2.2.4. Single model - Discrimination 
I now move onto measures of performance that are inherently 
individualistic in nature (as opposed to the group-based measure of 
calibration). These are useful if the intervention being considered is 
allocated to discrete individuals, by discrete clinicians (e.g. statin 
prescribing by GPs). Discrimination evaluates the probability that all cases 
(true positives plus false negatives) are assigned a higher predicted risk 
score when compared to all noncases (true negatives plus false 
positives). In logistic regression models (where follow-up time is not 
considered) discrimination is evaluated using the Area Under the Receiver 
Operating Characteristic (AUROC). In survival models (where follow-up 
time is considered, as is the case of most contemporary CVD risk 
prediction models), discrimination is evaluated with a C-statistic, such as 
Harrell’s C-Statistic.(286) 
 
As a summary, calibration is usually a function of how well the baseline 
risk of disease has been modelled (for participants with no risk factors, or 
average risk factors), while discrimination is usually a function of the 
Hazard Ratios ascribed to risk factors.  
 
A2.2.5. Single model - Classification 
It is possible for a model to have perfect calibration and good 
discrimination, but this may be less relevant if the discrimination benefits 
are driven by good performance at the extremes of the risk distribution, 
where this is unlikely to have any effects on clinical management 
decisions. This is because clinical management decisions are often made 
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at discrete risk thresholds, such as 1%, 5% and 10% absolute risk for 
CVD mortality. Therefore, the question of whether a participant’s risk is 
15% or 16% is merely academic and clinically irrelevant, as in both 
instances, this individual will be offered the same intervention. What is 
more important is how accurately models classify individuals into two or 
more predicted risk categories. 
 
In the CVD example cited there may be as many as four categories 
stemming from three clinical thresholds (1%, 5%, and 10%). Usually one 
of these thresholds is perhaps the most important (e.g. the 5% 
thresholds). This is because the interventions offered to someone with a 
predicted risk of 4.9% is substantially different to the interventions offered 
to someone with a predicted risk of 5.1% (e.g. advised to start statins). 
Other instances, such as the development of cancer screening tests, also 
tend to use just one clinical threshold.  
 
Many CVD clinical guidelines propose an additional complication: that 
statins are advised in case that predicted risk is high AND cholesterol 
readings are high. Although formal statistical techniques rarely discuss 
such two-by-two conditionality in the context of risk prediction, pragmatic 
articles in this area usually partition participants into two groups: those 
who meet and those who do not meet the wider set of conditions. This can 
be seen as an adaptation of the conventional classification process, with 
the caveat that the more conditionalities there are for participants to be 
designated as “for intervention”, then the more this restricts the potential 
for superior risk prediction model to improve clinical reclassification. 
 
When just one clinical threshold is deemed as important, then Sensitivity, 
Specificity, Positive Predictive Value (PPV) and Negative Predictive Value 
(NPV) can be used to sufficiently describe classification performance. In 
simple terms, sensitivity means “How many cases did it correctly 
predict?”; specificity means “How many controls did it correctly predict”; 
PPV means “If the test result reads ‘high risk’ for one individual, then what 
is the probability that they will become a case?”; NPV means “If the test 
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result reads ‘low risk’ for one individual, then what is the probability that 
they will become a control?”. 
 
Sensitivity and Specificity are more useful at the perspective of the 
population (e.g. to those optimizing population-level resource allocation), 
while PPV and NPV are more useful at the perspective of the individual 
undergoing the test, who may ask their clinician “Now that you have told 
me how my risk is ‘high’, what is the  probability that you are correct – i.e. 
that I will indeed develop the disease?”  
 
A2.2.6. Single model – Classification thresholds and uptake 
In most clinical instances, the PPV is lower than 50% and often lower than 
10%. For example, in the context of predicting 10-year CVD risk in 
asymptomatic individuals, designation of “high risk”, where absolute risk is 
greater than 5%, means that most people have an absolute risk between 
5% to 10%. In other words, the clinician will have to typically respond to 
the patient that “There is a 90% to 95% probability that I am wrong, and 
that you will not develop CVD in the next 10 years”. This level of precision 
is poor, indicating how individual risk prediction science is still in its 
infancy, with much more progress to be made than has been made so far. 
However, a 10-year risk of 6% may still translate into a lifetime risk of 
60%. Secondly, these interventional thresholds were initially about four 
times more stringent (e.g. 20% instead of 5%, when ASSIGN was 
developed in 2007(186)). As the cost of preventative interventions like 
statins has fallen, as well as emerging evidence of a better benefits-to-
side effect profile than initially thought,(256) this has led to a decline in the 
absolute threshold at which clinical interventions are deemed to be cost-
effective and recommended. Notably however, the decision of whether a 
patient ought to begin statin therapy once their absolute predicted risk 
exceeds 5% or 10% is heavily dependent on the disutility that a patient 
attributes to the burden of having to take a daily pill. This may well show 
large inter-individual variation. As a result, patients are increasingly being 
encouraged to be told not just that their risk is “high” but the actual 
absolute risk (i.e. “6%”), and to assist them in weighing the pros and cons 
 
 
328 
 
of statin therapy with information like “for other people like yourself [who 
are above a predefined criteria of 5%], studies have found the benefits of 
statins to outweigh the costs and side effects, however it depends much 
on how much you mind having to take a daily pill”.  
 
In some respects, this discussion, of moving away from dichotomous 
classifiers back towards continua of risk gradients has brought this 
introductory discussion full circle. Continua of risk are the mathematical 
basis of all statistical risk prediction models. These should be converted 
into dichotomous classifications, particularly to advise on cost-
effectiveness and to form guidance around average practice for a large 
group of patients with similarly predicted risk. Thereafter, however, the 
final decision to proceed or decline personalized interventions is 
nonetheless personal, subjective and holistic, beyond the realm of 
statistical modelling. This withstanding, if the uptake of a given 
intervention in a population is substantially lower than what is predicted as 
optimal from statistical models, then this suggests either than clinicians 
should intervene more aggressively, or that the statistical models and 
guidance be updated to better reflect missing real-life disutilities of 
intervention.  
 
A2.2.7. Single model – Classification trade-offs, and Net Benefit 
The present discussion of classification has posited that there are two 
fundamental axes which are irreconcilable (e.g. sensitivity-axis Vs. 
specificity-axis if viewed from the perspective of the population; or PPV-
axis Vs. NPV-axis if viewed from the perspective of the individual). Under 
the assumption of infinite clinical thresholds, discrimination statistics such 
as C-statistic posit that a one-unit increase in sensitivity is equivalent to a 
one-unit increase in specificity. In other words, that the losses of failing to 
identify one True Positive (who will hence forego a potentially useful 
intervention) is equivalent to the losses of identifying an additional False 
Positive (who will be subject to increased harm from needless 
intervention). In reality, the benefit-to-harms ratio of most interventions is 
rarely close to one. This is apparent in how most clinical interventional 
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thresholds are not set to 50% of the predicted individual probability, but 
are much lower than this to reflect the large potential benefits and small 
potential harms. 
 
This can be illustrated with the hypothetical example of three healthy 
participants, each with a 10-year CVD mortality prediction of 1%, 5%, and 
10% respectively. Virtually all clinicians and public health practitioners will 
agree, that no participants at 1% risk will benefit from statin therapy. 
Virtually all clinicians and public health practitioners will agree, that all 
participants at 10% risk will benefit from statin therapy. That is, they will 
willingly treat 10 such high-risk individuals for the benefit of 1 participant, 
despite the fact that 9 out of 10 of these participants will seemingly be 
treated needlessly. From these two extremes, we can infer that the cost-
to-benefit ratio of statin use is smaller than 10:1 (latter example), and 
larger than 100:1 (former example).  
 
If clinicians are presented with a hypothetical cohort of participants with 
5% risk, then this may be the point of greatest ambivalence. That is, half 
the clinicians may err towards treating while half will err towards not 
treating. Having identified this, we can infer that the cost-to-benefit ratio of 
statins is approximately 20:1. In other words, 20 units of needless cost in 
20 newly over treated participants (i.e. the combined total of side effects, 
financial cost, as well a burden of taking a daily pill and being labelled as 
unhealthy) are equal to 1 unit of benefit in one participant who has been 
newly identified correctly as being at risk. This observation can be 
exploited to evaluate risk prediction models, by inferring that the benefit 
gained from correctly identifying one additional True Positives is 
approximately 20x as important, when compared to the cost of incorrectly 
labelling one additional person as a False Positive. This was first noted by 
Peirce in an article published in Science in 1884, to allow for the 
calculation of a weighted Net Benefit of using a risk prediction model.(287) 
The formulation was extended by Vickers in 2006, who developed a 
graphical method of evaluating Net Benefit across a range of cost-to-
benefit ratios,(255) which in my CVD example might stretch from 100:1 to 
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10:1. The underlying rationale is that when the true cost-to-benefit ratio is 
100:1, a strategy of “Treat nobody. There is no need to predict risk” is 
preferred, as this results in greater Net Benefit. When the true cost-to-
benefit ratio is 10:1, a strategy of “Treat everybody. There is no need to 
predict risk” is preferred, as this results in greater Net Benefit. Graphical 
methods, called Decision Curve Analysis, can determine the range of 
cost-to-benefit ratios, for which risk prediction is deemed superior to these 
two extreme examples where no risk prediction takes place. For example, 
if Decision Curve Analysis suggest that the Net Benefit of the risk 
prediction approach is superior when then cost-to-benefit ratio is smaller 
than 80:1 but larger than 12:1, then this can be transformed to ask “is it 
plausible, that the risk thresholds at which clinicians are maximally 
ambivalent about intervention is somewhere between 1.3% and 8%?” If 
the answer is yes, then this denotes that use of the risk prediction strategy 
may be warranted. Ideally, this would be followed by formal modelling of 
cost-effectiveness, which in turn would benefit from data taken from 
randomized trials. I have also not seen the use of metrics such as the 
Number Needed to Treat and/or the Number Needed to Screen. Both are 
well established in other applied domains of epidemiology (e.g. drug 
development and cancer screening, respectively), but have been seldom 
used in the literature on cardiovascular risk prediction. These could 
potentially assist in translating the utility of a model to a wider range of 
readers, who may not otherwise be able to discern whether the wider 
programme appears beneficial enough to implement, or not.  
 
A2.2.8. Comparing two models – what to change in model 2 
In CVD risk prediction settings, the baseline model that researchers 
typically try to improve already contains a number of predictors, some of 
which like serum cholesterol, are both invasive and time-consuming to 
collect. A little-researched area of risk prediction might be the 
demonstration of noninferiority: that the substitution of an invasive and 
time-consuming test in model1, for a non-invasive and instant test in 
model2 might show similar discrimination performance, at least in a pre-
screen first stage approach.  
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By extension, most prediction models and screening tests are applied in a 
two-or-three step design. The first step is stratification by age and sex 
alone, leading to invitation. The second step is typically the face-to-face 
collection of less invasive data (incl. cholesterol for CVD, mammography 
for Breast Cancer, and PAP test for Cervical Cancer). The third step is 
either intervention (e.g. statins), more invasive testing (e.g. biopsy), or 
more frequent testing (shorter recall time between subsequent PAP tests). 
Most research efforts have concentrated on improving performance in the 
second and third stages. However, many countries hold substantial 
patient-level data that could also improve the automatic selection that 
takes place before invitation. For example, postcode could be additionally 
considered alongside age and sex, so that people living in more deprived 
areas with greater risk are invited for screening at an earlier age, when 
compared with people living in more affluent areas. Similar adjustments 
could potentially be made after considering existing data on marital and 
employment status, as well as data from electronic healthcare records for 
known comorbidities. 
 
A2.2.9. Comparing two models – calibration, discrimination, and net benefit 
I am not aware of a single analytical technique which directly compares 
the calibration performance of two competing models. Instead, calibration 
is best assessed visually.  
 
For comparing discrimination, one common approach is to subtract the 
two C-statistics from one another, to derive ΔC. Some authors also offer a 
confidence interval around ΔC, but Harrell himself finds this inappropriate.  
Of note, if the baseline model1 being improved is already a very poor 
model (e.g. with a C-statistic of 0.60), then it is much easier for an 
updated model2 to improve this to say 0.65, when compared to the more 
difficult challenge of updating a good model1 with C-statistic of 0.80 to an 
updated model2 with a C-statistic of 0.85. This phenomenon can be 
thought of as “low hanging fruit” – the first predictors substantially improve 
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discrimination, while demonstrating additional benefit from “higher hanging 
fruit” is statistically more challenging. 
 
To assess improvements in classification, one could inspect Δsensitivity 
and Δspecificity (if taking the population view) or ΔPPV and ΔNPV (if 
taking the individual view). As explained section A2.2.7, these two axes 
can be synthesized, by applying a cost-to-benefit ratio, to derive a Net 
Benefit statistic. This downweighs potential costs, arising from more False 
Positives and loss of specificity and PPV, while upweighing potential 
benefits, arising from more True Positives and improvements to sensitivity 
and NPV.  
 
The ΔNet Benefit metric is perhaps one of the best all-rounder metrics to 
evaluate whether a new prediction tool adds incremental clinical value or 
not. However, its shortcoming is the fact that different clinical questions 
have different scales of Net Benefit, which is capped by the disease 
prevalence. Hence a Net Benefit of 0.05 might be seen as the peak for 
CVD models, while for rare diseases the peak could be as low as 0.0001. 
Furthermore, since ΔNet Benefit does not have a confidence interval, it is 
difficult to judge whether a ΔNet Benefit of 0.001 is clinically meaningful or 
not, and whether practitioners ought to change practice. Ideally, a formal 
cost-effectiveness analysis could model whether spending more funds on 
a new risk prediction approach is financially warranted, and these could 
be explored in all instances where ΔNet Benefit exceeds zero.  
 
A range of ΔNet Benefit scenarios can be investigated, by varying the 
cost-to-benefit weighting in a Decision Curve Analysis (figure A2-1). 
Despite the strong theoretical basis for Net Benefit and Decision Curve 
Analysis, these rarely been applied to risk prediction papers to date. 
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Figure A2-1. Theoretical examples of decision curve analyses. 
Thin line: assume no patient has disease (treat none)  
Dotted line: assume all patients have disease (treat all) 
Thick line: a perfect prediction model.  
Grey line: a near perfect binary predictor (99% sensitivity and 99% 
specificity). Solid line: a sensitive binary predictor (99% sensitivity and 
50% specificity). Dashed line: a specific binary predictor (50% sensitivity 
and 99% specificity). 
 
If clinical guidelines advise interventions at some threshold which is 
between 0 to 25%, then sensitive predictors and models are preferred 
over specific predictors for that application. Adapted from (255). 
 
A2.2.10. Comparing two models – net reclassification and its critique 
A popular metric which is used to compare two risk prediction models is 
the Net Reclassification Index (NRI) and its various formulations. This is 
the proportion of cases now classified better with the new model, plus the 
proportion of controls now classified better with the new model. The 
original and most common formulation assumes an infinite number of 
clinical risk thresholds, also known as Continuous NRI.  
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Theoretically, as NRI is the sum of two proportions (each with a range of 
0-100%), the maximum NRI value is 2. Summary NRI values themselves 
should never be presented or interpreted as proportions or percentages, 
although a recent review showed how most published examples fail to 
follow this advice.(288) 
 
Despite the popularity of Continuous NRI in published risk prediction 
papers, the construct contains considerable limitations, as detailed by 
Kerr(289): 
1) It is not clear why one would want to allocate 50% weighting to 
improvement seen among cases, and another 50% weighting to 
improvement seen among controls. A population-based approach 
might instead weigh the case improvement by the prevalence of 
disease (e.g. 5%), and the control improvement by the prevalence of 
controls (e.g. 95%). Perhaps the allocation of more weight can be 
seen to reflect the small cost-to-benefit ratio of most interventions. 
However, Continuous NRI is not formally weighted as such, so the 
50:50 allocation can rightly be criticized as arbitrary. 
2) Continuous NRI is larger, if the baseline model being improved 
already has better discrimination. For example, a continuous NRI of 
0.62 is just as compatible with a small C-statistic improvement from 
0.900 to 0.919, as it is with a large C-statistic improvement from 0.700 
to 0.780. In other words, imprecise models have to work harder to 
demonstrate improvements in Continuous NRI. This is a function of 
how precise models already discriminate well between cases and 
controls, and so slight amplification of this risk divergence between 
these two groups leads to large apparent reclassification. 
3) Continuous NRI is larger, if the baseline model being improved is 
poorly calibrated to the validation dataset, where improvements are 
tested. 
4) The unit of measure is binary movement, either up or down in 
predicted risk, without consideration of the magnitude of this change. 
For example, if the predicted risk of a case moves from 6.0% to 6.1%, 
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then this is equivalent to if the predicted risk of a case moves from 
6.0% to 60.0%. 
 
Many authors have recommended to refrain from presenting the combined 
Continuous NRI. If the clinical example being studied truly contains no 
categories of risk thresholds for intervention, then it may be more 
appropriate to present the percentage reclassification among cases as 
one statistic, and the percentage reclassification among controls as 
another statistic. However, in the case of CVD prediction, Categorical 
formulations are preferred. 
 
Categorical NRI creates more stringent conditions before a change in risk 
prediction between two models “counts”. This makes their values smaller 
than the values of Continuous NRI. In cases where there are at least three 
categories (i.e. at least two thresholds): 
5) Categorical NRI can easily be increased by increasing the number of 
risk thresholds. 
6) Classifying cases as “high → intermediate risk” is given equivalent 
penalty, as is classifying cases from “high → low risk”. Treatment 
decisions for these two cases could diverge, which is not captured in 
the indiscriminate way that intermediate changes are handled. 
Reclassification tables have been proposed as a more granular way to 
presenting such data. 
 
Finally, one can consider a special case of Categorical NRI, which 
contains just two categories (i.e. one threshold). I will call this Binary NRI. 
The main limitation here is the same as number 1 above – that 
improvements to cases and controls are weighted equally (agnostic of the 
true prevalence of disease). 
 
An adaptation of Binary NRI is to up-weight the improvement in cases, 
and down-weight the improvement in controls. These formulations do not 
usually adjust for the prevalence of case and control status. This may 
have the effect of giving excess attention to improvements in cases, 
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without giving due attention to potential deterioration among controls. i.e. it 
risks biasing the final weighted-binary-NRI measure towards models that 
are very sensitive, but lack specificity, thereby propagating overtreatment. 
 
By formally accounting for both the cots-to-benefit ratio of undertreating 
cases and overtreating controls, as well as the prevalence of the case: 
control mix, we have come full circle back to a more simplified metric: the 
ΔNet Benefit. Therefore, in clinical decisions where there is often one 
main risk threshold (such as recommending statins for primary CVD 
prevention), one might be best placed to avoid the NRI construct 
altogether. On the other hand, NRI statistics remain popular with editors 
and peer-reviewers, so a cautious approach would be to include these as 
a sensitivity analysis. 
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Annex 3 – Peer-reviewed papers 
A3.1. Mendelian randomization 
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A3.2. Mediation and international differences 
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